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ABSTRACT
There is considerable interest in the synthesis of K-antagonists as therapeutic agents 
but also as a means of further understanding the role of the K-opioid receptor. In the search 
for irreversible and selective reversible K-opioid antagonists, it was decided to modify the 
structures o f the two most well-known K-antagonists, GNTI and norBNI. In particular, two 
main approaches have been used for the design of novel ligands; these explored the 
introduction of electrophilic (isothiocyanate) or lipophilic (substituted/unsubstituted 
benzyl) groups onto the guanidinium moiety of GNTI or at the pyrrolic nitrogen of 
norBNI.
In the first series of compounds, jp-hydroxy-, w-hydroxy-, p-methoxy-, jp-methyl- 
and 3,4-dichlorobenzylGNTI analogues have been prepared. Binding and functional 
studies of /?-hydroxy- and m-hydroxy-derivatives have confirmed the results of molecular 
modelling studies, which had suggested that the phenolic group of the former should 
mimic the second phenolic group of norBNI that was previously shown to be crucial for k -  
antagonist selectivity. Electrophilic ligands modelled on GNTI have also been prepared 
and N ’-(5-isothiocyanatopentyl)GNTI has been sent for biological evaluation, while the 
successful synthesis of N ’-(4-aminobutyl)GNTI will allow the preparation of the 
corresponding isothiocyanate to be achieved.
Modification of norBNI followed previous studies where the duration o f action of 
naltrindole was extended by indolic N-benzylation. In-vivo, BnorBNI was a p-agonist 
when administered sc and an irreversible K-antagonist when administered icv. This led us 
to prepare 17,17’-di-NMe derivatives o f norBNI and BnorBNI as potential mixed p- 
agonist/K-antagonist ligands. Binding and functional studies of these analogues showed 
that replacement of the cyclopropyl methyl groups with methyl groups led to a decrease in 
K-antagonist potency and p-agonist potency with concomitant increase in p-agonist 
efficacy. We have also prepared isothiocyanates modelled on BnorBNI, with the 
electrophilic moiety attached directly to the benzyl group of BnorBNI or linked by a 
methylene spacer. At the time of submission, pharmacological evaluation of these ligands 
was still outstanding.
Finally, unexpected reactions with norBNI have led us to investigate whether the p- 
phthalimidobenzyl group can be used as a general protecting group for indolic and pyrrolic 
nitrogens. Evaluation on carbazole, tetrahydrocarbazole and an indolomorphinan has 
shown this is not the case.
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Opioid research is not new in that it goes back to early centuries when the 
experimental use of the poppy, Papaver somniferum, proved to confer central 
analgesic relief to severe pains. However, the exotic origin of the substance together 
with the euphoric effects experienced upon consumption saw the use of opium drift 
from therapeutic background to recreational abuse. In 1803, the German pharmacist 
Sertumer isolated morphine (1), the component responsible for the analgesic and 
rewarding properties o f opium. With the popularisation of morphine, drug addiction 
became increasingly associated with loss of production, death, delinquency and safer 
alternatives were urgently required.
In the 1920’s, Gulland and Robinson revealed the structure of morphine1 and 
in 1952 its total synthesis was reported.2 Ironically, initial efforts to produce harmless 
analogues led to the synthesis of heroin (2) (the diacetyl derivative of morphine), a 
somewhat more addictive substance. In order to produce opioids free of addictive 
effects, a better knowledge of the underlying mechanisms involved in opioid activity 
was therefore necessary.
NMe
R1 = R2 = H 
Ri = R2 = Ac
The existence of the opioid receptor was postulated in the 1930’s by two 
stereochemists Beckett and Casy and later confirmed by the pioneering work of 
Martin et al. in 1976.3,4 It is now well established that at least three different types of 
opioid receptors -known as “classical” types- are present within the central nervous 
system and peripheral sites: p for the receptors that mediate the actions of morphine, k 
for the ones that mediate the actions of the synthetic ligand ketocyclazocine and 8 
associated with the actions of the endogenous endorphin and enkephalin.3,4,5 In 1992, 
the first opioid receptor (mouse 5) was cloned, soon followed by the cloning of the 
mouse p and k receptors in 1993,6 before the cloning o f human opioid receptors was 
achieved.7,8
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The existence of subtypes within the p, 8 and k opioid receptors has also been 
proposed by several research groups.9,10,11 However, there is still a lot of debate on 
both the nature and existence of these subtypes,10 as cloning of these receptors has not 
been achieved yet and it is increasingly believed that they could instead represent 
posttranslational modification of the 3 classical types.12 Further confusion arose when 
additional opioid receptors such as the e type 13,14 or opioid receptor-like (ORL) 
receptors were proposed. Although the latter have been shown to mediate analgesia, 
they fundamentally differ from opioid receptors in that they do not bind any 
endogenous or synthetic opioids.15
A revolutionary concept for the explanation of additional opioid receptors has 
recently emerged and relies on the organisation of opioid receptors as 
dimers/oligomers,16 a process already known for other receptor systems. The 
existence of 8/k heterodimers 17,18 and 8/p heterodimers10 has already been proposed, 
with however some controversy still remaining around the theory; indeed, the bivalent 
ligands used to prove the existence of these receptors have for long consisted o f two 
pharmacophores linked by a bridge of 20 atom units,16,19 a somewhat large spacer 
(around 22 A) that could bind two adjacent receptors. Only recently have bivalent 
ligands with a reduced spacer such as compound 3 been used to probe the existence of 
dimeric receptors.20
1st pharmacophore spacer 2nd pharmacophore
3
However, these ligands still do not constitute irrefutable proof, as it is possible 
that the observed pharmacological profile stems from the mixture of monomers 
obtained after metabolism of the drugs. Definite evidence is therefore required but 
such heterodimeric structural rearrangement of opioid receptors would represent a 
valuable tool to account for many “odd” pharmacological behaviours that are not 
consistent with a “classical” monomeric model. Heterodimers should indeed exhibit
13
different selectivity and signal transduction pathways than monomers,21 and this could 
explain, for example, why a highly selective K-antagonist such as norBNI has been 
shown to antagonise the activity of highly selective 5-agonists;17 this is illustrated in 
figure 1 and explained below.19
critical com p onent for K -selectivity
critical component for 5-selectivity
Figure 1 Schematic model of a heterodimeric opioid receptor;
the numbers represent transmembrane domains (TM) 19
The figure 1 represents a heterodimeric receptor constituted from a K-opioid 
receptor (full circles) and a 5-opioid receptor (open circles) presenting a 
transmembrane (TM) 5,6 interface. Let us suppose for example that the molecular 
features critical for k- and 5-selectivity are contained respectively in TM 6 of the k- 
receptor and extracellular loop (EL) 3 of the 5-receptor (all these terms will be 
described later). One might thus also envisage the heterodimeric receptor as 
constituted of hybrid receptors A and B. An agonist X selective for the 5-receptor will 
therefore bind to the hybrid receptor B. When a K-selective antagonist Y binds to 
hybrid A, it produces a conformational change of both A and B; this might result in 
the shifting of B to an inactive state and subsequent antagonism of X.
1.2 The structure of opioid receptors and ligand recognition
All opioid receptors belong to the superfamily of G-protein-coupled receptors 
(GPCRs) and are formed with a 7-TM domain, an extracellular N-terminal and an 








Figure 2 Structural model of the K-opioid receptor 19
Studies using site directed mutagenesis and mutant opioid receptors have 
helped in elucidating the role of each portion of the receptor. It is now generally 
acknowledged that the TM domain is highly conserved between the three different 
opioid receptor types and is the region involved in the message recognition site 
(explained further) 22 whereas selectivity may be conferred by the highly divergent 
EL, mainly through favourable interactions between the ligands and the amino acid 
residues of the EL and partially by a process of exclusion (unfavourable 
interactions).23,24 It is noteworthy that selectivity observed with very small ligands is 
still poorly understood, as such molecules are believed to bind exclusively to the TM 
domain of the receptor, with no interaction with the EL. The region between TM5 and 
TM6 -third intracellular loop (IL)- is highly conserved among the three types and is 
the main portion responsible for G-protein activation.25,26
1.3 Pharmacological responses
1.3.1 Analgesic response
Opioid receptors are situated on the neuronal circuit responsible for pain 
perception (ascending sensory pathway) and modulation (descending inhibitory 
pathway). In response to the events experienced as painful or stressful, endogenous
15
opioid ligands are synthesised and released within the central nervous system; binding 
of these ligands to the EL and/or TM of the opioid receptors causes conformational 
changes of the IL that act as a switch to activate the G-protein, thereby triggering a 
whole series of intracellular reactions ultimately leading to analgesia 
(antinociception).
There is still substantial uncertainty surrounding the mechanisms evoked in G- 
protein activation and subsequent signaling responses, for example little is known 
about which conformational changes of the third IL are necessary to obtain the active 
state of the receptor.24,27 The signal transduction process is however now well 












Figure 3 Ligand binding and pharmacological responses
The G-protein coupled to all opioid receptors is heterotrimeric and composed 
of three different units: Ga, Gp and G7. Upon activation of the receptor, the a  subunit 
dissociates from GDP and associates with GTP, resulting in dissociation of the G- 
protein from the receptor (phase a, figure 3) and in separation of the a  unit from the
16
py dimer (phase b).28 Each of these units associates with different effectors and 
modulates biochemical responses, namely decrease of adenylyl cyclase and cAMP, 
which in turn causes reduction of Ca2+ influx and K+ efflux at ion channels (phase c). 
This results in hyperpolarisation of the cell, reduced excitability and blunting of the 
“pain” signal. Hydrolysis of GTP to GDP (phase d) leads to the reassociation of the 
apy heterotrimer (phase e) and to a return to the resting state (phase f).
1.3.2 Side effects
Although analgesia is a pharmacological response to activation of all three 
opioid receptors, each receptor type mediates a unique pattern of biological responses 
















Table 1 Pharmacological responses mediated by opioid receptors
The side effects mediated by the opioid receptors are troublesome and, in the 
case of acute pain, generally leave the practitioner with a dilemma: either the 
practitioner opts for low analgesic doses free of side effects but the pain is not 
adequately controlled or the pain is fully controlled but the patient experiences 
significant debilitating side effects.29 Of additional and greater concern are however 
the side effects related to tolerance, dependence and addiction.
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1.3.3 Development o f tolerance, dependence and addiction
The present project has been sponsored by the National Institute on Drug 
Abuse from the USA and a large part of our efforts are directed towards a better 
management of opioid and cocaine abuse. Before emphasising the therapeutic 
potential of K-selective ligands as a treatment of addictive behaviours, it seems 
therefore of interest to give a brief insight into the mechanisms leading to tolerance, 
dependence and addiction.
Agonist binding to the opioid receptor leads to immediate phosphorylation of 
the latter by protein kinases, which in turn triggers the recruitment o f p-arrestin.30 
This protein has been shown to produce uncoupling of the G-protein from the receptor 
(desensitisation) and internalisation of the receptor by endocytosis. The receptor can 
then undergo degradation or be recycled back to the surface. It was originally thought 
that receptor down-regulation was the cause of tolerance 32 but it has recently been 
proposed that receptor internalisation would in fact avoid development of tolerance by 
recycling the receptor back to the surface in a fully active state.30,33 With this in mind, 
drugs might be ranked with a RAVE (relative activity versus endocytosis) value: 
drugs with a high RAVE value, that is drugs that fail to invoke rapid internalisation 
and recycling of the receptor (such as morphine), maintain the receptor in an active 
state and therefore provoke changes at downstream levels, leading to development of 
tolerance and dependence.
New models are increasingly focussing on the post-receptor level 34,35 and it is 
nowadays postulated that opiate activation of the cAMP pathway and CREB in the 
nucleus accumbens (NAc) represents a “mechanism of motivational tolerance and 
dependence”,34 resulting in addiction (see figure 4).36 Depending on whether the 
addictive behaviour is motivated by the search for euphoric effects or is directed by 
the willingness to avoid amotivational depressing effects experienced when ceasing 
the drug, the use of K-agonists or K-antagonists appears an attractive solution to the 
treatment of addiction (see figure 4).
The identity of the genes which cAMP and CREB target to produce this 
abnormal behaviour remains to be elucidated but one early finding evokes the CREB- 
mediated regulation of dynorphin (the endogenous K-agonist).34 This is interesting 
since K-agonists are known to inhibit the release of dopamine and the reinforcing and 
rewarding effects of morphine, heroin, alcohol34 and cocaine 37 have been shown to 
be in part related to the increase of dopamine in the NAc. It seems therefore possible
18
that CREB activation upon repeated opioid administration leads to change of 
dynorphin levels, which in turn modifies dopamine levels, thereby triggering 
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Phase (1): opioid administration (e.g. morphine) elicits analgesia, euphoria and other 
biochemical responses.
Phase (2): tolerance to euphoric effects develops, hence dose escalates to attain
HQ
euphoric state = dependence; since they mediate dysphoria, K-agonists might help in 
reducing the euphoric effects observed in (1).
Phase (3): treatment of addiction by p-antagonists (e.g. naloxone) or cessation of 
drug-taking precipitates withdrawal symptoms characterised by amotivational state 
(depression, anhedonia) and other “horrible” feelings,40 leading to reinstatement of 
drug-seeking behaviour; administration of K-antagonists might represent a solution by 
suppressing depression.26,39
Figure 4 K-Agonists and antagonists in the control of euphoria and dysphoria: 
a solution to opioid addiction? (adapted from reference 34)
19
1.4 Significance of the K-opioid receptor
Since opioid ligands originally disclosed were overwhelmingly p-selective, the 
p-opioid receptor has been thus far the most intensively investigated and, to the 
exception of the two partial agonists nalbuphine (4) and butorphanol (5), all clinically 
available opioid drugs are p-agonists.41 However, addiction and other side effects 
associated with p-agonists have led to the search for other medications.
The K-opioid receptor represents a target o f particular interest in that its 
population is more abundant than p- and 5-opioid receptors in humans.42 In addition, 
activation of K-opioid receptors does not elicit constipation, urinary retention, 
respiratory depression or euphoria 43 and has been reported to mediate less tolerance 
and physical dependence than observed with other opioid receptors.44 However, 
psychotomimetic effects observed in clinical trials have so far impaired the 
therapeutic potential o f K-agonists,45 albeit some studies have nevertheless suggested 
that these effects might be circumvented by slow increase in the drug dosage.46 
Special precaution is therefore required when dosing K-agonists but further confusion 
arises from the lack o f consistency on the statement o f optimal doses; for instance, 
preliminary clinical studies of enadoline (6) showed that diuresis, dizziness, fatigue 
and dysphoria were mediated at doses that failed to produce analgesic effects, which 
led to the discontinuation of the development o f the drug.47 However, recent 
reassessment of enadoline has demonstrated that this K-agonist can be safely 
administered at higher doses than previously used (up to 80 pg/70 kg), with 
psychotomimetic effects being only observed at higher doses (160 pg/70 kg)47 It is 
possible that the discrepancy between these results stems from the fact that the second 




1.4.1 Significant interest in the synthesis o f K-opioid agonists
Though opioids have been historically associated with pain relief, it has 
become increasingly apparent that K-agonists have a significant role to play in a wider 
range of clinical situations.
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K-Agonists have been reported to regulate the gastrointestinal motility in 
rats,48 to lower arterial pressure and heart rate,49 to be involved in the treatment of 
cerebral oedema o f the focal ischemia type 50 and to stimulate food intake.51 A few 
patents have recently appeared, claiming therapeutic applications of K-agonists for the 
treatment of ocular and octic pains, pruritus, restless leg syndrome, irritable bladder 
syndrome or septicaemia.52 Work on the ^-selective agonist GR89696 (7) showed 
that the ^-receptor subtype might offer an approach in the control of neuropathic 
pains (hyperalgesia, allodynia) in patients with chronic or persistent pain.53 It should 
be noted however that the implication of the K-opioid receptor in allodynia needs to be 
further elucidated; although the K-antagonist norBNI has been shown to enhance this 
condition,54 it is increasingly believed that allodynia could be in fact mediated 
through non-opioid effects of dynorphin, the endogenous K-selective agonist.54,55 It 
seems that initiation of the neuropathic pain leads to upregulation of dynorphin, 
thereby promoting its non-opioid pronociceptive actions, a possible critical factor for 
the maintenance of abnormal neuropathic pain.
Studies using rhesus monkeys have demonstrated that K-agonists inhibit many 
behavioural and neurochemical effects of cocaine related to its reinforcing 
properties,56 most probably through their ability to inhibit the cocaine-induced 
enhancement o f extracellular dopamine levels.47,57 More recently, it has been 
suggested that opioids presenting a mixed K-agonist/p-agonist profile could represent 
better drug candidates for the treatment of cocaine addiction in that they should 
mediate fewer side effects than highly selective K-agonists.20,38 In particular, p- 
mediated euphoric effects are expected to counterbalance K-mediated dysphoria, 
resulting in dramatically enhanced treatment compliance; this should avoid repeating 
previous failures with K-agonists CI-977 (8) and U-50488 (9) which were abandoned 
as potential treatments against cocaine abuse because of their psychotomimetic 
effects.38 Also o f  significant interest regarding the mixed K-agonist/p-agonist profile is 
that K-agonists have been suggested to suppress tolerance and rewarding effects 
experienced upon persistent activation of the p-opioid receptor.32
In the particular cases of somatic and visceral pains (inflammation, abdominal 
surgery, pancreatitis pain), analgesia might be conferred whilst avoiding centrally- 
mediated side effects by either administrating small, systemically inactive doses of 
agonists directly into the injured tissue (useful in the case of localised pain) or by
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administrating peripheral agonists that have difficulties in crossing the blood/brain 
barrier (BBB).43,58,59 In this perspective, K-agonists appear as most useful as it is 
believed peripheral analgesia might be mediated by peripheral K-opioid receptors.60 
Early experiments have evoked relief to capsaicin-induced hyperalgesia conferred by
f O  iTI
the K-agonist U50,488 (10) in studies using rats and rhesus monkeys.
However, these constitute specific pain models and a better determination of 
the level at which K-efficacy leads to dysphoria is required for more general practice. 
There is a fundamental need for K-antagonists, as assessment of K-agonist efficacy is 
commonly achieved through the use o f antagonists as a means of immobilising the 
receptor reserve in a preparation, thereby placing a higher efficacy demand on 
agonists to produce a response.
1.4.2 Significant interest in the synthesis o f  K-antagonists
Although antagonists are mainly perceived as a tool for blocking a receptor 
population, K-antagonists may also present additional pharmacological interest since 
they have been reported to improve recovery after traumatic brain injury and might 
prove useful in the treatment of Parkinson’s disease; it is indeed suggested that the 
standard K-antagonist norBNI might prevent motor fluctuations that normally develop 
under levodopa therapy.63
In feeding studies, administration of norBNI has been shown to attenuate 
drinking in genetically polydipsic mice 64 and to decrease food intake induced by food
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deprivation, electrically-stimulated feeding, nocturnal feeding or exposure to a high- 
fat diet.51
k-Antagonists may also help in the treatment of depression, as GNTI (11), 
ANTI (12) and norBNI (13) have been reported to inhibit immobility in the forced
that these drugs mediate antidepressant effects by blocking K-opioid receptors that 
normally decrease neurotransmitter release from mesolimbic dopaminergic neurons in 
the NAc.39
The antidepressant effects of K-antagonists have also been investigated for the 
treatment of drug abuse, as dysphoria is a likely condition observed upon drug 
withdrawal. In post-detoxification treatment of heroin addicts, Rothman and 
associates have demonstrated that a combination of naltrexone (p-antagonist) and 
buprenorphine (partial p-agonist/K-antagonist) produced a greater positive response 
than naltrexone alone, indicating a possible therapeutic use o f K-antagonists in the 
treatment of opioid addiction.66
On a more general point of view, K-antagonists might also find therapeutic use 
as modulatory agents to prevent the tolerance and side effects mediated by p-selective 
analgesics. With this aim, peripheral antagonists could provide the best alternative 
since they do not antagonise centrally-mediated analgesia and one single antagonist 
could prevent several peripherally-mediated side effects.





1.5.1 General remarks concerning the design o f opioid ligands
Pioneering efforts directed towards the synthesis of opioid ligands consisted of 
bringing slight modifications to the structure of morphine in the hope it would 
suppress the unwanted effects. These modifications were achieved either through the 
design of more complex ligands -e.g. orvinol ligands (14)- or via simplification of 
the morphine structure into diphenylpropylamines (15), 6,7-benzomorphans (aka 2,6- 
methano-3-benzazocine) (16), morphinans (17), 4-phenylpiperidines (18), 4- 
anilinopiperidines (19) and iV-benzylpiperazines (20). However, regardless of the 








High doses o f opioids required for the treatment o f acute pain might result in 
high accumulation o f metabolites in the body, and consequently in increased risks of 
toxicity and/or activity. Though appearing a crucial issue, metabolism has for long 
been disregarded when designing new ligands because of its inconsistent and 
unpredictable impact on the pharmacological profile of the drug. A good illustration 
of the problem is provided with opioid drugs containing a hydroxy group (including 
phenolic) such as morphine (1); morphine is known to give two metabolites, namely 
morphine-3-glucuronide (21) and morphine-6-glucuronide (22) and the latter has been 
reported to possess higher potency and toxicity than morphine on an equimolar basis 
68 (though interestingly the drug is being developed by the pharmaceutical company
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CeNeS and is now on phase III of clinical trials). In addition, since metabolism of 
hydroxy groups by glucuronidation and sulfonation causes rapid excretion of the 
drug,20,69 it seems attractive to develop analogues with substituted hydroxy 
groups.70,71 Yet, the diacetyl derivative of morphine, heroin (2), penetrates more easily 
into the brain because of its higher lipophilicity; it is then quickly hydrolysed into 
morphine, which on the whole tantamounts to rapid delivery of morphine into the 
brain and therefore higher abuse liability.
In the case of peptidic ligands, for which biodegradation is a fundamental 
issue, bioavailability might be increased by the right choice of amino acids; for 
example, the use of D-amino acids has proved successful with FE200041 (D-Phe-D- 
Phe-D-Nle-D-Arg-NH2) reported as a peripheral peptidic K-selective agonist 
presenting long-lasting bioavailability;43 DAMGO (Tyr-D-Ala-Gly-MePhe-Gly-OH), 
the p-selective agonist currently used in binding and functional assays, DADLE (Tyr- 
D-Ala-Gly-Phe-D-Leu-OH) and DPDPE (Tyr-D-Pen-Gly-Phe-D-Pen-OH), both used 
as 8-selective agonists in binding assays, constitute other examples.
R1 = R2 = H 1
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1.5.1. b Pharmacokinetic profile
Although opioid analgesics almost exclusively refer so far to CNS-acting 
medications, there are encouraging signs that peripherally-acting drugs might prove 
useful for the treatment of specific pains (discussed above). As a consequence, when 
designing opioid ligands, medicinal chemists need to consider selectivity issues 
relating to the site of action. When penetrating into the brain, drugs need to cross the 
BBB, a very impermeable barrier to lipid-insoluble compounds: therefore, presence of 
extra basic groups -hence in a protonated state in-vivo- might be envisaged as a 




In addition, since the transition between adequate pain management to pain 
might occur through a small variation of the drug blood concentration,72,73 it is 
essential to design drugs with the right pharmacokinetics, hydrophilicity/hypophilicity 
ratio, rate of absorption, desired onset and duration of action. For instance, the 
introduction of ester functional groups in the series of fentanyl-derived ligands has 
proved judicious for modulating the pharmacokinetic profile of the parent drugs. The 
outcome was indeed better tissue solubility of the drug (remifentanil (23)) and rapid 
degradation by plasma esterases, which resulted in rapid onset and short duration of 
action. This prevents the drug from accumulating in the tissue, thereby alleviating 
dosing history issues.73 The other striking example to illustrate the importance of 
pharmacokinetic properties of opioid ligands is norBNI (13) and this will be discussed 
in section 1.5.2.b.
fentanyl
1.5.1. c Absence o f a well-defined spatial arrangement o f the receptor
Although opioid receptor cloning constituted a real advance in ligand design 
in that binding studies using chimeras and site directed mutagenesis studies allowed 
the determination of specific amino acids involved in ligand recognition, it is still 
difficult to predict whether a ligand will target the desired key sites as no three- 
dimensional (3-D) crystal structure of opioid receptors is currently available. The 
transmembrane nature of the GPCRs has long proved challenging for crystal structure 
analysis and only recently has the 3-D structure of bovine rhodopsin, a member of the 
GPCR family, been elucidated.74 Based on these data, 3-D computer-generated 
models of the three opioid receptors have appeared (see figure 5); these models rely 
on the assumption that the structural organisation of the transmembrane domains 
should be conserved within the members of the GPCR family because o f high amino- 
acid sequence homology. Such models have since proved reliable and docking studies
75using these tools have been supported by site directed mutagenesis.
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Figure 5 Illustration o f a 3-D model o f the K-opioid receptor (docked ligand is 13)
1.5. 1.d  Structure/Activity Relationship (SAR)
The difference between an agonist and an antagonist is that an agonist shifts 
the receptor conformation to an active state. The switch from agonist activity to 
antagonist activity o f  opioid ligands is very subtle and can be imparted by a single 
change in rather complex molecules. For example, replacement o f a single amino acid 
o f peptidic ligands has been reported to change their activity (see example in section
1.5.2.a). Regarding the morphine derivatives selective for the p-receptor, it is 
noteworthy that antagonist ligands are usually obtained when the nitrogen atom is 
substituted with an allyl or cyclopropyl methyl group whereas substitution with a 
methyl group leads mainly to pure agonists.76 On the contrary, members o f  the 
phenylpiperidine class have been shown to retain their antagonist activity irrespective 
o f the N-substituent (discussed below in section 1.5.2.b).
1.5.2 k-A ntagonists
1.5.2. a Peptidic antagonists
In the 1970’s, isolation from brain tissue o f two opioid peptides,77 namely 
methionine-enkephalin (Met-enkephalin) (24) and leucine-enkephalin (Leu-
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enkephalin) (25), spurred pharmaceutical companies to synthesise peptidic ligands, as 
it was believed they would reveal non-addictive drugs. However, it came quickly 
apparent that a major challenge with peptidic opioid ligands would be enzymatic 
cleavage observed in-vivo.44 Exchange of one or several amino acids of dynorphin A 
(26) (the endogenous ligand for the K-receptor) led to the discovery of numerous
78peptidic K-agonists with increased selectivity, stability and activity. However, 
disclosure of peptidic selective K-antagonists based on the core of 26 remained an 
elusive goal for many years until Schiller and co-workers disclosed dynantin (27) in 
2001.78 The design of 27 was based on the observation that a positively charged N- 
terminal amino group seems to be required for signal transduction but not for the 
binding of peptidic ligands to opioid receptors. This led Schiller and associates to 
replace the N-terminal Tyr1 residue with 2’,6’-dimethyltyrosine (Dmt), in which the 
terminal nitrogen was replaced with a methyl group. It is interesting to note that other 
examples of peptidic opioid antagonists have been reported using this technique and 








In 1987, Portoghese and co-workers reported the first two non-peptidic ligands 
selective towards the K-receptor: binaltorphimine (BNI) (28) and norbinaltorphimine 
(norBNI) (13).79 To date, norBNI remains the most widely used K-selective opioid 
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NorBNI does not bind irreversibly to the K-opioid receptor, but the slow  onset
on
and very long duration of action of 13 -up  to 11 weeks in vivo -  are rather a 
consequence of the drug’s bulky nature that impairs both its solubility and diffusion
Ol
rates into and out of the brain. The disclosure of norBNI led therefore to SAR 
studies in view of simplifying the drug’s structure. These studies revealed that the 
binding of norBNI with the K-opioid receptor follows the “message-address” concept 
introduced by Schwyzer: in a series of bivalent ligands, the message refers to the 
common molecular features that result in binding to a family of receptors whereas the 
part of the ligand that provides additional selectivity towards a subsite unique to one 
of the receptors is called the address.82 Explicitly, Portoghese showed that only one 
morphinan pharmacophore (the message) and the basic nitrogen of the second 
morphinan (the address) were required for norBNI to maintain its activity and 
selectivity.83 O f significant importance was the spatial orientation of the second basic 
nitrogen, as it was supposed to mimic the basic Arg7 residue of dynorphin A. 19,83 With 
this in mind, Portoghese and colleagues developed a series of “smaller” analogues, 
using rigid scaffolds in order to hold the basic nitrogen in the same position as that 
occupied in norBNI; this ultimately led to the discovery of GNTI (11) 84 and the 










Subsequent chimera studies have supported Portoghese’s intuition and have 
demonstrated that the second basic nitrogen interacts with an acidic residue Glu297, 
present in K-receptors but not in p- or 5-receptors, hence conferring k-
9 7  R^ R4selectivity. ’ ’ However, there is recent suggestion that the spatial orientation of the 
second basic nitrogen atom might not be optimal in the structure of norBNI (13) and
or
its derivatives 11 and 29. Subsequent series of compounds with different spatial 
arrangement and basicity level conferred to the second basic nitrogen have therefore
<ye or 07
been synthesised and evaluated in pharmacological assays. ’ ’ Although these 
studies further emphasized the importance of both pKa and position of the nitrogen in
RRthe selectivity and activity of the ligands, no clear conclusion could be reached on 
the optimal design. It is noteworthy that moving the guanidine group from the 5’- 
position to the 6 ’-position resulted in a change of activity of the parent drug (from an 
antagonist to an agonist), while moving the guanidine group from the 5 ’-position to 
the 7’-position resulted in a predictable change of selectivity (from k to 5) . 89
Efforts directed towards the synthesis of “small” K-antagonists focussed 
initially on /raws-(3,4)-dimethyl-4-(3-hydroxyphenyl)piperidines (30) and 4/?-methyl- 
5-(3-hydroxyphenyl)morphans (31).90,91’92,93 Although early antagonists disclosed 
within the former family did not exhibit K-selectivity, their discovery nevertheless 
constituted a major advance in the search for K-antagonists in that antagonist activity 
was retained upon modification of the N-substituent.94 This then allowed Thomas et 
al. to use a library of compounds based on the general structure 30 and biased for 
opioid antagonist activity and reduced p-affinity. This led to the discovery of the k-
Q9selective antagonist 32 and further refinement using the message/address concept 
culminated in the disclosure of JDTic (33), as a K-antagonist with remarkable 
selectivity and potency.91
HO
R 1 = R 2 = R 3 = unspecified 30
30
Despite structural resemblance between the /raw.s-(3,4)-dimethyl-4-(3- 
hydroxyphenyl)piperidine family and the 5-(3-hydroxyphenyl)morphan family, the 
disclosure of K-antagonists has proved more difficult in the latter case. However, the 
discovery of 34, a potent antagonist at the three opioid receptors, 95 and application of 
the message/address concept led to 35, the first potent and selective K-antagonist 
within this family.93
R1
R 1 = R 2 = unspecified 31
34
In addition, it is interesting to note that in a similar way to the trans-{3,4)- 
dimethyl-4-(3-hydroxyphenyl)piperidine family (30) and unlike morphine-based
Ol 0*7
antagonists, ’ there is no evidence of efficacy being introduced when changing the 
N-substituent.95 It is believed that the discrepancy in SAR behaviours stems from the 
fact that, upon binding o f the ligands to the receptor, the N-substituent occupies 
different binding pockets o f the receptor and thereby does not play the same role; this 
is illustrated on figure 6 . 95 For opioid antagonists having a piperidine ring in a chair 
conformation and substituted with an axial 3-hydroxyphenyl group, e.g. morphinones 
36 or fra«j-(3,4)-dimethyl-4-(3-hydroxyphenyl)piperidines 37, the N-substituent is 
postulated to be in the equatorial position and would therefore represent the trigger for 
antagonist activity; for opioid antagonists having a piperidine ring in a chair 
conformation and substituted with an equatorial 3-hydroxyphenyl group, such as 5-(3- 
hydroxyphenyl)morphans 38 or /rart5 -(3 ,4 )-dimethyl-4 -(3 -hydroxyphenyl) piperidines 
39, it is the axial 3-methyl group of 39 or the 9/?-methyl group o f 38 that are supposed 
to be responsible for antagonist activity; in 38 and 39, the N-substituent confers 
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Figure 6  Putative elements responsible for antagonist activity (circled)
K-Antagonists are also known in the arylacetamide class of compounds, a 
family usually associated with K-agonists. The rationales behind the two irreversible 
K-selective ligands UPHIT (40) and ICI 199411 (41) were identical and explored the 
introduction of an electrophilic group onto the two K-selective agonists U50488 (42) 
and DIPPA (43) with the aim of promoting irreversible binding.96,97 However, this 
approach did not prove completely successful since, in both cases, irreversible 
antagonism is preceded by agonism. It is believed that 40 and 41 initially mimic 42 
and 43, thereby shifting the receptor to an activated state; subsequent nucleophilic 
attack on the isothiocyanate groups results in conformational change of the receptor 
and loss of activity. Such tools might be used once their initial agonism has worn off, 
but it can be inferred that agonist effects of 40 and 41 might alter subsequent 
antagonist activity. It should be noted that the pharmacological profile of both drugs is 
however highly debated, including among our collaborators.
R
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1.6 Aim of the present project
The need for K-antagonists as a means o f farther understanding the biological 
processes associated with the K-opioid receptor and as a means o f better 
characterising K-agonists has prompted us to develop new selective antagonists and 
potential irreversible antagonists for the K-opioid receptor. Since norBNI (13) and 
GNTI (11) are the two most prominent K-selective antagonists thus far reported, it 
was decided to modify their structure with the aim of promoting covalent binding 
with the K-opioid receptor or pseudo-irreversible binding. In particular, two main 
approaches are investigated in the present project, namely introduction of a lipophilic 
group (substituted/unsubstituted benzyl) or electrophilic group (isothiocyanate) onto 
the guanidinium group of GNTI (11) or at the pyrrolic nitrogen of norBNI (13).
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2. DISCUSSION
2.1 Benzylguanidinyl substituted ligands
2.1.1 Rationale
Since GNTI (11) is a highly selective K-antagonist, it represented an ideal 
starting point for the design o f potentially irreversible K-selective antagonists. In 
particular, the unsubstituted guanidinyl group appeared to provide an ideal position 
for farther structural modification.
In 1992, Lewis and associates reported that the substitution of the 14-hydroxy 
group of naltrexone (44), a reversible p-selective antagonist, with a p- 
chlorocinnamoylamido group afforded C-CAM (45) as an irreversible p-selective
QQ
antagonist (scheme 1). The irreversibility in the binding of 45 does not stem from 
Michael addition on the cinnamoyl group of C-CAM, as originally believed, but is 
likely due to very strong lipophilic interactions presumably between the styryl group 
o f 45 and a lipophilic pocket o f  the p-opioid receptor (pseudo-irreversible binding); 
studies with strong electron-withdrawing groups on the phenyl ring (e.g. NO2) have 
indeed failed to promote covalent binding with the receptor, thus emphasising the 
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Scheme 1 Design of C-CAM (45)
Interestingly, the addition o f a lipophilic group (benzyl) onto the indolic 
nitrogen of NTI has also been reported to result in longer duration of action of the 
drug (this will be further detailed in section 2.4.1.b) . 100 It was thus decided to 
investigate the effect of similar introduction of a lipophilic group, in particular benzyl, 
to the reversible K-antagonist GNTI (11). In the pioneering series o f benzylGNTI 
analogues synthesized by Dr Shannon Black, the p-chlorobenzylGNTI derivative (46) 
proved particularly promising since the binding in C6 (8 ) and CHO (k) cells remained 
after washing, suggesting irreversible binding with the receptors (see scheme 2 ).
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However, it was found in the opioid antagonist functional assay that selectivity 
towards the K-receptor (37-fold k/p. selectivity and 55-fold k/8  selectivity) was modest 
compared to that exhibited by GNTI (81-fold K/p selectivity and 389-fold k/8 
selectivity) . 101 The present project thus explores further modification of benzylGNTI 
in order to enhance K-opioid receptor selectivity.
Scheme 2 Pioneering work within our group on benzylGNTI analogues
2.1.2 Design
As mentioned in the introduction, the phenolic group of the first 
pharmacophore of norBNI (13) has been reported to be crucial for K-antagonist 
activity. To demonstrate this point, Portoghese et al. synthesised the 3-0,3’-0- 
dimethylated and 3’-0-monomethylated norBNI derivatives (47 and 48
1 (V)respectively). Biological evaluation of the opioid antagonist activity showed that 
the dimethylated analogue 47 was inactive at all three receptors, while the 
monomethylated derivative 48 exhibited potency and selectivity similar to that of 
norBNI. It was later concluded that the second phenolic group o f norBNI was not 
important for K-antagonist selectivity 20,83 and this was corroborated by GNTI being a 
highly selective K-antagonist.84 However, when disclosing JDTic (33), Thomas et al. 
demonstrated that both amino groups and both phenolic groups were required to 
maintain K-opioid potency and selectivity. 103 Intrigued by this point, they decided to 
synthesise the dehydroxy analogue of norBNI (49) . 104 Unexpectedly, evaluation of 13 
and 49 in the binding assay showed that loss of the hydroxy group had little impact on 
k -  and 8 -affinity but entailed a 1 0 -fold increase in ji-affinity, which resulted on the 
whole in no change of k / 8  selectivity but in a 10-fold decrease o f k / jx selectivity. In 
the functional assay, loss o f the hydroxy group produced a 3.5-fold loss of k -  




k  reversible antagonist
35
decrease in 5-antagonist potency; this resulted therefore in a decrease o f K/g 
selectivity and huge enhancement o f k / 5  selectivity, thus demonstrating the 
importance o f the second phenolic group in determining K-antagonist selectivity. The 
discrepancy between these findings and Portoghese’s earlier conclusions might be 
explained by the fact that Portoghese and associates used the monomethylated 
analogue o f norBNI (48) to study the importance o f the second phenolic group. It is 
possible that the oxygen atom of the second phenolic group o f 13 unfavourably 
interacts with a group present in the lipophilic pocket o f the p-receptor. The presence 
o f the hydrogen-bond accepting oxygen atom may therefore be important for k - 
antagonist selectivity but not the presence of a hydrogen-bond donor.104
r o
OH HO
R 1 = OH, R 2 = OH 13 R 1 = OH, R 2 = OMe 
R 1 = OMe, R 2 = OMe 47 R 1 = OH, R 2 = H
48
49
We have demonstrated by using the “flexible align” function implemented in 
MOE that, when in a low energy conformation, the phenolic group o f p- 
hydroxybenzylGNTI (50) can be exactly overlaid on the second phenolic group o f 
norBNI (see figure 7) and therefore could be expected to have a beneficial effect on k - 
selectivity, if not affinity.
Benzyl guanidine
rvotRNi]
Figure 7 Overlay o f  norBNI (13) and p-hydroxybenzylGNTI (50)
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The synthesis and biological evaluation o f p-hydroxybenzylGNTI (50), m- 
hydroxybenzylGNTI (51) and /?-methoxybenzylGNTI (52) are therefore reported in 
the present project. Comparison of 50 and 51 should provide information on the 
importance of the orientation of the hydroxyl group, while comparison of 50 and 52 
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The synthesis of 50 and 51 was carried out simultaneously and will be 
described in section 2.1.3.a, with the synthetic route further exploited for the 
preparation o f 52 (section 2.1.3.b).
2.1.3. a Synthesis o f p~ and m-hydraxybenzylGNTI analogues (50) and (51)
The synthesis of GNTI (11) is reported in the literature and involves 
guanidinylation of amine 53 with l,3-bis-terf-butoxycarbonyl-2-methyl-2- 















Scheme 3 Synthetic route reported in the literature for the preparation of 11 84,88
With this in mind, two different approaches might be envisaged for the 
synthesis o f 50 and 51, namely guanidinylation o f 53 with substituted guanidinylating 
agents (path A) or direct alkylation of 11 (path B) as shown in scheme 4 . 105 Since the 
latter method would require protection and deprotection of the hydroxy groups of 55,
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it was decided to synthesise 50 and 51 via guanidinylation of 53 with appropriately N- 














Scheme 4 Two possible synthetic approaches for the preparation of 50 and 51
The method employed by Portoghese and associates for the preparation of 
amine 53 involved a Fisher indole reaction between naltrexone hydrochloride (44) and 
4-nitrophenylhydrazine, followed by reduction of the nitro group with Raney nickel
QQ









(a) 1.1 equi. 4-nitrophenylhydrazine, AcOH/conc. HC1, 110°C, 7 days;
(b) Raney Ni/7.7 equi. NH2NH2.XH2O, EtOH, 2 hrs, room T°
Scheme 5 Preparation of amine 53 reported in the literature 88
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Portoghese and co-workers reported that very harsh conditions were required 
for the first step because o f the strong electron-withdrawing effect of the nitro group 
on phenylhydrazine; stirring the materials for 7 days at 110°C in a mixture of acetic 
acid/conc. HC1 thus afforded 5’-nitronaltrindole (56) in modest yield (43%).
However, earlier work within our group had suggested that a shorter reaction 
time, a less tedious workup and a better yield could be obtained when the first step 
was carried out in ethanol/conc. HC1 (50/50) under reflux. 106 Modifications had also 
been reported for subsequent reduction of the nitro group into the corresponding 
amine, as Raney nickel-catalysed transfer hydrogenation with cyclohexene was found 
preferable. 106 While the modified first step proceeded relatively well during this 
current study (26 % yield), the reduction of 56 to 53 using Raney Ni/cyclohexene 
transfer hydrogenation could not be repeated. Hydrogenation, using Raney Nickel or 
palladium as catalysts under an atmospheric pressure o f hydrogen, also proved 
unsuccessful. Pd-catalytic hydrogenation, increasing the hydrogen pressure to 5 bars, 
gave somewhat better results, as the desired product was obtained in 31% yield. It was 
then decided to reproduce Portoghese’s method (Raney nickel/hydrazine hydrate 
transfer hydrogenation) , 88 which afforded the amine in 47% yield (vs 69% reported in 
the literature). Reduction using iron(II) sulfate heptahydrate/NPLiOH was also 
attempted to see if this would allow a more efficient preparation o f 53, as this method 
had been satisfactorily employed within our group for the reduction of aromatic nitro 
groups;107 indeed, stirring morphinan 56 and 9 equivalents of iron(II) sulfate 
heptahydrate at 80°C for 3 hours in a mixture of methanol/H2 0 /conc. NH4OH 
afforded 53 in 56 % yield.
As noted earlier, the synthetic approach used in the present project for the 
preparation of 50 and 51 required the synthesis of suitable guanidinylating agents. 
Guanidines are generally commercially synthesised via the nucleophilic displacement 
of methyl mercaptan from S-methylisothiouronium salts by amines. 108 However, since 
methyl mercaptan is a highly smelly noxious gas, such a procedure requires 
subsequent transformation o f the byproduct. The synthesis o f guanidines has also 
been achieved by reaction of ammonia derivatives with cyanamides, 109,110 
chloroformamidines, 111 aminoiminomethanesulfonic acids 112 or carbodiimides 108 but 
these procedures generally involve corrosive, moisture-sensitive starting materials and 
require high temperatures. More recently, guanidinylation employing protected
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guanidinylating agents, such as pyrazole carboxamidine 57 or thiourea derivatives 54 
and 58, in presence o f Mukaiyama’s reagent (59) or a thiophile (such as mercury, 
copper or lead salts) 113,114 have emerged and this proved more attractive to us as the 
desired guanidinylating agents could be prepared by direct N-alkylation of these. Such 
a procedure was also employed by Portoghese and colleagues for the disclosure of 
GNTI (11), with mercury(II) chloride being used as the catalyst for the coupling of 54 
with 53.84,88 Although it is generally agreed that mercury forms a complex with the 
sulfur atom, resulting in activation of the carbon atom towards nucleophilic attack by 
the amine, it is not clear however whether the reaction proceeds via formation of a 
tetrahedral intermediate115 or a carbodiimide intermediate. 116
O i l !I ' ^ muDaa RnrHMN
BocN^^NHBoc
57 54 58 59
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As N-benzylation of 54 with benzyl bromide derivatives 60 and 61 required 
the use o f sodium hydride, the synthesis of guanidinylating agents 62 and 63 started 
with the protection o f the hydroxy group of 3- and 4-hydroxybenzaldehydes (see 
scheme 6 ). Three protecting groups were initially investigated, namely benzyl, 0 - 
tetrahydropyranyl and trityl, but it appeared very early in the synthesis that the use of 
the benzyl group was the most promising. Benzy 1-protection of 3- and 4- 
hydroxybenzaldehydes was achieved following the procedure used by Nicolaou et a l , 
117 which quantitatively afforded 64 and 65 that were subsequently reduced with 
sodium borohydride into the corresponding alcohols 6 6  and 67 (93% and 84% 
respectively). The latter were then converted into their bromide derivatives 60 and 61 
according to a general procedure reported by Lange et al. for the conversion of
n o
alcohols into alkyl iodides; this procedure involved forming 
iodotriphenylphosphonium iodide salt before subsequent reaction with 0.83 
equivalent of alcohol in the presence of one equivalent o f imidazole; in our case, 
iodotriphenylphosphonium iodide was replaced by the bromide salt. Deprotonation of 
l,3-bis-tert-butoxycarbonyl-2-methyl-2-thiopseudourea (54) with 1.2 equivalents of 
sodium hydride and subsequent nucleophilic attack on 1 .1  equivalents of 60 and 61,
40
using a similar procedure to that previously reported within our group, 106 afforded the 














(a) 1.5 equi. K 2 C O 3 ,  1 equi. BnBr, DMF, overnight, room T°; (b) 0.5 equi. NaBfij, 
dry THF, overnight, room T°; (c) 1.2 equi. PPI13, 1.2 equi. imidazole, 1.2 equi. Br2, 
dry DCM, overnight, room T°; (d) 0.9 equi. 54, 1.1 equi. NaH, dry DMF, 14 hrs, 
room T°
Scheme 6  Preparation of guanidinylating agents 62 and 63
Coupling of 53 with 62 and 63 was achieved following an analogous HgCh- 
promoted guanidinylation procedure to that reported in the literature, namely using 
0.56 equivalent of mercury(II) chloride and 1.0 equivalent of both triethylamine and
OA
53. However, since initial attempts showed that some unreacted amine 53 was still 
present at the end of the reaction, we eventually decided to increase the number of 
equivalents of mercury(II) chloride, triethylamine and guanidinylating agent (1.5, 2.0 
and 2.0 equivalents respectively) (scheme 7). Simultaneous removal of the BOC and 
benzyl protecting groups of 6 8  and 69 was then attempted using a large excess of 
trifluoroacetic acid but this afforded products still bearing the benzyl protecting 
group. Since it was reported in the literature that debenzylation with TFA might be 
improved by adding a strong nucleophile (thioanisole) or a benzylic cation scavenger 
(pentamethylbenzene) , 119,120 the benzyl-protected morphinans were stirred overnight
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at 40°C in TFA with 20 equivalents of thioanisole, but this gave only unreacted 
materials. However, simultaneous benzyl and BOC deprotection was eventually 
achieved stirring 6 8  and 69 overnight in a mixture o f conc. HCl/MeOH (50/50) at 




















(a) 1.2 equi. 4-nitrophenylhydrazine, EtOH/conc. HC1 (50/50), 24 hrs, reflux; (b) 9 
equi. FeS04.7H20 , MeOH/^O/NEUOH, 3 hrs, 80°C; (c) 1.5 equi. HgCl2, 2.0 equi. 62 
or 63, 2.0 equi. NEt3, dry DMF, 24 hrs, 60°C; (d) conc. HC1/ MeOH (50/50), 
overnight, 80°C
Scheme 7 Synthetic approach used for the preparation of compounds 50 and 51
2.1.3.b Synthesis o f p-methoxybenzylGNTI (52)
The synthetic pathway described in section 2.1.3.a was further employed for 
the preparation of 52. 4-Hydroxybenzaldehyde was reacted with 1 equivalent of
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methyl iodide and 1.5 equivalents of potassium carbonate in DMF, which led to the 
methoxy derivative 70 in 92% yield (scheme 8 ). 70 was quantitatively reduced with 
sodium borohydride to the corresponding alcohol 71 before conversion into 4- 
methoxybenzyl bromide (72), using the same conditions as described above for 60 
and 61. It is noteworthy that 72 could not be purified by column chromatography 
because of decomposition and was subsequently used without any purification. 
Reaction of 72 with 54 in presence of sodium hydride led to the guanidinylating agent 
73 (49% yield) that was in turn coupled with 53 using the same mercury(II) chloride- 
promoted guanidinylation as used for the preparation o f 6 8  and 69. This afforded a 
mixture containing the desired di-BOC-protected morphinan 74 and its mono-BOC- 
protected analogue. Deprotection of the mixture with a large excess of TFA afforded 
cleanly and quantitatively the target compound 52 (see scheme 8 ).
NBoc
70 71 72 73
TFA










(a) 1.5 equi. K2CO3, 1.0 equi. CH3I, DMF, overnight, room T°; (b) 0.5 equi. NaBH4, 
dry THF, overnight, room T°; (c) 1.2 equi. PPI13, 1.2 equi. imidazole, 1.2 equi. Br2, 
dry DCM, overnight, room T°; (d) 0.9 equi. 54, 1.8 equi. NaH, dry DMF, 14 hrs, 
room T°; (e) 1.65 equi. HgCh, 2.0 equi. 73, 2.0 equi. NEt3, dry DMF, 24 hrs, 60°C; 
(d) DCM/TFA, overnight, room T°
Scheme 8  Synthetic route used for the preparation o f /?-methoxybenzylGNTI (52)
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2.2 F urther w ork with benzylGNTI derivatives
2.2.1 Rationale
Still intrigued by the results reported by Thomas et al. relating to the 
contribution of the second phenolic group towards the binding of norBNI 104 and in 
our effort to develop antagonists with increased K-opioid receptor selectivity and 
activity, we decided to further study the interaction between the benzylic group of 
benzylGNTI analogues and the lipophilic pocket o f the K-opioid receptor. A Topliss 
approach was thus implemented in order to investigate which physicochemical 
parameters o f the substituent on the phenyl ring are optimal for K-antagonist potency 
and selectivity. The Topliss method requires the synthesis and biological evaluation of 
a first series o f derivatives, namely / 7-chloro, 3,4-dichloro, / 7-methyl, / 7-methoxy and 
unsubstituted benzyl analogues; according to the rank order of potency of these 
compounds, one can predict which type of substitution on the phenyl ring is optimal 
for activity. 121 As Dr Shannon Black had already synthesised / 7-chlorobenzylGNTI 
and benzylGNTI, 106 it was decided to prepare and evaluate 3,4-dichlorobenzylGNTI 
(75) and /7-methylbenzylGNTI (76) (see scheme 9).
2.2.2 Synthesis
The preparation of 76 and 75 was achieved using a similar synthetic strategy 
as used in section 2.1 and started with the synthesis of guanidinylating agents 77 and 
78. l,3-Bis-ter/-butoxycarbonyl-2-methyl-2-thiopseudourea (54) was thus 
deprotonated with 1 .1  equivalents of sodium hydride in presence of 0 .1  equivalent of 
15-crown-5; the corresponding base was subsequently reacted with commercially 
available 4-methylbenzyl bromide (79) or 3,4-dichlorobenzyl chloride (80), stirring 
the mixture overnight at 70°C, which afforded the desired products 77 and 78 in 74% 
and 47% yields respectively (see scheme 9). Subsequent HgCh-promoted 
guanidinylation o f amine 53 with 77 and 78, using the procedure described in section 
2.1, led to 81 and 82 in 6 8 % and 74% yields respectively. It is noteworthy that both 
81 and 82 were isolated as a mixture of mono- and di-BOC protected morphinans. 
Finally, deprotection of the morphinans (mixture of mono- and di-BOC protected 
derivatives) was accomplished stirring the compounds overnight at room temperature 
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(a) 1.1 equi. NaH, 0.1 equi. 15-crown-5, 1.2 equi. 79 or 80, dry DMF, 14 hrs, 70°C;
(b) 1.5 equi. HgCh, 2.0 equi. 77 or 78, 2.0 equi. NEt3, dry DMF, 24 hrs, 60°C;
(c) DCM/TFA, overnight, room T°
Scheme 9 Synthetic approach used for the preparation o f 75 and 76
2.3 Irreversible guanidinyl substituted ligands
2.3.1 Design
We have explored in sections 2.1 and 2.2 the possibility o f promoting 
irreversible binding with the receptor via additional lipophilic interactions. This 
resulted in benzylGNTI analogues exhibiting pseudo-irreversible binding with the k -  
receptor (see section 2.1.1). During the present project, the possibility o f eliciting
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covalent binding between GNTI-derived ligands and the K-opioid receptor was also 
investigated.
With that aim, it was decided to substitute the guanidinium group of GNTI so 
as to orientate an electrophilic group in close proximity to a putative nucleophile near 
or at the active site of the K-opioid receptor. The use of a wide range of electrophiles 
has been reported in the literature for promoting covalent binding with opioid 
receptors, including nitrogen mustard, 122 Michael acceptor 123 and disulfide 
compounds. 124 However, the isothiocyanate group appeared more attractive to us 
because of its reactivity profile and fairly small size, the latter generally resulting in 
little modification in the selectivity of the parent ligand. Isothiocyanates are known to 
react preferentially with amino and sulfhydryl groups while reacting slowly with 
water and hydroxyl functions, hence limiting non-specific binding. It was therefore 
decided to substitute the guanidinium group of GNTI with a series of side chains of 
different length terminating with an isothiocyanate group (targets of type A or B).
r<i
OH







Although the synthesis of isothiocyanates via nucleophilic attack of 
thiocyanate ions on acyl halides, 125 alkyl halides 126 or aryl diazonium compounds 127 
is reported in the literature, these methods did not appear most attractive to us as S- 
alkylation is also generally observed. We instead sought to prepare the targeted 
isothiocyanates via the corresponding primary amino precursors, using one of several 
reagents reported in the literature, including carbon disulfide in combination with
19R 190 1 1rtBOP or dicyclohexylcarbodiimide, thiophosgene, or di-2-pyridyl
thionocarbonate. 131
With this in mind, it was proposed to prepare the target compounds according 
to the same approach as used in sections 2 .1  and 2 .2 , but using guanidinylating agents 
bearing a side chain terminating with a protected amino group or a moiety that could 
be easily transformed into an amino group.
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2.3.2 m  Synthesis with guanidinylating agents bearing a terminal BOC-protected
amino group
Although coupling of amine 53 with derivatives of 54 had proved relatively 
successful (from 30 to 74% yield, see sections 2.1 and 2.2), we decided to prepare 
guanidinylating agents modelled on 58 since they have been reported to give best
1 1 o
results for the guanidinylation of sterically hindered amines; for our purpose, 
guanidinylating agents would therefore be reagents o f type C. Although it is reported 
in the literature that the presence of one proton on each of the nitrogen atoms o f 58 is 
required for the guanidinylation to succeed, 116 suggesting that the reaction proceeds 
via the formation of a carbodiimide intermediate, preliminary results within our group 
with N,N’-disubstituted derivatives of 58 have shown this is not a necessary 
condition, which suggests the reaction might also evolve via a tetrahedral 
intermediate. 106 It is noteworthy that the BOC groups not only play the role of 
protecting groups but also facilitate the guanidinylating step, a consequence o f their 
electron-withdrawing properties; thus, unprotected N,N’-dialkyl substituted thioureas 
have been reported not to undergo guanidinylation while di-BOC-protected thioureas 
have been shown to react more swiftly than mono-BOC derivatives. 116 Again 
however, preliminary findings within our group tended to be in disagreement with 
that stated in the literature, as coupling of mono-BOC protected thioureas with amine 
53 had been found to proceed with great facility. 106
R
X  ^ W a 8
B ocH N ^^N H B oc NHBoc
54 58 C
P= protected amine or amino precursor 
R= H or BOC
Since it was intended to utilise BOC protecting groups on the nitrogens of the 
thiourea moiety, it seemed particularly attractive to use a BOC group for the 
protection of the terminal amino group of agents C (P = NHBoc) with the view of 
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(a) 0.75 equi. HgCb, 0.5 equi. 53, 1.0 equi. NEt3, dry DMF, 24 hrs, 60°C; (b) conc. 
HCl/MeOH (50/50), overnight, room T°; (c) 6.0 equi. NaHCC>3, 1.3 equi. CSCI2, 
MeOH/H2 0 , room T°
Scheme 10 Synthetic route planned for the preparation of 101-103
The route planned for the synthesis of guanidinylating agents of type C is 
presented in scheme 11 and started with the mono-BOC protection of diaminoalkanes. 
This was achieved by reacting the diamines with 0.1 equivalent of di-terf-butyl 
dicarbonate as reported by Muller and co-workers (80-90% yields, based on di-tert- 
butyl dicarbonate) . 132 The free amino group of 83-85 was then converted into an 
isothiocyanate functional group (compounds 8 6 -8 8 ) using two equivalents of 
thiophosgene in presence of one equivalent of calcium carbonate. Nucleophilic attack 
o f ammonia (aqueous solution) onto 8 6 - 8 8  yielded thioureas 89-91 that were 
subsequently BOC-protected using two equivalents of both sodium hydride and di- 
terf-butyl dicarbonate. This afforded a mixture o f N-mono and N,N’-di-BOC-
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protected thioureas 92-94 but no separation was undertaken as it was believed that all 
products would successfully undergo guanidinylation with 53. The coupling step was 
achieved using analogous HgCh-promoted guanidinylation described in section 2.1, 
which gave a mixture containing di-BOC-protected morphinans 95-97 and their 
mono-BOC-protected analogues. These were subsequently stirred overnight at room 
temperature in a mixture of methanol/conc. HC1 (50/50), affording deprotected 
derivatives 98-100.
a b
H2N^ jNH2 ----------------------► BocN H ^ ,N H 2  B o c W ^ ^ -N C S
83 n = 2 86 n = 2
84 n = 4 87 n = 4
85 n = 6  88 n = 6
B o c N H ^ ^ [ l^ ^ 'S  ► B o c N H ^ ^ N ^ ^
NH2 NHBoc
89 n = 2 92 n = 2
90 n = 4 93 n = 4
91 n = 6  94 n = 6
(a) 0.1 equi. (Boc^O, CHCI3, 24 hrs, room T°; (b) 1.0 equi. CaCC>3, 2.0 equi. CSCI2 
CHCI3/H2O, 24 hrs, room T°; (c) 10 equi. conc. NH4OH, Acetone, 24 hrs, room T°;
(d) 2.0 equi. NaH, 2.0 equi. (Boc)2 0 , dry THF, overnight, room T°
Scheme 11 Synthetic route used for the preparation of guanidinylating agents 92-94
The last step of the synthesis involved conversion o f 98-100 into the 
corresponding isothiocyanates. Previously, it has been shown within our group that 
the preparation of an isothiocyanate from an aniline can be achieved in presence of 
the hydrochloride salt of an imidazoline ring by using acetone/water as the solvent 
mixture (see scheme 1 2 ) .133
c i"
CSC12 (1.5 equi.) scn.
H20/Acetone n
Scheme 12 Previous preparation of an isothiocyanate from the corresponding aniline
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Thus, we attempted an equivalent procedure for the preparation of target 
compounds 101-103 from the hydrochloride salts o f 98-100; the free base of the 
terminal ammonium group was first generated in-situ in a mixture of acetone/water by
equivalents of thiophosgene. However, this procedure failed to give the desired 
products, probably as a direct consequence of the reacting conditions; a high 
proportion of water in the acetone/water solvent system was indeed required to 
dissolve amines 98-100 because of their highly protonated state. It is possible that the 
tiny amount of thiophosgene used in the reaction (a few pL) was partially destroyed in 
presence of water before reacting with the amines; this resulted in a complex mixture 
o f materials that could not be purified by column chromatography due to the highly 
polar nature of the compounds.
Although the synthetic pathway did not lead to the target compounds, it would 
be interesting to evaluate the pharmacological profile o f these amines as they might 
represent useful peripheral K-selective antagonists. GNTI (11) has indeed been 
suggested to penetrate into the brain to a lesser extent than ANTI (12) because of the 
higher pKa of the guanidinium group compared to that o f the amidinium group.39 
Thus, systemic administration of GNTI, at doses up to 10 mg/kg, was ineffective in 
providing anti-depressant effects (forced swim test) whereas administration of an 
equivalent dose of ANTI proved successful. We believe that the extra ammonium 
group present in compounds 98-100 will further impair access through the BBB, thus 
possibly restricting the bioavailability of the drugs to peripheral sites. Amines 98-100 
have therefore been sent for pharmacological evaluation.
2.3.2,b Synthesis with guanidinylating agents bearing a terminalphthalimido-
protected amino group
Since the preparation of guanidinylating agents modelled on 58 proved more 
tedious than that modelled on 54, we decided to return to using the latter. It was thus
using an excess of sodium hydrogencarbonate and was subsequently reacted with 1.3
HOHO 11 12
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planned to react the conjugate base of 54 with electrophiles that could be later 
transformed into amino derivatives. However, attempts employing acrylonitrile or 
acrolein as such electrophiles proved unsuccessful despite varying the reacting 
conditions, including time, temperature or amount of base and electrophile (entries 1- 
5 table 2). The reactivity of 54 was then evaluated with bromobutane and bromo- and 
chloroacetyl chloride but all attempts proved again unsuccessful (entries 6 to 10). It 
was finally possible to successfully react 54 by using 3 equivalents of sodium hydride, 
2  equivalents of allyl bromide or acetyl chloride and heating the reaction mixture, 
which afforded compounds 104 and 105 (entries 12 and 15). This led us to react 54 
with l,4-dibromo-2-butene and 4-chlorobutyryl chloride, leading respectively to 
analogues 106 and 107 that could be further converted into amino derivatives.
Unfortunately, attempts to react the more reactive compound, allyl bromide 
106, with potassium cyanide proved unsuccessful despite following a general
halides can be directly converted into protected amines by using potassium 1,1,3,3- 
tetramethyldisilazide (108),135 it was hoped that similar treatment of 106 with 108 
would lead to 109 (see scheme 13). In our case, 108 was replaced by the sodium salt, 
prepared from commercially available 1,1,3,3-tetramethyldisilazane with sodium 




procedure reported in the literature. 134 Since Itsuno et al. have reported that alkyl
HN(SiHM^ )2 1.1 equi. KH KN(SiHM^ ) 2 + I^




Scheme 13 Synthetic route planned for the preparation of 109
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R eagents1 Conditions used Result
Acrylonitrile (1 equi.) 
Sodium hydride (1 equi.)
reaction at room temperature for 24 hours unreacted starting materials
Acrylonitrile (1.1 equi.) 
Sodium hydride (1.2 equi.)
reaction at room temperature for 5 days unreacted starting materials
Acrylonitrile (1 equi.) 
Sodium hydride (1 equi.)
reaction at 72°C for 40 hours no trace of product
Acrylonitrile (2 equi.) 
Sodium hydride (3 equi.)
reaction at 70°C for 25 hours no trace of product
Acrolein (1.1 equi.) 
Sodium hydride (1.2 equi.)
reaction at 48°C for 24 hours no trace of product
Bromobutane (1.1 equi.) 
Sodium hydride (1.2 equi.)
reaction at 48°C for 24 hours no trace of product
Bromobutane (1.1 equi.) 
Sodium hydride (1.2 equi.)
presence of 18-crown-6 (0.1 equi.) 
reaction at 48°C for 24 hours
no trace of product
Chloroacetyl chloride (1.1 equi.) 
Sodium hydride (1.2 equi.)
reaction at room temperature for 5 days no trace of product
Chloroacetyl chloride (2 equi.) 
Sodium hydride (3 equi.)
presence of 18-crown-6 (0.1 equi.) 
attempts with heating at 58°C and 86°C
no trace of product
Bromoacetyl chloride (2 equi.) 
Sodium hydride (3 equi.)
presence of 18-crown-6 (0.1 equi.) 
attempts with heating at 58°C and 86°C
no trace of product
Allyl bromide (1.1 equi.) 
Sodium hydride (1.2 equi.)
reaction at 80°C for 41 hours no trace of product
Allyl bromide (2 equi.) 
Sodium hydride (3 equi.)
reaction at 70°C for 41 hours yield = 61 %
Acetyl chloride (1 equi.) 
Sodium hydride (1 equi.)
reaction at room temperature for 25 hours no trace of product
Acetyl chloride (1 equi.) 
Triethylamine (1.1 equi.)
reaction at 50°C for 41 hours no trace of product
Acetyl chloride (2 equi.) 
Sodium hydride (3 equi.)
presence of 18-crown-6 (0.1 equi.) 
reaction at 48°C for 24 hours
yield = 19 %
1: for one equivalent of l,3-bis-BOC-2-methyl-2-thiopseudourea
Table 2 Preliminar experiments for the preparation of guanidinylating agents
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A Gabriel synthesis, one of the most popular methods used for the preparation 
of primary amines, was then envisaged to convert the bromo group of 106; however, 
the small amount o f 106 left at this stage required preparing more starting material.
Instead, we decided to react first l,4-dibromo-2-butene with potassium 
phthalimide before subsequent reaction with 54; indeed, it seemed more economically 
sound to proceed in this order since the first attack on l,4-dibromo-2-butene with one 
equivalent of nucleophile leads to some disubstituted derivative and potassium 
phthalimide is much cheaper than 54. Nucleophilic attack of potassium phthalimide 
on l,4-dibromo-2-butene was achieved following a similar method reported by 
Langenbeck et al. but employing one equivalent of potassium phthalimide instead of 
two (scheme 14).136 The product (110) was isolated in 51% yield and further reacted 
with 54 according to the same procedure as reported in sections 2.1 and 2.2. I l l  was 
obtained in very good yield (80%) and subsequently coupled with 53 via HgCh- 
promoted guanidinylation, which afforded a mixture containing the desired product
112 and its mono-BOC-protected analogue. It was then proposed to remove the BOC 
and phthalimido protecting groups in one single step employing acidic conditions 
(conc. HCl/MeOH (50/50), room temperature, three days), but this afforded 113 still 
bearing the phthalimido protecting group; the reaction was repeated stirring the 
mixture at 80°C for 2 days, but this resulted in no further deprotection of 113. 
Although deprotection of phthalimido groups is reported using hydrolytic (in acidic or 
alkaline solutions), aminolytic and hydrazinolytic (Ing-Manske) procedures, 137,138 the 
latter is generally the preferred method because of quicker kinetics. This led us to 
attempt deprotecting phthalimide 113 under hydrazinolytic conditions, first stirring
113 overnight at room temperature with 12 equivalents of hydrazine hydrate, which 
did not lead to full deprotection of 113, then at 60°C with 28 equivalents of hydrazine 
hydrate, but this resulted in a complex mixture of materials. It seems that the primary 
amine was formed but could not be isolated from 2,3-dihydrophthalazine formed 
during the reaction. The crude product could not be purified by column 
chromatography because o f the extreme polarity of the guanidinium salt and the side 
product could not be washed out with any solvent. At this stage, there was insufficient 
quantity of morphinan 113 to allow further work. Since strong lipophilic interactions 
are possible between the phthalimido group of 113 and the lipophilic pocket of the k -  
receptor, in a similar manner as observed with the benzyl group of p-
53
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(a) 1.0 equi. potassium phthalimide, dry DMF, overnight, room T°; (b) 1.1 equi. NaH, 
0.9 equi. 54, dry DMF, overnight, 70°C; (c) 1.5 equi. HgCk, 2.0 equi. I l l ,  2.0 equi. 
NEt3, dry DMF, 24 hrs, 60°C; (d) conc. HCI/ MeOH (50/50), 3 days, room T°
Scheme 14 Synthetic route used for the preparation of 113
The problems encountered with the previous synthetic strategy led us to plan a 
different chronology for the removal of the protecting groups present on the guanidine 
moiety and on the terminal amino group, in order to allow purification of the opioid 
after cleavage of the phthalimido group. Moreover, we decided to use guanidinylating 
agents bearing a fully saturated side chain in order to afford greater flexibility of the 
ligand, thereby enhancing the possibility of forming a covalent bond with the 
receptor. Since reaction of the conjugate base of 54 with alkyl bromide proved 
unsuccessful (see table 2 ), we decided to use the synthetic pathway presented in 
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(a) 1.0 equi. N-carbethoxy-phthalimide, 1.0 equi. NEt3, THF, overnight, room T°; (b)
1.0 equi. NEt3, 1.0 equi. /?-toluenesulfonyl chloride, DCM, 3 hrs, room T°; (c) 0.9 
equi. NaH, 1.0 equi. 116, dry DMF, overnight, 80°C; (d) 0.5 equi. HgCk, 0.5 equi. 53,
1.0 equi. NEt3, dry DMF, 24 hrs, 60°C; (e) 1.2 equi. NH2NH2.XH2O, EtOH, room T°; 
(f) 6.0 equi. N aHC03, 1.3 equi CSC12, CHC13/H20 , room T°, (g) = (h) DCM/TFA, 
overnight, room T°
Scheme 15 Synthetic route planned for the preparation of 114
Phthalimido-protection of 3-aminopropanol was achieved in 8 6 % yield, 
following a procedure reported by Li and co-workers, namely by reacting the amine 
with one equivalent of both N-carbethoxy-phthalimide and triethylamine. 139 The 
product 3-phthalimidopropanol (115) was then tosylated using / 7-toluenesulfonyl 
chloride in presence of either triethylamine or pyridine, both methods giving the
55
desired tosylate 116 with similar yields (around 60%). 116 was then reacted with the 
conjugate base of 54, affording the guanidinylating agent 117 that was subsequently 
coupled with amine 53 according to the procedure previously described in sections 2.1 
and 2.2. Unfortunately, phthalimido-deprotection of di-BOC protected morphinan 
118 and its mono-BOC-analogue with 1.2 equivalents of hydrazine hydrate did not 
lead to the expected product 119 but to the recovery of amine 53 as a result of the 
high nucleophilicity of hydrazine together with the electron-withdrawing effect of the 
BOC groups. Basic hydrolysis o f 118 with NaOH (2M aqueous solution) was then 
attempted but this resulted in decomposition of the starting material with no useful 
product being isolated. 118 was instead BOC-deprotected with trifluoroacetic acid and 
the corresponding salt 1 2 0  was sent for in-vitro pharmacological evaluation; 
comparison of 113 and 120 will provide information on the importance, or not, of the 
flexibility of the side chain in lipophilic interactions with the opioid receptors.
2J,2.c Synthesis with guanidinylating agents bearing a terminal dibenzyl - 
protected amino group
In 1991, Purchase and co-workers reported the synthesis o f a pirmenol 






Scheme 16 Preparation of a pirmenol metabolite (121) reported in the literature 140
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Having been unsuccessful in preparing 121 via reaction of phthalimide 122 
with 2 -pyridyllithium, they decided to replace the phthalimido-protecting group by a 
dibenzyl-protecting group (compound 123), which ultimately led to the successful 
synthesis of the target product 1 2 1 .
Although only two primary amines had been successfully prepared via N,N- 
didebenzylation at that time, 140 suggesting that the reaction was troublesome, they 
reported that the didebenzylation proceeded with great facility when catalytic transfer 
hydrogenation was used (Pd/C 10 wt. %, ammonium formate). We thus investigated 
whether the use of a dibenzyl-protecting group would resolve the difficulties 
encountered during the preparation of the irreversible ligand 114. This led us to adopt 
a similar route as presented in scheme 15, but replacing the phthalimido-group with a 
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(a) 1.0 equi. benzyl bromide, DCM, overnight, room T°; (b) 1.0 equi. NEt3, 1.0 equi. 
/?-toluenesulfonyl chloride, DCM, 3 hrs, room T°; (c) 1.0 equi. NaH, 0.1 equi. 15- 
crown-5, 1.1 equi. 125, dry DMF, overnight, 80°C; (d) 0.7 equi. HgCh, 0.5 equi. 53,
1.0 equi. NEt3, dry DMF, 24 hrs, 60°C; (e) Pd/C (10 wt. %), 20 equi. NH4HCO2, 
EtOH, 6  hrs, reflux or Pd/C (10 wt. %), cyclohexene/EtOH, reflux, overnight
Scheme 17 Synthetic route planned for the preparation of 119 
(route involving a dibenzyl protecting group)
57
The N,N-dibenzyl protecting group was introduced by stirring overnight 3- 
aminopropanol with one equivalent of benzyl bromide in DCM. N,N- 
dibenzylaminopropanol (124) was obtained in 42% yield and subsequently converted 
into its tosylate derivative 125, using one equivalent of both p-toluenesulfonyl 
chloride and triethylamine in a similar manner as used for the preparation of 116. 
Nucleophilic attack of the conjugate base of l,3-bis-BOC-2-methyl-2-thiopseudourea 
(54) on 125 afforded the guanidinylating agent 126, which was in turn coupled with 
amine 53, yielding a mixture of mono- and di-BOC-protected morphinans 127. 
Unfortunately, attempted debenzylation of the latter by transfer hydrogenation, using 
Pd/C and ammonium formate, resulted mainly in recovery of the starting material; 
monitoring o f the reaction by thin-layer chromatography (TLC) showed the 
appearance of a weak spot that was believed to correspond to the mono-benzylated 
derivative but there was no evidence of formation of the desired primary amine 119.
When preparing 6N-cinnamoyl-p-naltrexamine (128), Derrick et al. reported 
that while catalytic hydrogenation of the 6 N,6 N-dibenzyl intermediate 129 led to the 
didebenzylated intermediate 130 in poor yield, transfer hydrogenation using a 
suspension of Pd/C in ethanol/cyclohexene afforded the desired product 130 with 
remarkable ease (83% yield) . 141









Thus we attempted a similar procedure for the deprotection of 127, but this 
led to the same concluding remarks as when using Pd/C and ammonium formate. 
Since the cleavage o f the dibenzyl protecting group proved uncannily troublesome, it 
was instead decided to remove the BOC protecting groups of 127 with an excess of 
trifluoroacetic acid. The corresponding product 131 was sent for binding studies in 
order to investigate whether the presence of benzylic groups would lead to pseudo- 
irreversible binding with the receptor through strong lipophilic interactions.
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2. 3.2. d  Synthesis with guanidinylating agents hearing a nitro precursor to the
terminal amino group
A last alternative was explored for the preparation of the targeted 
isothiocyanates and involved the preparation of guanidinylating agents bearing a side 
chain terminating with an aliphatic nitro group. It was planned to reduce the nitro 
group after guanidinylation with 53; the amine would then be converted into the 






































(a) 1.0 equi. NaH, 0.1 equi. 15-crown-5, 3.3 equi. 1,5-diiodopentane, dry DMF, 
overnight, room T°; (b) 1.7 equi. NaNCh, DMF/H2O (5/1), 2 hrs, room T°, (c) 1.4 
equi. HgCh, 2.0 equi. 133, 2.0 equi. NEt3, dry DMF, 24 hrs, 60°C; (d) 9.0 equi. 
FeS04.7H20 , MeOH/HiO/NI^OH, 3 hrs, 80°C; (e) 6.0 equi. NaHC03, 1.1 equi 
CSCI2, CHCI3/H2 0 ,2hrs, room T°, (f) DCM/TFA, overnight, room T°
Scheme 18 Synthetic route used for the preparation of 137
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54 was deprotonated with one equivalent of sodium hydride and subsequently 
reacted with three equivalents of 1,5-diiodopentane, yielding the desired product 132.
The conversion of halides into nitro derivatives has been reported in the 
literature through the use o f diverse reagents including sodium nitrite, 142 silver nitrite 
143 or Na0 Me/CH3N0 2 , 144 this latter method of course extending the chain by one 
methylene. Given there was no particular length of side chain, we opted for the former 
method since the latter was reported to be low yielding; moreover, we believed that 
decomposition of the starting material via elimination was likely to occur when using 
Na0 Me/CH3N0 2 . Nucleophilic displacement of iodide by sodium nitrite gave the 
guanidinylating agent 133; although modest (40%), the yield obtained when stirring 
both starting materials in DMF/H2O (5/1) was substantially better than when stirring 
both starting materials in pure DMF, probably as a result of higher solubility of 
sodium nitrite.
133 was subsequently coupled with amine 53 in presence o f triethylamine and 
mercury(II) chloride in a similar way as used in sections 2.1 and 2.2, which gave a 
mixture of mono- and di-BOC-protected morphinans 134.
The reduction of aliphatic nitro compounds into primary amines has been far 
less investigated than the reduction o f aromatic derivatives and traditionally involved 
the use of high pressure catalytic hydrogenation. 145 However, Ram et al. reported in 
1984 that aliphatic nitro derivatives could be easily reduced into the corresponding 
amines by catalytic transfer hydrogenation (with ammonium formate as the hydrogen 
transfer agent) when other methods such as cyclohexene/Pd-C, hydrazine/Raney Ni, 
Zn/AcOH or FeSCVNFLiOH had proved unsuccessful. 145 Other reducing agents have 
since been successfully used for the reduction of aliphatic nitro groups, including 
O A I H 4 ,  NaBH4/BH3 or more recently NaBKU/ZrCLj.146 However, we decided to 
reduce 134 using either 9 equivalents of iron(II) sulfate heptahydrate or transfer 
hydrogenation (palladium 1 0  wt. % on activated carbon, ammonium formate) since 
these procedures appeared more convenient to us (easier procedure, quicker reaction 
time, less tedious workup). In both cases, the product 135 was isolated in modest 
yield (43% and 29% respectively).
Conversion into the corresponding isothiocyanate 136 was accomplished 
following the procedure reported by Korlipara and associates, 129 who used an excess 
of sodium hydrogencarbonate and freshly distilled thiophosgene in a biphasic 
CHCI3/H2O solvent system. However, in the current work, only 1.1 equivalents of
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thiophosgene were added instead of the two equivalents reported, so as to avoid 
possible reaction with the oxygen atoms of 135. After two hours, monitoring of the 
reaction by TLC showed complete conversion of the starting material and purification 
by column chromatography afforded the desired product 136 in 71% yield. Finally, 
BOC deprotection using TFA afforded the target compound 137.
The same synthetic strategy was utilised to target analogues of 137 bearing 
shorter side chains. However, nucleophilic attack of the conjugate base of 54 on 1,2- 
diiodoethane or 1,2-dibromoethane proved unsuccessful while reaction with 1,3- 
diiodopropane afforded 1,3-bis-fc/7-butoxycarbonyl-1 -allyl-2-methyl-2-thiopseudo- 
urea (138). 1,3-Diiodopropane was then replaced with 1,3-dibromopropane, which led 
to 1,3-bis-te/7-butoxycarbonyl-1 -(3 ’-bromopropyl)-2-methyl-2-thiopseudourea (139). 
However, subsequent attempts to displace the bromo group by sodium nitrite in DMF 
or in a mixture of DMF/H2O (5/1) did not give the desired product. A similar two-step 
sequence using 1,4-dibromobutane gave somewhat better results with 1,3-bis-ter/- 
butoxycarbonyl-l-(4’-bromobutyl)-2-methyl-2-thiopseudourea (140) isolated in 48 % 
yield and converted into 1,3 -bis-fer/-butoxycarbonyl-1 -(4 ’ -nitrobutyl)-2-methyl-2- 





























(a) 1.0 equi. NaH, 0.1 equi. 15-crown-5, 3.3 equi. 1,4-dibromobutane, dry DMF, 
overnight, room T°; (b) 2.0 equi. NaNC>2, DMF/H2O (5/1), 16 hrs, room T°; (c) 1.5 
equi. HgCl2, 2.0 equi. 141, 2.0 equi. NEt3, dry DMF, 48 hrs, 60°C; (d) 0.6 equi. Pd/C 
(10 wt. %), 20 equi. NH4HCO2, dry MeOH, 2  hrs, reflux
Scheme 19 Synthetic route employed for the preparation of 143
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Coupling of 141 with 53 in presence of triethylamine and mercury(II) chloride 
afforded a mixture containing di-BOC-protected morphinan 142 and its mono-BOC- 
protected analogue that were subsequently reduced to 143 (mixture of mono- and di- 
BOC-protected morphinans) by transfer hydrogenation (palladium on activated 
carbon, ammonium formate). There was however insufficient material left at this 
stage to undertake the conversion into the corresponding isothiocyanate. However, the 
successful synthesis of 143 will allow the synthesis to be repeated on a larger scale.
Since the synthesis of the two-carbon analogue 144 had not been possible by 
the route used for 133 or 141, an alternative approach was envisaged from 
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Scheme 20 Synthetic route planned for the preparation of 144
Unfortunately, tosylation of nitroethanol, using one equivalent o f  p- 
toluenesulfonyl chloride in pyridine, proved unsuccessful; it is possible that the 
product 145 was formed but immediately decomposed in presence of pyridine 
(scheme 21, reaction a). Similar decomposition was also proposed by Riebsomer who 
failed to isolate any ester when reacting 2 -nitro-l-butanol with benzenesulfonyl 
chloride in pyridine. 147 He believed that the ester 146 was initially formed but 
immediately decomposed into benzenesulfonic acid and 2 -nitro-l-butene as a 
consequence of the acidity of the proton attached to the carbon bearing the nitro group 
(scheme 21, reaction b). This was a plausible explanation since the acidity o f such 
protons had been demonstrated in an experiment reported by Schmidt and Rutz, who 
found out that heating nitro esters of type 147 in presence of sodium bicarbonate led 
to the nitro olefin derivatives 148 (scheme 21, reaction c) . 147 Of additional support is
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the fact that tosylation of 2 -nitro-2 -methylpropanol (ie a nitro-alcohol lacking a proton 
attached to the carbon bearing the nitro group) using similar conditions as used in the 
present project has been reported to lead smoothly to the tosylated derivative 149 (see 
scheme 2 1 , reaction d) . 148
OCOCH. NaHCO. CH.COOH
Scheme 21 Decomposition o f arylsulfonyl esters of nitro alcohols in 
presence of pyridine: a consequence of acidity?
In summary, one ligand (137), modelled on GNTI (11) and modified by the 
introduction of a side chain terminating with an isothiocyanate group, has been 
successfully prepared, while the successful synthesis of 143 should allow the 
preparation of the corresponding isothiocyanate.
2.4 Benzylnorbinaltorphimine
2.4.1 Rationale and design
Since norBNI (13) is a highly K-selective opioid antagonist with long lasting 
but surmountable effects, the present work explores the synthesis o f a new irreversible 
ligand for the K-opioid receptor modelled upon the structure o f norBNI. It is 
recognised that the already long duration of action of norBNI will make assessment of 
relative irreversibility of analogues somewhat difficult.
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2.4.1. a Modification o f norBNI: at which position?
As already mentioned, norBNI (13) is a bivalent ligand, whose binding with 
the K-receptor is based upon the “message-address” concept: the first pharmacophore 
(message component) binds to the region o f the K-receptor responsible for activity 
whereas the scaffold (pyrrolic spacer) of 13 rigidly holds the second basic nitrogen 
(address) towards the acidic residue Glu297 present within the K-receptor. Docking 
studies of GNTI (11) (whose binding mimics that of 13) into the K-receptor have also 
suggested an ion pair interaction between N-17 and the carboxylate group of Asp 138 
(TM3), which was confirmed by site directed mutagenesis. 88 In addition, it was also 
demonstrated that the cyclopropyl methyl and phenolic moieties of the first
go
pharmacophore of 13 are prominent in conferring affinity and activity. This was 
later confirmed by docking studies of GNTI (11), which suggested that the phenolic 
group might indeed interact with the imidazoline ring o f His291.102 Therefore, it was 
not appropriate to modify these groups and since the synthesis of unsymmetrical 
derivatives of norBNI has been reported to be low yielding, 102 it was decided not to 
modify those groups on the second pharmacophore.
With this in mind, there remain only two viable positions for the modification 
of 13, namely the 14,14’-hydroxy groups and the pyrrolic nitrogen (see figure 8 ). It 
was believed that the pyrrolic group was the more readily accessible and the present 
project sought to investigate the possibility of conferring irreversible binding to 
norBNI via substitution of its pyrrolic nitrogen.
lipophilic pocket
His291
for N -1T  orientation unidentified yet





2.4. L b Modification o f norBNI: which substituent?
In 1994, Korlipara et al. explored the modification of the 5-selective 
antagonist naltrindole (NTI) (150) by benzyl substitution at the indolic nitrogen; this 
resulted in benzylnaltrindole (BNTI) (151) as a 5 2 -antagonist with longer duration of 
action (see scheme 22) . 100 Although the effects of 151 were still surmountable, true 
irreversible binding via formation of a covalent bond with the receptor was eventually 













5 selective antagonist with 
long duration of action
Scheme 22 Strategy employed for the design o f BNTI (151) and analogues
Since norBNI (13) is already a long-lived K-antagonist, it was of interest to 
investigate whether benzylation of norBNI was sufficient to produce a K-selective 
irreversible or pseudo-irreversible antagonist. In addition, and in an analogous 
approach to that used by Korlipara, 129 subsequent incorporation of an isothiocyanate 









k  competitive antagonist with 
long duration of action
R=H 152 (BnorBNI) 
irreversible k antagonist ?
Scheme 23 Strategy employed for the design of BnorBNI (152)
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2.4.2 Synthesis
A synthesis of 152, based on the method reported for the preparation o f BNI 
(28) 79 and modified by the use of N-benzylhydrazine sulfate, had already been 









HO N -N OH
152 1 %
153 20%
Scheme 24 A previous synthetic approach for the preparation of BnorBNI (152) 149
Although straightforward, this route was not satisfactory because of the long 
reaction time (9 days) and low yield reported (1%). It is noteworthy that azine 153 
was isolated as a side product; although 153 could result from debenzylation o f the 
expected intermediate 154, it cannot be ruled out that an alternative complex 






Schmidhammer and Schwarz have also reported unexpected reactions when 
stirring azines 155 and 156 with methanesulfonic acid in dry DMSO . 150 They found 
out that the main product isolated after reaction was inexplicably not the expected 














(a) CH3SO3H/DMSO, Room T°, 3 hrs
Scheme 25 Unexpected reactions of azines in presence of methanesulfonic acid 150
In any case, if  BnorBNI had to be prepared on a larger scale, another synthetic 
approach was required. The method employed in the present project explored direct 
benzylation of norBNI (13). It was believed that in presence o f a large excess of 
strong base, benzylation of the penta-anion of 13 with one equivalent of benzyl 
bromide should occur at the pyrrolic nitrogen because of its higher reactivity 
compared to the phenoxide groups and because of less steric hindrance compared with 
the alkoxide groups at the 14 and 14’ positions.
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13 was synthesised from naltrexone (44) according to the Piloty procedure 
used by Ivy Carroll, except that hydrazine hydrochloride was replaced with hydrazine 
sulfate. 151 Deprotonation o f 13 with 10 equivalents of sodium hydride and subsequent 
benzylation with one equivalent of benzyl bromide led to the quantitative addition of 
one benzyl group onto the starting material as expected; however, NMR analysis 
showed that the reaction had not occurred at the targeted pyrrolic site but most 
probably at one o f the hydroxyl groups.
This led us to envisage the formation o f BnorBNI (152) in several steps, 
namely benzylation o f 13 with three equivalents o f benzyl bromide followed by 
debenzylation of the phenolic benzyl ethers under acidic conditions, as it was believed 
that, once formed, the benzylated pyrrolic group should remain stable under such 














(a) 0.53 equi. NH2NH2.H2SO4, dry DMF, 6  hrs, 100°C then 0.51 equi. CH3SO3H, 
DMSO, 3.5 hrs, 130°C; (b) 10.0 equi. NaH, 0.25 equi. 18-crown-6, 3.0 equi. BnBr, 
DMF, 43 hrs, room T°; (c) HCl/MeOH (50/50), 40 hrs, 90°C
Scheme 26 Total synthesis o f BnorBNI (152)
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Deprotonation of 13 with ten equivalents of sodium hydride and subsequent 
benzylation with three equivalents of benzyl bromide afforded a mixture o f tri- and 
pentabenzyl-substituted norBNI. The fact that no starting material was left at the end 
of the reaction and that some penta-substituted product was obtained when using only 
three equivalents of benzyl bromide suggested that some decomposition had occurred 
during the reaction or during the purification. The mixture of tri- and pentabenzyl- 
substituted norBNI was immediately treated with a mixture of methanol/conc. HCI 
(50/50) at 90°C; this gave after purification benzylnorbinaltorphimine (152) in a 40% 
overall yield from naltrexone, a hugely improved yield compared to the first method 
employed within our group for the preparation o f 152 (1% yield).
2.5 Irreversible ligands modelled on benzylnorbinaltorphimine (152)
2.5.1 Rationale
We decided to investigate whether introduction of an isothiocyanate group 
onto the benzyl ring of BnorBNI would result in covalent binding with the receptor 
and whether such modification would have an influence on the selectivity and/or 
affinity of the parent compound. It was thus proposed to synthesize the o, m, and p  
isothiocyanate regioisomers 160, 161, 162, 163, 164, and 165 derived from the 
equivalent anilines 166,167 and 168 and benzylamines 169,170 and 171.
2.5.2 Synthesis o f compounds 160-162
Since the synthetic strategy employed for the preparation of BnorBNI (152) 
gave satisfactory results, we decided to employ a similar route for the synthesis of 
160-162, but replacing benzyl bromide with suitable alternatives; the use o f nitro 
groups as precursors to isothiocyanates proving successful for the preparation of 
irreversible benzylGNTI analogues (section 2.3.2.d), it was planned to benzylate
R = p NCS 160 R = p NHj 166
R = m  NCS 161 R = m NHj 167
R = o NCS 162 R = o NH, 168
R = p ChyviCS 163 R = pCH2NH2 169
R = /n CHgNCS 164 R = mCH2NH2 170
R ^ C H jN C S  165 R = o CH2NH2 171
R
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norBNI (13) with o-, m- and p-nitrobenzyl halides. The synthetic approach is 
presented in scheme 27.
HOHOOH OH
HO OH
R = p-N02, 174 




R = p-N02 R = m-N02 R = o-N02
C C^R  = p-NH2,166
d r
\  R = p-NCS.160
2 * '  ~  ""^2  
R = 167 R = o-NH*, 16 8
R = ro-NCS,161 R = o-NCS.162
(a) 10 equi. NaH, 3 equi. NO2C6H4CH2X, DMF, overnight, 70°C; (b) HCl/MeOH 
(50/50), overnight, 80°C; (c) 9 equi. FeS04.7H20 , Me0 H/H20 /NH4 0 H, 3 hrs, 80°C; 
(d) 6 equi. NaHCC>3, 1.2 equi. CSCI2, CHCI3/H2O, room T°
Scheme 27 Synthetic route planned for the preparation of 160,161 and 162
Deprotonation of norBNI (13) with ten equivalents o f sodium hydride, 
followed by nucleophilic attack on readily-available p-nitrobenzyl chloride (three 
equivalents, room temperature) led to a mixture of mono- and di-benzylated products 
172 and 173 in 10% and 30% yield respectively; no expected product 174 was 
isolated, probably as a consequence o f the low nucleophilicity o f the pyrrolic nitrogen 
together with the low reactivity o f p-nitrobenzyl chloride.
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p-Nitrobenzyl bromide was then utilised due to the better leaving group 
properties of bromide, though it was acknowledged that the deactivating nitro group 
might still prevent reaction; this was indeed confirmed since benzylation of 13 using 
p-nitrobenzyl bromide, stirring the reaction mixture at 60°C, led to the same result as 
before with only phenolic ether products isolated. Reaction of the conjugate base of 
13 with p-nitrobenzoyl chloride also failed to give the desired product despite several
155similar benzoylations o f pyrrolic nitrogens reported in the literature. Though direct 
benzylation of 13 did not give the desired product, it was felt desirable to use 173 to 
confirm whether the necessary 3,3’-0-debenzylations could be achieved before trying 
to improve the benzylation step. Thus, 173 was stirred overnight at 80°C in a mixture 
of methanol/conc. HCI (50/50) but this led only to unreacted starting materials.
Since nitro groups are less deactivating in m-position, benzylation of the 
penta-anion of 13 with three equivalents of wi-nitrobenzyl bromide was carried out, 
initially stirring at room temperature then warming to 52°C overnight. This gave two 
fractions, the main one being identified as the di-substituted product 175 and the other 
as the desired tri-substituted product 176 (28% yield). Unfortunately, stirring 176 
overnight in a mixture o f methanol/conc. HCI (50/50) at 94°C resulted in recovery of 
the tri-benzylated starting material.
As the difficulties in both introducing the benzyl group at the pyrrolic nitrogen 
and its subsequent removal from the phenolic hydroxyls appeared to be due to the 
electron-withdrawing effect o f the nitro group, it was decided to convert the nitro 
group of the benzyl bromides into a protected amino group before subsequent 
benzylation of 13. In order to avoid polymerisation o f the aminobenzyl bromides,
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both reduction and protection would have to be achieved under acidic conditions, 
which led us to envisage the synthetic route presented in scheme 28.
Fe, CH3COOH
CHoCOOH
Scheme 28 Synthetic route planned for the preparation of benzyl bromide derivatives
Broggini et al. have reported that quantitative reduction of nitrobenzyl 
derivatives into the corresponding amines can be achieved when refluxing the former 
for 3 hours with iron powder in ethanol/acetic acid (20% aqueous solution).153 
Reduction o f p-nitrobenzyl bromide was thus attempted following an equivalent 
procedure, first stirring the reaction mixture at room temperature then under reflux, 
but unfortunately this proved unsuccessful.
The reactivity of the pentaanion of 13 was then evaluated with a-bromo-p- 
tolunitrile. The groups added at 3- and 3’-positions would then be removed before 
hydrogenating the nitrile moiety. However, stirring 13 with 10 equivalents of sodium 
hydride before adding three equivalents of a-bromo-p-tolunitrile did not afford any 
useful product.
Although it is acknowledged that the pentaanion of norBNI could be 
successfully reacted with benzyl bromide, it appeared that the poor solubility of the 
pentaanion, in combination with other parameters such as low reactivity o f the 
electrophiles, could be prejudicial to the success of the reaction. As we had already 
shown during the synthesis of 152 that 13 could be readily benzylated (section 2.4) 
and that the phenolic benzyl ethers were readily cleaved under acidic conditions, it 
was decided to first protect the phenolic hydroxyls of 13 with benzyl groups. This was 
achieved in quantitative yield by stirring 13 overnight in DMF with 1.5 equivalents of 
potassium carbonate and 2.5 equivalents o f benzyl bromide. The product (177) was 
then deprotonated with 10 equivalents of sodium hydride and reacted with 5 
equivalents o f p-nitrobenzyl bromide, but this resulted in recovery of 177.
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This led us to envisage the protection of all four hydroxy groups o f 13; we 
opted for an acetate protecting group since this group had been successfully used by 
Nelson and colleagues for the protection of 3- and 14-hydroxy groups of naltrexone- 
derived ligands, with its deprotection being achieved with remarkable ease (this will 
be discussed later).154,155 A procedure for the preparation of the tetraacetyl 178 was 
reported by Portoghese and involved stirring 13 in acetic anhydride and pyridine for 2 
days at 24°C.102 The esterification was initially postulated to occur via formation of 
acylonium groups in 17- and 17’-positions of 13 followed by intramolecular transfer 
to the neighbouring hydroxyls (14- and 14’-positions), hence explaining the 
remarkable ease of the tetraacylation.102 It seems however more likely that the basic 
nitrogens in 17- and 17’-positions act as hydrogen acceptors from the 14- and 14’- 
hydroxyls, thereby resulting in higher nucleophilicity of the oxygen atoms.156
OAc AcOHOPH
177
However, we instead decided to prepare 178 by refluxing 13 in acetic 
anhydride since we believed that the reaction would reach completion in a much 
shorter time; 178 was indeed obtained in quantitative yield after stirring the reaction 
mixture for only two hours. The tetraacetyl compound was subsequently deprotonated 
with sodium hydride and reacted with an excess of p-nitrobenzoyl chloride, p- 
nitrobenzyl bromide, m-nitrobenzyl bromide and a-bromo-p-tolunitrile. The results 
are presented in figure 9: no desired product was isolated in any case while reactions 
with a-bromo-/?-tolunitrile and w-nitrobenzyl bromide afforded the di-substituted 
products 179 and 180 respectively. These products seem to arise from cleavage of the 
acetate esters in 3- and 3’-positions before nucleophilic attack o f the phenoxide 
groups onto the benzyl bromide derivatives; it is noteworthy that the acyl group has
73
moved to the pyrrolic nitrogen in the former case. 180 was further reacted with m- 
nitrobenzyl bromide, which gave the desired tri-substituted product 181. However, the 
overall yield ( 1 1 %) prompted us to find another synthetic route.
no product
no product
no2 /  R=H 180
6 V R=CH,(C6H4)NQ, 181
(a) 4.0 equi. NaH, then 1.2 equi. / 7-NO2C6H4COCI, dry THF, overnight, 60°C; (b) 4.4 
equi. NaH, then 2.0 equi. m-NC^CelLiC^Br, dry THF, overnight, 60°C; (c) 10.0 
equi. NaH, 0.1 equi. 18-crown-6, then 2.0 equi./?-NC(C6H4)CH2Br, dry THF, 2 days, 
room T° then 6 hrs, 70°C; (d) 10.0 equi. NaH, 0.1 equi. 18-crown-6, then 3.0 equi. p- 
N0 2 CeH4CH2Br, dry THF, overnight, 60°C; (e) 10.0 equi. NaH, then 3.0 equi. m- 
N0 2C6H4CH2Br, dry THF, overnight, 60°C
Figure 9 Attempted pyrrolic N-substitutions of 178
Again, it was believed that replacing the deactivating nitro and cyano groups 
of the benzyl bromides with protected amino groups should result in greater facility of 
pyrrolic N-benzylation. We opted for a phthalimido-protecting group as it would 
remove both protons from the nitrogen of the aminobenzyl bromides and therefore 
alleviate problems likely to be encountered when using sodium hydride for the
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subsequent deprotonation and benzylation of 178. We planned to prepare p-, m- and 
o-phthalimidobenzyl bromides 182,183 and 184 from the corresponding aminobenzyl 
alcohols 185, 186 and 187 by protecting first the hydroxy groups, since preliminary 
attempts to react 187 with phthalimide or phthalic anhydride had failed to give the 
desired product. The choice of ter/-butyldimethylsilyl (TBDMS) and 
tetrahydropyranyl (THP) protecting groups appeared most attractive for this purpose, 
as THP- and TBDMS-ethers can be directly converted into the corresponding 
bromides. Although 185 is commercially available, it is either expensive or of 
unsatisfactory quality depending on the source; this prompted us to start the synthesis, 
in this particular case, with the nitro-analogue (see scheme 29).
(a) 1.0 equi. 3,4-dihydro-2//-pyran, 0.01 equi. p-toluenesulfonic acid monohydrate, 
CHCI3, overnight, room T°; (b) 0.03 equi. Pd/C (10 wt. %), EtOH, H2, overnight, 
room T°; (c) 1.0 equi. phthalic anhydride, xylenes (mixed), reflux, overnight; (d) 2.0 
equi. PPI13, 2.0 equi. imidazole, 2.0 equi. Br2, dry DCM, 3 hrs, room T°
Tosic acid-catalysed addition of 4-nitrobenzyl alcohol on one equivalent of
3,4-dihydro-2i/-pyran gave the THP-protected derivative 188 that was subsequently
c
190
Scheme 29 Preparation o f /7-phthalimidobenzyl bromide (182)
75
reduced to the corresponding aniline 189 via standard catalytic hydrogenation (room 
temperature, Pd/C, ethanol, hydrogen). Subsequent attempts to react 189 with one 
equivalent of phthalimide in boiling xylenes (mixed) failed to yield the desired 
product; however, reaction with phthalic anhydride, using a modified procedure based
1 ^ 7on reaction of aniline with phthalic anhydride in p-cymene, proved somewhat 
successful, with 190 isolated in 16% yield.
Direct conversion of THP ethers into the corresponding bromides is most 
commonly achieved using PPh3/CBr4. In some specific cases, such as bromination of 
THP ethers of secondary alcohols, the use of these reagents has however proved 
unsuccessful and other reagents such as triphenylphosphine and 2,4,4,6-tetrabromo-
2,5-cyclohexadienone were required. 158 For 190, the standard conditions were 
sufficient, with the desired product 182 readily obtained in 3 hours when using 
bromine, triphenylphosphine and imidazole (60% yield).
Surprisingly, o-phthalimidobenzyl bromide could not be prepared by an 
analogous route as THP-protection o f 2-aminobenzyl alcohol with 3,4-dihydro-2//- 
pyran failed to give the desired product. An alternative protecting group was thus 
required and the TBDMS protecting group appeared to be suitable; the new synthetic 
route is presented in scheme 30.
P m 0
A = 185 186 187
B = 191 192 193
C = 194 195 196
D = 182 183 184
(a) 1.5 equi. tert-butyldimethylsilyl chloride, 2.0 equi. imidazole, dry THF, overnight 
room T°; (b) 1.0 equi. phthalic anhydride, mixed xylenes, overnight, reflux; (c) 1.2 
equi. triphenylphosphine, 1.2 equi. Br2, dry DCM, 3 hrs, room T°
Scheme 30 Preparation of phthalimidobenzyl bromides 182,183 and 184 




Since the previous route did not provide sufficient p-phthalimido benzyl 
bromide (182), we decided to repeat the preparation of this compound according to 
this new strategy. This involved first preparing 4-aminobenzyl alcohol; this was 
achieved by reducing the nitro analogue via standard hydrogenation procedure (Pd/C, 
ethanol, hydrogen, room temperature), which afforded the desired product 185 in 67% 
yield, along with a side-product identified as p-toluidine (17% yield).
The aminobenzyl alcohols 185, 186 and 187 were quantitatively protected into 
TBDMS ethers 191, 192 and 193 by stirring overnight at room temperature with 1.5 
equivalents o f /ert-butyldimethylsilyl chloride and 2.0 equivalents of imidazole. The 
anilines were subsequently refluxed in mixed xylenes with one equivalent of phthalic 
anhydride, which afforded 194, 195 and 196 in 96, 71 and 45% yields respectively. 
Conversion of these into the corresponding bromides 182, 183 and 184 was achieved 
following a general procedure reported by Aizpurua et al. , 159 with a slight 
modification of the amount of PPh3.Br2 complex used ( 1 .2  equivalents vs 1.1 
equivalents).
Deprotonation o f 178 with three equivalents o f sodium hydride and 
benzylation with 182, 183 and 184 in presence of a catalytic amount of 18-crown-6 
gave the desired tetraacetyl N-substituted norBNI-derivatives 197 and 198 (scheme 
31). However, it seems that steric hindrance observed with o-phthalimidobenzyl 
bromide precluded nucleophilic attack of 178 in this case.
(a) 4.0 equi. NaH, 0.1 equi. 18-crown-6,3.0 equi. 182 or 183, THF, overnight, 70°C 
Scheme 31 Benzylation of 178 with phthalimidobenzyl bromide derivatives
A<
p  -position 197 
m  -position 198 <y
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Since the cleavage of acetate protecting groups in the 14-position had been 
reported in the literature by simply stirring acetyls 199 and 200 in methanol (see 
scheme 32),154,155 we attempted to deprotect 197 and 198 using the same procedure, 
but this resulted only in the recovery of starting materials.
A solution o f the tetraacetyl compounds 197 and 198 in ethanol was then 
treated with sodium hydroxide (2M aqueous solution) but mass spectrometry 
suggested this had only resulted in formation of N-substituted phthalamic acids 201 
and 2 0 2  via saponification of the phenolic esters and hydrolysis of the phthalimido- 











Scheme 32 Methods reported in the literature for deprotection of 14-OAcetates 154,155




p  -position 2 0 1  o 
m -position 2 0 2
HO
Scheme 33 Reaction of tetraacetyls 197 and 198 with NaOH (2M)
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Though unexpected, ring-opening o f phthalimido-protecting groups into stable 
N-substituted phthalamic acids has been reported in the literature, with subsequent 
cleavage into the corresponding amines being accomplished using a mild enzymatic 
approach. 160 Unfortunately, we were unable to purchase the enzyme used in this 
experiment (o-phthalyl amidase). All four esters were eventually cleaved stirring the 
acetyls overnight in a mixture of methanol/conc. HC1 (50/50) at 85°C. This method 
proved to be somewhat successful for the deprotection of the w-derivative 198, with 
203 being isolated in 6 8 % yield (see scheme 34).
OAc AcO
OAcAcO
m -position 198 
p  -position 197
HOOH
HO OH
m -position 203 









(a) conc. HCl/MeOH (50/50), overnight, 85°C; (b) 3 equi. NH2NH2.XH2O, 30 hrs, 
room T°; (c) 6.0 equi. NaHC03, 1.1 equi CSC12, CHCI3/H2O, 2hrs, room T°
Scheme 34 Deprotection of 197 and 198 and subsequent preparation o f 161
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However, the result was much less satisfactory with the /^-derivative since it 
afforded the desired product 204 in only 5% yield. The main product was identified as 
norBNI, which suggests that the bond between the pyrrolic nitrogen and the benzylic 
carbon is particularly weak when substituted with a / 7-phthalimidobenzyl group. This 
was corroborated with attempted phthalimido-deprotection o f 204, using 1.2 
equivalents of hydrazine hydrate, leading exclusively to unsubstituted norBNI (13). 
This led us to investigate whether the p-phthalimidobenzyl group could represent a 
general protecting group for indolic and pyrrolic nitrogens and this will be discussed 
in another chapter (see section 2.7).
Deprotection of phthalimide 203 with 3 equivalents of hydrazine hydrate 
afforded the corresponding aniline 205, that was subsequently converted into the 
corresponding isothiocyanate 161; this was achieved using 6  equivalents of sodium 
hydrogencarbonate and 1 .1  equivalents of freshly distilled thiophosgene according to 
a similar procedure as employed in section 2.3.2.d for the preparation of 136.
2.5.3 Synthesis o f compounds 163,164, and 165 
2.5.3.a Preliminary work
It was decided to prepare the irreversible ligands 163, 164, and 165 using an 
analogous approach to that employed in section 2.5.2, namely via benzylation of 
protected norBNI with benzyl bromide derivatives 206, 207 and 208 (see scheme 35). 
These were obtained through nucleophilic attack of potassium phthalimide on 
commercially available dibromoxylenes in presence of 18-crown-6 in refluxing 
toluene (or in DMF) following a similar procedure reported by Fisher and 
colleagues. 161
Given the earlier difficulties encountered with the use o f acetate protecting 
groups for hydroxyls in 14- and 14’-positions, alternative protecting groups were 
sought that could be both introduced and removed in a facile manner. We instead 
elected to protect all four hydroxy groups of norBNI (13) as silyl ethers. Though 
known to be extremely labile, we initially opted for trimethylsilyl (TMS) ethers rather 
than TBDMS ethers because of steric hindrance around the hydroxyls in 14- and 14’- 
positions. 13 was thus reacted with an excess of both trimethylsilyl chloride and 
imidazole, which led in quantitative yield to the tetrasilyl ether 209. Deprotonation of 
the latter with sodium hydride and subsequent reaction with 206 led to disubstitution
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of 209, most probably as a result of cleavage of TMS ethers at 3- and 3’-positions 






P = TMS 209
P = TBDMS 210
+
B
P m . 0
A = 163 164 165
B = 206 207 208
(a) 1 .0  equi. potassium phthalimide, 0 .1  equi. 18-crown-6, toluene, overnight, reflux 
Scheme 35 Synthetic approach planned for the synthesis of 163,164, and 165
This led us to protect the hydroxyls of 13 as TBDMS ethers, since these are 
known to be more stable towards base than TMS ethers. 162 This was achieved in 
quantitative yield by reacting 13 at room temperature with terf-butyldimethylsilyl 
chloride (1.05 equivalents per hydroxy group) and imidazole (1.1 equivalents per 
hydroxy group). Since ]H NMR spectrometry of the crude material showed the 
product 2 1 0  to be formed cleanly, 2 1 0  was not purified but immediately deprotonated 
with sodium hydride and reacted with 206 according to the general procedure 
previously described for pyrrolic N-benzylation. After work-up and subsequent 
deprotection of the silyl ethers with TBAF, the crude product was shown to be very 
unclean by TLC. Repeated purification by column chromatography failed to afford 
definite evidence o f the desired product; although the main peak ( 1 0  times stronger 
than secondary peaks) on the mass spectrum corresponded to the correct molecular
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weight, !H-NMR showed that the fraction was a complex mixture of different 
materials.
Since it had not been possible to prepare the irreversible ligands 163, 164, and 
165 via an easy route utilising simultaneous protection of the phenolic and hydroxy 
groups of 13, we investigated preparing the 14,14’-dimethoxy analogue 211. 
Methylation o f the hydroxyl in 14 position of 44 and its 17-N-allyl derivative has 
indeed been reported to result in little modification of the pharmacological profile of 
the parent ligands, while methylation of the hydroxyls in the 14- and 14’-positions of 
13 has been shown to result in no modification of K-affinity. 163 One might thus 
envisage that the effect of N-benzylation o f 211 with 206, 207 and 208 should be 
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Scheme 36 Another approach for the preparation of irreversible 
ligands modelled on norBNI (13)
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The synthesis of 211 from 14-OMe naltrexone (212) has been previously 
reported by Schmidhammer and associates and involved a two-step synthesis, first 
reacting 212 with hydrazine hydrate, before heating the product (azine 213) in 
presence of methanesulfonic acid (20% yield, see scheme 37) . 163 However, it was felt 
that isolation of the azine intermediate was unnecessary and we instead envisaged 
preparing 2 1 1  using similar reacting conditions as employed for the preparation of 
norBNI in section 2.4 (scheme 26).











Scheme 37 Retrosynthetic route for the preparation of 211 163,164,165
The preparation of 212 has been reported in the literature starting either from 
44 163,164 or from 14-hydroxycodeinone (214).165 We opted for the first approach 
because naltrexone was readily available in our laboratory and also because this 
method was more straightforward (3 steps instead o f 6 ). These considerations led us 
to prepare 211 according to the synthetic route presented in scheme 38. Benzylation 
of naltrexone was achieved using one equivalent of benzyl bromide and an excess of 
potassium carbonate, which afforded 215 in quantitative yield. The attempted
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dimethylation of 215 employed a modified version of the procedure used by 
Schmidhammer et a / . ; 164 thus, 2.1 equivalents of methyl iodide and three equivalents 
of sodium hydride were used instead of 2.75 equivalents of dimethyl sulfate and an 
excess of sodium hydride due to the easier removal o f excess of methylating agent. 
The amount of methylating agent was decreased in order to avoid methylation of 17-N 
that was likely to occur. However, this did not prove successful as the formation of 
numerous side products was observed and 216 was eventually prepared following 
Schmidhammer’s procedure. It should be noted that monomethylation of 215 at the 
14-hydroxyl is not possible because of the propensity of the ketonic group of 
morphinan-6 -ones to exist in the enol form that is susceptible to alkylation. 156 216 was 
immediatly refluxed overnight in methanol/conc. HC1 (3/2) in accordance with the 
procedure reported by Schmidhammer’s group and this afforded. 212 that was 
purified, carefully dried and converted into its HC1 salt (71% overall yield from 
naltrexone).
OH OH OMe
O ' " ’ O'"HO OMe
215 216






(a) 1.3 equi. K2CO3, 1.0 equi. BnBr, DMF, overnight, room T°; (b) 3.0 equi. NaH, 
2.75 equi. dimethyl sulfate, DMF, 2 hrs, 0°C; (c) conc. HCl/MeOH (2/3), overnight, 
reflux; (d) 0.53 equi. NH2NH2.H2SO4, dry DMF, 6  hrs, 100°C then 0.51 equi. 
CH3SO3H, DMSO, 3.5 hrs, 130°C
Scheme 38 Synthetic route used for the preparation of 211
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Unfortunately, Piloty reaction between the hydrochloride salt of 212 and 
hydrazine sulfate, following the procedure used in section 2.4, failed to give the 
desired bivalent ligand 211. It is noteworthy that similar difficulties were encountered 
for the reaction of hydrazine sulfate with hydromorphone (217) (this will be discussed 
in section 2.6.2.a). Interestingly, both 212 and 217 lack a hydrogen-bond donor in the 
14-position (see figure 10). When the 14-position was occupied by a hydroxyl, a 
group capable of hydrogen-bond donation, the reaction was found to proceed in good 
yield (62% yield for reaction with 44 and 75% yield for reaction with 218, see 
sections 2.4 and 2.6.2.b respectively). This would suggest that intramolecular 






facile pyrrole formation via 





low-yielding or failed pyrrole formation 
via reaction with hydrazine sulfate
Figure 10 Substitution in 14-position and facility 
of pyrrole formation: a coincidence?
Interestingly, Nagase et al. have proposed in their study on 
dihydromorphinone and related opiates that hydrogen-bond donor/acceptor 
interactions might partly account for the remarkable enolic character o f these 
ketones. 156 In particular, it seems that the basic nitrogen in 17-position is capable of 
forming a hydrogen-bond with the hydroxyl in 14-position and that the oxygen atom 
in 14-position would then remove the axial proton in 7-position, thereby resulting in 






Figure 11 Importance of hydrogen-bonding in the enolisation of 
dihydromorphinone and related opiates 156
The observation that hydromorphone analogues, ie morphinans lacking a 
hydrogen-bond donor in 14-position, require much longer reaction time than 
equivalent oxymorphones {ie with a 14-hydroxyl) to undergo silylation o f their enolic 
group under mild conditions tend to demonstrate the importance of hydrogen-bonding 
and anchimeric assistance o f 17-N and 14-0 in the reactivity o f these opioids. 156 
However, the fact that hydromorphones still undergo silylation indicates that 
hydrogen-bonding interactions are not a requisite but only one o f many factors 
influencing enolisation. Of greater importance would be the dipolar interaction 
between the carbonyl group in 6 -position and the nearly eclipsed oxygen of the furan 
ether; since this unfavourable interaction is greatly reduced in the enolic form due to 
ring flattening, the enolic form is therefore the most thermodynamically favoured. 156
Since the nitrogen atom is less electronegative than the oxygen atom, it means 
that this negative dipolar interaction is less marked for imine derivatives than for the 
corresponding ketones. It is possible that the strong unfavourable dipolar interaction is 
a sufficient condition for morphinan-6 -ones to adopt the enol form but not for an 
imine to adopt the enamine form. In the latter case, another factor might be required, 
such as the presence of a hydrogen-bond donor in 14-position. The formation of 
pyrroles via the reaction of morphinan-6 -ones with hydrazine proceeds through an 
azine intermediate (see figure 12). In the absence of a hydrogen-bond donor in 14- 
position, it is possible that the azine intermediate would have difficulty tautomerising 
to its enamine form (this might require higher energy than provided by the reacting 
conditions), which would then result in the failure to react morphinan-6 -ones with 







Figure 12 The formation of pyrroles from the reaction of 
morphinan-6 -ones with hydrazine: azine intermediate
Accordingly, a better approach for the preparation of 211 would be via 
dimethylation o f norBNI (13), which initially requires selective protection of the 
pyrrolic nitrogen and phenolic groups. Such protection had been reported by 
Schmidhammer and colleagues in their efforts to develop a series of 14-alkoxy- 
substituted indolomorphinans and involved a MOM-protecting group. 166 This led us 
to react 13 with 4 equivalents of both sodium hydride and chloromethyl methyl ether, 
which afforded the tri-MOM-protected bimorphinan 219 (see scheme 39).
This was dimethylated into 220, using a similar procedure as employed for the 
preparation of 216, ie by deprotonating the hydroxy groups with 3 equivalents of 
sodium hydride before reacting the dianion with an excess of dimethyl sulfate. The 
yield (22%) was substantially lower than that observed for dimethylation of 215 
(72%) and is explained by the presence of monomethylated product and unreacted 
starting material 219 at the end of the reaction; however, the reaction time could not 
be extended because o f progressive formation of an unidentified side product.
It was not possible to selectively cleave the MOM-protecting group from the 
pyrrolic nitrogen due to the non-availability of the lone pair of electrons at nitrogen;
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indeed, while cleavage of the methoxymethyl group from alcohols is generally 
achieved under mild conditions, e.g. stirring the protected alcohols in methanol in 
presence o f a sulfonic acid, the cleavage from indolic nitrogens is inconsistent and 
requires much harsher reagents such as BF3.Et2 0 . Since Schmidhammer’s group 
had reported that deprotection of the MOM groups from both 3-hydroxyl and indolic- 
nitrogen could be achieved simultaneously stirring the morphinans in MeOH/lN. HC1 
under reflux, we also decided to use acidic hydrolysis. 166 We first attempted to 
remove all three MOM-protecting groups o f 220 by stirring overnight at room 
temperature in a mixture of conc. HCl/MeOH (50/50). However, this afforded 221 
still having its pyrrolic nitrogen protected with a MOM group. Complete deprotection 
into 2 1 1  was eventually achieved by treating 2 2 1  under similar conditions, but 
increasing the temperature to 80°C.
Selective reprotection of the phenolic groups of 211 was then required for 
subsequent benzylation of the pyrrolic nitrogen. Our previous experience with the 
protection o f phenolic groups of norBNI-derived ligands led us to opt for a protecting 
group that would be stable under strong basic conditions but also very easy to cleave 
under mild acidic conditions. Since each dimethoxy substitution on the trityl group 
has been demonstrated to enhance the rate o f deprotection by 1 0 0 -fold, resulting in 
very facile deprotection, the 4,4’-dimethoxytrityl protecting group appeared a perfect 
candidate for that aim . 167 211 was thus reacted with 4,4’-dimethoxytrityl chloride 
under DMAP-catalysed reacting conditions. Evidence of the formation o f the 
expected intermediate 212 was provided by NMR but the product was not purified 
by column chromatography since its deprotection was likely to occur in presence of 
silica. 2 2 2  was immediately deprotonated with sodium hydride and reacted with 206. 
Unfortunately, this did not lead to the desired product but to a main product identified 
as 223.
We then envisaged protecting the phenolic groups of 211 with the more stable 
benzyl group but there was however insufficient amount of material left at this stage 





















(a) 4.0 equi. NaH, 4.0 equi. chloromethyl methyl ether , dry DMF, 2 hrs, room T°;
(b) 3.0 equi. NaH, 2.5 equi. dimethyl sulfate, DMF, 3 hrs, 0°C; (c) conc. HCl/MeOH 
(1/1), overnight, room T°; (d) conc. HCl/MeOH (1/1), overnight, 80°C; (e) 2.0 equi. 
4,4'-dimethoxytrityl chloride, 1.6 equi. DMAP, pyridine, overnight, room T°; (f) 4.1 
equi. NaH, 3.0 equi. 206, dry DMF, overnight, 70°C
Scheme 39 Preparation o f bimorphinan 211 and subsequent pyrrolic N-substitution
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2.5.5. b Synthesis
Since studies focussing on the protection of 14- and 14’-hydroxyls of 13 did 
not lead to any useful alternative to the acetate protecting group, we eventually 
reverted to using acetates in the synthesis of the potential irreversible ligands 163, 
164, and 165 (see scheme 40).
P m 0
A = 206 207 208
B = 224 225 226
C = 227 228 229
D = 169 170 171
E = 163 164 165
(a) 1 .0  equi. potassium phthalimide, 0 .1  equi. 18-crown-6, toluene, overnight, reflux;
(b) 4.0 equi. NaH, 0.1 equi. 18-crown-6, 3.0 equi. 206, 207, or 208, dry THF or 
DMF, overnight, 70°C; (c) conc. HCl/MeOH (1/1), overnight, 85°C; (d) 3 equi. 
NH2NH2.XH2O, 16 to 48 hrs, room T°; (e) 6 . 0  equi. NaHC0 3 , 1.1 equi CSCI2, 
CHCI3/H2 0 ,2hrs, room T°
Scheme 40 Synthetic route used for the synthesis of 163,164, and 165
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In a similar manner as employed in section 2.5.2, the synthetic route thus 
involved deprotonation of 178 followed by nucleophilic attack onto benzyl bromides 
206, 207 and 208, which afforded the desired N-substituted products 224, 225 and 
226. As expected, attempts to cleave the acetate esters of 224, stirring in warm 
methanol, turned out to be unsuccessful. Basic saponification of 224, 225 and 226 in 
MeOH/HiO (9/1) -using potassium carbonate (1.2 to 5 equivalents per acetate group), 
lithium hydroxide (1.4 equivalents) or concentrated aqueous ammonia- resulted in 
either recovery or decomposition of the starting materials, with no desired product 
being isolated. Stirring 224 and an excess of sodium methoxide in methanol at room 
temperature or at 45 °C led again to the recovery of unreacted materials while 
reduction with diisobutylaluminium hydride ( 2  equivalents per acetate group) did not 
afford any useful product. Decomposition of the 14,14’-diacetyl analogue o f 224 was 
also observed when stirring overnight at room temperature in an anhydrous mixture of 
THF/MeOH (50/50) with 1.4 to 16 equivalents of magnesium. Deprotection of the 
acetyls 224, 225 and 226 into 227, 228 and 229 was eventually accomplished stirring 
the compounds overnight in a mixture of MeOH/conc. HC1 (50/50) at 85°C; it is 
noteworthy that amines 169 and 171 were also isolated when using such acidic 
conditions. Treatment of 227, 228 and 229 with an excess of hydrazine hydrate 
afforded the desired amines 169,170 and 171, which were finally converted into the 
corresponding isothiocyanates 163, 164 and 165, employing the same procedure as 
used for the preparation o f 161.
2.6 Ligands with mixed profile: p-agonist/K-antagonist
2.6.1 Rationale and design
As discussed in the pharmacological section, in-vivo biological evaluation of 
BnorBNI (152) showed that this bivalent ligand exhibits p-opioid receptor agonist 
activity with modest potency and duration o f action when administered 
subcutaneously (sc), while it displays K-opioid receptor antagonism with high 
potency, selectivity and very long duration o f action when administered 
intracerebroventricularly (icv) (see section 3.2). Since there is an interest in 
developing mixed p-agonist/x-antagonist ligands (see section 1.4.2), we decided to 
attempt to improve the pharmacological profile o f 152, more specifically regarding its 
p-agonist effects.
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When studying the SAR of BNI-related ligands, Portoghese and associates 
disclosed three members displaying full agonist activity (230, 231 and 232) in the 
guinea pig ileum (GPI) and mouse vas deferens (MVD) assays; interestingly, all three 
ligands were N-Me disubstituted derivatives. 102 Further study with 230 in the GPI 
assay showed that the agonist effects were mediated through the p-receptor, with 
similar selectivity likely for the other members. 102 This suggests that the SAR of 
norBNI derivatives, in particular regarding substitution at N-17 and N-17’, follows 
that displayed by other series of opioids; N-Me substitution typically leads to p- 
agonism, while N-CPM substitution generally results in a decrease in p-efficacy and a 
more K-profile. It was therefore o f interest to investigate whether similar N-Me 
disubstitution would optimise the p-agonist pharmacological profile o f BnorBNI; we 
here investigate the synthesis and biological evaluation of 233 and 234.
R1= OH, R2=OH 230 




R = OH 233 
R = H 234
2.6.2 Synthesis
2.6.2.a Synthesis o f 233
Replacement of N-substituents from the 17-position o f morphinans has been 
reported in the literature and involves alkylation of N-noralkaloid intermediates or
1ARquatemisation of the starting tertiary amine followed by dealkylation.
In the first approach, the starting tertiary amine is first reacted either with 
cyanogen bromide (von Braun reaction) or alkyl chloroformates before cleavage of 
the cyanamide or carbamate product; the N-noralkaloid intermediate is then alkylated 
with the appropriate alkyl bromide derivative. However, there were potential 
problems in applying this method for the conversion of BnorBNI (152) into the 
targeted derivative 233: reaction o f a tertiary amine (constituted o f three alkyl groups) 
with cyanoammonium bromide results indeed in cleavage o f the smallest alkyl
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bromide. 127 Thus, the method represents an attractive approach for replacing the N- 
Me group of morphinans, but not for replacing the CPM group of BnorBNI. Of 
concern was the possible formation of side products arising from cleavage at the 16- 
position since cyclic amines have been reported to be frequently cleaved through von 
Braun reaction. 127
The second approach, ie quatemisation o f BnorBNI with methyl iodide 
followed by dealkylation, should lead to the targeted product 233. However, such a 
method would present some disadvantages when applied to BnorBNI; firstly, 
protection and deprotection of the hydroxy groups o f BnorBNI was required, which 
we wished to avoid due to our previous experiences. Also tedious purification was 
predictable: since BnorBNI is a bivalent ligand, the N-Me disubstituted product 233 
would have to be isolated from a mixture likely to contain the N-CPM di-substituted 
starting material, the mono-converted compound, the products arising from mono/di- 
Hofinann elimination, amongst others. In the light o f these considerations, it seemed 
inappropriate to synthesise 233 from 152.
It was instead decided to prepare 17,17’-di-N-Me-substituted norBNI
107intermediate 235 reported by Portoghese, before subsequent pyrrolic N- 
benzylation, in a similar approach as used for BnorBNI (see scheme 41). 
Demethylation of oxycodone (236) has been reported under various conditions, e.g. 
heating the morphinan to 110-120°C in aqueous HBr (35% yield) 169 or stirring in 
aqueous HC1 in presence of Pd/C. 170 BBr3 has also been employed for this purpose, 171 
but it was believed that better yields would be achieved with BBr3.DMS because of 
the reduced propensity of BBr3 to complex with the electron-donor groups of 
oxycodone. We thus decided to utilise this reagent; the experiment was adapted from
177a general procedure described for dealkylation o f aryl ethers and afforded 
oxymorphone (218) in 63% yield. Similar Piloty reaction as used for the preparation 
of norBNI, starting with the hydrochloride salt of 218 and hydrazine sulfate, afforded 
the bivalent ligand 235; this was then deprotonated with sodium hydride and reacted 
with five equivalents of benzyl bromide, the conditions that had proved successful for 
the preparation of BnorBNI. This afforded the tri-benzylated product 237, which was 
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(a) 4.0 equi. BBr3.DMS, dichloroethane, overnight, 65°C; (b) 0.52 equi. 
NH2NH2.H2SO4, dry DMF, overnight, 105°C then 0.49 equi. CH3SO3H, DMSO, 4 
hrs, 130°C; (c) 10.0 equi. NaH, 0.38 equi. 18-crown-6, 5.1 equi. BnBr, DMF, 24 hrs, 
room T°; (d) MeOH/conc. HBr (aqueous solution) (1/1), overnight, room T°
2.6.2.b Synthesis o f  234
The successful preparation o f 233 via multiple benzylation and subsequent 
selective debenzylation prompted us to use the same strategy for the synthesis of 234, 
but with hydrocodone (238) as the starting material (see scheme 42).
Although demethylation o f hydrocodone (238) using four equivalents of 
BBr3.DMS led to the anticipated product hydromorphone (217), the yield turned out 
to be substantially lower than that observed for the demethylation of oxycodone (218) 
(33% compared to 63%). This was surprising since replacement of the hydroxyl in 14- 
position with a hydrogen atom was expected to result in reduced complexation with 
BBr3 and consequently in a higher yield. However, as discussed in section 2.5.3.a, 
intramolecular hydrogen-bond interactions generally exist between the basic nitrogen 
in 17-position, the hydroxyl in 14-position and the hydrogen atom in 7-position of 
morphinan-6 -ones;156 218 is no exception to that rule and this is demonstrated with
Scheme 41 Synthetic pathway used for the preparation of 233
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hydromorphone (217) being more polar than oxymorphone (218) (see Rf values in 
section 3) . 156 Although it is acknowledged that BBr3 was used in excess and as its 
methyl sulfide complex, it still remains that stronger complexation exists between 
BBr3 and 238 than between BBr3 and 236, which might explain why the reaction 
proceeds better in the latter case. Demethylation of 238 with two equivalents of boron 
tribromide (from -78°C to room temperature) gave a similar yield (40%). 
Trimethylsilyl iodide, formed in-situ from nucleophilic attack of sodium iodide on 
trimethylsilyl chloride, was also utilised to see if  this would allow a more efficient 












(a) 4.0 equi. BBr3.DMS, dichloroethane, overnight, 65°C; (b) 0.52 equi. 
NH2NH2.H2SO4, dry DMF, overnight, 105°C then 0.49 equi. CH3SO3H, DMSO, 4 
hrs, 130°C; (c) 10.0 equi. NaH, 0.38 equi. 18-crown-6, 5.1 equi. BnBr, DMF, 24 hrs, 
room T°; (d) MeOH/HBr (in AcOH) (1/1), overnight, room T°
Scheme 42 Synthetic route planned for the preparation o f  234
Although preparation o f the bivalent ligand 239 from 217 has been reported by
171Portoghese et al. using N-aminosuccimmide hydrochloride, we mstead decided to 
use 1 .1  equivalents of hydrazine sulfate in a similar way as used for the preparation of 
235. The desired product 239 was isolated in 35% yield; again, the yield was lower
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than that obtained with the 14-OH analogue 235, which is in line with our previous 
observation that pyrrole formation via reaction between hydrazine and morphinan-6 - 
ones proceeds in much better yield when the 14-position is occupied by a hydrogen- 
bond donor (see section 2.5.3.a).
Our greatest surprise came however when reacting deprotonated 239 with five 
equivalents of benzyl bromide. We indeed believed that the reaction would proceed 
better than when starting with 235 because of the lack o f hydroxy groups in 14- and 
14’-positions. However, this proved not to be the case and the desired product 240 
was obtained in very low yield (19 %). Moreover, repeating the reaction several times 
showed the result not to be reproducible, with highly-benzylated species being 
routinely formed; unfortunately, it was not possible to characterise these products. 
This led us to change the reacting conditions, including reducing the amount of 
sodium hydride and/or benzyl bromide, replacing sodium hydride with potassium tert- 
butoxide or sodium hydroxide. According to mass spectrometry, use of 4 equivalents 
of potassium hydroxide and 3.5 equivalents of benzyl bromide afforded a complex 
mixture of penta-, tetra- and tribenzylated derivatives, while hexa-, penta- and 
tetrabenzylated products were obtained when using 3.1 equivalents of terf-butoxide 
and 3.2 equivalents of benzyl bromide. In both cases, no starting material was 
isolated, suggesting that some decomposition had occurred during the reaction. 
Accepting the low yield of the original procedure, 240 was then treated with HBr in 
acetic acid in order to cleave the phenolic benzyl ethers. Unfortunately, no product 
was obtained and there was insufficient amount o f material left to try any other 
method of debenzylation.
This urged us to explore another approach for the preparation of 234, namely 
the two-step synthetic pathway presented in scheme 43. The first step involved a 
Piloty reaction between hydrocodone (238) and benzylhydrazine dihydrochloride; 
although reaction o f morphinan-6 -ones with substituted hydrazine seemed to prove 
difficult in our hands (for example, such a procedure afforded BnorBNI in only 1% 
yield, see section 2.4.2), we still hoped the reaction would work in this case since 
Schmidhammer and co-workers had reported that stirring a mixture of hydrocodone 
(238) and N-methylhydrazine sulfate in acetic acid for 3 hours at room temperature 











(a) 0.52 equi. B11NHNH2.2 HCI, dry DMF, overnight, 105°C then 0.49 equi. 
CH3SO3H, DMSO, 4 hrs, 130°C; (b) 8.0 equi. BBr3.DMS, dichloroethane, overnight, 
65°C
Scheme 43 Alternative approach for the preparation of 234
(via Piloty reaction between 238 and benzylhydrazine)
However, reacting the HC1 salt o f hydrocodone (238) with benzylhydrazine 
dihydrochloride in an analogous manner as usually employed within our group for 
pyrrole formation, ie stirring first in DMF at 100°C then in DMSO and 
methanesulfonic acid at 130°C, failed in giving any desired product 241. Modification 
o f the reacting conditions, namely stirring overnight the free base or the salt o f both 
hydrocodone and benzylhydrazine in refluxing ethanol in presence of molecular 
sieves before proceeding as described earlier for the second stage, did not afford the 
desired product. Finally, stirring hydrocodone (238) and benzylhydrazine in acetic 
acid, following an equivalent procedure to that employed by Schmidhammer and 
associates, also proved unsuccessful. 174 The reaction mixture was then stirred for one 
hour at 70°C, but this led to the same conclusion.
Since reaction of morphinan-6 -ones with substituted hydrazine had not proved 
successful in our hands, we instead planned to react 238 with unsubstituted hydrazine 
before subsequent pyrrolic N-benzylation and 3,3’-demethylation (see Scheme 44). 
This new approach also offered the advantage that both phenolic groups of 242 were
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“protected” during pyrrolic N-benzylation, which should reduce extra-benzylation 













(a) 0.50 equi. NH2NH2.H2SO4, dry DMF, overnight, 105°C then 0.51 equi. CH3SO3H, 
DMSO, 4 hrs, 130°C; (b) lithium diisopropylamide (from 1.05 equivalents to 1.5 
equivalents), 0.1 equivalent 18-crown-6, benzyl bromide (from 1.1 equivalents to 3.3 
equivalents), dry THF, overnight, reflux; (c) 8.0 equi. BB^.DMS, dichloroethane, 
overnight, 65 °C
Scheme 44 Alternative approach for the preparation of 234 
(via Piloty reaction between 238 and hydrazine)
Condensation of hydrocodone hydrochloride with hydrazine sulfate followed 
by acid-catalysed cyclisation, using an equivalent procedure to that employed for the 
preparation of norBNI (13), led to the desired product 242 in 71% yield. This suggests 
that substitution of hydrazine prior to its reaction with morphinan-6 -ones is a critical 
impediment to the success of the reaction; it is possible that steric hindrance inherent 
to the benzyl substituent shifts the azine intermediate to a conformation unfavourable 
to subsequent electron transfer.
We then decided to use lithium diisopropylamide for the deprotonation of 242 
since it is a hindered base, which might reduce the number o f deprotonated sites and 
result in selective benzylation of the pyrrolic nitrogen. Moreover, using freshly- 
titrated LDA solution appeared particularly convenient for our purpose, for the scale
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we were working on was quite small (less than 0.5 mmol). Unfortunately, all attempts 
to benzylate 242 using lithium diisopropylamide (from 1.05 equivalents to 1.5 
equivalents) and benzyl bromide (from 1.1 equivalents to 3.3 equivalents) led to the 
decomposition and/or recovery of 242, with no useful product 243 isolated.
2.7 Studies tow ards a new protecting group for pyrrolic and indolic nitrogens
Since it was found in section 2.5 that N-substitution of norBNI (13) with a p~ 
phthalimidobenzyl group did not survive acidic or hydrazinolytic environment, we 
decided to investigate whether such a group could find application as a protecting 
group for pyrrolic and indolic nitrogens. Should the /?-phthalimidobenzyl group be 
envisaged as a protecting group, a higher-yielding approach for its preparation had 
also to be achieved. This led us to plan the synthesis of 182 via the two-step route 
presented in scheme 45.
244 182
(a) 1.0 equi. phthalic anhydride, AcOH, 2 hrs, reflux
(b) 3.0 equi. NaBrCb, 3.0 equi. NaHSC>3, EtOAc/f^O, 6 hrs, room T°
Scheme 45 Two-step synthesis of 182
Reaction o f p-toluidine with one equivalent of phthalic anhydride in refluxing 
acetic acid led to the protected intermediate 244 in 84% yield. With greater and 
greater environmental concern, new procedures using environmentally-ftiendly 
solvents or generating bromine in-situ have recently appeared for benzylic
175 17Abrominations, ’ which led us to brominate 244 using a mixture of sodium 
bromate/sodium hydrogensulfite in a similar way as reported by Kikuchi and co­
workers.176 This led to 182 in 62% yield (52% overall yield from p-toluidine).
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We then evaluated the use of the p-phthalimidobenzyl group for the protection 
of indolic nitrogens. To that end, we reacted 182 with the conjugate base of carbazole 
(245) and tetrahydrocarbazole (246) according to the same procedure as employed for 
benzylation of 178.
In both cases, monitoring of the reaction by TLC showed the reaction mixture 
to be surprisingly messy; replacing sodium hydride with potassium te/7-butoxide or a 
milder base such as potassium carbonate did not result in cleaner reactions. It is 
unclear whether the product and/or starting materials decomposed during the reaction 
or during the purification; of additional concern, is the fact that both commercially 
available and freshly ordered carbazole and tetrahydrocarbazole gave similar messy 
TLCs despite getting very clean NMR spectra. Because of complex purification, the 
protection of tetrahydrocarbazole with 182 was abandoned, while indolic N- 
substitution of carbazole afforded the desired product 247 in modest yield (37%) 
(scheme 46). Deprotection o f 247 with three equivalents of hydrazine hydrate also 
proved to be messy when monitored by TLC but the fact that amine 248 was isolated 
suggested that the deprotection was not proceeding in an analogous manner to that 
with norBNI (13).
(a) 2.0 equi. NaH, 1.1 equi. 182, 0.1 equi. 15-crown-5, dry DMF, overnight, 70°C;
(b) 3.0 equi. NH2NH2.XH2O, EtOH, 2 days, room T°




Since it was clear that carbazole and tetrahydrocarbazole did not represent 
ideal candidates for the evaluation of the p-phthalimidobenzyl group as a nitrogen- 
protecting group, we further conducted our study with indolomorphinan 249 (scheme 
47); this was obtained from esterification of readily available 250 with acetic 











(a) acetic anhydride, 3 hrs, 100°C; (b) 4.0 equi. NaH, 0.1 equi. 15-crown-5,
3.0 equi. 182, dry DMF, overnight, 70°C
Scheme 47 Protection o f 249 with a p-phthalimidobenzyl group
Deprotonation of 249 with an excess of sodium hydride followed by 
nucleophilic attack on 182 gave the desired N-substituted product 251. 251 was 
subsequently treated with either a mixture of MeOH/conc. HC1 (50/50) at 85°C or 
with 3 equivalents of hydrazine hydrate at room temperature; in both cases, TLC 
showed consumption of the starting material with neither 249 or 250 being formed. In 
the light of these experiments, it seems that the p-phthalimidobenzyl group cannot be 




The initial pharmacological evaluation of all ligands was performed by NIDA- 
OTDP through a contract to SRI or by Dr. John R. Traynor and colleagues; all ligands 
were evaluated in binding assays, measuring the affinity at each receptor type, and in- 
vitro ([35S]GTPyS assay), measuring the antagonist and agonist potency (and efficacy) 
at each receptor. In some cases, the pharmacological profile of the test compound was 
also investigated in-vivo. At the time of submission, only pharmacological data 
related to compounds 13,152, 233, 235, 50 and 51 were available.
3.1.1 Binding assays
The identification and purification of homogenous populations of opioid 
receptors has allowed the development of assays that measure the amount of 
radiolabeled ligand bound to these receptors. By determining the concentration (IC50) 
of unlabeled test compound required to displace 50% of radiolabeled ligand from the 
receptor, one can calculate the affinity of the test compound for this receptor using the
Kj = dissociation constant of test compound 
[D] = concentration of radiolabeled ligand 
Kd = dissociation constant o f radiolabeled ligand
In the present project, in-vitro evaluation of the test compounds was based on 
stimulation of opioid receptor-mediated binding of the GTP analogue guanosine-5’- 
0-(3-[35S]thio)triphosphate ([35S]GTPyS) to human k, p and 5-receptors transfected 
into Chinese hamster ovary cells (NIDA-OTDP) or rat p and 5-receptors transfected 
into C6 cells (Traynor and colleagues).178,179 Thus, dose-response curves of 
[35S]GTPyS binding mediated by selective agonists DAMGO (for p), SNC80 (for 5, 
NIDA-OTDP), DPDPE (for 5, Traynor and colleagues) and U69593 (for k) were 
recorded in presence or absence of the test compound.
Antagonist potency was determined from the concentration of the test 
compound required to lower [35S]GTPyS binding by 50% according to the formula:
1 7 7following formula:
v- _  ^ so  where.




Ke = [antagonist]/(dose ratio -1), where dose ratio corresponds to the ratio between 
[antagonist] and the concentration of the radiolabeled ligand required to get 50% of 
maximal [35S]GTPyS binding.
Agonist potency at a receptor type was determined from the concentration 
(EC50) of the test compound required to get 50% o f the [35S]GTPyS binding value 
obtained with the standard agonist. Relative efficacy o f agonist test compounds at a 
receptor type was determined by the percentage of maximal stimulation of 
[ S]GTPyS binding obtained with the test ligand compared to that observed with the 
full agonist selective to that receptor.
3.1.3 In-vivo assays
In-vivo assays are often based upon response of rodents to a wide range of 
nociceptive stimuli including temperature, chemical irritants or electric shocks. In- 
vivo pharmacological evaluation of the ligands synthesised in the present project was 
achieved using the warm-water tail withdrawal assay, in which the temperature was 
50°C.180
3.2 Pharmacological evaluation of 13,152, 233 and 235
13, 152, 233 and 235 were evaluated in opioid binding assays and in-vitro 
stimulation o f [35S]GTPyS binding with BnorBNI (152) further evaluted in-vivo in the 
tail withdrawal assay (in mice).
The binding affinities are reported in table 3 and showed subnanomolar 
affinity of both 13 and 152 for K-receptors with modest selectivity over p and 5 (< 15- 
fold). When compared to 13, 152 had 8-fold lower p-affinity than norBNI and as a 
result slightly improved k/p selectivity. Although Takemori et al. have reported
o 1
similar low K-selectivity for the closely related analogue 28, the low selectivity 
observed with norBNI (13) is surprising and is in disagreement with previous reports 
(around 160-fold K-selectivity over both p and 5);81 it is unclear why the results are 
divergent but it is noteworthy that the methods used by Takemori et al. differed from 
that used by our collaborators (different tissue and different radiolabeled ligands). The 
N-Me analogues 235 and 233 also showed modest K-selectivity broadly in line with 
that seen for 13 and 152. The replacement of the N-CPM substituents by N-Me 
resulted in similar decreases in k  and 5-affinity o f around an order o f magnitude, but
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in contrast the effect on p-affmity was not consistent. While 235 exhibited 50-fold 
lower ji-affinity than 13, replacement of the N-CPM group of 152 resulted in slightly 
higher p-affinity for 233.
Kj (nM) Selectivity
5 K k /(i k /8
13 1 .2  ± 0 .2 5.8 ±0 .7 0.4 ±0.1 3 15
152 10.0 ±2.5 8 .6  ±0 .7 0.7 ±0.1 14 1 2
235 63.6 ±39.1 98.2 ±25.3 7.7 ± 1.0 8 13
233 6.4 ±1.1 207 ± 9 6 24.9 ± 5.6 0.3 8
Values are from 3 separate experiments, each performed in duplicate 
Radiolabeled ligand is nonselective antagonist [3H]diprenorphine
Table 3 Affinities in opioid receptor displacement binding assays
In the in-vitro functional assay, 152 exhibited partial fi- and K-agonist activity 
of modest and low potency respectively (see table 4); its agonists effects showed a 10- 
fold jj/k selectivity and reached respectively 38% and 29% of maximal effect 
compared with the full agonists at each receptor. 13 showed no opioid agonist activity 
at any receptor, which is in agreement with literature reports.81
EC50 (nM) and %  Stimulation
[3H]DAMGO - n % Stim [3H]SNC80 - S [3H]U69593 - k % Stim
13 a - a a -
152
S
ioo 38 a 1906c 29
235 1388 ±370 6 6 a a -
233 526 ±279 54 a a -
Values are from 3 separate experiments; a: no stimulation up to 10,000 nM; b: 95% Cl, 42-844 nM .; c: 95% Cl, 269-13490 nM.
Table 4 Opioid agonist effects measured by the [35S]GTPyS assay
104
Both 235 and 233 possessed weak p-agonist effects with no detectable 
agonism at k -  and 8-receptors. Both compounds showed higher efficacy than that 
exhibited by the corresponding N-CPM derivatives, which is in agreement with 
general SAR studies related to 17-N substitution of morphine derivatives (see section 
2.6.1). It is noteworthy that while pyrrolic benzylation of 13 to 152 had resulted in an 
increase in p-efficacy, equivalent benzylation of 235 to 233 had resulted in improved 
p-potency but slightly reduced p-efficacy.
As the compounds displayed little efficacy at opioid receptors, they were 
evaluated as opioid antagonists, the exception being 235 and 233 at p-receptors where 
they had too high efficacy. In the opioid antagonist functional assay, 152 exhibited 
potent K-antagonism with a 50-fold k / 8  and 100-fold ic/p selectivity (table 5). In both 
cases, the selectivity was similar or higher than that showed by norBNI (13) (47 and 
22-fold respectively). Both N-Me analogues 235 and 233 were weak antagonists at k -  
receptors, with a 2-3 order o f magnitude lower potency than the corresponding N- 
CPM derivatives 13 and 152.
Ke (nM) Selectivity
[3H]DAMGO - p [3H]SNC80 - 8 [3H]U69593 - k K /p k / 8
13 2.38 ±0.58 5.17 ±0.73 0.11 ±0.11 .22 47
152 25.5 ±2.3 13.3 ±4.5 0.26 ±0.09 98 51
235 NT NT 27.0 ±4.3 - -
233 NT NT 311 ± 30 - -
Values are from three separate experiments; N T : not tested
Table 5 Opioid receptor antagonist activity in the [35S]GTPyS assay
Replacement of the N-CPM substituents with N-Me has thus resulted in 
increased p-agonist efficacy o f both 13 and 152; of concomitant effect, was the huge 
decrease in K-antagonist potency observed upon such modification. It is difficult to 
compare this effect with previously reported similar replacement o f 17-N-CPM group 
o f GNTI (11) and NTI (150). While such modification has been reported to result in
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loss of selectivity and potency in the 5-antagonist activity o f 150, with simultaneous 
appearance of 5-agonism, the N-Me derivative of 11 exhibited no agonist activity but 
was a K-antagonist with decreased K-selectivity and potency compared to I I .88’181
The pharmacological profile of BnorBNI (152) was further investigated in- 
vivo', its agonist and antagonists effects on the dose-response curve of the selective k - 
agonist U69593 were evaluated with the drug being either administered sc or icv. The 
results are presented in tables 6  and 7 respectively (negative shift values reflect a 
leftward shift on the dose-response curve of the agonist, while positive values reflect a 
rightward shift).







+ vehicle at - l h  a 5.2 — —
+ 10 mg/kg BnorBNI at - l h 2 .0 -2.56 0 . 0 0 0 2
+ 10 mg/kg BnorBNI at -3h 2 .1 -2.55 0.0145
+ 10 mg/kg BnorBNI at —18h 9.0 1.73 n.s.
+ 10 mg/kg BnorBNI at -24h 4.4 -1.17 n.s.
+ 32 mg/kg BnorBNI at -24h 5.7 1.09 n.s.
+ 10 mg/kg BnorBNI at -48h 9.9 1.90 n.s.
+ norBNI vehicle at - l h 5.5 — —
+ 10 mg/kg norBNI at -24h 8 .1 1.47 n.s.
+ 32 mg/kg norBNI at -24h 22.7 4.12 0.0003
a vehicle is 10% DMSO in normal saline
b n .s .: not significant; shift significance represent the significance of difference between 
vehicle and drug curves
Table 6 Effect of sc administered antagonists on the dose-effect curve of U69593 
in the warm water tail withdrawal assay (U69593 administered sc)
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+ vehicle at - l h  b 5.2 — —
+ 10 nmol BnorBNI at - lh 26.3 5.04 <0.0001
+ 10 nmol BnorBNI at -24h 26.3 5.04 0.0003
+ 10 nmol BnorBNI at -48h 74.2 14.22 <0.0001
+ 10 nmol BnorBNI at -168h 37.0 7.09 <0.0001
+ 32 nmol BnorBNI at -24h c — <0.0003
+ 10 nmol norBNI at -24h 31.8 6.10 <0.0001
+ 32 nmol norBNI at -24h c — <0.0001
Morphine <0.0001
+ 10 nmol BnorBNI at - lh 5.4 2.00 0.3415
SNC80 d
+ 10 nmol BnorBNI at - lh 4.6 -1.41 0.1563
a shift significance represent the significance of difference between vehicle and drug curves; 
b vehicle is 10% DMSO in normal saline ; c EC5o could not be calculated because the curve 
was shifted beyond the agonist dose range;d SNC80 was not a full agonist
Table 7 Effect of centrally (icv) administered antagonists on the dose-effect curve 
in the warm water tail withdrawal assay (U69593 administered sc)
Subcutaneous administration of BnorBNI (152) (10 mg/kg) at pretreatment 
times up to 3 hours before U69593 administration sc produced a 2.5-fold shift to the 
left of the dose-response curve of the agonist, indicating an additive antinociceptive 
effect of 152 (table 6). By 24 hours, no significant effect could be observed when 152 
(10 or 32 mg/kg) was administered sc. This initial antinociceptive action of 152 could
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be antagonised by the selective ^-antagonist methocinnamox (M-CAM) as shown on 
figure 13 but not by norBNI (13) (data not shown), which suggests 152 is a p-agonist 
when administered sc. In contrast, 13 (32 mg/kg) administered icv 24 hrs before 
U69593 (sc) produced a 4.1-fold shift to the right of the dose-response curve of the 
agonist, reflecting an expected antagonist effect of the drug.
I 110 mg/kg 152




■1 h -3 h -24 h
Treatm ent Time
Figure 13 Evaluation of agonist activity of 152 in the tail withdrawal assay
When BnorBNI (152) (10 nmol) was administered icv before administration sc
of U69593, no antinociceptive effect was observed at any time (table 7) but instead
152 strongly antagonised the effect of U69593 with pretreatment times up to 168h (at
this time, the shift was still 7-fold). After lh  pretreatment, administration (icv) o f 152
(10 nmol) did not antagonise the effects o f SNC80 and morphine (see table 7), which
indicates 152 is a K-antagonist when administered centrally. It is unclear why 152 did
not exhibit any agonist activity when administered icv but it is noteworthy that similar
contradicting observations were reported for 14-cinnamoylaminocodeinone, which
displays potent p-agonism with high efficacy when administered sc, but is a p-
1 8 2  181antagonist devoid of any agonist effects when administered icv. ’
Finally, we investigated whether the introduction of a benzyl group at the 
pyrrolic site of norBNI (13) was sufficient to produce an irreversible antagonist. An 
irreversible antagonist reduces the number of available receptors, rendering the 
number o f receptors insufficient for an agonist to produce maximum response;
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therefore, an irreversible antagonist will flatten and shift to the right the dose-response 
curve of an agonist. As shown on figure 14, both 10 nmol and 32 nmol 
administrations icv o f 152, 24 h before U69593 administration (sc), produced a 
flattening of the dose-response curve of the agonist, indicating a non-competitive 
interaction of 152 with K-opioid receptors.
1 0 0 -I
UiQ.
S  50- B control
□  +10 nmol 152 (24 h pretreatment)
O +32 nmol 152 (24 h pretreatment)
0.0 0.5 1.0 2.01.5 2.5
Log [U69]
Figure 14 Effect of 152 administration (icv) on the dose-response curve o f U69593
The effect of equimolar administration (10 nmol, icv) of BnorBNI (152) and 
norBNI (13) was then compared (see figure 15); the pretreatment time was set at 24 h, 





*  No pretreatment 
“ •" + 10 nmol 152 (24 h pretreatment) 
“ O + 10 nmol 13 (24 h pretreatment)
0.0 0.5 1.0 1.5 2.0 2.5
log [U69593]
Figure 15 Comparison of the effect o f 13 and 152 (administered icv) 
on the dose-response curve of U69593 (administered sc)
Both compounds produced a rightward shift o f the dose-response curve of 
U69593, with evidence of flattening o f the U69593 dose-response curve observed 
upon administration o f BnorBNI (152) but not of norBNI (13); however, irreversible
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antagonism upon administration of 13 was observed when higher doses of 13 (32 
nmol, icv) were used (not shown on figure 15, but this is reflected by the fact that the 
U69593 dose-response curve was shifted beyond the agonist dose range, see table 7).
In conclusion, benzylation of the pyrrolic nitrogen o f norBNI (13) has resulted 
in dramatic modification o f the in-vivo pharmacological profile o f the ligand; while 13 
is a competitive K-antagonist devoid of agonist effects when administered sc or icv, 
152 is a partial p-agonist with short duration of action when administered sc and an 
irreversible K-antagonist upon central administration. Moreover, in-vitro 
pharmacological evaluation o f 235 and 233 has revealed that replacement o f the CPM 
groups (at 17- and 17’-N) of 13 and 152 with methyl groups has resulted in lower p- 
agonist potency/increased p-agonist efficacy than that displayed by the parent ligands 
with concomitant huge decrease in K-antagonist potency.
3.3 Guanidinyl substituted ligands (50) and (51)
p-HydroxybenzylGNTI (50) and m-hydroxybenzylGNTI (51) were evaluated
i f f
in opioid binding assays and in the in-vitro stimulation of [ S]GTPyS binding assay; 
the results are reported in table 8 and table 9 respectively.
Kj (nM) a’b Selectivity
V 5 K K/p k/S
50 14.67 ±3.65 41.86 ±0.93 3.26 ±0.12 4.5; 13
51 14.16 ±4.11 17.58 ±0.29 2.74 ±0.74 5 6
46 29.78 ± 0.50 82.05 ± 5.06 0.66 ±0.05 45 129
11 36.9 ± 2.3 70.0 ± 0.3 0.18 ± 0.10 205 389
13° 21.0 ± 5 .0 5.7 ±0.9 0.20 ±0.05 105 28
* Values are from 2 separate experiments, each performed in triplicate
b Radiolabeled ligands are [3H]-DAMGO (for pX [3H]C1-DPDPE (for 8) and [3H]-U69593 (for k )  • 
c Data are from reference 180
Table 8 Binding affinities to cloned human opioid receptors transfected 
into Chinese hamster ovary (CHO) cells
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In the binding assay, both 50 and 51 displayed modest affinity for the k -  
receptor with poor k / j i  selectivity (less than 5-fold for both compounds) and k / 8  
selectivity (13-fold for 50 and 6-fold for 51). In particular, the binding assay showed 
our efforts to recover K-selectivity unsuccessful since both 50 and 51 exhibited lower 
K-selectivity than that displayed by the pioneering ligand p-chlorobenzylGNTI (46) 
(45-fold k / | i  and 129-fold k /8  selectivity). In comparison, norBNI (13) and GNTI 
(11), the two standard K-antagonists, displayed much higher K-selectivity than 50 and 
51 in this assay (up to 60 times higher).
In the functional assay, both 50 and 51 failed to stimulate [35S]GTPyS binding 
for any type of opioid receptor (data not shown) and displayed potent and selective k -  
antagonist effects (table 9).
Kj (nM) ** Selectivity
8 K k / jX k / 8
50 12.66 ±0.84 18.31 ±0.95 0.10 ±0.01 127 183
51 4.28 ± 0.52 4.35 ± 0.22 0.13 ±0.02 33 33
46 5.24 ±1.13 7.67 ± 1.36 0.14 ±0.01 37 55
11 3.23 15.49 0.04 81 389
13 c 18.9 ±1.8 4.42 ± 0.38 0.04 ± 0.01 484 113
1 Values are from 5 or 6 experiments
b Radiolabeled ligands are [3H]-DAMGO (for p), [3H]C1-DPDPE (for 8) and [3H]-U69593 (for k)  
c Data are from reference 180
Table 9 Antagonist potency in [35S]GTPyS assays performed 
in cloned human opioid receptors
Interestingly, 50 exhibited a higher k / | i  selectivity than that observed with 
GNTI (11) (127- and 81-fold respectively) and higher k / 8  selectivity than that 
displayed by norBNI (13) (183- and 113-fold respectively). The K-selectivity of 50 
was about 4 or 5 times higher than that of the p-chlorobenzylGNTI analogue (46), 
which shows that substitution with a hydroxy group in p-position has successfully led 
to recovery of selectivity towards the K-receptor. In contrast, 51 showed less 
substantial selectivity (33-fold k / p  and k / 8  selectivity) and its K-selectivity was
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broadly similar to that observed with 46; these results thus appear to support the 
molecular modelling studies, which showed the superposition of the phenolic group of 
norBNI (13) and 50 to be much closer than that o f norBNI (13) and 51. It is also 
noteworthy that the improved K-selectivity observed with 50 did not result from 
enhanced K-potency but was rather a consequence of decreased potency at p. and 8- 
receptors due to the presence of the hydroxy group in p-position. Interestingly, this is 
in agreement with Thomas’s earlier findings, who proposed that the oxygen atom of 
the second phenolic group of norBNI (13) might unfavourably interact with a group 
present in the lipophilic pocket of p and 8-receptors.104
Finally, 46, 50 and 51 failed to flatten the dose-response curve of the agonist 
U69593 (data not shown), which suggests they do not bind irreversibly towards the k -  
receptor. It is interesting to note that, at the start of the present project, p- 
chlorobenzylGNTI (46) was believed to bind irreversibly towards the K-receptor since 
its antagonist effects remained after washing the membranes (see figure 16). 
However, the irreversible character of 46 was not confirmed in further antagonist 
assays (data not shown), which suggests that wash-resistant binding does not 
represent a suitable criterion for assessment o f irreversibility.
1500-.
o>
o 1000- Pretreatment with 100 nmol of 
■ naloxone (fully reversible antagonist)
•  Pretreatment with 100 nmol of 46
500-
0+-
0.0 2.0 2.50.5 1.0 1.5
[sH-diprenorphine]
Figure 16 Binding of [3H]diprenorphine in K-membranes (CHO cells) that have 




All chemicals were purchased from Aldrich, Acros or Lancaster chemical 
companies. All solvents were GPR grade, purchased from Merck or Fisher Scientific.
Column chromatography was performed under gravity over silica gel 60 (35- 
70pm) purchased from Merck, except for compounds 136, 161, 163, 164 and 165, 
which were purified on a pre-packed column of silica gel 60 (lOg, 30-90pm, 
purchased from International Sorbent Technology) using “Flash master personal” 
equipment (“anti-gravity” elution). Analytical TLC was performed using aluminium- 
backed plates coated with Kieselgel 60 F254, purchased from Merck. The 
chromatograms were visualised using either UV light (UVGL-58, short wavelength), 
ninhydrin (acidic) or PMA.
Infrared spectroscopy was performed on a Perkin-Elmer RX 1 FT-IR 
Instrument. *H NMR and 13C NMR spectra were recorded using either JEOL GX 270 
(operating at 270 MHz for !H and 67.8 MHz for 13C) or JEOL EX 400 (operating at 
400 MHz for *H and 100.5 MHz for 13C) spectrometers. Chemical shifts are expressed 
in ppm. Spectra were referenced internally using either tetramethylsilane as the 
standard or using the residual solvent resonance. Coupling constants (J) are reported 
in Hz and the multiplicities abbreviated as follows: s (singlet), d (doublet), t (triplet), 
m (multiplet) and br (broad). In the particular cases o f morphinan-derived compounds, 
only diagnostic peaks have been recorded for proton NMR. High and low resolution 
fast atom bombardment (FAB) mass spectra were carried out on a Fisons VG 
AutoSpec Q instrument, with a matrix of m-nitrobenzylalcohol. High and low 
resolution electron impact (El) mass spectra were recorded using El ionisation at 
70eV, on a VG AutoSpec instrument, equipped with a Fisons autosampler. All mass 
spectra were recorded in positive mode. Melting points were evaluated using a 
Gallenkamp MFB-595 melting point apparatus or a Reichert-Jung hot stage 
microscope apparatus and are uncorrected.
Microanalyses were performed with a Perkin-Elmer 240C analyser and were 
recorded by the Microanalysis Laboratory in the Department of Chemistry, University 
o f Bath.
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General Procedure A -  Guanidinylation of amine 53.
A solution of 53 (1 equi.), mercury(II) chloride (1.5 equi.) and freshly distilled 
triethylamine (2 equi.) in anhydrous A.ALdimethylformamide (DMF) (15 mL) was 
cooled to 0°C under a nitrogen atmosphere. A solution of the guanidinylating agent (2 
equi.) in anhydrous DMF (5 mL) was added and the mixture allowed to warm to room 
temperature. Stirring was continued at 60°C for 24 h, after which the reaction mixture 
was filtered through a short column of celite, eluting with acetate. Sodium bicarbonate 
(30 mL) was then added, the organic phase isolated and the aqueous phase further 
extracted with ethyl acetate. The organic phases were combined, washed with water 
and brine, dried over magnesium sulfate (MgS0 4 ) and concentrated. Purification by 
silica gel column chromatography, eluting first with dichloromethane (DCM) until 
removal o f unreacted guanidinylating agent, then with DCM/MeOH/NHLOH: 
250/10/1, afforded the desired product.
General procedure B -  P reparation  of guanidinylating agents. A-substitution of 
54.
A solution o f l,3-bis-ter/-butoxycarbonyl-2-methyl-2-thiopseudourea (54) (1 equi.), 
sodium hydride (3 equi.) and crown ether (18-crown-6 or 15-crown-5, 0.1 equi.) in 
dry tetrahydrofuran (THF) or DMF (5 mL) was cooled to 0°C under a nitrogen 
atmosphere. Stirring was continued for 20 minutes at that temperature before adding 
the appropriate benzyl bromide derivative (2 equi.). The reaction mixture was then 
allowed to warm to room temperature and stirring continued for 22-41 hours at 70°C. 
The reaction was quenched by slow addition of water (5 mL), the organic phase 
isolated and the aqueous phase further extracted with diethyl ether. The combined 
organic phases were washed with brine and dried (MgSCU). The crude product was 
purified by column chromatography, eluting first with n-hexanes/ethyl acetate: 2 0 /1  
then with n-hexanes/ethyl acetate: 9/1.
General Procedure C -  M ono-BOC-protection of diamines.
To a solution o f the diamine (1 equi.) in chloroform (CHCI3) (100 mL) at 0°C was 
added dropwise a solution o f di-tert-butyl-dicarbonate (0.1 equi.) in CHCI3 (45 mL). 
The ice bath was removed and stirring continued at room temperature for 24 hours. 
Brine (25 mL) was added, the organic phase isolated and the aqueous phase further
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extracted with diethyl ether. The organic phases were combined, dried (MgS0 4 ) and 
concentrated. Purification by silica gel column chromatography, eluting with 
DCM/MeOH/NRjOH: 85/10/5, afforded the protected diamine.
General Procedure D -  Preparation of isothiocyanates from primary amines.
To a solution of the primary amine (1 equi.) in CHCI3 (50 mL) was added a solution 
of calcium carbonate (1 equi.) in water (4 mL). The mixture was stirred for 5 minutes 
at room temperature before adding thiophosgene ( 2  equi.) and stirring continued for a 
further 24 hours. The organic phase was isolated, washed with water, dried (MgS0 4 ) 
and concentrated. Purification by column chromatography, eluting with 71-  
hexanes/ethyl acetate: 3/1, afforded the desired isothiocyanate.
General Procedure E -  Preparation of N,N’-disubstituted thioureas from 
isothiocyanates.
To a solution of the isothiocyanate (1 equi.) in acetone (30 mL) was added dropwise 
N H 4 O H  (concentrated aqueous solution, 10 equi.). The solution was stirred at room 
temperature for 24 hours, after which the solvents were removed under vacuum. 
Purification by silica gel column chromatography, eluting first with n-hexanes/ethyl 
acetate: 3/1 then with w-hexanes/ethyl acetate: 1/1, afforded the desired product.
General Procedure F -  BOC-Protection of N,N’-disubstituted thioureas.
A solution of the disubstituted thiourea (1 equi.) and sodium hydride (2 equi.) in dry 
THF (90 mL) was stirred for 10 min at 0°C under a nitrogen atmosphere. A solution 
of di-terf-butyl-dicarbonate (2 equi.) in THF (20 mL) was then added, the ice bath 
removed and stirring continued overnight at room temperature. The reaction was 
quenched by addition o f NaOH (aqueous solution, 0.1 M) and the mixture stirred for a 
further 20 min. The organic layer was isolated and the aqueous phase extracted with 
ethyl acetate. The combined organic phases were dried (MgS0 4 ) and concentrated. 
Purification by silica gel column chromatography, eluting with w-hexanes/ethyl 
acetate: 9/1, afforded a mixture of mono and di-BOC-protected NJ\T-disubstituted 
thioureas.
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General procedure G -  TBDMS-Protection of benzyl alcohols.
To a solution o f imidazole (2 equi.) and terZ-butyldimethylsilyl chloride (1.5 equi.) in 
dry THF (20 mL) under a nitrogen atmosphere was added slowly a solution o f the 
alcohol (1 equi.) in dry THF (10 mL). The reaction mixture was stirred overnight at 
room temperature, then water was added (5mL) and the reaction mixture extracted 
three times with diethylether. The organic phase was dried (MgS0 4 ) and the solvent 
evaporated. The crude oil was then taken up in n-hexanes and filtration of the solid -  
washing with n-hexanes- afforded the protected alcohol. If no precipitation was 
observed, the crude oil was purified by column chromatography, eluting with n- 
hexanes/ethyl acetate: 1 0 / 1 .
General procedure H -  Phthalimido-protection of primary amines.
A solution of the primary amine (1 equi.) and phthalic anhydride (1 equi.) in mixed 
xylenes was refluxed overnight under a nitrogen atmosphere. The reaction mixture 
was then cooled to room temperature and water was added. The aqueous phase was 
extracted several times with CHCI3, the organic phase was dried (MgS0 4 ) and the 
solvent evaporated. Purification by column chromatography, eluting with n- 
hexanes/ethyl acetate: 6 / 1 , afforded the desired phthalimide.
General procedure I -  N-Benzylation or N-alkykation of pyrrolic or indolic 
nitrogen.
To a solution o f 13 (or other pyrrole or indole derivative) (1 equi.) in dry THF or 
DMF (5 mL) under a nitrogen atmosphere were added sodium hydride (60% in oil, 4 
equi.) and 18-crown-6 (0.1 equi.). This mixture was stirred for 20 minutes at room 
temperature before adding a solution of the appropriate benzyl bromide (3 equi.) in 
dry THF or DMF (2 mL) and stirring continued overnight at 70°C. The reaction was 
quenched with water (5 mL), the aqueous phase extracted several times with 
DCM/MeOH: 5/1, the organic phase dried (MgSC>4) and the solvent evaporated. The 
crude oil was purified by column chromatography, eluting with CHCI3 until complete 
removal of unreacted benzyl bromide derivative, then with gradient elution 
(CHCl3/Me0 H/NH4 0 H: 900/10/1 to CHCh/MeOH/NTLOH: 200/10/1), which 
afforded the desired product.
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G eneral procedure J  -  P reparation of a , a ’-phthalimidobromoxylenes.
A mixture of dibromoxylene (1 equi.), potassium phthalimide (1 equi.) and 18-crown- 
6  (0.1 equi.) in toluene (30 mL) was refluxed overnight under a nitrogen atmosphere. 
Water was then added, the organic phase isolated, dried (MgS0 4 ) and evaporated. 
Purification by flash chromatography, eluting with n-hexanes/ethyl acetate: 4/1, 
afforded the desired product.
G eneral procedure K  -  P reparation of pyrroles from morphinan-6 -ones.
A solution of morphinan-6 -one (1 equi.) in anhydrous DMF (0.1 M) was heated to 
100°C under a nitrogen atmosphere. A solution of hydrazine sulfate (ground into a 
thin powder, 0.53 equi.) in DMF was added to the solution. The mixture was stirred 
for 6  hours at 100°C, then cooled to room temperature and the solvent evaporated 
under vacuum. The residue was dissolved in dry dimethylsulfoxide (DMSO) (0.25 M) 
and a solution of methanesulfonic acid (0.50 equi.) in dry DMSO (0.6 M) was added. 
The mixture was stirred at 130°C under a nitrogen atmosphere for 3.5 hours. The 
solution was then cooled to room temperature, diluted with water (10 mL) and 
basified to pH = 10 with NH4OH. The solution was extracted with DCM/MeOH:5/l, 
the organic phase was washed with brine and dried (MgS0 4 ). The solvent was 
removed by evaporation, yielding a dark brown oil that was purified by column 
chromatography (gradient elution, 100% DCM then DCM/MeOH/NLLjOH: 400/10/1 
to DCM/MeOH/NILOH: 110/10/1).
G eneral procedure L -  Conversion of benzyl alcohols into benzyl bromides. 
Bromine (1.2 equi.) was added dropwise to a solution of triphenylphosphine (1.2 
equi.) and imidazole (1.2 equi.) in dry DCM (20 mL) under a nitrogen atmosphere 
and stirring continued at room temperature for a further 20 minutes. A solution of the 
benzyl alcohol (1 equi.) in dry DCM (5mL) was added dropwise and the reaction 
mixture stirred at room temperature until completion. The solvent was then 
evaporated and the crude product purified by column chromatography eluting with n- 
hexanes/ethyl acetate: 3/1.
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General procedure M -  Reduction of benzaldehydes.
A solution of the benzaldehyde (2 equi.) in dry THF (10 mL) was added dropwise to a 
suspension of sodium borohydride (1 equi.) in dry THF (10 mL) and the reaction 
mixture was stirred overnight at room temperature. Water (4 mL) and a diluted 
solution of acetic acid (2.5 mL) were then added, the organic phase isolated and the 
aqueous phase further extracted with diethyl ether (2x25 mL). The organic phases 
were combined, washed first with a solution of sodium hydrogencarbonate (2x10 mL) 
then with water (2x10 mL) and dried (MgS(>4). The solvent was evaporated and the 
product used without any further purification.
General procedure N -  Preparation of isothiocyanates from primary amines in 
the morphinan series.
To a solution of the amine (1 equi.) in CHCI3 (2 mL) was added a solution of sodium 
hydrogencarbonate ( 6  equi.) in water (0.7 mL). The mixture was stirred for 20 
minutes before adding freshly distilled thiophosgene ( 1 .1  equi.) and stirring continued 
for a further 2 hours. The organic phase was isolated and the aqueous phase extracted 
with CHCI3. The organic phase was then dried (MgS0 4 ) and concentrated under 
vacuum. Purification of the crude product was performed on silica gel (10 g) using 
“Flash master personal” equipment and eluting under pressure and against gravity, 
first with 100% CHCI3 then with gradient elution (CHCh/MeOH: 300/5 to 
CHCl3/MeOH: 300/8).
General procedure O -  Deprotection of phthalimides.
The protected amine (1 equi.) was dissolved in ethanol (1 mL) and the solution was 
warmed up when necessary till complete dissolution of the material. Hydrazine 
hydrate (3 to 5 equi.) was added and the reaction mixture was stirred till complete 
deprotection (16 to 48 hours). The solvent was then removed under vacuum and the 
crude product purified by column chromatography, eluting first with 
CHCl3/Me0 H/NH4 0 H: 500/10/1, then with CHCh/M eOH/N^OH: 250/10/1.
General procedure P -  Deprotection of BOC groups with trifluoroacetic acid.
The mixture of mono- and di-BOC-protected morphinans was dissolved in DCM (3 
mL) and the solution was cooled to 0°C. Trifluoroacetic acid (2 mL) was added and
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the solution stirred for a further 30 minutes at 0°C. The ice bath was then removed 
and stirring continued overnight at room temperature. After evaporation under 
vacuum, the oil was precipitated with diethyl ether and the solid washed several times 
with diethyl ether.
lT jlT’-B isCcyclopropylm ethyl^^’jTjT’-te trad eh y d ro ^ jS ^ ’jS’-d iepoxy^^’-
o i
(imino) [TjT’-bimorphinanl-SjS’jH jH ’-tetrol (norbinaltorphim ine) (13)
Naltrexone hydrochloride (1.00 g, 2.65 mmol), hydrazine sulfate (0.18 g, 1.41 mmol) 
and methanesulfonic acid (0.08 mL, 1.31 mmol) were reacted according to the general 
procedure K. 13 was isolated as a brown solid (0.54 g, 62 %).
IR Vmax/cm (KBr): 3382 (br, bonded OH), 3075 and 3001 (C-H aromatic); *H NMR 
(400 MHz, CDC13): 0.12 (m, 4H, 2xNCH2CH(C/7HCtfH)), 0.52 (m, 4H, 
2xNCH2CH(CH//CH/7)), 0.79-0.88 (m, 2H, 2xNCH2C/7(CH2CH2)), 5.69 (s, 2H, 5-H 
+ 5’-H), 6.49 (d, 2H, .7=8.2 Hz, 1-H + l ’-H), 6 .6 6  (d, 2H, .7=8.2 Hz, 2-H + 2’-H); 13C 
NMR (100.5 MHz, CDC13): 4.27 (2xNCH2CH(CH2CH2)), 4.54
(2xN C H 2CH(CH2CH 2)), 9.87 (2xNCH2CH(CH2CH2)), 23.50 (10-C + lO’-C), 29.27 
(8 -C + 8 ’-C), 31.77 (15-C + 15’-C), 44.08 (16-C + 16’-C), 50.60 (13-C + 13’-C),
59.70 (18-C + 18’-C), 62.56 (9-C + 9’-C), 73.34 (14-C + 14’-C), 85.80 (5-C + 5’-C),
116.20 (7-C + 7’-C), 117.76 (2-C + 2’-C), 119.10 (1-C + l ’-C), 124.98 (C), 125.27 
(C), 130.80 (12-C + 12’-C), 139.32 (3-C + 3’-C), 143.08 (4-C + 4 ’-C); MS (FAB): 
m/z = 662 (M+H); C40H43N3O6 requires 661; mp > 240°C
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5’-(7VM-hydroxybenzyl) 
guanidinyl-3,14-dihydroxyindolo [Z’^ ’tf^ l-m orph inan  (50)
6 8  (mixture of mono- and di-BOC protected derivatives) (90 mg, 0.10 mmol) was 
dissolved in a mixture of conc. HCl/MeOH (2.5 mL/2.5 mL) and the solution stirred 
overnight at room temperature. The solvents were then removed under vacuum, the 
solid washed several times with diethyl ether and dried under vacuum for several 
days. 50 (HC1 salt) (0.058 g, 97%) was isolated as a brown solid.
IR vmax/cm (KBr): 3363-3234 (br, bonded OH and bonded NH), 1637 (C=N, NH and 
NH2); 'H  NMR (400 MHz, CD3OD): 0.48-0.62 (m, 2H, NCH2CH(CtfHC//H)), 0.72-
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0.93 (m, 2H, NCH2CH(CHtfCHtf)), 1.12-1.22 (m, 1H, NCH2C//(CH2CH2)), 4.26 (s, 
2H, CH2), 5.72 (s, 1H, 5-H), 6.64 (d, 1H, > 8 .0  Hz, 1-H), 6 .6 8  (d, 1H, > 8 .0  Hz, 2-H),
6.94-7.03 (m, 2H, Ar), 7.22-7.50 (m, 5H, Ar); 13C NMR (100.5 MHz, CD3OD): 2.59 
(NCH2CH(CH2CH2)), 5.50 (NCH2CH(CH2CH2)), 6.05 (NCH2CH(CH2CH2)), 24.22 
(10-C), 28.75 (CH2), 29.32 (CH2), 46.60 (CH2), 46.97 (CH2), 48.88 (13-C), 57.88 (18- 
C), 62.49 (9-C), 72.58 (14-C), 83.78 (5-C), 108.98 (Ar), 112.69 (Ar), 113.55 (Ar),
115.08 (Ar), 116.96 (Ar), 118.17 (Ar), 119.59 (Ar), 120.99 (Ar), 121.53 (Ar), 125.62 
(Ar), 127.28 (Ar), 129.08 (Ar), 129.58 (Ar), 131.29 (Ar), 136.92 (Ar), 140.82 (Ar), 
143.51 (Ar), 155.44 (Ar), 157.40 (NCNN); MS (FAB): m/z = 578.2743 (M+H); 
C34H36O4N5 requires 578.2767; Anal. (C34H35C>4N 5:3 HC1:2 H2C>) requires C 56.47 %, 
H 5.85 %, N 9.68 %, found : C 56.20 %, H 6.01 %, N 9.28 %; mp > 250°C
17-CycIopropylmethyl-6,7-didehydro-4,5a-epoxy-5’-(iV,-3-hydroxybeitzyl) 
guanidinyl-3,14-dihydroxyindolo [2’,3’:6,7]-morphinan (51)
69 (mixture o f mono- and di-BOC protected derivatives) (78 mg, 0.09 mmol) was 
dissolved in a mixture of conc. HCl/MeOH (2.5 mL/2.5 mL). A similar workup as 
used for the synthesis of 50 afforded 51 (HC1 salt) as a brown solid (51 mg, 98%).
IR Vmax/cm (KBr): 3348-3231 (br, bonded OH and bonded NH), 1637 (C=N, NH and 
NH2); ]H NMR (400 MHz, C D 3 O D ) :  0.46-0.62 (m, 2H, NCH2CH(C//HC//H)), 0.69- 
0.95 (m, 2 H, NCH2CH(CHtfCH//)), 1.08-1.21 (m, 1H, NCH2CZ/(CH2CH2)), 4.42 (s, 
2H, CH2), 5.70 (s, 1H, 5-H), 6.61-6.84 (m, 5H, Ar), 6.96 (d, 1H, > 8 .4  Hz, Ar), 7.18 
(t, 1H, > 8 .4  Hz, Ar), 7.28-7.34 (m, 1H, Ar), 7.38-7.52 (m, 1H, Ar); ,3C NMR (67.8 
MHz, C D 3 O D ) :  4.25 (NCH2CH(CH2CH2)), 7.11 (NCH2CH(CH2CH2)), 7.69 
(NCH2CH(CH2CH2)), 25.89 (10-C), 30.44 (CH2), 31.01 (CH2), 46.72 (CH2), 48.29 
(CH2), 48.73 (13-C), 59.08 (18-C), 64.29 (9-C), 74.40 (14-C), 85.60 (5-C), 110.91 
(Ar), 114.67 (Ar), 115.81 (Ar), 116.61 (Ar), 118.96 (Ar), 120.05 (Ar), 120.12 (Ar),
121.54 (Ar), 123.04 (Ar), 123.50 (Ar), 127.55 (Ar), 129.24 (Ar), 131.03 (Ar), 131.70 
(Ar), 133.22 (Ar), 138.86 (Ar), 139.96 (Ar), 142.77 (Ar), 145.49 (Ar), 158.38 (Ar), 
159.74 (NCNN); MS (FAB): m/z = 578.2748 (M+H); C34H36O4N5 requires 578.2767; 
Anal. (C34H3 5 0 4N5:3 HC1:2 H20 ) requires C 56.47 %, H 5.85 %, N 9.68 %, found : C
56.80 %, H 5.96 %, N 10.10 %; mp > 250°C
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17-CyclopropyImethyl-6,7-didehydro-4,5a-epoxy-5’-(Ar’-4-methoxybenzyI) 
guanidinyl-3,14-dihydroxyindolo [I’^ ’ib^J-m orphinan (52)
73 (0.67 g, 1.62 mmol), 53 (0.35 g, 0.81 mmol), mercury(II) chloride (0.24 g, 1.34 
mmol) and triethylamine (0.23 mL, 1.62 mmol) in DMF (18 mL) were reacted 
according to the general procedure A. A mixture containing the desired product 74 
and the mono-BOC protected analogue was obtained as a brown solid (0.31 g, 48 %).
No NMR data available as the product collected was a mixture containing 74 and its 
mono-BOC protected derivative. MS (FAB): m/z = 692 (M+H, one BOC), 792 (M+H, 
two BOC); mono-BOC protected product: C40H45N5O6 requires 691; di-BOC 
protected product: C45H53N5O8 requires 791
A solution of the above mixture (0.15 g, 0.19 mmol) in DCM (3 mL) was treated with 
trifluoroacetic acid (2 mL) as described in the general procedure P and 52 (TFA salt) 
was isolated as a brown solid (0.17 g, 96%).
IR vmax/cm (KBr): 3200 (br, bonded OH and NH), 1678, 1643 (C=N, NH and NH2); 
*H NMR (270 MHz, CD3OD): 0.43 (d, 2H, 7=4.9 Hz, NCH2CH(CflHC//H)), 0.63- 
0.80 (m, 2H, NCH2CH(CHtfCH#)), 1.01-1.09 (m, 1H, NCH2C//(CH2CH2)), 3.67 (s, 
3H, CH3), 4.28 (s, 2H, CH2), 5.61 (s, 1H, 5-H), 6.53-6.61 (m, 2H, 1-H and 2-H), 6.79-
6.90 (m, 3H, Ar), 7.14-7.21 (m, 3H, Ar), 7.31-7.34 (m, 1H, Ar); 13C NMR (67.8 MHz, 
CD3OD): 3.34 (NCH2CH(CH2CH2)), 6.17 (NCH2CH(CH2CH2)), 6.73
(NCH2CH(CH2CH2)), 24.95 (10-C), 29.59 (CH2), 30.11 (CH2), 45.55 (CH2), 47.46 
(CH2), 55.72 (CH3), 58.87 (18-C), 63.56 (9-C), 73.51 (14-C), 84.78 (5-C), 110.00 (C),
113.80 (CH), 115.19 (CH), 118.08 (CH), 119.33 (CH), 120.60 (CH), 122.25 (CH),
122.48 (C), 126.83 (C), 128.42 (C), 129.46 (C), 129.68 (CH), 130.15 (C), 132.40 (C),
138.08 (C), 142.01 (C), 144.70 (C), 157.47 (C), 160.80 (CN); MS (FAB): m/z = 
592.2895 (M+H), C35H38N5O4 requires 592.2923; Anal. (C35H37Ns0 4 :3 TFA) requires 
C 52.73 %, H 4.32 %, N 7.50 %, found : C 52.50 %, H 4.79 %, N 7.96; mp > 220°
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5’-Amino-17-cycIopropyImethyl-6,7-didehydro-4,5a-epoxy-3,14-dihydroxyindolo 
[2 \3 ’:6,7]-morphinan (53) 106
Method A
To a solution of 56 (1.08 g, 2.38 mmol) in methanol (15 mL) were added 2 spatula of 
Raney nickel. The mixture was stirred at room temperature under a nitrogen 
atmosphere for 10 minutes, after which hydrazine hydrate (2.3 mL, 47.3 mmol) was 
slowly added and stirring continued at 55°C for a further 6  hours. The mixture was 
then filtered through a short column of celite, concentrated and purified by column 
chromatography, eluting with DCM/MeOH/NfLOH: 110/10/1. 53 was isolated as a 
brown solid (0.47 g, 47 %).
Method B
A solution of 56 (2.50 g, 5.5 mmol) and iron(II)sulfate heptahydrate (13.62 g, 49.0 
mmol) in methanol (120 mL), water (24 mL) and NH4OH (84 mL) was stirred at 80°C 
for 3 hours. The reaction mixture was then allowed to cool to room temperature, 
filtered and extracted, first with D C M  then with DCM /M eO H : 5/1. The organic phase 
was dried (MgS0 4 ), concentrated under vacuum and the crude oil purified by column 
chromatography, eluting first with CHCI3 then with CH Ch/M eO H /NLLO H : 250/10/1. 
39 was isolated as a brown solid (1.31 g, 56 %).
*H NMR (270 MHz, CD3OD): 0.32-0.38 (m, 2H, NCH2CH(C/fflCi7H)), 0.65-0.76 
(m, 2H, NCH2CH(CHtfCHtf)), 0.91-1.02 (m, 1H, NCH2Gtf(CH2CH2)), 5.74 (s, 1H, 
5-H), 6.54 (d, 1H, J= 8.3 Hz, 1-H), 6.70 (d, 1H, 7=8.3 Hz, 2-H), 7.29 (m, 1H, 7’-H), 
7.98 (m, 1H, 6 ’-H), 8.37 (m, 1H, 4 ’-H); 13C NMR (67.8 MHz, CD3OD): 3.42 
(NCH2CH(CH2CH2)), 3.89 (NCH2CH(CH2CH2)), 8.63 (NCH2CH(CH2CH2)), 23.31 
(10-C), 28.26 (CH2), 30.64 (CH2), 43.81 (16-C), 47.28 (13-C), 58.47 (18-C), 62.17 (9- 
C), 72.48 (14-C), 84.65 (5-C), 104.02 (Ar), 109.23 (Ar), 111.83 (Ar), 113.67 (Ar), 
117.01 (Ar), 118.41 (Ar), 124.08 (Ar), 126.48 (Ar), 129.13 (Ar), 130.35 (Ar), 132.61 
(Ar), 137.05 (Ar), 139.42 (Ar), 143.10 (Ar); MS (FAB): m/z = 430 (M); C26H28N30 3  
requires 430; Rf (DCM/MeOH/NFLOH: 110/10/1): 0.33
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17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5’-nitro-3,14-dihydroxyindolo 
[I’^ ’^ ^ l-m o rp h in an  (56)106
A solution of naltrexone (3.00 g, 8 .8  mmol) and 4-nitrophenylhydrazine (1.61 g, 10.5 
mmol) in ethanol/conc. HC1 (45 mL/45 mL) was refluxed for 24 h under a nitrogen 
atmosphere. The solvents were then removed under vacuum and the residue basified 
to pH = 10 with NH4OH. The solution was extracted with DCM, the organic phase 
was dried (MgSCU) and the solvent removed by evaporation. The dark residue was 
purified by column chromatography, eluting first with 100 % DCM, then with 
DCM/MeOH/NLLOH: 300/10/1. 56 was isolated as a brown solid (1.07 g, 26 %).
IR vmax/cm (KBr): 3391 (br, bonded OH and bonded NH), 1156 (C-N); ]H NMR (270 
MHz, CDCI3): 0.10-0.26 (m, 2H, NCH2CH(CifflC//H)), 0.48-0.61 (m, 2H, 
NCH2CH(CH//CH//)), 0.86-1.03 (m, 1H, NCH2C//(CH2CH2)), 5.50 (s, 1H, 5-H), 
6.45-6.52 (m, 2H, 1-H and 2-H), 7.10-7.18 (m, 1H, Ar), 7.20-7.29 (m, 2H, Ar); 13C 
NMR (67.8 MHz, CDCI3): 4.08 (NCH2CH(CH2CH2)), 4.14 (NCH2CH(CH2CH2)),
9.28 (NCH2CH(CH2CH2)), 23.24 (10-C), 27.94 (CH2), 31.28 (CH2), 43.51 (16-C), 
48.12 (13-C), 59.23 (18-C), 62.08 (9-C), 72.49 (14-C), 84.36 (5-C), 110.08 (Ar), 
113.59 (Ar), 114.97 (Ar), 116.87 (Ar), 117.83 (Ar), 119.97 (Ar), 124.72 (Ar), 125.86 
(Ar), 130.28 (Ar), 131.87 (Ar), 138.24 (Ar), 139.36 (Ar), 139.84 (Ar), 143.02 (Ar); 
MS (FAB): m/z = 460 (M); C26H26N30 5  requires 460; Rf (DCM/MeOH/NFLOH: 
89/10/1): 0.54; mp > 230°C (lit.: >230°C)183a
4-(Benzyloxy)benzyl brom ide (60) 184,185
Triphenylphosphine (1.57 g, 6.0 mmol), imidazole (0.408 g, 6.0 mmol), bromine 
(0.31 mL, 6.0 mmol) and 6 6  (1.07 g, 5.0 mmol) in dry DCM (25mL) were reacted 
according to general procedure L. 60 was obtained as a white solid after purification 
by column chromatography (1.29 g, 93%).
IR Vmax/cm (neat): 3064 and 3030 (C-H aromatic); *H NMR (400 MHz, CDC13): 4.50 
(s, 2H, CH2Br), 5.06 (s, 2H, CH2), 6.92-6.96 (m, 2H, Ar), 7.25-7.44 (m, 7H, Ar); 13C 
NMR (100.5 MHz, CDCI3): 34.01 (CH2Br), 70.02 (CH20 ) , 114.97 (CH), 127.31 
(CH), 127.91 (CH), 128.48 (CH), 130.03 (C), 130.31 (CH), 136.49 (C), 158.61 (C); 
Rf (n-hexanes/ethyl acetate: 1/1): 0.93; mp : 82°C (lit.: 78-82°C)184
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3-(Benzyloxy)benzyl bromide (61)184,186
Triphenylphosphine (3.51 g, 13.4 mmol), imidazole (0.91 g, 13.4 mmol), bromine 
(0.69 mL, 13.4 mmol) and 67 (2.39 g, 11.2 mmol) in dry DCM (15mL) were reacted 
according to general procedure L. 61 was obtained as a colourless solid after 
purification by column chromatography (2.73 g, 8 8 %).
IR Vm ax/cm  (neat): 3063 and 3032 (C-H aromatic); JH NMR (400 MHz, CDC13): 4.47 
(s, 2H, CH2Br), 5.07 (s, 2H, CH2), 6.90-6.93 (m, 1H, Ar), 6.99-7.03 (m, 2H, Ar),
7.24-7.46 (m, 6 H, Ar); 13C NMR (100.5 MHz, CDC13): 33.56 (CH2Br), 69.99 (CH20),
114.82 (CH), 115.29 (CH), 121.42 (CH), 127.38 (CH), 127.90 (CH), 128.46 (CH),
129.70 (CH), 136.52 (C), 138.99 (C), 158.71 (C); MS (FAB): m/z = 276 (M, 79Br), 
277 (M+H, 79Br), 278 (M, 81Br), 279 (M+H, 81Br); C i^ n O B r requires 277; Rf («- 
hexanes/ethyl acetate: 1/1): 0.93; mp : 37°C (lit.: 37-39°C) 186
1.3-Bis-terf-butoxycarbonyl-l-(4’-benzyloxybenzyl)-2-methyl-2-thiopseudourea
(62)
1.3-Bis-terr-butoxycarbonyl-2-methyl-2-thiopseudourea (0.79 g, 2.7 mmol), sodium 
hydride (60% in oil, 0.13 g, 3.3 mmol) and 60 (0.83 g, 3.0 mmol) in dry DMF (11 
mL) were reacted according to the procedure B. Purification by column 
chromatography, eluting with w-hexanes/ethyl acetate: 9/2, afforded 62 as a very 
viscous colourless oil (0.91 g, 62 %).
IR Vmax/cm (neat): 2978, 2932 (C-H aromatic), 1742 (carbamate), 1715 (C=N), 1612 
(carbamate), 1153 (C-N); *H NMR (270MHz, CDC13): 1.42 (s, 9H, C(CH3)3), 1.53 (s, 
9H, C(CH3)3), 2.27 (s, 3H, SCH3), 4.72 (s, 2H, CH2N), 5.05 (s, 2H, CH20), 6.91-6.96 
(d, 2H, > 8 .4  Hz, Ar), 7.25-7.43 (m, 7H, Ar); 13C NMR (67.8 MHz, CDC13): 15.53 
(SCH3), 27.95 (2xC(CH3)), 51.79 (CH2N), 69.92 (CH20), 81.71 (C(CH3)), 82.56 
(C(CH3)), 114.63 (CH), 127.44 (CH), 127.89 (CH), 128.50 (CH), 129.31 (CH),
129.65 (C), 136.89 (C), 152.17 (C), 157.99 (CO), 158.15 (CO), 163.40 (CN); MS 





1.3-Bis-ter/-butoxycarbonyl-2-methyl-2-thiopseudourea (0.29 g, 1.01 mmol), sodium 
hydride (60% in oil, 48 mg, 1.21 mmol) and 61 (0.31 g, 1.11 mmol) in dry DMF (5 
mL) were reacted according to the procedure B. After purification by column 
chromatography, eluting with n-hexanes/ethyl acetate: 9/2, 63 was isolated as a very 
viscous colourless oil (0.29 g, 54 %).
IR vmax/cm (neat): 2978, 2931 (C-H aromatic), 1721 (br, C=N), 1611 (carbamate), 
1140 (C-N); NMR (400 MHz, CDC13): 1.39 (s, 9H, C(CH3)3), 1.52 (s, 9H, 
C(CH3)3), 2.28 (s, 3H, SCH3), 4.76 (s, 2H, CH2N), 5.06 (s, 2H, CH20), 6.94 (m, 2H, 
Ar), 7.01 (s, 1H, 2-H), 7.21-7.26 (m, 2H, Ar), 7.29-7.44 (m, 5H, Ar); 13C NMR (100.5 
MHz, CDC13): 15.72 (SCH3), 28.04 (C(CH3)), 28.13 (C(CH3)), 52.40 (CH2N), 69.84 
(CH20 ), 81.65 (C(CH3)), 82.71 (C(CH3)), 113.63 (CH), 114.08 (CH), 120.05 (CH),
127.32 (CH), 127.74 (CH), 128.38 (CH), 129.25 (CH), 136.82 (C), 138.83 (C),
151.66 (3-C), 157.71 (CO), 158.63 (CO), 163.08 (CN); Rf (w-hexanes/ethyl acetate: 
9/2): 0.52
4-(Benzyloxy)benzaldehyde (64) 187,188
To a solution of 4-hydroxybenzaldehyde (1.22 g, 10.0 mmol) and anhydrous 
potassium carbonate (2.07 g, 15.0 mmol) in dry DMF (5mL) was added dropwise a 
solution o f benzyl bromide (1.71 g, 1.2 mL, 10.0 mmol) in dry DMF (lm L). The 
mixture was stirred overnight at room temperature under a nitrogen atmosphere. 
Water (3 mL) was then added and the solution extracted with diethyl ether (2x25 mL). 
The organic phase was washed with water (2x10 mL), dried (MgS0 4 ) and the solvent 
removed by evaporation. 64 was isolated as a white solid and used without any further 
purification (1.94 g, 91 %).
IR vmax/cm (KBr): 3034 and 3071 (C-H aromatic), 2810 and 2727 (C-H aldehyde), 
1694 (CO); !H NMR (400 MHz, CDC13): 5.15 (s, 2H, CH2), 7.07 (d, 2H, .7=8.6 Hz), 
7.32-7.45 (m, 5H, Ph), 7.83 (d, 2H, ,7=8.6 Hz), 9.89 (s, 1H, CHO); 13C NMR (100.5 
MHz, CDC13): 70.25 (CH20), 115.01 (CH), 127.34 (CH), 128.19 (CH), 128.58 (CH), 
129.93 (C), 131.84 (CH), 135.74 (C), 163.47 (C), 190.51 (CO); MS (FAB): m/z = 213
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(M+H); C14H 12O2 requires 212; Rf (n-hexanes/ethyl acetate: 1/1): 0.87; mp. : 65 °C 
(lit.: 67-68°C)188
3-(Benzyloxy)benzaldehyde (65) 188,189
3-Hydroxybenzaldehyde (1.22 g, 10.0 mmol), anhydrous potassium carbonate (2.07 g,
15.0 mmol) and benzyl bromide (1.71 g, 1.2 mL, 10.0 mmol) in dry DMF were 
reacted as for the synthesis of 64. 65 was isolated as a white solid and used without 
any further purification (2.02 g, 95 %).
IR Vmax/cm (KBr): 3024 and 3055 (C-H aromatic), 2829 and 2744 (C-H aldehyde), 
1686 (CO); ‘H NMR (400 MHz, CDCI3): 5.13 (s, 2H, CH2), 7.26 (m, 1H), 7.33-7.49 
(m, 8 H), 9.97 (s, 1H, CHO); 13C NMR (100.5 MHz, CDCb): 70.19 (CH20), 113.07 
(CH), 122.06 (CH), 123.56 (CH), 127.39 (CH), 128.06 (CH), 128.52 (CH), 129.96 
(CH), 136.10 (C), 137.61 (C), 159.05 (C), 191.79 (CO); MS (FAB): m/z = 213 
(M+H); C14H12O2 requires 212; Rf (n-hexanes/ethyl acetate: 1/1): 0.87; mp : 52°C 
(lit.: 52-53°C)190
4-(Benzyloxy)benzyl alcohol (6 6 ) 185,187
Sodium borohydride (0.38 g, 5.0 mmol) and 64 (2.12 g, 10.0 mmol) in dry THF (20 
mL) were reacted according to the general procedure M. 6 6  was isolated as a white 
solid (2.0 g, 93 %).
IR vmax/cm (KBr): 3329 (br, bonded OH), 3060 and 3034 (C-H aromatic); *H NMR 
(270 MHz, CDC13): 4.49 (s, 2H, C tf2OH), 5.05 (s, 2H, CH2), 6.93 (d, 2H, J=8.4 Hz, 
Ar), 7.25-7.45 (m, 7H, Ar); 13C NMR (100.5 MHz, CDC13): 64.74 (CH2OH), 69.89 
(CH20 ), 114.66 (CH), 127.23 (CH), 127.74 (CH), 128.36 (CH), 128.41 (CH), 133.16 
(C), 136.67 (C), 157.98 (C); MS (FAB): m/z = 214 (M), 215 (M+H); Ci4Hi40 2 
requires 214; Rf (n-hexanes/ethyl acetate: 1/1): 0.64; mp : 83°C (lit.: 86-90°C)191
3-(Benzyloxy)benzyl alcohol (67) 191
65 (1.06 g, 5.0 mmol) and sodium borohydride (0.19 g, 5.0 mmol) in dry THF (10 
mL) were reacted according to the general procedure M. This afforded 67 as a white 
solid (0.90 g, 84 %).
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IR Vmax/cm (KBr): 3340 (br, bonded OH), 3063 and 3032 (C-H aromatic); ]H NMR 
(400 MHz, CDC13): 4.64 (s, 2H, Ci/2OH), 5.07 (s, 2H, CH2), 6.90-7.03 (m, 3H, Ar),
7.25-7.46 (m, 6 H, Ar); 13C NMR (100.5 MHz, CDC13): 65.15 (CH2OH), 69.89 
(CH20), 113.06 (CH), 113.94 (CH), 119.21 (CH), 126.81 (CH), 127.32 (CH), 127.47 
(CH), 127.80 (CH), 128.41 (CH), 129.45 (CH), 136.73 (C), 142.37 (C), 158.77 (C); 
MS (FAB): m/z = 214 (M), 215 (M+H); Ci4Hi4 0 2 requires 214; Rf (n-hexanes/ethyl 
acetate: 1/1): 0.72; mp : 44°C (lit.: 44.5-45°C) 190
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-bis-rerr-butoxycarbonyl-(A’-
4-benzyloxybenzyl)guanidinyl-3,14-dihydroxyindolo [2’,3’:6,7]-morphinan (6 8 )
62 (0.35, 0.72 mmol), 53 (0.153 g, 0.36 mmol), mercury(II) chloride (0.158 g, 0.58 
mmol) and triethylamine (0.10 mL, 0.72 mmol) in dry DMF (10 mL) were reacted 
according to the general procedure A. A mixture containing 6 8  and the mono-BOC 
protected analogue was obtained as a brown solid (0,11 g, 35%).
Data for di-BOC protected product:
IR Vmax/cm (KBr): 3368 (br, bonded OH and bonded NH), 1671 (C=N); *H NMR (400 
MHz, CDCI3): 0.09-0.17 (m, 2H, NCH2CH(C//HC//H)), 0.45-0.58 (m, 2H, 
NCH2CH(CHtfCHtf)), 0.80-0.92 (m, 1H, NCH2Ci/(CH2CH2)), 1.38 (s, 9H, 
C(CH3)3), 1.46 (s, 9H, C(CH3)3), 4.85 (s, 2H, CH2), 5.03 (s, 2 H, CH20), 5.60 (s, 1H,
5-H), 6.45 (d, 1H, 7=7.8 Hz, 1-H), 6.56 (d, 1H, 7=7.8 Hz, 2-H), 6.64-7.06 (m, 4H, 
Ar), 7.29-7.43 (m, 8 H, Ar); 13C NMR (100.5 MHz, CDC13): 4.25
(NCH2CH(CH2CH2)), 4.42 (NCH2CH(CH2CH2)), 9.92 (NCH2CH(CH2CH2)), 23.62 
(10-C), 28.04 (C(CH3)), 28.60 (C(CH3)), 29.26 (CH2), 31.90 (CH2), 43.81 (16-C),
48.34 (CH2N), 50.84 (13-C), 59.85 (18-C), 62.75 (9-C), 70.29 (CH20), 72.75 (14-C),
80.14 (C(CH3)), 82.02 (C(CH3)), 85.29 (5-C), 111.94 (Ar), 112.54 (Ar), 114.64 (Ar), 
115.03 (Ar), 117.51 (Ar), 118.57 (Ar), 119.07 (Ar), 124.93 (Ar), 126.97 (Ar), 127.53 
(Ar), 127.63(Ar), 128.15 (Ar), 128.73 (Ar), 129.94 (Ar), 130.51 (Ar), 130.89 (Ar),
130.97 (Ar), 135.47 (Ar), 137.09 (Ar), 139.65 (Ar), 143.11 (Ar), 152.64 (Ar), 158.10 
(CO), 158.35 (CO), 162.82 (NCNN); MS (FAB): m/z = 8 6 8  (M+H); C51H57N5O8 




63 (0.52 g, 1.07 mmol), 53 (0.23 g, 0.53 mmol), mercury(II) chloride (0.158 g, 0.88 
mmol) and triethylamine (0.15 mL, 1.07 mmol) in dry DMF (12 mL) were reacted 
according to the general procedure A. A mixture containing 69 and the mono-BOC 
protected analogue was obtained as a brown solid (0.14 g, 30%).
Data for di-BOC protected product:
IR Vmax/cm (KBr): 3362 (br, bonded OH and bonded NH), 1671 (C=N); *H NMR (400 
MHz, CDCI3): 0.12-0.20 (m, 2H, NCH2CH(C77HC/m)), 0.51-0.62 (m, 2H, 
NCH2CH(CH//CH//)), 0.99-1.12 (m, 1H, NCH2Gtf(CH2CH2)), 1.37 (s, 9H, 
C(CH3)3), 1.47 (s, 9H, C(CH3)3), 4.98 (s, 2H, CH2N), 5.02 (s, 2H, CH20), 5.61 (s, 1H,
5-H), 6.49 (d, 1H, .7=8.2 Hz, 1-H), 6.58 (d, 1H, 7=8.2 Hz, 2-H), 6.67-7.38 (m, 12H, 
Ar); 13C NMR (100.5 MHz, CDC13): 3.92 (NCH2CH(CH2CH2)), 4.11
(NCH2CH(CH2CH2)), 9.53 (NCH2CH(CH2CH2)), 23.18 (10-C), 28.03 (C(CH3)),
28.15 (C(CH3)), 28.70 (CH2), 31.37 (CH2), 43.46 (16-C), 47.96 (CH2N), 50.60 (13- 
C), 59.43 (18-C), 62.41 (9-C), 69.74 (CH20), 72.36 (14-C), 81.95 (C(CH3)), 82.55 
(C(CH3)), 84.97 (5-C), 111.51 (Ar), 112.32 (Ar), 114.27 (Ar), 114.75 (Ar), 117.16 
(Ar), 118.11 (Ar), 118.76 (Ar), 121.56 (Ar), 124.62 (Ar), 126.60 (Ar), 127.25 (Ar),
127.42 (Ar), 127.61 (Ar), 128.25 (Ar), 129.21 (Ar), 129.98 (Ar), 130.48 (Ar), 135.00 
(Ar), 136.72 (Ar), 136.93 (Ar), 139.12 (Ar), 142.63 (Ar), 143.72 (Ar), 149.32 (Ar), 
158.35 (CO), 158.44 (CO), 162.46 (NCNN); MS (FAB): m/z = 868.4294 (M+H); 
CsiHsgNsOg requires 868.4285; Rf (DCM/MeOH/NILOH: 110/10/1): 0.57
4-Methoxybenzaldehyde (70)192
To a mixture o f 4-hydroxybenzaldehyde (6.10 g, 50.0 mmol) and anhydrous 
potassium carbonate (10.35 g, 75.0 mmol) in dry DMF (25mL) was added dropwise 
methyl iodide (3.1 mL, 50.0 mmol). The mixture was stirred overnight at room 
temperature under a nitrogen atmosphere. Water (15 mL) was added and the solution 
extracted with diethyl ether (2x50 mL). The organic phase was washed with brine 
(2x20 mL), dried (MgS0 4 ) and concentrated under vacuum. 70 was used without any 
further purification and isolated as an orange oil (6.26 g, 92 %).
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IR Vmax/cm (neat): 2840 and 2740 (C-H aldehyde), 1682 (CO); ‘H NMR (270 MHz, 
CDCb): 3.85 (s, 3H, CH3), 6.98 (d, 2H, 7 =8 .8  Hz), 7.81 (d, 2H, 7=8.8 Hz), 9.86 (s, 
1H, CHO); l3C NMR (67.8 MHz, CDCI3): 55.86 (CH3), 114.47 (CH), 130.02 (C), 
132.06 (CH), 164.64 (C), 190.77 (CHO); MS (El): m/z = 136.0510 (M), CSH80 2  
requires 136.0524; Rf (n-hexanes/ethyl acetate: 6/1): 0.44
4-Methoxybenzyl alcohol (71 )193
A suspension of sodium borohydride (1.52 g, 40.0 mmol) in dry THF (35 mL) and a 
solution o f 70 (5.44 g, 40.0 mmol) in dry THF (35 mL) were reacted according to the 
general procedure M. 71 was obtained as a yellow oil (5.49 g, 99 %).
IR vmax/cm (neat): 3338 (br, bonded OH), 3064 and 3033 (C-H aromatic); *H NMR 
(270 MHz, CDC13): 2.95 (br, s, 1H, OH), 3.76 (s, 3H, CH3), 4.51 (s, 2H, CH2OH),
6.84 (d, 2H, 7=8.6 Hz), 7.23 (d, 2H, 7=8.6 Hz); 13C NMR (67.8 MHz, CDC13): 55.08 
(CH3), 64.40 (CH2), 113.68 (CH), 128.44 (CH), 133.04 (C), 158.83 (C); MS (El): m/z 
= 138.0682 (M), C8H10O2 requires 138.0680; Rf (n-hexanes/ethyl acetate: 1/1): 0.51
4-Methoxybenzyl bromide (72) 194,195
Triphenylphosphine (6.25 g, 24.0 mmol), imidazole (1.63 g, 24.0 mmol), bromine 
(1.22 mL, 24.0 mmol) and 71 (2.76 g, 20.0 mmol) in dry DCM (lOOmL) were reacted 
according to the general procedure L. 72 was used with no further purification (only a 
small quantity of the crude product has been purified on column chromatography for 
NMR characterisation).
'H  NMR (270 MHz, CDC13): 3.78 (s, 3H, CH3), 4.49 (s, 2H, C ftB r), 6.85 (d, 2H, 
7=8.6 Hz), 7.31 (d, 2H, 7=8.6 Hz); 13C NMR (100.5 MHz, CDCI3): 34.50 (CH2Br),
55.70 (CH3), 114.45 (CH), 130.14 (C), 130.67 (CH), 159.78 (C)
1.3-Bis-te/7-butoxycarbonyl-l-(4’-methoxybenzyl)-2-methyl-2-thiopseudourea 
(73) 196
1.3-Bis-te/7-butoxycarbonyl-2-methyl-2-thiopseudourea (5.35 g, 18.2 mmol), sodium 
hydride (60% in oil, 1.41 g, 35.2 mmol), 15-crown-5 (0.2 mL, 1.0 mmol) and 4- 
methoxybenzyl bromide (72) (4.02 g, 20.0 mmol) in dry DMF (27 ml) were reacted
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according to the general procedure B. 73 was isolated as a very viscous colourless oil 
(4.0 g, 49 %).
IR Vmax/cm (neat): 1719 (C=N), 1613 (carbamate), 1141 (C-N); *H NMR (270 MHz, 
CDC13): 1.40 (s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3), 2.24 (s, 3H, SCH3), 3.77 (s, 3H, 
OCH3), 4.69 (s, 2H, CH2), 6.83 (d, 2H, 7=9.0 Hz), 7.26 (d, 2H, 7=9.0 Hz); 13C NMR 
(100.5 MHz, CDC13): 15.43 (SCH3), 27.91 (C(CH3)), 27.94 (C(CH3)), 51.74 (CH2),
55.04 (OCH3), 81.49 (C(CH3)), 82.39 (C(CH3)), 113.63 (CH), 129.26 (CH), 151.87 
(C), 157.87 (CO), 158.98 (CO), 163.05 (CN); MS (FAB): m/z = 411.1952 (M+H); 
C2oH3iN20 5 S requires 411.1953; Rf (n-hexanes/ethyl acetate: 5/1): 0.33
17-CyclopropyImethyl-6,7-didehydro-4,5a-epoxy-5’-(Ar’-3,4-dichlorobenzyl) 
guanidinyl-3,14-dihydroxyindolo [2%3’:6,7]-morphinan (75)
78 (0.49 g, 1.09 mmol), 53 (0.24 g, 0.55 mmol), mercury(II) chloride (0.22 g, 0.83 
mmol) and triethylamine (0.15 mL, 1.10 mmol) in dry DMF (10 ml) were reacted 
according to the general procedure A. A mixture containing 17-cyclopropylmethyl-
6,7-didehydro-4,5a-epoxy-5’-bis-ter/-butoxycarbonyl-(Ar-3,4-dichlorobenzyl) 
guanidinyl-3,14-dihydroxyindolo [2’,3’:6,7]-morphinan (82) and the corresponding 
mono-BOC-protected analogue was obtained as a brown solid (0.34 g, 74 %).
No NMR data available. IR (82) vmax/cm (neat): 3393 (br, bonded OH), 1712 (C=N), 
1611 (carbamate); MS (FAB): m/z = 730 (M+H, 35C12), 732 (M+H, 35C137C1), 830 
(M+H, 35C12), 832 (M+H, 35C137C1); mono-BOC protected product: C39H4 i35Cl2N50 5  
requires 730; di-BOC protected product: C44H4935C12N5<>7 requires 830; HRMS (di- 
Boc protected compound): 830.3088 (M+H, 35C12), 832.3080 (M+H, 35C137C1); 
C44H5o35C12N50 7  requires 830.3087 and C44H5035Cl37ClN5O7 requires 832.3057; Rf 
(DCM/MeOH/NFLtOH: 200/12/1): 0.66
The above mixture (0.26 g, 0.31 mmol) was dissolved in DCM (3 mL) and treated 
with trifluoroacetic acid (2 mL) as described in the general procedure P. 75 (TFA salt) 
was isolated as a brown solid (0.25 g, 90%).
IR vmax/cm (KBr): 3193 (br, bonded OH and NH), 1678 and 1633 (C=N, NH and 
NH2); 'H  NMR (270 MHz, CD3OD/CDCI3: 6/1): 0.52 (d, 2H, 7 =4 . 2  Hz,
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NCH2CH(C//HC//H)), 0.72-0.88 (m, 2H, NCH2CH(CHi/CHtf)), 2.32 (s, 3H, CH3), 
4.45 (s, 2H, CH2), 5.69 (s, 1H, 5-H), 6.64-6.71 (m, 2H, 1-H and 2-H), 6.97 (d, 1H, 
J= 8.7 Hz, 6 ’-H), 7.22-7.27 (m, 2H), 7.41 (d, 1H, > 8 .7  Hz, 4 ’-H), 7.47-7.50 (m, 2H); 
13C NMR (67.8 MHz, CD30D/CDC13: 6/1): 3.85 (NCH2CH(CH2CH2)), 6.70 
(NCH2CH(CH2CH2)), 7.22 (NCH2CH(CH2CH2)), 25.44 (10-C), 30.02 (CH2), 30.57 
(CH2), 45.18 (CH2), 47.85(CH2), 48.36 (13-C), 59.33 (18-C), 63.96 (9-C), 73.97 (14- 
C), 85.24 (5-C), 110.47 (C), 114.37 (CH), 118.49 (CH), 119.82 (CH), 121.15 (CH), 
122.65 (CH), 122.92 (C), 127.15 (C), 128.36 (CH), 128.85 (C), 130.67 (CH), 132.27 
(CH), 132.85 (C), 133.05 (C), 134.03 (C), 138.51 (C), 139.09 (C), 142.43 (C), 145.12 
(C), 158.11 (NCNN); MS (FAB): m/z = 630.2026 (M+H, 35C12), 632.2014 (M+H, 
35C137C1), 634.2019 (M+H, 37C12), C34H3435C12N50 3 requires 630.2038,
C34H3435C137C1N50 3 requires 632.2008, C34H3437C12N 50 3 requires 634.1979; Anal. 
(C34H33N50 3C12:2TFA:2H20 )  requires C 51.01 %, H 4.39 %, N 7.83 %, found : C
50.90 %, H 4.03 %, N 7.78 %; mp: 190°C
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5’-(A’-4-methylbenzyl) 
guanidinyl-3,14-dihydroxyindolo [2’,3’:6,7]-morphinan (76)
77 (0.43 g, 1.09 mmol), 53 (0.24 g, 0.55 mmol), mercury(II) chloride (0.22 g, 0.83 
mmol) and triethylamine (0.15 mL, 1.10 mmol) in dry DMF (10 ml) were reacted 
according to the general procedure A. A mixture containing 17-cyclopropylmethyl-
6,7-didehydro-4,5a-epoxy-5,-bis-ter/-butoxycarbonyl-(A,-4-methylbenzyl)guanidinyl 
-3,14-dihydroxyindolo [2’,3’:6,7]-morphinan (81) and the corresponding mono-BOC 
protected analogue was obtained as a brown solid (0.29 g, 6 8  %).
No NMR data available as the product collected contained a mixture of di-BOC 
protected compound (81) and its mono-BOC protected derivative; IR vmax/cm (neat): 
3395 (br, bonded OH), 1706 (O N ), 1609 (carbamate); MS (FAB): m/z = 676 (M+H), 
776 (M+H); mono-BOC protected product: C40H45N 5O5 requires 675; di-BOC 
protected product: C45H53Ns0 7  requires 775; HRMS (FAB) m/z = 776.4037 (M+H), 
C45H54N50 7  requires 776.4023; Rf (DCM/MeOH/NFLOH: 200/12/1): 0.66
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The above mixture (0.19 g, 0.24 mmol) in DCM (3 mL) was deprotected with 
trifluoroacetic acid (2 mL) as described in the general procedure P and 76 (TFA salt) 
was isolated as a brown solid (0.22 g, 96%).
IR Vmax/cm (KBr): 3310 (br, bonded OH and NH), 1681 (O N , NH and NH2); ]H 
NMR (270 MHz, CD30D/CDC13: 6/1): 0.53 (d, 2H, .7=4.0 Hz, NCH2CH(C//HCtfH)), 
0.74-0.93 (m, 2H, NCH2CH(CH/7CHtf)), 2.32 (s, 3H, CH3), 4.23 (d, 1H, 7= 6.0 Hz, 
C77H), 4.41 (s, 2H, CH2), 5.72 (s, 1H, 5-H), 6.64 (d, 1H, .7=8.2 Hz, 1-H), 6.68 (d, 1H, 
.7=8.2 Hz, 2-H), 7.01 (dd, 1H, 7=1.8Hz and .7=8.7 Hz, 6’-H), 7.18 (d, 2H, .7=8.9 Hz),
7.20 (d, 2H, .7=8.9 Hz), 7.33 (d, 1H, .7=1.8 Hz, 7 ’-H), 7.44 (d, 1H, .7=8.7 Hz, 4 ’-H); 
13C NMR (67.8 MHz, CD30D/CDC13: 6/1): 3.86 (NCH2CH(CH2CH2)), 6.69 
(NCH2CH(CH2CH2)), 7.16 (NCH2CH(CH2CH2)), 21.72 (CH3), 25.39 (10-C), 29.96 
(CH2), 30.52 (CH2), 46.19 (CH2), 47.87 (CH2), 48.29 (13-C), 59.30 (18-C), 63.90 (9- 
C), 73.90 (14-C), 85.18 (5-C), 110.38 (C), 114.27 (CH), 118.52 (CH), 119.77 (CH),
121.04 (CH), 122.66 (CH), 122.74 (C), 127.09 (C), 128.61 (CH), 128.79 (C), 130.47 
(C), 130.87 (CH), 132.78 (C), 134.79 (C), 138.45 (C), 139.19 (C), 142.39 (C), 145.06 
(C), 157.90 (NCNN); MS (FAB): m/z = 575.2952 (M), 576.3008 (M+H); C35H38N50 3 
requires 576.2974; Anal. (C35H37N50 3:3TFA:2H20 )  requires C 51.62 %, H 4.65 %, N
7.34 %, found : C 51.30 %, H 4.42 %, N 7.28 %; mp > 190°C (decomposition)
1.3-Bis-te#7-butoxycarbonyl-l-(4’-methylbenzyl)-2-methyl-2-thiopseudourea (77)
1.3-Bis-ter/-butoxycarbonyl-2-methyl-2-thiopseudourea (2.90 g, 10.0 mmol), sodium 
hydride (60% in oil, 0.44 g, 11.0 mmol), 15-crown-5 (0.2 mL, 1 mmol) and 4- 
methylbenzyl bromide (2.22 g, 12.0 mmol) in dry DMF (20 ml) were reacted 
according to the general procedure B. 77 was isolated as a colourless oil (2.93 g, 74 
%).
IR Vmax/cm (neat): 3350 (br, bonded OH), 1612 (carbamate); *H NMR (270 MHz, 
CDC13): 1.40 (s, 9H, C(CH3)3), 1.51 (s, 9H, C(CH3)3), 2.26 (s, 3H, SCH3), 2.31 (s, 3H, 
CH3), 4.72 (s, 2H, CH2), 7.11 (d, 2H, 7=7.9 Hz), 7.21 (d, 2H, 7=7.9 Hz); 13C NMR 
(67.8 MHz, CDC13): 14.79 (SCH3), 20.43 (CH3), 27.26 (C(CH3)), 27.32 (C(CH3)),
51.43 (CH2), 80.76 (C(CH3)), 81.73 (C(CH3)), 127.08 (CH), 128.34 (CH), 133.58 (C),
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136.27 (C), 151.21 (CO), 157.15 (CO), 162.35 (CN); MS (FAB): m/z = 395.2007
(M+H); C20H31N2O4 S requires 395.2004; Rf (w-hexanes/ethyl acetate: 5/1): 0.42
1.3-Bis-terf-butoxycarbonyl-l-(3’,4’-dichlorobenzyI)-2-methyl-2-thiopseudourea 
(78)
1.3-Bis-ter/-butoxycarbonyl-2-methyl-2-thiopseudourea (2.90 g, 10.0 mmol), sodium 
hydride (60% in oil, 0.44 g, 11.0 mmol), 15-crown-5 (0.2 mL, 1 mmol) and 3,4- 
dichlorobenzyl chloride (1.66 mL, 12.0 mmol) in dry DMF (20 ml) were reacted 
according to the general procedure B. 78 was isolated as a colourless oil (2.11 g, 47 
%).
IR Vmax/cm (neat): 1721 (C=N), 1617 (carbamate); 'H  NMR (270 MHz, CDCI3): 1.41 
(s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3), 2.31 (s, 3H, SCH3), 4.68 (s, 2H, CH2), 6.94 
(m, 2H), 7.19 (dd, 1H, 7=8.2 Hz and 7=1.9Hz), 7.38 (d, 1H, 7=8.2 Hz), 7.42 (d, 1H, 
7=1.9 Hz); l3C NMR (67.8 MHz, CDC13): 15.17 (SCH3), 27.50 (C(CH3)), 27.54 
(C(CH3)), 50.72 (CH2), 81.41 (C(CH3)), 82.70 (C(CH3)), 126.82 (CH), 129.43 (CH), 
129.92 (CH), 130.99 (C), 131.86 (C), 137.21 (C), 151.28 (CO), 157.21 (CO), 161.82 
(CN); MS (FAB): m/z = 449.1051 (M+H, 35C12) and 451.1032 (M+H, 35C137C1); 
Ci9H2735C12N20 4S requires 449.1067; Ci9H2735C137C1N20 4S requires 451.1037; Rf (n- 
hexanes/ethyl acetate: 5/1): 0.40
jV-(ferf-Butyloxycarbonyl)diaminoethane (83)197,198,199
Diaminoethane (12.02 g, 200 mmol) in CHCI3 (150 mL) and di-terf-butyl-dicarbonate 
(4.36 g, 2 0  mmol) in CHCI3 (70 mL) were reacted according to the general procedure
C. Purification by silica gel chromatography, eluting with DCM/MeOH/NILOH: 
85/10/5, gave 83 (2.57 g, 80%) as a colourless oil.
IR Vmax/cm (neat): 3360 (br, bonded NH), 1693 (carbamate); JH NMR (270 MHz, 
CDCI3): 1.28 (s, br, 2H, NH2), 1.33 (s, 9H, C(CH3)3), 2.64-2.73 (m, 2H, C //2NH2),
3.00-3.12 (m, 2H, Ctf2NH), 5.42 (s, br, 1H, NH); 13C NMR (67.8 MHz, CDC13):
28.08 (C(CH3)3), 41.53 (CH2NH2), 43.09 (CH2NH), 78.61 (C(CH3)3), 156.04 (CO); 




1,4-Diaminobutane (9.0 mL, 90 mmol) in CHCI3 (90 mL) and di-terf-butyl- 
dicarbonate (1.95 g, 9 mmol) in CHCI3 (45 mL) were reacted according to the general 
procedure C. Purification by silica gel column chromatography, eluting with 
DCM/MeOH/NELOH: 85/10/5, afforded the desired product 84 as a colourless oil 
(1.51 g, 89%).
IR Vmax/cm (neat): 3358 (br, bonded NH), 1694 (carbamate); *H NMR (270 MHz, 
CDCI3): 1.27 (s, br, 2H, NH2), 1.44 (s, 9H, C(CH3)3), 1.46-1.56 (m, 4H, 2xCH2), 2.69 
(t, 2H, .7=6.2 Hz, C/72NH2), 3.12 (t, 2H, .7=6.2 Hz, C772NH), 4.95 (s, br, 1H, NH); 13C 
NMR (67.8 MHz, CDC13): 27.85 (CH2), 28.80 (C(CH3)3), 31.27 (CH2), 40.75 
(CH2NH2), 42.17 (CH2NH), 79.17 (C(CH3)3), 156.13 (CO); MS (FAB): m/z = 189 
(M+H), 377 (2M+H); C9H20N2O2 requires 188; Rf (DCM/MeOH/NH4 0 H: 85/10/5): 
0.33
iV-(fe/*-ButyIoxycarbonyI)diaininohexane (85) 197
1 ,6 -Diaminohexane (10.47 g, 90 mmol) in CHCI3 (90 mL) and di-/er/-butyl- 
dicarbonate (1.95 g, 9 mmol) in CHCI3 (45 mL) were reacted according to the general 
procedure C. Purification by silica gel column chromatography, eluting with 
DCM/MeOH/NILOH: 85/10/5, afforded 85 as a colourless oil (1.73 g, 89%).
IR Vmax/cm (neat): 3357 (br, bonded NH), 1692 (carbamate); ]H NMR (270 MHz, 
CDCI3): 1.28 (s, br, 2H, NH2), 1.31-1.37 (m, 4H, 2xCH2), 1.44 (s, 9H, C(CH3)3), 
1.48-1.54 (m, 4H, 2xCH2), 2.68 (t, 2H, .7=6.6 Hz, C772NH2), 3.08-3.13 (m, 2H, 
CT72NH), 4.77 (s, br, 1H, NH); 13C NMR (67.8 MHz, CDC13): 26.93 (CH2), 27.02 
(CH2), 28.81 (C(CH3)3), 30.42 (CH2), 34.07 (CH2), 40.83 (CH2), 42.45 (CH2), 79.16 
(C(CH3)3), 156.11 (CO); MS (FAB): m/z = 217 (M+H); CnH 24N20 2 requires 216; Rf 
(DCM/MeOH/NILjOH: 85/10/5): 0.40
[[(l,l-Dimethy!ethoxy)carbonyl]amino]ethylisothiocyanate (8 6 ) 199
83 (2.50 g, 15.6 mmol), calcium carbonate (1.53 g, 15.6 mmol) and thiophosgene 
(2.40 mL, 31.2 mmol) in CHCI3 (50 mL) were reacted according to the general 
procedure D. Purification by column chromatography yielded 8 6  as a white solid
(2.60 g, 82%).
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IR vmax/cm (neat): 3348 (br, bonded NH), 2978 (br, N-H), 2198 and 2113 
(isothiocyanate), 1694 (carbamate); ]H NMR (270 MHz, CDCI3): 1.46 (s, 9H, 
C(CH3)3), 3.38 (virtual quartet, 2H, .7=5.5 Hz, C7/2NH), 3.65 (t, 2H, 7=5.5 Hz, 
CH2NCS), 5.02 (s, br, 1H, NH); 13C NMR (67.8 MHz, CDC13): 28.41 (C(CH3)3),
40.63 (CH2), 43.97 (CH2), 80.02 (C(CH3)3), 132.23 (NCS), 155.55 (CO); MS (FAB): 
m/z = 203 (M+H) and 405 (2M+H); C8HmN20 2S requires 202; Rf (n-hexanes/ethyl 
acetate:4/l): 0.33; mp : 62°C (lit.: 63-64°C)199
[[(l,l-Dimethylethoxy)carbonyl]amino]butylisothiocyanate (87)
84 (1.73 g, 9.2 mmol), calcium carbonate (0.90 g, 9.2 mmol) and thiophosgene (1.41 
mL, 18.4 mmol) in CHC13 (50 mL) were reacted according to the general procedure 
D. After purification by column chromatography, 87 was isolated as a yellowish oil 
(1.90 g, 90%).
IR Vmax/cm (neat): 3357 (br, bonded NH), 2978 (br, N-H), 2185 and 2107 
(isothiocyanate), 1698 (carbamate); ]H NMR (75.45 MHz, CDC13): 1.43 (s, 9H, 
C(CH3)3), 1.35-1.55 (m, 2H, CH2), 1.67-1.73 (m, 2H, CH2), 3.09 (virtual quartet, 2H, 
7=6.3 Hz, C i/2NH), 3.53 (t, 2H, 7=6.3 Hz, C/72NCS), 4.84-4.91 (m, br, 1H, NH); 13C 
NMR (67.8 MHz, CDC13): 27.27 (CH2), 27.38 (CH2), 28.45 (C(CH3)3), 39.46 (CH2),
44.63 (CH2), 79.16 (C(CH3)3), 130.05 (NCS), 155.88 (CO); MS (FAB): m/z = 231 
(M+H); CioHisN20 2S requires 230; Rf (n-hexanes/ethyl acetate: 3/1): 0.33
[[(l,l-Dimethylethoxy)carbonyl]amino]hexylisothiocyanate (8 8 )
85 (1.75 g, 8.1 mmol), calcium carbonate (0.80 g, 8.1 mmol) and thiophosgene (1.22 
mL, 16.2 mmol) in CHC13 (50 mL) were reacted according to the general procedure
D. 8 8  was isolated as a colourless oil (1.61 g, 77%) after purification by column 
chromatography (elution with n-hexanes/ethyl acetate: 3/1).
IR Vmax/cm (neat): 3351 (br, bonded NH), 2976 (br, N-H), 2183, 2105 
(isothiocyanate), 1693 (carbamate); *H NMR (270 MHz, CDC13): 1.29 (s, 9H, 
C(CH3)3), 1.41-1.65 (m, 8 H, 4xCH2), 3.01 (virtual quartet, 2H, 7=6.4 Hz, C772NH),
3.43 (t, 2H, 7=6.4 Hz, C //2NCS), 4.79-4.86 (m, br, 1H, NH); ,3C NMR (67.8 MHz, 
CDC13): 28.47 (CH2), 28.50 (CH2), 29.65 (C(CH3)3), 40.80 (CH2), 42.00 (CH2), 42.13
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(CH2), 46.02 (CH2), 78.78 (C(CH3)3), 129.54 (NCS), 155.74 (CO); MS (FAB): m/z =
259 (M+H); Ci2H22N20 2S requires 258; Rf (n-hexanes/ethyl acetate: 3/1): 0.34
1.1-Dimethylethoxycarbonyl /V-(2-(thioureido)ethyl)carbamate (89)
A solution o f 8 6  (2.54 g, 12.6 mmol) in acetone (30 mL) and NH4OH (14.43 mL, 0.25 
mol) were reacted according to the general procedure E. After purification by column 
chromatography, 89 was isolated as a white solid (2.26 g, 82%).
IR vmax/cm (KBr): 3404-3190 (br, bonded NH), 2980 (br, N-H), 1686 (carbamate), 
1243 (C=S), 1152 (C-N); 'H  NMR (270 MHz, CDCb): 1.44 (s, 9H, C(CH3)3), 3.23- 
3.31 (m, 2 H, CH2), 3.44-3.48 (m, 2H, CH2), 3.64 (s, br, 1H, NH), 5.57-5.90 (m, br, 
2H, 2xNH), 6.43 (s, br, 1H, NH); l3C NMR (67.8 MHz, CDCb): 28.37 (C(CH3)3),
40.18 (CH2), 45.27 (CH2), 80.06 (C(CH3)3), 157.24 (CO), 184.09 (CS); MS (FAB): 
m/z = 220 (M+H); CsHi7N30 2S requires 219; Rf (ethyl acetate: 100%): 0.57; mp : 
127°C
1.1-Dimethylethoxycarbonyl jV-(4-(thioureido)butyl)carbamate (90)201
A solution o f 87 (2.50 g, 10.8 mmol) in acetone (30 mL) and NH4OH (12.46 mL, 0.22 
mol) were reacted according to the general procedure E. After purification by column 
chromatography, 90 was isolated as a white solid (2.35 g, 8 8 %).
IR vmax/cm (neat): 3305 (br, bonded NH), 2977, 2932 (br, N-H), 1682 (carbamate), 
1252 (C=S), 1169 (C-N); *H NMR (270 MHz, CDC13): 1.43 (s, 9H, C(CH3)3), 1.49- 
1.68 (m, 6 H, 3xCH2), 3.06-3.18 (m, 2H, CH2), 3.53 (s, br, 1H, NH), 5.09 (s, br, 1H, 
NH), 6.52 (s, br, 1H, NH), 6.75 (s, br, 1H, NH); 13C NMR (100.5. MHz, CDCb):
26.67 (CH2), 27.97 (CH2), 28.87 (C(CH3)3), 40.61 (CH2), 45.21 (CH2), 79.82 
(C(CH3)3), 156.88 (CO), 183.21 (CS); MS (FAB): m/z = 248 (M+H); Ci0H2 iN3O2S 
requires 247; Rf (w-hexanes/ethyl acetate: 1/1): 0.26; mp : 152°C ( lit.: 157-159°C)201
1.1-Dimethylethoxycarbonyl 7V-(6-(thioureido)hexyl)carbamate (91)
A solution o f 8 8  (3.07 g, 11.9 mmol) in acetone (30 mL) and NH4OH (13.55 mL, 0.24 
mol) were reacted according to the general procedure E. After purification by column 
chromatography, 91 was isolated as an off-white solid (3.21 g, 98%).
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IR Vmax/cm (neat): 3305 (br, bonded NH), 2977, 2933 (br, N-H), 1687 (carbamate), 
1529 (N-H), 1252 (C=S), 1170 (C-N); 'H  NMR (270 MHz, CDClj): 1.31-1.38 (m, 
6 H, 3xCH2), 1.43 (s, 9H, C(CH3)3), 1.45-1.50 (m, 2H, CH2), 1.56-1.63 (m, 2H, CH2),
3.06-3.10 (m, 2H, CH2), 3.52 (s, br, 1H, NH), 4.85 (s, br, 1H, NH), 6.36 (s, br, 2H, 
NH2); l3C NMR (100.5 MHz, CDC13): 26.45 (CH2), 28.87 (C(CH3)3), 29.12 (CH2), 
30.23 (CH2), 40.61 (CH2), 45.28 (CH2), 60.78 (CH2), 79.69 (C(CH3)3), 156.67 (CO), 
183.33 (CS); MS (FAB): m/z = 276 (M+H); Ci0H2 iN3O2S requires 275; Rf (n- 




A solution of the disubstituted thiourea 89 (2.13 g, 9.7 mmol), sodium hydride (0.776 
g, 19.4 mmol) and di-fer/-butyl-dicarbonate (2.33 g, 10.7 mmol) in dry THF (110 mL) 
were reacted according to the general procedure F. After purification, a mixture 
containing 92 and the mono-BOC protected analogue was isolated. Rf (71- 
hexanes/ethyl acetate: 3/1): 0.5
53 (0.269 g, 0.63 mmol), mercury(II) chloride (0.255 g, 0.94 mmol), triethylamine 
(0.17 mL, 1.25 mmol) and 92 (mixture o f mono and di-BOC-protected thioureas) 
(0.40 g, 1.25 mmol) were reacted according to the general procedure A. After 
purification, a mixture containing 95 and the mono-BOC protected analogue was 
isolated as a brown solid (0.09 g, 20%).
*H NMR (270 MHz, CDCI3, di-BOC protected derivative): 0.16 (d, 2H, .7=4.8 Hz, 
NCH2CH(C7/HC7/H)), 0.57 (d, 2H, .7=8.1 Hz, NCH2CH(CH//CHH)), 0.85-0.96 (m, 
1H, NCH2C/7(CH2CH2)), 1.30 (s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3), 4.87 (s, br, 
1H, NH), 5.25 (s, br, 1H, NH), 5.63 (s, 1H, 5-H), 6.50 (d, 1H, .7=7.8 Hz, 1-H), 6.63 (d, 
1H, .7=7.8 Hz, 2-H), 6.82 (m, 1H, 6 ’-H), 7.12 (m, 1H, 7’-H), 7.21 (m, 1H, 4 ’-H), 8.89 
(s, br, 1H, NH); 13CNM R (67.8 MHz, CDC13, mono-BOC protected derivative): 3.89 
(NCH2CH(CH2CH2)), 4.04 (NCH2CH(CH2CH2)), 9.69 (NCH2CH(CH2CH2)), 22.86 
(10-C), 28.44 (C(CH3)3), 28.97 (CH2), 31.62 (CH2), 39.49 (CH2), 42.56 (CH2), 43.84 
(CH2), 48.24 (13-C), 59.76 (18-C), 62.68 (9-C), 72.90 (14-C), 79.80 (C(CH3)3), 85.52
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(5-C), 110.87 (C), 111.70 (CH), 117.43 (CH), 117.63 (CH), 119.11 (CH), 125.25 (C),
127.18 (CH), 130.00 (C), 130.11 (C), 131.06 (C), 134.60 (C), 139.46 (C), 143.37 (C), 




A solution of the disubstituted thiourea 90 (0.54 g, 2.18 mmol), sodium hydride 
(0.174 g, 4.36 mmol) and di-/er/-butyl-dicarbonate (0.95 g, 4.36 mmol) in dry THF 
(25 mL) were reacted according to the general procedure F. After purification, a 
mixture containing 93 and the mono-BOC protected analogue was isolated (0.49 g, 
65%). Rf (n-hexanes/ethyl acetate: 3/1): 0.5
53 (0.278 g, 0.65 mmol), mercury(II) chloride (0.263 g, 0.97 mmol), triethylamine 
(0.18 mL, 1.30 mmol) and 93 (mixture of mono and di-BOC-protected thioureas) 
(0.45 g, 1.30 mmol) were reacted according to the general procedure A. After 
purification, a mixture containing 96 and the mono-BOC protected analogue was 
isolated as a brown solid (0.19 g, 39%).
Data for di-BOC protected product:
IR vmax/cm (neat): 3319 (br, bonded OH and NH), 2976 (br, N-H), 1697 (O N , NH 
and NH2), 1149 (C-N); 'H  NM R (400 MHz, CDCb): 0.13-0.18 (m, 2H, 
NCH2CH(C#HCHH)), 0.52-0.61 (m, 2H, NCH2CH(CH#CHff)), 0.83-0.95 (m, 1H, 
NCH2Ctf(CH2CH2)), 1.10-1.22 (m, 2H, CH2), 1.40 (s, 9H, C (C ft)3), 1.46 (s, 9H, 
C(Ctf3)3), 4.52 (s, br, 1H, NH), 4.93 (s, br, 1H, NH), 5.68 (s, 1H, 5-H), 6.49 (d, 1H, 
J= 7.8 Hz, 1-H), 6.63 (d, 1H, 7=7.8 Hz, 2-H), 6.70 (s, 1H, 6 ’-H), 7.09 (m, 1H, 7’-H), 
7.17 (m, 1H, 4’-H), 9.83 (s, br, 1H, NH); l3C NMR (100.5 MHz, CDCb): 4.33 
(NCH2CH(CH2CH2)), 4.53 (NCH2CH(CH2CH2)), 9.89 (NCH2CH(CH2CH2)), 23.54 
(CH2), 27.26 (CH2), 28.53 (CH2), 28.62 (C(CH3)3), 28.87 (C(CH3)3), 29.10 (CH2),
31.90 (CH2), 40.29 (CH2), 40.77 (CH2), 44.01 (CH2), 48.31 (13-C), 59.81 (18-C), 
62.60 (9-C), 7 3 .1 0  (14-C), 78.75 (C(CH3)3), 79.40 (C(CH3)3), 85.18 (5-C), 111.15 
(C), 113.06 (CH), 117.37 (CH), 117.58 (CH), 119.14 (CH), 121.52 (CH), 124.88 (C), 
126.78 (C), 127.35 (C), 130.92 (C), 131.29 (C), 136.41 (C), 139.97 (C), 143.38 (C),
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156.28 (CO), 159.91 (CO), 162.84 (NCNN); MS (FAB): m/z = 743 (M+H); 
C4 iH54N60 7  requires 742; Rf (DCM/MeOH/N^OH: 200/10/1): 0.40
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-bis-terf-butoxycarbony^(iV,-
6-r^rr-b utoxy car bony la mino-hexyl)gu a nidiny 1-3,14-dihydroxy in dolo [2’,3’: 6,7]- 
morphinan (97)
A solution of the disubstituted thiourea 91 (0.83 g, 3.01 mmol), sodium hydride (0.24 
g, 6.02 mmol) and di-tert-butyl-dicarbonate (1.31 g, 6.02 mmol) in dry THF (45 mL) 
were reacted according to the general procedure F. After purification, a mixture 
containing 94 and the mono-BOC protected analogue was isolated (0.82 g, 72%). Rf 
(n-hexanes/ethyl acetate: 3/1): 0.45
53 (0.24 g, 0.55 mmol), mercury(II) chloride (0.22 g, 0.82 mmol), triethylamine (0.15 
mL, 1.1 mmol) and 94 (mixture of mono and di-BOC-protected thioureas) (0.41 g, 
1.10 mmol) were reacted according to the general procedure A. After purification, a 
mixture containing 97 and the mono-BOC protected analogue was isolated as a brown 
solid (0.12 g, 28%).
Data for mono-BOC protected product:
IR vmax/cm (neat): 3389 (br, bonded OH and NH), 2976 (br, N-H), 1697 (C=N, NH 
and NH2), 1149 (C-N); *H NMR (270 MHz, CDC13): 0.11-0.21 (m, 2H, 
NCH2CH(CifflC//H)), 0.50-0.61 (m, 2H, NCH2CH(CH//CHtf)), 0.83-0.93 (m, 1H, 
NCH2Ci/(CH2CH2)), 1.01-1.12 (m, 2H, CH2), 1.18-1.30 (m, 2H, CH2), 1.44 (s, 9H, 
C(CH3)3), 1.46-1.51 (m, 2H, CH2), 4.67 (s, br, 1H, NH), 5.71 (s, 1H, 5-H), 6.52 (d, 
1H,/=8.1 Hz, 1-H), 6.65 (d, 1H,/=8.1 Hz, 2-H), 6.81 (m, 1H, 6’-H), 7.12 (m, 1H, 7’- 
H), 7.26 (m, 1H, 4 ’-H), 9.30 (s, br, 1H, NH); 13C NMR (67.8 MHz, CDC13): 3.72 
(NCH2CH(CH2CH2)), 3.98 (NCH2CH(CH2CH2)), 9.33 (NCH2CH(CH2CH2)), 23.05 
(CH2), 25.97 (CH2), 26.15 (CH2), 27.97 (CH2), 28.41 (C(CH3)3), 29.25 (CH2), 29.51 
(CH2), 31.49 (CH2), 40.27 (CH2), 40.77 (CH2), 43.62 (CH2), 47.85 (13-C), 59.40 (18- 
C), 62.18 (9-C), 72.74 (14-C), 78.38 (C(CH3)3), 85.06 (5-C), 110.74 (C), 113.38 
(CH), 116.93 (CH), 117.57 (CH), 118.78 (CH), 121.13 (CH), 124.36 (C), 126.37 (C), 
127.11 (C), 130.62 (C), 131.11 (C), 136.41 (C), 140.28 (C), 143.33 (C), 159.87 (CO),





95 (mixture of mono and di-BOC-protected products) (108 mg, 0.15 mmol) was 
dissolved in a mixture of conc. HCl/methanol (2.5 mL/2.5 mL). The solution was 
stirred overnight at room temperature then the solvent was removed until dryness. The 
solid was washed several times with diethyl ether then dried under vacuum, yielding 
98 (HC1 salt) as a brown solid (70 mg, 95%).
IR vmax/cm (KBr): 3400 (br, bonded OH and NH), 1623 (O N , NH and NH2); *H 
NMR (270 MHz, CD3OD): 0.46 (d, 2H, .7=4.7 Hz, NCH2CH(C//HC77H)), 0.69-0.79 
(m, 2H, NCH2CH(CH77CH7/)), 1.01-1.12 (m, 1H, NCH2C/7(CH2CH2), 5.64 (s, 1H, 5- 
H), 6.56 (d, 1H, .7=8.1 Hz, 1-H), 6.60 (d, 1H, .7=8.1 Hz, 2-H), 6.92-6.98 (m, 1H, 6 ’- 
H), 7.25-7.38 (m, 2H, 7’-H and 4’-H); 13C NMR (100.5 MHz, CD3OD): 3.38 
(NCH2CH(CH2CH2)), 6.29 (NCH2CH(CH2CH2)), 6.87 (NCH2CH(CH2CH2)), 25.04 
(CH2), 29.69 (CH2), 30.26 (CH2), 39.59 (CH2N), 40.23 (CH2N), 47.57 (16-C), 48.02 
(13-C), 58.86 (18-C), 63.52 (9-C), 73.62 (14-C), 84.85 (5-C), 110.17 (C), 113.85 
(CH), 118.43 (CH), 119.31 (CH), 120.65 (CH), 122.33 (CH), 122.66 (C), 126.54 (C),
128.55 (C), 130.28 (C), 132.52 (C), 138.25 (C), 142.08 (C), 144.76 (C), 157.81 
(NCNN); MS (FAB): m/z = 515 (M+H); C29H34N60 3 requires 514; Anal. 
(C29H34N60 3:4HC1:2H20 ) requires C 50.0 %, H : 6.0 %, N : 12.0 %, found C 50.6 %, 
H : 5.7 %, N : 11.5 %; mp > 225°C
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5’-(A’-4-aminobutyl) 
guanidinyl-3,14-dihydroxyindoIo [2’,3’:6,7]-morphinan (99)
96 (mixture of mono and di-BOC-protected products) (93 mg, 0.13 mmol) was 
dissolved in a mixture conc. HCl/methanol (2.5 mL/2.5 mL). The solution was stirred 
overnight at room temperature then the solvent was removed until dryness. The solid 
was washed several times with diethyl ether then dried under vacuum, yielding 99 
(HC1 salt) as a brown solid (64 mg, 99%).
IR vmax/cm (KBr): 3401 (br, bonded OH and NH), 1635 (C=N, NH and NH2); *H 
NMR (270 MHz, CD3OD): 0.43-0.62 (m, 2H, NCH2CH(C/mC//H)), 0.69-0.92 (m, 
2H, NCH2CH(CH//CH/7)), 1.07-1.23 (m, 1H, NCH2C77(CH2CH2)), 1.59-1.90 (m,
140
4H, 2xCH2), 2.62-2.90 (m, 2H, CH2), 4.25 (s, br, 1H, NH), 5.71 (s, 1H, 5-H), 6.63 (d, 
1H, 7=8.1 Hz, 1-H), 6.70 (d, 1H, 7=8.1 Hz, 2-H), 6.98 (m, 1H, 6 ’-H), 7.34 (m, 1H, 7’- 
H), 7.42 (d, 1H, 7=8.1 Hz, 4’-H), 7.90 (s, br, 1H, NH); 13C NMR (67.8 MHz, 
CD3OD): 3.43 (NCH2CH(CH2CH2)), 6.33 (NCH2CH(CH2CH2)), 6.91
(NCH2CH(CH2CH2)), 25.10 (CH2), 25.69 (CH2), 26.98 (CH2), 29.68 (CH2), 30.26 
(CH2), 40.32 (CH2), 42.07 (CH2), 47.56 (16-C), 47.95 (13-C), 58.88 (18-C), 63.54 (9- 
C), 73.64 (14-C), 84.86 (5-C), 110.13 (C), 113.84 (CH), 118.37 (CH), 119.33 (CH),
120.69 (CH), 122.37 (CH), 122.69 (C), 126.79 (C), 128.53 (C), 130.27 (C), 132.45 
(C), 138.14 (C), 142.03 (C), 144.74 (C), 157.53 (NCNN); MS (FAB): m/z = 543 
(M+H); C31H38N6O3 requires 542; Anal. (C3 iH38N6 0 3 :4 HCl:3 H20 ) requires C 50.14 
%, H : 6.51 %, N : 11.31 %, found C 50.15 %, H : 6.39 %, N : 11.25 %; mp > 220°C
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5’-(A’-6-aminohexyl) 
guanidinyl-3,14-dihydroxyindolo [2 \3 ’:6,7]-morphinan (100)
97 (mixture of mono and di-BOC-protected products) (140 mg, 0.18 mmol) was 
dissolved in a mixture conc. HCl/methanol (2.5 mL/2.5 mL). The solution was stirred 
overnight at room temperature then the solvent was removed until dryness. The solid 
was washed several times with diethyl ether then dried under vacuum, yielding 1 0 0  
(HC1 salt) as a brown solid (95 mg, 96%).
IR Vmax/cm (KBr): 3400 (br, bonded OH and NH), 2936 (br, N-H), 1634 (C=N, NH 
and NH2); 'H  NMR (270 MHz, CD3OD): 0.49-0.63 (m, 2H, NCH2CH(CHHCHH)), 
0.71-0.91 (m, 2H, NCH2CH(CHHCHfl)), 1.09-1.23 (m, 1H, NCH2CH(CH2CH2)), 
1.34-1.49 (m, 4H, 2xCH2), 1.57-1.76 (m, 4H, 2xCH2), 2.94 (t, 2H, > 7 .3  Hz, CH2), 
4.27 (s, br, 1H, NH), 5.71 (s, 1H, 5-H), 6 . 6 8  (d, 1H, > 8 .4  Hz, 1-H), 6.75 (d, 1H, 
> 8 .4  Hz, 2-H), 6.95-6.99 (m, 1H, 6 ’-H), 7.29-7.34 (m, 1H, 7’-H), 7.46 (d, 1H, > 8 .4  
Hz, 4 ’-H), 7.92 (s, br, 1H, NH); l3C NMR (67.8 MHz, CD3OD): 3.45 
(NCH2CH(CH2CH2)), 6.33 (NCH2CH(CH2CH2)), 6.91 (NCH2CH(CH2CH2)), 25.10 
(CH2), 26.97 (CH2), 27.08 (CH2), 28.30 (CH2), 29.64 (CH2), 30.22 (CH2), 40.61 
(CH2), 42.58 (CH2), 47.51 (16-C), 47.95 (13-C), 58.86 (18-C), 63.46 (9-C), 73.66 (14- 
C), 84.85 (5-C), 110.12 (C), 113.97 (CH), 118.25 (CH), 119.32 (CH), 120.76 (CH),
122.32 (CH), 122.77 (C), 126.85 (C), 128.47 (C), 130.28 (C), 132.42 (C), 138.04 (C), 
141.95 (C), 144.69 (C), 157.46 (NCNN); MS (FAB): m/z = 571 (M+H); C33H42N60 3
141
requires 570; Anal. (C33H42N6C>3:4HC1:3H2C>) requires C 51.43 %, H : 6.80 %, N :
10.90 %, found C 51.40 %, H : 6.56 %, N : 11.00 %; mp > 220°C
1.3-Bis-terf-butoxycarbonyl-l-acetyl-2-methyI-2-thiopseudourea (104)
1.3-Bis-te/7-butoxycarbonyl-2-methyl-2-thiopseudourea (0.87 g, 3.0 mmol), sodium 
hydride (0.36 g, 9.0 mmol), 18-crown-6 (50 mg) and acetyl chloride (0.51 mL, 6.0 
mmol) in dry THF (5 mL) were reacted according to the general procedure B. After 
purification by silica gel column chromatography, eluting with n-hexanes/ethyl 
acetate: 9 /1 ,104 was isolated as a white solid (0.17 g, 19%).
IR Vmax/cm (neat): 1750 (carbamate), 1727 (C=N), 1629 (carbamate); ]H NMR (400 
MHz, CDC13): 1.44 (s, 9H, C(CH3)3), 1.49 (s, 9H, C(CH3)3), 2.42 (s,.3H, CH3), 2.44 
(s, 3H, CH3); 13C NMR (67.8 MHz, CDC13): 14.95 (SCH3), 24.80 (CH3), 27.08 
(C(CH3)3), 27.18 (C(CH3)3), 81.81 (C(CH3)3), 84.36 (C(CH3)3), 149.35 (COCH3), 
152.81(CN), 162.04 (CO), 170.82 (CO); Rf (n-hexanes/ethyl acetate: 9/1): 0.22; mp : 
54°C
1.3-Bis-terM)utoxycarbonyI-l-allyI-2-methyI-2-thiopseudourea (105)
1.3-Bis-ter/-butoxycarbonyl-2-methyl-2-thiopseudourea (0.87 g, 3.0 mmol), sodium 
hydride (0.36 g, 9.0 mmol), 18-crown-6 (50 mg) and allyl bromide (0.51 mL, 6.0 
mmol) in dry THF (5 mL) were reacted according to the general procedure B. After 
purification by silica gel column chromatography, eluting with n-hexanes/ethyl 
acetate: 9 /1 ,105 was isolated as a colourless oil (0.60 g, 61%).
IR vmax/cm (neat): 1722 (C=N), 1619 (carbamate); ]H NMR (400 MHz, CDC13): 1.46 
(s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3), 2.37 (s, 3H, SCH3), 4.12 (d, 2 H, .7=5.8 Hz, 
CH2), 5.16-5.26 (m, 2H, CH=CH2), 5.83-5.93 (m, 1H, CH= CH2); 13C NMR (67.8 
MHz, CDCI3): 15.48 (SCH3), 27.97 (2 xC(CH3)3), 51.19 (CH2), 81.66 (C(CH3)3),
82.42 (C(CH3)3), 117.83 (CH=CH2), 132.95 (CH=CH2), 151.63 (CN), 157.81 (CO),
162.84 (CO); MS (FAB): m/z = 331 (M+H); C 15H26N2O4S requires 330; Rf (n- 




1.3-Bis-ter/-butoxycarbonyl-2-methyl-2-thiopseudourea (1.74 g, 6.0 mmol), sodium 
hydride (0.29 g, 7.2 mmol) and l,4-dibromo-2-butene (1.41 g, 6 .6  mmol) in 
anhydrous DMF (20 mL) were reacted according to the general procedure B. The 
crude product was purified by flash column chromatography, eluting with n- 
hexanes/ethyl acetate: 9/1, yielding 106 as a colourless oil (1.25 g, 49 %).
IR Vroax/cm (neat): 1743 (C=N); *H NMR (400 MHz, CDC13): 1.44 (s, 9H, C(CH3)3),
1.48 (s, 9H, C(CH3)3), 2.35 (s, 3H, CH3), 3.91 (t, 2H, 7=6.6 Hz, CH2), 4.10 (t, 2H, 
7=5.5 Hz, CH2), 5.76-5.92 (m, 2H, CH=CH)\ 13C NMR (67.8 MHz, CDC13): 15.50 
(SCH3), 27.86 (2xC(CH3)3), 31.68 (CH2Br), 49.56 (NCH2), 81.57 (C(CH3)3), 82.59 
(C(CH3)3), 129.70 (CH=CH), 129.80 (CH=CH), 151.34 (CN), 157.62 (CO), 162.42 
(CO); MS (FAB): m/z = 423 (M+H, 79Br) and 425 (M+H, 81Br); Ci6H27N20 4S79Br




1.3-Bis-terf-butoxycarbonyl-2-methyl-2-thiopseudourea (0.87 g, 3.0 mmol), sodium 
hydride (0.36 g, 9.0 mmol) and 4-chlorobutyryl chloride (0.67 mL, 6.0 mmol) in 
anhydrous DMF (7 mL) were reacted according to the general procedure B. The crude 
product was purified by column chromatography, eluting with w-hexanes/ethyl 
acetate: 9/1, and 107 was isolated as a colourless oil (0.40 g, 34 %).
IR Vmax/cm (neat): 1750 (carbamate), 1728 (C=N), 1629 (carbamate); *H NMR (270 
MHz, CDC13): 1.47 (s, 9H, C(CH3)3), 1.52 (s, 9H, C(CH3)3), 2.13 (virtual quintet, 2H, 
7=6.4 Hz, CH2), 2.46 (s, 3H, CH3), 3.04 (t, 2H, 7=6.4 Hz, COCH2), 3.63 (t, 2H, 7=6.4 
Hz, CH2C1); 13C NMR (67.8 MHz, CDC13): 16.07 (SCH3), 27.55 (CH2), 28.15 
(C(CH3)3), 28.27(C(CH3)3), 34.62 (COCH2), 44.48 (CH2C1), 82.86 (C(CH3)3), 85.48 
(C(CH3)3), 149.00 (CN), 157.18 (CO), 159.97 (CO), 172.18 (COCH2); MS (FAB): 
m/z = 395 (M+H, 35C1) and 397 (M+H, 37C1); Ci6H27N20 5S35Cl requires 394 and 
Ci6H27N2OsS37Cl requires 396; Rf (n-hexanes/ethyl acetate: 9/1): 0.25
143
7V-(4-Bromo-2-butenyl)phthalimide (110) 202
A mixture of l,2-dibromo-2-butene (2.56 g, 12.0 mmol) and potassium phthalimide 
(2.22 g, 12.0 mmol) in anhydrous DMF (30 mL) was stirred overnight at room 
temperature under a nitrogen atmosphere. The reaction was quenched by addition of 
water (10 mL). The precipitate was filtered, washed with water and dried under 
vacuum. The crude product was purified by column chromatography, eluting with n- 
hexanes/ethyl acetate: 3/1, affording 110 as a white solid (1.72 g, 51 %).
IR vmax/cm (neat): 2926 (C-H aromatic), 1715 (amide); !H NMR (270 MHz, CDCb):
3.90 (d, 2H, .7=6.3 Hz, CH2Br), 4.30 (d, 2H, .7=5.6 Hz, NCH2), 5.78-6.02 (m, 2H, 
CH=CH), 7.71-7.77 (m, 2H), 7.84-7.89 (m, 2H); 13C NMR (100.5 MHz, CDC13): 
31.40 (CH2Br), 38.98 (NCH2), 123.49 (CH), 128.54 (CH=CH), 130.21 (CH=CH),
132.30 (C), 134.13 (CH), 167.17 (CO); MS (FAB): m/z = 280 (M+H, 79Br), 282 
(M+H, 81Br), Ci2HioN0279Br requires 279 and Ci2HioN0281Br requires 281; Rf (n- 
hexanes/ethyl acetate: 3/1): 0.45; mp : 95°C (lit.: 95-96°C)202
1.3-Bis-te/'f-butoxycarbonyl-l-(4,-phthalimido-2-butenyl)-2-methyl-2- 
thiopseudourea (1 1 1 )
1.3-Bis-terf-butoxycarbonyl-2-methyl-2-thiopseudourea (1.93 g, 6 .6  mmol), sodium 
hydride (0.32 g, 8.0 mmol) and 110 (2.05 g, 7.3 mmol) in anhydrous DMF (20 mL) 
were reacted according to the general procedure B. Purification by column 
chromatography, eluting with n-hexanes/ethyl acetate: 9/1, afforded 111 as a 
colourless oil (2.62 g, 80 %).
IR Vmax/cm (neat): 2979, 2932 (C-H aromatic), 1717 (C=N), 1615 (CO); ]H NMR 
(270 MHz, CDCI3): 1.43 (s, 9H, C(CH3)3), 1.48 (s, 9H, C(CH3)3), 2.34 (s, 3H, SCH3), 
4.09 (d, 2H, J=4.6 Hz, CH2), 4.28 (d, 2H, .7=4.3 Hz, CH2), 5.75-5.82 (m, 2H, 
CH=CH), 7.70-7.77 (m, 2H), 7.81-7.88 (m, 2H); 13C NMR (100.5 MHz, CDC13):
15.90 (SCH3), 28.38 (2xC(CH3)3), 39.21 (CH2Nphtha), 50.14 (CH2N), 81.92 
(C(CH3)3), 82.71 (C(CH3)3), 123.36 (CH), 127.73 (CH=CH), 128.87 (CH=CH), 
132.37 (C), 134.01 (CH), 151.64 (CN), 157.80 (CO), 162.63 (CO), 167.71 (CO); MS 






53 (0.43 g, 1.0 mmol), mercury(II) chloride (0.41 g, 1.5 mmol), triethylamine (0.27 
mL, 2.0 mmol) and 111 (0.98 g, 2.0 mmol) were reacted according to the general 
procedure A. After purification, a mixture containing 112 and the mono-BOC 
protected analogue was obtained as a brown solid (0.23 g, 13%).
Data for 112:
]H NMR (400 MHz, CDC13): 0.17 (d, 2H, 7=4.7 Hz, NCH2CH(C77HC//H)), 0.51-0.62 
(d, 2H, 7=7.4 Hz, NCH2CH(CH//CH//)), 0.84-0.94 (m, 1H, NCH2C//(CH2CH2)),
1.36 (s, 9H, C(CH3)3), 1.48 (s, 9H, C(CH3)3), 3.94-4.32 (m, 4H, C //2CH=CHC//2),
5.67 (s, 1H, 5-H), 5.72-5.95 (m, 2H, CH=CH), 6.43-6.58 (m, 2H, 1-H and 2-H), 6.77 
(m, 1H, 6 ’H), 7.02-7.27 (m, 2H, 4 ’-H and 7 ’-H), 7.46-7.68 (m, 4H, Ar); 13C NMR 
(67.8 MHz, CDC13): 4.31 (NCH2CH(CH2CH2)), 4.38 (NCH2CH(CH2CH2)), 9.85 
(NCH2CH(CH2CH2)), 23.57 (10-C), 28.24 (C(CH3)3), 28.49 (C(CH3)3), 29.19 (CH2), 
31.82 (CH2), 39.18 (CH2), 39.31 (CH2), 44.07 (16-C), 48.41 (13-C), 59.93 (18-C), 
62.81 (9-C), 73.01 (14-C), 82.30 (C(CH3)3), 82.85 (C(CH3)3), 85.60 (5-C), 111.64 
(C), 112.37 (CH), 112.92 (CH), 117.97 (CH), 119.43 (CH), 123.44 (CH), 123.56 
(CH), 125.24 (C), 127.29 (C), 127.41 (CH), 127.75 (CH), 130.62 (C), 131.11 (C),
132.33 (C), 134.10 (CH), 134.25 (C), 135.78 (C), 139.88 (C), 143.36 (C), 150.08 




The above mixture (0.16 g, 0.18 mmol) was dissolved in a mixture of MeOH/conc. 
HC1 (5 mL/5mL) and the solution was heated at 80°C overnight. The solvents were 
removed by evaporation until dryness. The solid was washed several times with 
diethyl ether then dried under vacuum to give 113 (HC1 salt) as a brown solid (0.12 g, 
97%).
145
IR Vmax/cm (KBr): 3393 (br, bonded OH and bonded NH), 1707 (C=N, NH and NH2), 
1610 (CO); !H NMR (270 MHz, C D 3OD): 0.50-0.61 (m, 2H, NCH2CH(C/mC7m )), 
0.73-0.95 (m, 2H, NCH2CH(CH//CHtf)), 1.11-1.24 (m, 1H, NCH2C//(CH2CH2)), 
3.82-3.91 (m, 2H, CH2Nguan), 4.23-4.33 (m, 2H, CH2Nphtha), 5.73 (s, 1H, 5-H), 
5.73-5.86 (m, 2H, CH=CH), 6.62 (d, 1H, .7=8.1 Hz, 1-H), 6 . 6 6  (d, 1H, J= 8.1 Hz, 2-H),
6.94-7.02 (d, 1H, .7=8.4 Hz, 6 ’-H), 7.33 (s, 1H, 4’-H), 7.39 (d, 1H, .7=8.4 Hz, 7’-H),
7.75-7.87 (m, 4H, Ar); 13C NMR (67.8 MHz, CD3OD): 3.75 (NCH2CH(CH2CH2)), 
6.64 (NCH2CH(CH2CH2)), 7.25 (NCH2CH(CH2CH2)), 25.43 (10-C), 30.09 (CH2),
30.66 (CH2), 40.03 (CH2NPhta), 43.72 (16-C), 47.99 (CH2), 49.05 (13-C), 59.25 (18- 
C), 63.91 (9-C), 73.98 (14-C), 85.19 (5-C), 110.53 (C), 114.26 (CH), 118.67 (CH),
119.83 (CH), 121.12 (CH), 122.78 (CH), 123.10 (C), 124.17 (CH), 127.27 (C),
128.30 (CH), 129.00 (C), 129.38 (CH), 130.74 (C), 132.99 (C), 133.26 (C), 135.49 
(CH), 138.69 (C), 142.60 (C), 145.23 (C), 158.00 (CN), 169.74 (CO); MS (FAB): m/z 
= 671 (M+H); C39H38N6O5 requires 670; mp > 250°C
3-Phthalimidopropanol (115)139’203’204
A solution of 3-aminopropanol (3.2 mL, 41.5 mmol), A-carbethoxy-phthalimide (9.1 
g, 41.5 mmol) and triethylamine (5.8 mL, 41.5 mmol) in THF (100 mL) was stirred 
overnight at room temperature. The solvent was removed by evaporation and the 
crude oil purified by column chromatography, eluting with w-hexanes/ethyl acetate: 
1/1.115 was isolated as a white solid (7.35 g, 8 6  %).
IR vmax/cm (KBr): 3413 (br, bonded OH), 1722 (C=N), 1604 (carbamate); !H NMR 
(270 MHz, CDCI3): 2.15 (virtual quintuplet, 2H, .7=6.7 Hz, CH2), 3.56 (t, 2H, .7=6.6 
Hz, CH2N), 3.83 (t, 2H, .7=6.8 Hz, CH20), 7.69-7.72 (m, 2H), 7.82-7.85 (m, 2H); 13C 
NMR (100.5 MHz, CDC13): 31.10 (CH2), 34.23 (CH2N), 58.96 (CH20 ), 123.06 (CH),
131.70 (C), 133.86 (CH), 168.59 (CO); MS (FAB): m/z = 206.0814 (M); CnH i2N 0 3 
requires 206.0817; Rf (w-hexanes/ethyl acetate: 1/1): 0.45; mp : 65 °C
3-Phthalimidopropyl / 7-toluenesulfonate (116)205
Method A
To a solution of 115 (1.08 g, 5.25 mmol) and pyridine (1.41 mL, 17.5 mmol) in DCM 
(5 mL) at 0°C was added a solution ofp-toluenesulfonyl chloride (1.00 g, 5.25 mmol)
146
in DCM. The reaction mixture was stirred overnight at room temperature. Water was 
then added and the mixture acidified with conc. HC1 (1.0 mL, 12.3 mmol). The 
aqueous phase was extracted several times with DCM and the organic phase dried 
over MgSC>4 and concentrated under vacuum. Further purification by column 
chromatography, eluting with DCM, afforded 116 as a white solid (1.18 g, 63%).
Method B
To a solution of 115 (2.16 g, 10.5 mmol) and triethylamine (1.46 mL, 10.5 mmol) in 
DCM (5 mL) at 0°C was added a solution of p-toluenesulfonyl chloride (2.00 g, 10.5 
mmol) in DCM. The reaction mixture was stirred at room temperature for 3 hours; 
water was added, the aqueous phase then extracted several times with DCM and the 
organic phase dried over MgSC>4 and evaporated under vacuum. Similar purification 
than used in method A afforded 116 as a white solid (2.07 g, 55%)
IR vmax/cm (KBr): 3104-2970 (C-H aromatic), 1698 (C=N), 1615 (carbamate); *H 
NMR (270 MHz, CDCb): 2.03 (virtual quintuplet, 2H, .7=6.6 Hz, CH2), 2.41 (s, 3H, 
CH3), 3.71 (t, 2H, .7=6.9 Hz, CH2N), 4.08 (t, 2H, .7=6.4 Hz, CH20 ), 7.30 (d, 2H, .7=8.4 
Hz), 7.67-7.72 (m, 2H), 7.75 (d, 2H, .7=8.4 Hz), 7.78-7.81 (m, 2H); 13C NMR (100.5 
MHz, CDCb): 21.68 (CH3), 27.98 (CH2), 34.61 (CH2N), 67.78 (CH20), 123.34 (CH),
127.98 (CH), 129.88 (CH), 131.97 (C), 134.07 (CH), 144.87 (C), 168.12 (CO); MS 
(FAB): m/z = 360.0915 (M+H); C 18H 17NO5S requires 359.0826; Rf (n-hexanes/ethyl 
acetate: 3/1): 0.31; mp : 164 °C
1.3-Bis-tert-butoxycarbonyI-l-(3’-phthalimidopropyI)-2-methyl-2- 
thiopseudourea (117)
1.3-Bis-ter/-butoxycarbonyl-2-methyl-2-thiopseudourea (0.74 g, 2.56 mmol), sodium 
hydride (60% in oil, 92 mg, 2.30 mmol) and 116 (0.92 g, 2.56 mmol) in dry DMF (5 
mL) were reacted according to the general procedure B. The crude oil was purified by 
column chromatography, eluting with n-hexanes/ethyl acetate: 9/1. 117 was isolated 
as a colourless oil (0.60 g, 49%).
IR vmax/cm (neat): 2974, 2933 (C-H aromatic), 1737 (CO), 1716 (br, O N ), 1621 
(carbamate), 1146 (C-N); ]H NMR (270 MHz, CDCb): 1.41 (s, 9H, C(CH3)3), 1.46 (s,
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9H, C(CH3)3), 2.04 (m, 2H, CH2), 2.34 (s, 3H, CH3), 3.54-3.60 (m, 2H, CH2NPhtha),
3.70 (t, 2H, .7=7.1 Hz, CH2N), 7.66-7.69 (m, 2H), 7.79-7.82 (m, 2H); 13C NMR (67.8 
MHz, CDC13): 15.64 (CH3), 28.06 (2xC(CH3)3), 28.23 (CH2), 35.67 (CH2), 46.71 
(CH2), 81.93 (C(CH3)3), 82.59 (C(CH3)3), 123.30 (CH), 132.14 (C), 134.02 (CH),




53 (0.24 g, 0.55 mmol), mercury(II) chloride (0.17 g, 0.60 mmol), triethylamine (0.16 
mL, 1.18 mmol) and 117 (0.54 g, 1.13 mmol) were reacted according to the general 
procedure A. After purification, a mixture containing 118 and the mono-BOC 
protected analogue was isolated as a brown solid (0.11 g, 23 %).
Data for 118:
*H NMR (270 MHz, CDC13): 0.15 (d, 2H, .7=4.2 Hz, NCH2CH(C/*HC/m)), 0.55 (d, 
2H, .7=7.4 Hz, NCH2CH(CH77CH7/)), 0.82-0.93 (m, 1H, NCH2C7/(CH2CH2)), 1.35 (s, 
9H, C(CH3)3), 5.62 (s, 1H, 5-H), 6.48 (d, 1H, .7=8.0 Hz, 1-H), 6.56 (d, 1H, .7=8.0 Hz, 




The above mixture (40 mg, 47 pmol) in DCM (2 mL) was treated with trifluoroacetic 
acid (0.2 mL) as described in the general procedure P. The desired product 120 (TFA 
salt) was recrystallised from ethanol/diethyl ether and isolated as a brown solid (27 
mg, 58%).
*H NMR (270 MHz, CD3OD): 0.54 (d, 2H, .7=4.7 Hz, NCH2CH(Ci7HC7/H)), 0.72- 
0.89 (m, 2H, NCH2CH(CH/7CH7/)), 1.11-1.21 (m, 1H, NCH2C77(CH2CH2)), 1.88-
2.00 (m, 2H, CH2), 3.73 (t, 2H, .7=6.5 Hz, CH2N), 4.24 (d, 1H, 7=5.9 Hz), 5.73 (s, 1H,
5-H), 6.63 (d, 1H, 7=8.3 Hz, 1-H), 6.67 (d, 1H, 7=8.3 Hz, 2-H), 7.04 (dd, 1H, 7=2.0 
Hz and 7=8.6 Hz, 6 ’-H), 7.39 (d, 1H, 7=2.0 Hz, 4 ’-H), 7.44 (d, 1H, 7=8.6 Hz, 7’-H),
148
7.76-7.84 (m, 4H); 13C NMR (67.8 MHz, CD3OD): 3.40 (NCH2CH(CH2CH2)), 6.24 
(NCH2CH(CH2CH2)), 6 .8 8  (NCH2CH(CH2CH2)), 25.04 (CH2), 28.93 (CH2), 29.74 
(CH2), 30.29 (CH2), 35.95 (CH2), 40.07 (CH2), 47.60 (16-C), 49.84 (13-C), 58.90 (18- 
C), 63.60 (9-C), 73.63 (14-C), 84.89 (5-C), 110.11 (C), 113.87 (CH), 118.26 (CH),
119.36 (CH), 120.61 (CH), 122.38 (CH), 122.63 (C), 124.16 (CH), 126.91 (C),
128.57 (C), 130.30 (C), 132.50 (C), 133.29 (C), 135.43 (CH), 138.20 (C), 142.11 (C),
144.80 (C), 157.60 (NCNN), 169.90 (CO); Anal. (C38H38N60 5 :3 TFA:6 H20 ) requires 
C 47.7 %, H : 4.8 %, N : 7.6 %, found C 47.7 %, H : 5.3 %, N : 8.2 %; mp > 220 °C
AyV-Dibenzylaminopropanol (124)206
To a solution o f aminopropanol (3.06 mL, 40 mmol) in DCM (5 mL) was added a 
solution o f benzyl bromide (4.75 mL, 40 mmol) in DCM (5 mL). The reaction 
mixture was stirred overnight at room temperature, then the solution was basified to 
pH=10 with NH4OH; water was added, the organic phase separated and the aqueous 
phase further extracted with DCM. The organic phase was washed with brine, dried 
over MgS0 4  and concentrated. Purification by flash chromatography eluting first with 
n-hexanes, then with w-hexanes/ethyl acetate: 6/1, afforded 124 as a colourless oil 
(2.14 g, 42% ).
IR Vmax/cm (neat): 3339 (br, bonded OH), 2945 (C-H aromatic); !H NMR (270 MHz, 
CDCI3): 1.73-1.79 (m, 2H, CH2), 2.64 (t, 2H, .7=5.8 Hz, CH2N), 3.56 (s, 4H, 
2xCH2Ph), 3.64 (t, 2H, .7=5.3 Hz, CH20), 4.67 (s, 1H, OH), 7.23-7.36 (m, 10H); 13C 
NMR (100.5 MHz, CDC13): 28.02 (CH2), 53.21 (CH2), 58.64 (CH2), 63.91 (CH2),
127.33 (CH), 128.52 (CH), 129.21 (CH), 138.33 (C); Rf (w-hexanes/ethyl acetate: 
3/1): 0.43
A^V-Dibenzylaminopropyl p-toluenesulfonate (125)
124 (1.28 g, 5.0 mmol), triethylamine (0.70 mL, 5.0 mmol) and p-toluenesulfonyl 
chloride (0.95 g, 5.0 mmol) in DCM (5 mL) were reacted according to a similar way 
as employed for the preparation of 116 (method B). 125 (0.84 g, 39%) was isolated as 
an off-white solid.
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IR Vmax/cm (neat): 3442 (br, bonded OH), 2922 (C-H aromatic), 1187 (C-N); !H NMR 
(270 MHz, CDC13): 1.78 (virtual quintuplet, 2H, J=6.1 Hz, CH2), 2.41 (s, 3H, CH3),
2.43 (t, 2H, 7= 6.7 Hz, CH2N), 3.46 (s, 4H, 2xCH2Ph), 4.03 (t, 2H, 7=6.8 Hz, CH20), 
7.21-7.31 (m, 12H), 7.72 (d, 2H, 7=8.4 Hz); 13C NMR (100.5 MHz, CDCI3): 14.35 
(CH2), 21.34 (CH3), 59.23 (CH2), 64.65 (CH2), 126.00 (CH), 128.73 (C), 128.76 
(CH), 129.36 (CH), 130.42 (CH), 132.59 (CH), 139.40 (C), 143.79 (C); mp > 220 °C
1.3-Bis-tert-butoxycarbonyl-l-(AyV-dibenzylaminopropyl)-2-methyl-2- 
thiopseudourea (126)
1.3-Bis-ter/-butoxycarbonyl-2-methyl-2-thiopseudourea (0.64 g, 2.21 mmol), sodium 
hydride (60% in oil, 8 8  mg, 2.20 mmol), 15-crown-5 (40 pL, 0.22 mmol) and 125 
(1.04 g, 2.44 mmol) in dry DMF (5 mL) were reacted according to the general 
procedure B. 126 was isolated as a colourless oil (0.82 g, 71%).
*H NMR (270 MHz, CDCI3): 1.42 (s, 9H, C(CH3)3), 1.48 (s, 9H, C(CH3)3), 1.83-1.94 
(m, 2H), 2.32 (s, 3H, CH3), 2.42 (t, 2H, 7=6.8 Hz, CH2N), 3.53 (s, 4H, 2xCH2Ph),
3.53 (m, 2H, CH2NCN), 7.18-7.36 (m, 10H); 13C NMR (100.5 MHz, CDC13): 15.53 
(CH3), 26.36 (CH2), 28.04 (C(CH3)3), 28.09 (C(CH3)3), 47.53 (CH2), 50.78 (CH2),
58.18 (2 xCH2), 81.69 (C(CH3)3), 82.20 (C(CH3)3), 126.85 (CH), 128.21 (CH), 128.85 




53 (0.13 g, 0.30 mmol), mercury(II) chloride (0.12 g, 0.43 mmol), triethylamine (0.08 
mL, 0.56 mmol) and 126 (0.31 g, 0.59 mmol) were reacted according to the general 
procedure A. After purification, a mixture containing 127 and the mono-BOC 
protected derivative was isolated as a brown solid (0.13 g, 48%). MS (FAB): m/z = 
909 (M+H); C s ^ N e O ?  requires 908; Rf (DCM/MeOH/NFLOH: 200/10/1): 0.31
The above mixture ( 6 6  mg, 73 pmol) in DCM (3 mL) was treated with trifluoroacetic 
acid (0.2 mL) as described in the general procedure P and 131 (TFA salt) was isolated 
as an off-white solid (70 mg, 82%).
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]H NMR (270 MHz, CD3OD): 0.54 (d, 2H, J=4.2 Hz, NCH2CH(CimCtfH)), 0.74- 
0.91 (m, 2H, NCH2CH(CHtfCHtf)), 1.11-1.21 (m, 1H, NCH2C//(CH2CH2)), 4.37 (s, 
4H, 2xCH2Ph), 5.73 (s, 1H, 5-H), 6.65 (d, 1H, .7=8.2 Hz, 1-H), 6.67 (d, 1H, 7=8.2 Hz,
2-H), 6.93 (dd, 1H, 7=1.9 Hz and 7=8.6 Hz, 6’-H), 7.29 (d, 1H, 7=1.9 Hz, 4 ’-H), 7.44 
(d, 1H, 7=8.6 Hz, 7’-H); 13C NMR (67.8 MHz, CD3OD): 3.34 (NCH2CH(CH2CH2)),
6.20 (NCH2CH(CH2CH2)), 6.81 (NCH2CH(CH2CH2)), 24.49 (CH2), 24.99 (CH2), 
29.68 (CH2), 30.23 (CH2), 39.61 (CH2), 47.56 (16-C), 50.68 (CH2), 58.48 (2xCH2Ph),
58.90 (18-C), 63.62 (9-C), 73.57 (14-C), 84.86 (5-C), 110.05 , 113.84, 118.26, 
119.36, 120.63, 122.32, 122.57, 126.71, 128.54, 130.27, 130.47, 130.83, 131.20, 
132.18, 132.53, 138.21, 142.13, 144.78, 157.56 (NCNN); mp : 188 °C; Anal. 
(C44H48N603:3TFA:2H20 )  requires C 55.25 %, H 5.10 %, N 7.73 %, found: C 55.3 
%, H 4.92 % ,N  7.60%
1.3-Bis-terf-butoxycarbonyl-l-(5’-iodopentyl)-2-methyl-2-thiopseudourea (132)
1.3-Bis-ter/-butoxycarbonyl-2-methyl-2-thiopseudourea (2.95 g, 10.1 mmol), sodium 
hydride (60% in oil, 0.41 g, 10.2 mmol), 15-crown-5 (0.2 mL, 1 mmol) and 1,5- 
diiodopentane (4.5 mL, 33.5 mmol) in dry DMF (5 mL) were reacted according to the 
general procedure B, but the reaction mixture was stirred at room temperature 
overnight. 132 was isolated as a colourless oil (2.50 g, 51%).
IR Vmax/cm (neat): 2977, 2932 (C-H aromatic), 1719 (C=N), 1618 (carbamate), 1143 
(C-N); *H NMR (270 MHz, CDC13): 1.30-1.40 (m, 2H), 1.46 (s, 9H, C(CH3)3), 1.48 
(s, 9H, C(CH3)3), 1.61-1.72 (m, 2H), 1.83 (virtual quintuplet, 2H, 7=7.2 Hz), 2.37 (s, 
3H, SCH3), 3.16 (t, 2H, 7=6.9 Hz, CH2I), 3.48 (m, 2H, CH2N); 13C NMR (67.8 MHz, 
CDC13): 6.59 (CH2I), 15.55 (CH3), 27.60 (CH2), 27.70 (CH2), 27.98 (C(CH3)3), 28.05 
(C(CH3)3), 32.93 (CH2), 48.56 (CH2N), 81.79 (C(CH3)3), 82.25 (C(CH3)3), 151.85 
(CO), 157.83 (CO), 162.79 (NCN); MS (FAB): m/z = 486.9 (M); Ci7H3iIN20 4S 
requires 486.410; Rf (w-hexanes/ethyl acetate: 5/1): 0.65
1.3-Bis-terf-butoxycarbonyl-l-(5’-nitropentyl)-2-methyI-2-thiopseudourea (133)
A solution of sodium nitrite (2.16 g, 3.08 mmol) and 132 (0.90 g, 1.86 mmol) in a 
mixture of DMF (5 mL) and water (1 mL) was stirred for 2 hrs at room temperature.
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Water was added and the aqueous solution extracted with ethyl acetate. The organic 
phase was washed with brine, dried over MgSC>4 and the solvent removed under 
vacuum. Purification by column chromatography, eluting with n-hexanes/ethyl 
acetate: 9/1, afforded 133 as a colourless oil (0.30 g, 40%).
I R  V m ax/cm  (neat): 2978, 2934 (C-H aromatic), 1719 (O N ), 1617 (carbamate), 1143 
(C-N); *H NMR (270 MHz, CDC13): 1.36-1.46 (m, 2H), 1.46 (s, 9H, C(CH3)3), 1.49 
(s, 9H, C(CH3)3), 1.65-1.76 (m, 2H), 2.03 (virtual quintuplet, 2H, 7= 7.3 Hz), 2.37 (s, 
3H, SCH3), 3.47-3.53 (m, 2H, CH2NBoc), 4.37 (t, 2H, 7= 6.9 Hz, CH2N 0 2); 13C NMR 
(67.8 MHz, CDC13): 15.60 (CH3), 23.39 (CH2), 26.89 (CH2), 28.00 (C(CH3)3), 28.07 
(C(CH3)3), 48.22 (CH2NCN), 75.42 (CH2N 0 2), 81.93 (C(CH3)3), 82.45 (C(CH3)3), 
151.85 (CO), 157.85 (CO), 162.67 (NCN); Rf (n-hexanes/ethyl acetate: 3/1): 0.64
17-CycIopropyImethyI-6,7-didehydro-4,5a-epoxy-5,-bis-te/?-butoxycarbonyl-(/Y’-
5’-nitropentyl)guanidinyl-3,14-dihydroxyindolo[2’,3’:6,7]~morphinan(134)
53 (0.30 g, 0.71 mmol), mercury(II) chloride (0.28 g, 0.99 mmol), triethylamine (0.20 
mL, 1.41 mmol) and 133 (0.57 g, 1.41 mmol) were reacted according to the general 
procedure A. After purification, a mixture containing 134 and its mono-BOC 
protected analogue was isolated as a brown solid (0.18 g, 32%).
IR Vm ax/cm  (neat): 3394 (br, bonded OH and NH), 2976, 2931 (C-H aromatic), 1707 
(C=N), 1614 (carbamate), 1148 (C-N); 'H  NMR (270 MHz, CDCb) (data for di-BOC 
protected derivative): 0.14 (d, 2H, .7=4.3 Hz, NCH2CH(C77HC77H)), 0.54 (d, 2H, 
7=7.9 Hz, NCH2CH(CHHCHH)), 0.83-0.92 (m, 1H, NCH2C//(CH2CH2)), 1.37 (s, 9H, 
0 (0 7 / 3)3), 1.48 (s, 9H, 0 (0 7 / 3)3), 5.64 (s, 1H, 5-H), 6.48 (d, 1H, 7=8.0 Hz, 1-H), 6.53-
6.59 (m, 1H), 6.76-6.81 (m, 1H), 7.02-7.16 (m, 2H); ’H NMR (270 MHz, CDCb) 
(data for mono-BOC protected derivative): 0.14 (d, 2H, 7=4.2 Hz,
NCH2CH(C//HC//H)), 0.55 (d, 2H, 7=7.6 Hz, NCH2CH(CH//CH//)), 0.81-0.93 (m, 
1H, NCH2C//(CH2CH2)), 1.13 (s, 9H, C(Ctf3)3), 5.59 (s, 1H, 5-H), 6.46 (d, 1H, 7=8.2 
Hz, 1-H), 6.56 (d, 1H, 7=8.2 Hz, 2-H), 6.74-6.85 (m, 1H), 7.02-7.10 (m, 2H); MS 
(FAB): m/z = 687 (M+H), 787 (M+H); P (mono-BOC protected derivative) 
C37lL»6N6 0 7  requires 6 8 6 ; P (di-BOC protected derivative) C42Hs4N6 0 9  requires 786; 





The above mixture (50 mg, 64 pmol) and iron(II)sulfate heptahydrate (0.16 g, 0.58 
mmol) in methanol (2 mL), water (0.5 mL) and concentrated ammonia (1 mL) were 
reacted according to the same procedure as employed for the preparation of 53. After 
purification by column chromatography, eluting first with CHCI3 then with 
CHCL/MeOH/NRjOH: 250/10/1, a mixture containing 135 and its mono-BOC 
protected analogue was isolated as a brown solid (21 mg, 43 %).
Method B
To a suspension of palladium (10 wt. % on activated carbon) (40 mg, 38 pmol) in dry 
methanol (1.5 mL) were added 134 (and its mono-BOC protected derivative) (60 mg, 
76 pmol) and ammonium formate (60 mg, 0.95 mmol). The solution was refluxed for 
2 hrs, after which the solid was removed by filtration and the solvent evaporated. The 
crude product was purified by column chromatography, eluting first with CHCI3: 
100%, then with gradient elution (CHCL/MeOH/NFLOH: 500/10/1 to
CHCL/MeOH/NfLOH: 250/10/1). A mixture containing 135 and its mono-BOC 
protected analogue was isolated as a brown solid (17 mg, 29%).
IR Vmax/cm (neat): 3529 (br, bonded OH and NH), 2926 (C-H aromatic), 1717 (C=N), 
1611 (carbamate), 1145 (C-N); *H NMR (270 MHz, CDC13): 0.14 (d, 2H, .7=4.7 Hz, 
NCH2CH(C7/HC7/H)), 0.55 (d, 2H, .7=8.4 Hz, NCH2CH(CH//CHfl)), 0.84-0.96 (m, 
4H), 3.77 (t, 1H), 5.63 (s, 1H, 5-H), 6.42-6.60 (m, 3H, 1-H + 2-H + Ar), 6.89-6.92 (m, 
1H), 7.08-7.14 (m, 1H), 7.97-8.02 (br, m, 1H); MS (FAB): m/z = 757 (M+H); 




135 and its mono-BOC protected analogue (12 mg, 16 pmol), sodium 
hydrogencarbonate (8.0 mg, 95 pmol) and thiophosgene (1.3 pL, 17 pmol) were
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reacted according to the general procedure N. After purification, a mixture containing 
136 and the mono-BOC analogue was isolated as a white solid (9 mg, 71%).
Data for 136:
IR Vmax/cm (neat): 3329 (br, bonded OH and NH), 2183 and 2106 (isothiocyanate), 
1704 (C=N, NH and NH2), 1644 and 1613 (carbamate); ]H NMR (270 MHz, CDC13): 
0.14 (d, 2H, .7=4.7 Hz, NCH2CH(C77HC77H)), 0.55 (d, 2H, .7=7.9 Hz, 
NCH2CH(CH77CH7/)), 0.83-0.94 (m, 1H, NCH2C77(CH2CH2)), 1.37 (s, 9H, 
C(C/73)3), 1.49 (s, 9H, C(C773)3), 5.65 (s, 1H, 5-H), 6.51 (d, 1H, 7=8.0 Hz, 1-H), 6.57 
(d, 1H, 7=8.0 Hz, 2-H), 6.80 (s, 1H, 6’-H), 6.99-7.18 (m, 2H, 4 ’-H + 7’-H), 9.13 (s, 
br, 1H, NH); Rf (DCM/MeOH: 10/1): 0.51
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-(Ar’-5’-isothiocyanatopentyI) 
guanidinyl-3,14-dihydroxyindolo[2’,3’:6,7]-morphinan (137)
The above mixture (136 and its mono-BOC protected analogue) (12.7 mg, 15.9 pmol) 
in DCM (2 mL) was treated with trifluoroacetic acid (0.2 mL) as described in the 
general procedure P. 137 (TFA salt) was isolated as a white solid (6.9 mg, 46%).
IR Vmax/cm (neat): 3342 (br, bonded OH and NH), 2184 and 2105 (isothiocyanate), 
1704 (C=N, NH and NH2); lU NMR (270 MHz, CD3OD): 0.54 (d, 2H, 7=3.7 Hz, 
NCH2CH(C77HC77H)), 0.76-0.92 (m, 2H, NCH2CH(CH77CHH)), 1.11-1.22 (m, 1H, 
NCH2C77(CH2CH2)), 1.93-2.02 (m, 2H, CH2), 3.58 (t, 2H, 7=6.5 Hz, CH2), 4.23 (d, 
1H, 7=6.1 Hz, CH), 5.73 (s, 1H, 5-H), 6.64 (d, 1H, 7=8.2 Hz, 1-H), 6.68 (d, 1H, 7=8.2 
Hz, 2-H), 7.01-7.06 (m, 1H, 6’-H), 7.34-7.36 (m, 1H, 4 ’-H), 7.46 (dd, 1H, 7=2.2 Hz 
and 7=8.6 Hz, 7’-H); MS (FAB): m/z = 599.2822 (M+H); C33H39N60 3S requires 
599.2804; mp > 250°C
1.3-Bis-tert-butoxycarbonyl-l-aIIyl-2-methyl-2-thiopseudourea (138) .
1.3-Bis-tert-butoxycarbonyl-2-methyl-2-thiopseudourea (3.86 g, 13.3 mmol), sodium 
hydride (60% in oil, 0.52 g, 12.9 mmol), 15-crown-5 (0.26 mL, 13 mmol) and 
diiodopropane (4.58 mL, 39.9 mmol) were reacted according to the general procedure 
B, but the reaction mixture was stirred overnight at room temperature. 138 was 
isolated as a colourless oil (2.04 g, 47 %)
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IR Vmax/cm (neat): 3084 (CH, alkene), 1722 (C=N), 1618 (carbamate), 1144 (C-N); ]H 
NMR (270 MHz, CDC13): 1.44 (s, 9H, C(CH3)3), 1.48 (s, 9H, C(CH3)3), 2.35 (s, 3H, 
SCH3), 4.11 (td, 2H, 7=1.4 and 7=5.9 Hz, CH2NBOC), 5.13-5.26 (m, 2H), 5.79-5.93 
(m, 1H); 13C NMR (100.5 MHz, CDCb): 15.55 (CH3), 28.02 (C(CH3)3), 28.04 
(C(CH3)3), 51.26 (CH2), 81.74 (C(CH3)3), 82.51 (C(CH3)3), 117.90 (CH2), 133.01 
(CH), 151.59 (CO), 157.86 (CO), 162.98 (CN); MS (FAB): m/z = 331.1695 (M+H); 
Ci5H27N20 4S requires 331.1691; Rf (n-hexanes/ethyl acetate: 5/1): 0.57
1.3-Bis-terf-butoxycarbonyI-l-(4’-broinobutyl)-2-inethyl-2-thiopseudourea (140)
1.3-Bis-ter/-butoxycarbonyl-2-methyl-2-thiopseudourea (2.95 g, 10.2 mmol), sodium 
hydride (60% in oil, 0.41 g, 10.2 mmol), 15-crown-5 (0.2 mL, 1.0 mmol) and 1,4- 
dibromobutane (4.0 mL, 33.5 mmol) in dry DMF (5 mL) were reacted according to 
the general procedure B, but the reaction mixture was stirred overnight at room 
temperature. 140 was isolated as a colourless oil (2.07 g, 48%).
IR Vmax/cm (neat): 2979, 2932 (C-H aromatic), 1720 (C=N), 1648 (carbamate), 1139 
(C-N); *H NMR (270 MHz, CDCb): 1.45 (s, 9H, C(CH3)3), 1.48 (s, 9H, C(CH3)3),
1.76-1.90 (m, 4H), 2.36 (s, 3H, SCH3), 3.39 (t, 2H, 7=6.4 Hz, CH2Br), 3.52 (t, 2H, 
7=7.2 Hz, CH2NBOC); 13C NMR (67.8 MHz, CDCb): 15.17 (SCH3), 27.20 (CH2),
27.61 (C(CH3)3), 27.66 (C(CH3)3), 29.52 (CH2), 32.64 (CH2), 47.47 (CH2N), 81.30 
(C(CH3)3), 81.92 (C(CH3)3), 151.35 (CO), 157.34 (CO), 162.15 (NCN); Rf (w- 
hexanes/ethyl acetate: 3/1): 0.69
1.3-Bis-te/?-butoxycarbonyl-l-(4’-nitrobutyl)-2-methyl-2-thiopseudourea (141)
A solution of sodium nitrite (2.74 g, 4.70 mmol) and 140 (1.00 g, 2.35 mmol) in DMF 
(5 mL) was stirred for 16 hrs at room temperature. Water was then added and the 
solution extracted with ethyl acetate. The organic phase was washed with brine, dried 
over MgS04 and the solvent removed under vacuum. Purification by column 
chromatography, eluting with «-hexanes/ethyl acetate: 9/1, afforded 141 (0.17 g, 
19%). The reaction was repeated with DMF/H20 : 5/1 as the solvent mixture and the 
yield improved to 36%.
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!H NMR (270 MHz, CDC13): 1.45 (s, 9H, C(CH3)3), 1.47 (s, 9H, C(CH3)3), 1.65-1.78 
(m, 2H), 1.95-2.06 (m, 2H), 2.36 (s, 3H, SCH3), 3.55 (t, 2H, .7=7.2 Hz, CH2NBOC),
4.39 (t, 2H, .7=6.9 Hz, CH2N 0 2); 13C NMR (67.8 MHz, CDC13): 15.46 (SCH3), 24.31 
(CH2), 25.53 (CH2), 27.85 (C(CH3)3), 27.90 (C(CH3)3), 47.47 (CH2NCN), 74.89 




53 (0.17 g, 0.43 mmol), mercury(II) chloride (0.18 g, 0.65 mmol), triethylamine (0.12 
mL, 0.86 mmol) and 141 (0.18 g, 0.43 mmol) were reacted according to the general 
procedure A. The reaction mixture was stirred at 60°C for 48 hours. After 
purification, a mixture containing 142 and its mono-BOC protected derivative was 
isolated as a yellowish solid (91 mg, 27%).
]H NMR (270 MHz, CDC13): 0.15 (d, 2H, .7=4.2 Hz, NCH2CH(C77HC7/H)), 0.56 (d, 
2H, .7=8.2 Hz, NCH2CH(CH77CH7/)), 0.84-0.93 (m, 1H, NCH2C77(CH2CH2)), 1.36 (s, 
9H, C(CH3)3), 1.48 (s, 9H, C(CH3)3), 3.80 (t, 2H, 7=7.3 Hz, CH2NBoc), 4.14 (s, br, 
1H, NH), 4.38 (t, 2H, 7=6.6 Hz, CH2N 0 2), 5.63 (s, 1H, 5-H), 6.50 (d, 1H, 7=7.7 Hz,
1-H), 6.54-6.60 (m, 1H, 2-H), 6.78-6.82 (m, 1H, 6 ’-H), 7.04-7.18 (m, 2H, 7*-H and 
4’-H), 8 .6 6  (s, br, 1H, NH); Rf (DCM/MeOH/NILOH: 100/16/1.6): 0.46
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5’-bis-te/*r-butoxycarbonyI-(vV’- 
4’-aminobutyl)guanidinyl-3,14-dihydroxyindolo[2’,3’:6,7]-morphinan (143)
A suspension of the above mixture (142 and its mono-BOC protected derivative) (40 
mg, 52 pmol), palladium (10 wt. % on activated carbon) (33 mg, 31 pmol) and 
ammonium formate (64 mg, 1.01 mmol) in dry methanol (5 mL) were reacted 
according to the same procedure as used for the preparation of 135 (method B). A 
mixture containing 143 and its mono-BOC protected analogue was isolated as a 
brown solid ( 8  mg, 2 1 %).
IR Vmax/cm (neat): 3320 (br, bonded OH and NH), 2926 (C-H aromatic), 1700 (C=N); 
'H  NMR (270 MHz, CDCI3 for 143): 0.15 (d, 2H, 7=4.7 Hz, NCH2CH(CHHCHH)),
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0.56 (d, 2H, > 6 .9 Hz, NCH2CH(CH//CH7/)), 0.81-0.93 (m, 1H,
NCH2C//(CH2CH2)), 1.40 (s, 9H, C(CH3)3), 1.49 (s, 9H, C(CH3)3), 3.32-3.38 (m, 1H), 
5.64 (s, 1H, 5-H), 6.43-6.61 (m, 2H, 1-H and 2-H), 6.75-6.81 (m, 1H, 6 ’-H), 6.96-7.16 
(m, 2H, 7’-H and 4 ’-H); Rf (DCM/MeOH/N^OH: 100/16/1.6): 0.44; MS (FAB): m/z 
-  643 (M+H), 743 (M+H); P (mono-BOC protected derivative) C^ILtfNeOs requires 
642; P (di-BOC protected derivative) C41H54N6O7 requires 742
17,17,-Bis(cyclopropylmethyl)-6,6,,7,7,-tetradehydro-4,5:4’,5’-diepoxy-6,6’- 
(benzylimino) [7,7’-bimorphinan]-3,3’,14,14’-tetrol (152)
NorBNI (13) (0.30g, 0.45 mmol), sodium hydride (0.18g, 4.52 mmol), 18-crown-6 
(30 mg, 0.11 mmol) and benzyl bromide (0.16 mL, 1.36 mmol) were treated 
according to the general procedure I, the reaction being carried out however at room 
temperature and for 43 hours. The crude oil was purified by column chromatography, 
eluting with DCM/MeOH/NRtOH: 400/10/1 to 290/10/1, to yield a mixture of tri- 
and pentabenzyl-substituted norBNI (0.33g). This mixture was dissolved in 
MeOH/conc. HC1 (20 mL, 1/1) and heated to 90°C for 40 h. Cooling, basification 
(NH4OH) and removal of the precipitate by filtration, was followed by evaporation o f 
the filtrate to dryness. Column chromatography, eluting with DCM/MeOH/NBUOH: 
200/10/1, yielded BnorBNI (152) as an off-white solid (0.21g, 63%).
IR vmax/cm (KBr): 3401 (br); ]H NMR (400 MHz, CDC13): 0.09 (d, 4H, .7=5.1 Hz, 
2xNCH2CH(C7/HC/7H)), 0.49 (d, 4H, > 8 .2  Hz, 2xNCH2CH(CH//CH//)), 0.78-0.83 
(m, 2H, 2xNCH2C/7(CH2CH2)), 3.02 (d, 2H, > 1 8 .3  Hz, 10-H + lO’-H), 3.16 (d, 2H, 
> 5 .9  Hz, 9-H + 9’-H), 5.27 (d, 1H, > 1 5 .8  Hz, NCH7/), 5.33 (s, 2H, 5-H +5’-H),
5.51 (d, 1H, > 1 5 .8  Hz, NCHtf), 6.42 (d, 2H, > 8 .2  Hz, 1-H + l ’-H), 6.49 (d, 2H, 
> 8 .2  Hz, 2-H + 2 ’-H), 6.88-6.90 (m, 2H, Ar), 7.22-7.29 (m, 3H, Ar); 13C NMR (67.8 
MHz, CDC13): 3.79 (2xNCH2CH(CH2CH2)), 3.90 (2xNCH2CH(CH2CH2)), 9.40 
(2xNCH2CH(CH2CH2)), 22.99 (10-C + lO’-C), 28.98 (8-C + 8’-C), 31.44 (15-C + 
15’-C), 43.55 (16-C + 16’-C), 47.27 (CH2), 48.06 (13-C + 13’-C), 59.34 (18-C + 18’- 
C), 62.37 (9-C + 9’-C), 72.72 (14-C + 14’-C), 85.00 (5-C + 5’-C), 116.44 (7-C + 7’- 
C), 116.76 (2-C + 2’-C), 118.61 (1-C + l ’-C), 125.29 (11-C + l l ’-C), 125.50 (CH),
125.63 (6-C + 6’-C), 126.81 (CH), 128.62 (CH), 130.72 (12-C + 12’-C), 138.63 (3-C 
+ 3’-C), 140.33 (C), 142.89 (4-C + 4 ’-C); MS (FAB): m/z = 752.3715 (M+H), 
C47H5oN30 6 requires 752.3698; Rf (DCM/MeOH/NH4 0 H: 110/10/1): 0.76; m p  >
157
240°C; Anal. (C47H49N306:2HC1:5H20 ) requires C 61.73 %, H 6.72 %, N  4.59 %, 
found : C 62.06 %, H 6.95 %, N 4.76 %
17,17’-Bis(cycIopropylmethyl)-6,6,,7,7,-tetradehydro-4,5:4,,5’-diepoxy-6,6’-(3- 
isothiocyanatobenzyIimino)[7,7,-bimorphinan]-3,3\14,14,-tetrol (161)
205 (15 mg, 20 pmol), sodium hydrogencarbonate (9.8 mg, 117 pmol) and 
thiophosgene (1.6 pL, 21 pmol) were reacted according to the general procedure N. 
After purification, 161 was isolated as a white solid (7 mg, 44%).
IR Vmax/cm (neat): 3294 (br, bonded OH), 2111 (isothiocyanate); *H NMR (270 MHz, 
CDC13): 0.10 (d, 4H, 7=4.2 Hz, NCH2CH(C//HC/ffl)), 0.47-0.52 (m, 4H, 
NCH2CH(CH//CHH)), 0.76-0.88 (m, 2H, NCH2Ci/(CH2CH2)), 1.58 (d, 2H, 7=8.6 
Hz), 3.03 (d, 2H, 7=18.5 Hz), 3.16 (d, 2H, 7=5.2 Hz), 5.24 (d, 1H, 7=17.1 Hz, 
NC//HPh), 5.27 (s, 2H, 5-H + 5’-H), 5.41 (d, 1H, 7=17.1 Hz, NCHtfPh), 6.48 (d, 2H, 
7=8.3 Hz, 1-H + l ’-H), 6.58 (d, 2H, 7=8.3 Hz, 2-H + 2’-H), 6.69-6.74 (m, 1H), 7.01 
(s, 1H), 7.09-7.14 (m, 1H), 7.21-7.27 (m, 1H); 13C NMR (67.8 MHz, CDC13): 3.79 
(2xNCH2CH(CH2CH2)), 3.91 (2xNCH2CH(CH2CH2)), 9.32 (2xNCH2CH(CH2CH2)), 
23.03 (10-C + lO’-C), 28.94 (8 -C + 8 ’-C), 31.40 (15-C + 15’-C), 43.53 (16-C + 16’- 
C), 46.85 (CH2), 48.06 (13-C + 13’-C), 59.30 (18-C + 18’-C), 62.31 (9-C + 9’-C),
72.61 (14-C + 14’-C), 84.83 (5-C + 5’-C), 116.78 (CH), 118.74 (CH), 123.25 (CH),
124.45 (CH), 124.84 (CH), 125.26 (C), 125.57 (C), 129.82 (CH), 130.54 (C), 131.50 
(C), 135.06 (NCS), 138.62 (C), 141.52 (C), 142.71 (C); MS (FAB): m/z = 808.3351 
(M), 809.3359 (M+H); C48H49N4O6S requires 809.3372; Rf (DCM/MeOH: 10/1): 
0.44; mp > 220°C
17,17,-Bis(cyclopropylmethyl)-6,6’,7,7’-tetradehydro4,5:4,,5,-diepoxy-6,6’-(4-( 
isothiocyanatomethyl)benzylimino)[7,7,-bimorphinan]-3,3’,14,14’-tetrol (163)
169 (16 mg, 21 pmol), sodium hydrogencarbonate (10.3 mg, 122 pmol) and 
thiophosgene (1,7 pL, 21 pmol) were reacted according to the general procedure N. 
After purification, 163 was isolated as a white solid (15 mg, 89%).
IR Vmax/cm (neat): 3385 (br, bonded OH), 2179 and 2096 (isothiocyanate); !H NMR 
(270 MHz, CDCI3): 0.09 (d, 4H, 7=4.3 Hz, 2xNCH2CH(CM1C//H)), 0.49 (d, 4H,
158
7=7.9 Hz, 2xNCH2CH(CH//CHtf)), 0.75-0.88 (m, 2H, 2xNCH2C//(CHHCHH)), 3.02 
(d, 2H, 7=18.5 Hz), 3.15 (d, 2H, 7=5.9 Hz), 4.67 (s, 2H, CH2NCS), 5.27 (d, 1H, 
7=17.1 Hz, NC//HPh), 5.29 (s, 2H, 5-H + 5’-H), 5.47 (d, 1H, 7=17.1 Hz, NCHtfPh),
6.47 (d, 2H, 7=8.1 Hz, 1-H + l ’-H), 6.56 (d, 2H, 7=8.1 Hz, 2-H + 2 ’-H), 6.90 (d, 2H, 
7=8.2 Hz, Ar), 7.23 (d, 2H, 7=8.2 Hz, Ar); 13C NMR (100.5 MHz, CDC13): 3.77 
(2xNCH2CH(CH2CH2)), 3.89 (2xNCH2CH(CH2CH2)), 9.31 (2xNCH2CH(CH2CH2)),
23.01 (10-C + lO’-C), 28.95 (8 -C + 8 ’-C), 31.37 (15-C + 15’-C), 43.51 (16-C + 16’- 
C), 47.02 (NCH2), 48.02 (13-C + 13’-C), 48.29 (CH2NCS), 59.29 (18-C + 18’-C), 
62.31 (9-C + 9’-C), 72.66 (14-C + 14’-C), 84.87 (5-C + 5 ’-C), 116.59 (C), 116.72 
(CH), 118.67 (CH), 125.21 (C), 125.60 (C), 126.20 (CH), 127.17 (CH), 130.67 (C),
131.98 (NCS), 132.85 (C), 138.63 (C), 140.19 (C), 142.75 (C); MS (FAB): m/z = 
822.3418 (M), 823.3495 (M+H); C49H50N4O6S requires 822.3451; Rf (DCM/MeOH: 
10/1): 0.43; mp > 220°C
17,17,-Bis(cyclopropylmethyl)-6,6’,7,7’-tetradehydro-4,5:4,,5,-diepoxy-6,6’-(3-( 
isothiocyanatomethyl)benzylimino)[7,7,-bimorphinan]-3,3,,14,14’-tetrol (164)
170 (11 mg, 14 pmol), sodium hydrogencarbonate (7.1 mg, 84 pmol) and 
thiophosgene (1.2 pL, 15 pmol) were reacted according to the general procedure N. 
After purification, 164 was isolated as a white solid ( 8  mg, 70%).
IR Vmax/cm (neat): 3303 (br, bonded OH), 2165 and 2096 (isothiocyanate); 13C NMR 
(100.5 MHz, CDCb): 3.80 (2xNCH2CH(CH2CH2)), 3.91 (2xNCH2CH(CH2CH2)), 
9.33 (2xNCH2CH(CH2CH2)), 23.06 (10-C + lO’-C), 28.95 (8 -C + 8 ’-C), 31.43 (15-C 
+ 15’-C), 43.50 (16-C + 16’-C), 47.09 (NCH2), 48.01 (13-C + 13’-C), 48.44 
(CH2NCS), 59.31 (18-C + 18’-C), 62.31 (9-C + 9’-C), 72.74 (14-C + 14’-C), 84.92 
(5-C + 5’-C), 116.62 (CH), 116.68 (C), 118.74 (CH), 124.07 (CH), 125.32 (C), 
125.43 (CH), 125.62 (C), 125.68 (CH), 129.13 (CH), 130.74 (C), 131.14 (NCS), 
135.06 (C), 138.55 (C), 140.87 (C), 142.77 (C); Rf (DCM/MeOH: 10/1): 0.43; mp 




171 (20 mg, 26 pmol), sodium hydrogencarbonate (19 mg, 226 pmol) and 
thiophosgene (2.1 pL, 28 pmol) were reacted according to the general procedure N. 
After purification, 165 was isolated as a white solid (7.4 mg, 35%).
IR Vmax/cm (neat): 3370 (br, bonded OH), 2161 and 2094 (isothiocyanate); NMR 
(270 MHz, CDC13): 0.09 (d, 4H, .7=4.4 Hz, 2xNCH2CH(C77HC//H)), 0.46-0.52 (m, 
4H, 2xNCH2CH(CH7/CH/7)), 0.75-0.87 (m, 2H, 2xNCH2C/7(CHHCHH)), 3.02 (d, 
2H, .7=18.3 Hz), 3.15 (d, 2H, > 6 .4  Hz), 4.84 (d, 1H, > 1 6 .2  Hz, C77HNCS), 4.92 (d, 
1H, > 1 6 .2  Hz, CH/7NCS), 5.23 (d, 1H, > 1 7 .3  Hz, NCTTHPh), 5.29 (s, 2H, 5-H + 5’- 
H), 5.52 (d, 1H, > 1 7 .3  Hz, NCHflPh), 6.35 (d, 1H, > 6 .9  Hz), 6.50 (d, 2H, > 8 .2  Hz,
1-H + l ’-H), 6.57 (d, 2H, > 8 .2  Hz, 2-H + 2’-H), 7.21-7.41 (m, 3H); 13C NMR (67.8 
MHz, CDCI3): 3.79 (2xNCH2CH(CH2CH2)), 3.90 (2xNCH2CH(CH2CH2)), 9.38 
(2xNCH2CH(CH2CH2)), 23.03 (10-C + lO’-C), 28.97 (8 -C + 8 ’-C), 31.43 (15-C + 
15’-C), 43.52 (16-C + 16’-C), 44.49 (CH2), 46.73 (CH2), 48.10 (13-C + 13’-C), 59.33 
(18-C + 18’-C), 62.34 (9-C + 9’-C), 72.64 (14-C + 14’-C), 84.80 (5-C + 5’-C), 116.74 
(CH), 116.88 (C), 118.77 (CH), 125.28 (C), 125.68 (C), 126.23 (CH), 127.46 (CH), 
128.01 (CH), 129.48 (CH), 130.18 (C), 130.60 (C), 132.48 (NCS), 137.69 (C), 138.57 
(C), 142.71 (C); MS (FAB): m/z = 822.3449 (M), 823.3537 (M+H); C49H51N4O6S 
requires 823.3529; Rf (DCM/MeOH: 10/1): 0.44; mp > 220°C
17,17,-Bis(cycIopropylmethyI)-6,6’,7,7,-tetradehydro-4,5:4’,5’-diepoxy-6,6’-(3- 
aminobenzylimino)[7,7’-bimorphinan]-3,3,,14,14’-tetrol (167)
198 (60 mg, 56 pmol) was dissolved in a mixture of conc. HCl/MeOH (5mL, 1/1) and 
the reaction was stirred overnight at 85°C. The solvents were then removed and water 
was added. The aqueous phase was basified to pH= 8  with diluted NH4OH and 
extracted with DCM/MeOH: 5/1. The organic phase was dried (MgS0 4 ) and the 
solvent evaporated. Purification by column chromatography, eluting first with 
CHCl3/MeOH/NH4OH: 450/10/1, then with CHCU/MeOH/N^OH: 300/10/1, 
afforded 203 (34 mg, 6 8 %). 203 (29 mg, 32 pmol) and hydrazine hydrate (3.0 pL, 96 
pmol) in ethanol (1 mL) were reacting according to the general procedure 0 . 167 was 
isolated as a brown solid (22 mg, 90%).
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IR Vmax/cm (neat): 3368 (br, bonded OH and NH); *H NMR (270 MHz, CDC13): 0.08- 
0.10 (m, 4H, NCH2CH(C//HC//H)), 0.48-0.51 (m, 4H, NCH2CH(CH//CHtf)), 0.79- 
0.88 (m, 2H, NCH2Ctf(CH2CH2)), 3.02 (d, 2H, .7=18.3 Hz), 3.15 (d, 2H, .7=6.1 Hz),
5.17 (d, 1H, .7=17.0 Hz, NC7/H), 5.35 (s, 2H, 5-H + 5’-H), 5.39 (d, 1H, > 1 7 .0  Hz, 
NCHfl), 6.09 (s, 1H), 6.44 (d, 2H, > 8 .0  Hz, 1-H + l ’-H), 6.46-6.57 (m, 2H), 6.55 (d, 
2H, > 8 .0  Hz, 2-H + 2’-H), 7.08 (t, 1H, > 7 .8  Hz); 13C NMR (100.5 MHz, CDC13): 
3.76 (2xNCH2CH(CH2CH2)), 3.90 (2xNCH2CH(CH2CH2)), 9.35 (2xNCH2CH 
(CH2CH2)), 23.00 (10-C + lO’-C), 28.94 (8 -C + 8 ’-C), 31.41 (15-C + 15’-C), 43.54 
(16-C + 16’-C), 47.28 (NCH2), 48.01 (13-C + 13’-C), 59.31 (18-C + 18’-C), 62.30 (9- 
C + 9’-C), 72.75 (14-C + 14’-C), 84.88 (5-C + 5’-C), 112.76 (CH), 113.84 (CH), 
116.08 (CH), 116.17 (C), 117.30 (CH), 118.55 (CH), 125.37 (C), 125.71 (C), 129.20 
(CH), 130.80 (C), 138.62 (C), 140.84 (C), 143.28 (C), 146.72 (C); MS (FAB): m/z = 




227 (39 mg, 43 pmol) in ethanol (1 mL) and hydrazine hydrate (6.3 pL, 202 pmol) 
were reacted according to the general procedure O. 169 was isolated as a brown solid 
(18 mg, 54%).
*H NMR (270 MHz, CDCI3): 0.05 (d, 4H, > 5 .0  Hz, 2xNCH2CH(C7/HC//H)), 0.39- 
0.50 (m, 4H, 2xNCH2CH(CH77CH7/)), 0.68-0.79 (m, 2H, 2xNCH2C//(CH2CH2)), 
3.00 (d, 2H, > 1 8 .3  Hz), 3.15 (d, 2H, > 6 .2  Hz), 3.62 (s, 2H, C/72NH2), 3.72-4.18 (br, 
s, 2H, NH2), 5.22 (d, 1H, > 1 6 .8  Hz, NC/ffl), 5.27 (s, 2H, 5-H + 5’-H), 5.43 (d, 1H, 
> 1 6 .8  Hz, NCH7/), 6.46 (d, 2H, > 8 .0  Hz, 1-H + 1 ’-H), 6.57 (d, 2H, > 8 .0  Hz, 2-H + 
2 ’-H), 6.80 (d, 2H, > 7 .6  Hz), 7.12 (d, 2H, > 7 .6  Hz); 13 C NMR (67.8 MHz, CDC13):
3.62 (2xNCH2CH(CH2CH2)), 3.96 2xNCH2CH(CH2CH2)), 9.32 
(2xNCH2CH(CH2CH2)), 22.98 (10-C + lO’-C), 28.97 (8 -C + 8 ’-C), 31.46 (15-C + 
15’-C), 43.65 (16-C + 16’-C), 45.32 (CH2NH2), 47.06 (NCH2), 48.01 (13-C + 13’-C),
59.29 (18-C + 18’-C), 62.22 (9-C + 9’-C), 72.73 (14-C + 14’-C), 84.56 (5-C + 5’-C), 
116.40 (C), 117.24 (CH), 118.66 (CH), 124.56 (C), 125.57 (C), 126.15 (CH), 127.62 
(CH), 130.66 (C), 138.30 (C), 139.32 (C), 140.76 (C), 142.94 (C); MS (FAB): m/z =
161
781.3952 (M+H); C48H53N4O6 requires 781.3864; Rf (D CM M eO H /N ^O H: 
100/16/1.6): 0.34; mp > 220°C
17.17,-Bis(cyclopropylmethyl)-6,6’,7,7’-tetradehydro-4,5:4,,5’-diepoxy-6,6’-(3-( 
aminomethyl)benzylimino)[7,7’-bimorphinan]-3,3’,14,14’-tetrol (170)
228 (32 mg, 35 pmol) in ethanol (1 mL) and hydrazine hydrate (4.4 pL, 141 pmol) 
were reacted according to the general procedure 0 . 170 was isolated as a brown solid 
(13 mg, 47%).
IR Vmax/cm (neat): 3419 (br, bonded OH and NH), 1640 (N-H); 13C NMR (67.8 MHz, 
CDCI3): 3.73 (2 xNCH2CH(CH2CH2)), 3.91 (2xNCH2CH(CH2CH2)), 9.34
(2xNCH2CH(CH2CH2)), 23.01 (10-C + lO’-C), 28.96 (8 -C + 8 ’-C), 31.57 (15-C + 
15’-C), 43.59 (16-C + 16’-C), 45.30 (CH2), 47.66 (CH2), 47.99 (13-C + 13’-C), 59.30 
(18-C + 18’-C), 62.31 (9-C + 9’-C), 72.73 (14-C + 14’-C), 84.63 (5-C + 5’-C), 116.14 
(C), 118.10 (CH), 118.46 (CH), 125.00 (C), 125.86 (CH), 125.91 (CH), 126.44 (CH),
128.29 (CH), 130.76 (C), 139.14 (C), 141.81 (C), 143.92 (C); Rf
(DCM/MeOH/NttiOH: 100/16/1.6): 0.35; mp > 220°C
17.17,-Bis(cyclopropylmethyl)-6,6,,7,7,-tetradehydro-4,5:4’,5’-diepoxy-6,6,-(2- 
(aminomethyl)benzylimino)[7,7,-bimorphinan]-3,3’,14,14’-tetrol (171)
229 (30 mg, 33 pmol) in ethanol (1 mL) and hydrazine hydrate (5.0 pL, 160 pmol) 
were reacted according to the general procedure O. 171 was isolated as a brown solid 
( 2 2  mg, 8 6 %).
IR Vmax/cm (neat): 3353 and 3076 (br, bonded OH and NH); *H NMR (270 MHz, 
CDCI3): 0.04 (d, 4H, .7=4.4 Hz, 2xNCH2CH(C//HC//H)), 0.44 (d, 4H, .7=8.0 Hz, 
2xNCH2CH(CH/7CH7/)), 0.68-0.80 (m, 2H, 2xNCH2C77(CH2CH2)), 3.06 (d, 2H, 
J=6.2 Hz), 3.29 (d, 1H, 7=14.1 Hz, CHHNH2), 3.77 (d, 1H, .7=14.1 Hz, CHtfNH2), 
4.95 (s, 2H, 5-H + 5’-H), 5.24 (d, 1H, .7=15.0 Hz, NCflH), 5.44 (d, 1H, 7=15.0 Hz, 
NCH77), 6.38 (d, 2H ,7=8.1 Hz, 1-H + l ’-H), 6.50 (d, 2H, 7=8.1 Hz, 2-H + 2 ’-H), 7.10 
(d, 1H, 7=7.2 Hz), 7.21-7.32 (m, 2H), 7.49 (d, 1H, 7=7.2 Hz); 13 C NMR (67.8 MHz, 
CDCI3/CD3OD: 8/1): 3.64 (2xNCH2CH(CH2CH2)), 3.73 (2xNCH2CH(CH2CH2)),
9.18 (2xNCH2CH(CH2CH2)), 22.81 (10-C + lO’-C), 28.70 (8 -C + 8 ’-C), 31.43 (15-C
162
+ 15’-C), 42.14 (CH2), 43.36 (16-C + 16’-C), 47.50 (CH2 or 13-C + 13’-C), 47.60 
(CH2 or 13-C + 13’-C), 59.19 (18-C + 18’-C), 62.14 (9-C + 9’-C), 72.59 (14-C + 14’- 
C), 84.19 (5-C + 5’-C), 116.20 (C), 117.56 (CH), 118.57 (CH), 124.04 (C), 126.03 
(C), 127.39 (CH), 128.64 (CH), 129.74 (CH), 130.57 (C), 131.93 (CH), 134.13 (C),
139.64 (C), 141.31 (C), 142.84 (C); MS (FAB): m/z = 781 (M+H); C48H52N406 
requires 780; Rf (DCM/MeOH/NFLOH: 100/16/1.6): 0.37; mp > 220°C
17,17’-Bis(cyclopropylmethyl)-3-(4-nitrobenzyloxy)-6,6,,7,7,-tetradehydro- 
4,5:4’,5’-diepoxy-6,6’-(imino)[7,7,-bimorphinan]-3,14,14’-triol (172)
NorBNI (13) (0.66 g, 1.0 mmol), sodium hydride (60% in oil, 0.40 g, 10.0 mmol), 18- 
crown-6 (20 mg, 0.08 mmol) and 4-nitrobenzyl chloride (0.51 g, 3.0 mmol) in dry 
THF (20 mL) were reacted according to the general procedure I. 172 (0.08 g, 10 %) 
and 173 (0.28 g, 30 %) were isolated as brown solids, but no desired product could be 
isolated.
*H NMR (270 MHz, CDC13): 0.07-0.12 (m, 4H, 2xNCH2CH(C/7HC77H)), 0.51-0.53 
(m, 4H, 2xNCH2CH(CH7/CH//)), 0.79-0.91 (m, 2H, 2xNCH2C//(CH2CH2)), 5.04 (d, 
1H, .7=13.2 Hz, OC//H), 5.18 (d, 1H, .7=13.2 Hz, OCHT/)> 5.52 (s, 1H, 5-H or 5’-H),
5.62 (s, 1H, 5-H or 5’-H), 6.47-6.55 (m, 3H, 1-H + l ’-H + 2-H or 2’-H), 6.64 (d, 1H, 
.7=8.2 Hz, 2-H or 2’-H), 7.44 (d, 2H, 7=8.6 Hz), 8.11 (d, 2H, 7=8.6 Hz), 8.82 (br, s, 
1H, NH); Rf (DCM/MeOH/NH4OH: 200/20/1): 0.29
17,17’-Bis(cyclopropylmethyl)-3,3,-(4-nitrobenzyloxy)-6,6,,7,7,-tetradehydro- 
4,5:4,,5’-diepoxy-6,6,-(imino)[7,7,-bimorphinan]-14,14’-diol (173)
Obtained as a side product from the reaction that gave 172 (brown solid).
*H NMR (270 MHz, CDC13): 0.08 (d, 4H, 7=4.7 Hz, 2xNCH2CH(C77HC77H)), 0.49 
(d, 4H, 7=7.9 Hz, 2xNCH2CH(CH//CHfl)), 0.73-0.88 (m, 2H,
2xNCH2C77(CH2CH2)), 5.07 (d, 2H, 7=13.4 Hz, 2xOC//H), 5.24 (d, 2H, 7=13.4 Hz, 
2xOCH/7), 5.45 (s, 2H, 5-H + 5’-H), 6.45 (d, 2H ,7=8.1 Hz, 1-H + l ’-H), 6.54 (d, 2H, 
7=8.1 Hz, 2-H + 2 ’-H), 7.42 (d, 4H, 7=8.1 Hz), 8.14 (d, 4H, 7=8.1 Hz), 8.32 (br, s, 
1H, NH), 13C NMR (67.8 MHz, CDC13): 3.56 (2xNCH2CH(CH2CH2)), 3.76 
(2xNCH2CH(CH2CH2)), 9.21 (2xNCH2CH(CH2CH2)), 22.93 (10-C + lO’-C), 28.66
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(8-C + 8’-C), 31.34 (15-C + 15’-C), 43.30 (16-C + 16’-C), 47.49 (13-C + 13’-C), 
58.97 (18-C + 18’-C), 61.84 (9-C + 9’-C), 69.66 (2xOCH2), 72.27 (14-C + 14’-C),
85.19 (5-C + 5’-C), 116.26 (C), 116.39 (CH), 118.40 (CH), 123.38 (CH), 124.59 (C), 
126.91 (C), 127.74 (CH), 131.50 (C), 141.06 (C), 144.65 (C), 147.14 (C); Rf 
(DCM/Me0 H/NH4 0 H: 200/12/1): 0.16
17,17’-Bis(cyclopropylmethyl)-3,3,-(3-nitroberizyloxy)-6,6’,7,7,-tetradehydro- 
4,5:4’,5,-diepoxy-6,6,-(imino)[7,7’-bimorphinan]-14,14,-diol (175)
Isolated as a side product from the reaction that afforded 176 (brown solid).
*H NMR (270 MHz, CDC13): 0.13 (d, 4H, .7=4.2 Hz, 2xNCH2CH(C//HC77H)), 0.48- 
0.55 (m, 4H, 2xNCH2CH(CH//CH//)), 0.77-0.90 (m, 2H, 2xNCH2C77(CH2CH2)),
3.04 (d, 2H, .7=18.5 Hz, 10-H + lO’-H), 3.18 (d, 2H, .7=5.7 Hz, 9-H + 9’-H), 5.05 (d, 
2H, 7= 11.9 Hz, 2xOC77H), 5.12 (d, 2H, 7= 11.9 Hz, 2xOCH//), 5.45 (s, 2H, 5-H + 5’- 
H), 6.48 (d, 2H ,.7=8.2 Hz, 1-H + l ’-H), 6.66 (d, 2H, .7=8.2 Hz, 2-H + 2’-H), 7.24-7.42 
(m, 8H), 8.10 (br, s, 1H); MS (FAB): m/z = 932 (M); C54H53N5O10 requires 932
17,17’-Bis(cyclopropylmethyl)-3,3,"(3-nitrobenzyloxy)-6,6’,7,7’-tetradehydro- 
4,5:4,,5’-diepoxy-6,6’-(3-nitrobenzylimino)[7,7’-bimorphinan]-14,14’-diol (176) 
NorBNI (13) (0.10 g, 0.15 mmol), sodium hydride (60% in oil, 66 mg, 1.65 mmol) 
and 3-nitrobenzyl bromide (0.108 g, 0.50 mmol) in dry DMF (5 mL) were reacted 
according to the general procedure I. 176 (45 mg, 28 %) was isolated as a brown 
solid.
*H NMR (270 MHz, CDC13): 0.10 (d, 4H, .7=4.2 Hz, 2xNCH2CH(C77HC77H)), 0.51 
(d, 4H, .7=7.9 Hz, 2xNCH2CH(CH77CH77)), 0.77-0.89 (m, 2H,
2xNCH2CT7(CH2CH2)), 4.96 (s, 4H, OCH2), 5.26 (s, 2H, 5-H + 5’-H), 5.44 (d, 1H, 
7=17.3 Hz, NC77H), 5.54 (d, 1H, 7= 17.3 Hz, NCH7/), 6.54 (d, 2H, 7=8.2 Hz, 1-H + 
l ’-H), 6.64 (d, 2H, 7=8.2 Hz, 2-H + 2’-H), 7.11-7.25 (m, 2H), 7.45-7.58 (m, 4H), 7.71 
(d, 1H, 7=8.4 Hz), 7.93 (s, 1H), 8.15 (d, 2H, 7=7.9 Hz), 8.19 (s, 2H); MS (FAB): m/z 
= 1067 (M); C6iH58N6Oi2 requires 1067; Rf (DCM/MeOH/NHUOH: 200/12/1): 0.18
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n jT ’-BisCcyclopropylmethy^-S^’-Cbenzyloxy^^’ j^T’-tetradehydro^^^^S’- 
diepoxy-6,6,-(imino)[7,7,-bimorphinan]-14,14’-diol (177)
A solution o f norBNI (13) (0.15 g, 0.23 mmol), benzyl bromide (0.14 mL, 1.13 
mmol) and potassium carbonate (0.10 g, 0.68 mmol) in dry DMF (2 mL) was stirred 
at room temperature for 22 hrs. Water (3 mL) was then added, the organic phase 
isolated and the aqueous phase further extracted with DCM. The combined organic 
phase was dried over MgSC>4 and concentrated under vacuum. The crude product was 
purified by column chromatography, eluting first with 100% DCM, then with 
DCM/MeOH/NFLOH: 450/10/1, which afforded 177 as a brown solid (0.18 g, 94 %).
!H NMR (400 MHz, CDC13): 0.12 (d, 4H, J=4.3 Hz, 2xNCH2CH(C/7HC//H)), 0.52 
(d, 4H, .7=8.2 Hz, 2xNCH2CH(CH//CH//)), 0.83-0.90 (m, 2H,
2xNCH2C77(CH2CH2)), 3.05 (d, 2H, .7=18.8 Hz), 3.18 (d, 2H, .7=6.2 Hz), 5.07 (d, 2H, 
.7=11.9 Hz, 2xOC77H), 5.12 (d, 2H, .7=11.9 Hz, 2xOCHtf), 5.46 (s, 2H, 5-H + 5’-H), 
6.48 (d, 2H, .7=8.2 Hz, 1-H + l ’-H), 6.65 (d, 2H, .7=8.2 Hz, 2-H + 2’-H), 7.27-7.42 (m, 
10 H), 8.11 (br, s, 1H, NH); MS (FAB): m/z = 842 (M); C54H55N3O6 requires 842; Rf 
(DCM/MeOH/NFLOH: 290/10/1): 0.49
17,17’-Bis(cyclopropylmethyl)-3,3’,14,14,-tetraacetoxy-6,6,,7,7,-tetradehydro- 
4 ,5 :4 \5 ,-diepoxy-6,6,-(imino)[7,7’-bimorphinan] (178)102 
NorBNI (13) (0.62 g, 0.93 mmol) was dissolved in acetic anhydride (15 mL) and the 
solution was stirred for two hours at 100°C under a nitrogen atmosphere. Excess o f 
acetic anhydride was then removed under vacuum and the residual oil was basified to 
pH=7 with NH4 OH. The aqueous phase was extracted with DCM and the organic 
phase washed with brine, dried over MgSCU and concentrated under vacuum. 
Purification by column chromatography, eluting first with CHCI3 then with 
CHCl3/Me0 H/NH4 0 H: 450/10/1, afforded 178 as an off-white solid (0.75 g, 97%).
IR  vmax/cm (KBr): 3348 (br, bonded NH), 1770 and 1729 (CO); JH NMR (270 MHz, 
CDCI3): 0.01-0.06 (m, 4H, NCH2CH(C77HC/m)), 0.42-0.45 (m, 4H,
NCH2CH(CH/7CH/7)), 0.68-0.76 (m, 2H, NCH2C77(CH2CH2)), 1.88 (s, 6H, 2xCH3),
2.19 (s, 6H, 2xCH3), 3.09 (d, 2H, .7=18.8 Hz, 10-H and lO’-H), 3.17 (d, 2H, .7=16.6 
Hz, 8-H and 8’-H), 4.43 (d, 2H, .7=5.9 Hz, 9-H and 9’-H), 5.48 (s, 2H, 5-H and 5’-H),
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6.61 (d, 2H, 7=8.2 Hz, 1-H and l ’-H), 6.75 (d, 2H ,7=8.2 Hz, 2-H and 2’-H), 8.39 (br, 
s, 1H, NH); 13C NMR (67.8 MHz, CDC13): 3.53 (2xNCH2CH(CH2CH2)), 3.68 
(2xN CH2CH(CH2 CH2)), 9.40 (2xNCH2CH(CH2CH2)), 20.49 (2xCH3), 22.40 
(2xCH3), 23.79 (10-C + lO’-C), 24.37 (8-C + 8’-C), 30.91 (15-C + 15’-C), 43.49 (16- 
C + 16’-C), 48.05 (13-C + 13’-C), 55.77 (9-C + 9’-C), 59.44 (18-C + 18’-C), 84.04 
(14-C + 14’-C), 85.81 (5-C + 5’-C), 115.44 (7-C + 7’-C), 118.36 (1-C + l ’-C), 121.98 
(2-C + 2 ’-C), 124.21 (6-C + 6’-C), 130.86 (12-C + 12’-C), 132.00 (11-C + l l ’-C),
132.45 (3-C + 3’-C), 146.89 (4-C + 4 ’-C), 168.58 (CO), 170.97 (CO); MS (FAB): m/z 
= 830.3638 (M+H); C48H52N3Oio requires 830.2652; Rf (DCM/MeOH/N^OH: 
200/12/1): 0.26; mp > 220°C
17,17’-Bis(cyclopropylmethyl)-3,3’-(4-cyanobenzyloxy)-14,14’-diacetoxy-
6,6,,7,7’-tetradehydro-4,5:4,,5,-diepoxy-6,6’-(imino)[7,7’-bimorphinan] (179)
178 (0.25 g, 0.30 mmol), sodium hydride (60% in oil, 0.12 g, 3.00 mmol), 18-crown-6 
(10 mg, 0.04 mmol) and a-bromo-/?-tolunitrile (0.12 g, 6.12 mmol) in dry THF (10 
mL) were reacted according to the general procedure I. 179 (0.10 g, 33 %) was 
isolated as a brown solid, but no desired product could be isolated.
*H NMR (270 MHz, CDC13): 0.02-0.07 (m, 4H, NCH2CH(Ci7HC//H)), 0.44-0.47 (m, 
4H, NCH2CH(CHtfCHtf)), 0.67-0.81 (m, 2H, NCH2Ci/(CH2CH2)), 1.95 (s, 6H, 
2xCH3), 4.43 (d, 2H, 7=5.7 Hz, 9-H and 9’-H), 5.10 (d, 2H, 7=13.1 Hz, 2xOCtfH),
5.21 (d, 2H, 7=13.1 Hz, 2xOCHH), 5.90 (s, 2H, 5-H and 5’-H), 6.57 (d, 2H, 7=8.2 Hz,
1-H and l ’-H), 6.69 (d, 2H, 7=8.2 Hz, 2-H and 2’-H), 7.45 (d, 4H ,7=8.3 Hz), 7.63 (d, 
4H, 7=8.3 Hz); 13C NMR (67.8 MHz, CDC13): 3.53 (NCH2CH(CH2CH2)), 3.90 
(NCH2CH(CH2CH2)), 9.55 (NCH2CH(CH2CH2)), 22.58 (2xCH3), 23.47 (10-C + 10’- 
C), 24.78 (8-C + 8’-C), 26.08 (CH3), 31.55 (15-C + 15’-C), 43.55 (16-C + 16’-C),
47.90 (13-C + 13’-C), 55.56 (9-C + 9’-C), 59.59 (18-C + 18’-C), 71.39 (2xOCH2),
82.57 (14-C + 14’-C), 85.23 (5-C + 5’-C), 111.57 (C), 118.16 (CH), 118.72 (C),
118.98 (CH), 121.41 (C), 126.93 (C), 127.69 (4xCH), 128.14 (C), 130.83 (C), 132.22 
(4xCH), 141.19 (C), 143.02 (C), 144.56 (C), 169.81 (NCO), 170.87 (2xCO); MS 





178 (0.20 g, 0.24 mmol), sodium hydride (60% in oil, 41 mg, 1.03 mmol) and 3- 
nitrobenzyl bromide (0.10 g, 0.48 mmol) in dry THF ( 6  mL) were reacted according 
to the general procedure I. 180 (70 mg, 29 %) was isolated as a brown solid, but no 
desired product could be isolated.
lR  NMR (270 MHz, CDC13): 0.01-0.08 (m, 4H, NCH2CH(C//HC//H)), 0.44 (d, 4H, 
.7=7.4 Hz, NCH2CH(CH77CH77)), 0.68-0.78 (m, 2H, NCH2C7/(CH2CH2)), 1.56 (d, 
2H, .7=10.7 Hz), 1.79 (s, 3H, CH3), 1.80 (s, 3H, CH3), 3.04 (d, 2H, .7=18.5 Hz), 3.24 
(d, 2H, .7=16.6 Hz), 4.43 (d, 2H, .7=5.7 Hz), 4.81-5.02 (m, 4H, 2xOCH2), 5.33 (s, 2H, 
5-H and 5’-H), 6.39 (d, 2H, .7=8.3 Hz, 1-H and l ’-H), 6.44 (d, 2H, .7=8.3 Hz, 2-H and 
2 ’-H), 7.40 (virtual double triplet, 2H, > 1 .5  and 7.9 Hz), 7.64 (d, 2H, > 7 .4  Hz), 8.09 
(d, 2H, > 8 .2  Hz), 8.21-8.24 (m, 2H); 13C NMR (67.8 MHz, CDC13): 3.45 
(2xNCH2CH(CH2CH2)), 3.87 (2xNCH2CH(CH2CH2)), 9.52 (2xNCH2CH(CH2CH2)), 
22.42 (2xCH3), 23.56 (10-C + lO’-C), 24.62 (8 -C + 8 ’-C), 31.19 (15-C + 15’-C), 
43.50 (16-C + 16’-C), 48.07 (13-C + 13’-C), 55.85 (9- C + 9 ’-C), 59.51 (18- C + 18’- 
C), 70.13 (2xOCH2), 83.99 (14-C + 14’-C), 84.93 (5-C + 5 ’-C), 115.76 (C), 116.08 
(CH), 118.48 (CH), 122.70 (CH), 122.77 (CH), 124.65 (C), 127.88 (C), 129.27 (CH),
130.51 (C), 133.73 (CH), 139.29 (C), 141.14 (C), 144.47 (C), 148.15 (C), 170.68 




180 (70 mg, 69 pmol), sodium hydride (60% in oil, 29 mg, 0.72 mmol) and 3- 
nitrobenzyl bromide (47 mg, 0.22 mmol) in dry THF (5 mL) were reacted according 
to the general procedure 1 .181 (32 mg, 40 %) was isolated as a brown solid.
IR vmax/cm (neat): 1762 and 1731 (CO); JH NMR (270 MHz, CDC13): 0.01-0.07 (m, 
4H, NCH2CH(CtfHC//H)), 0.43 (d, 4H, > 6 .9  Hz, NCH2CH(CH//CH//)), 0.67-0.77 
(m, 2H, NCH2C//(CH2CH2)), 1.87 (s, 6 H, 2xCH3), 4.44 (d, 2H, > 5 .9  Hz), 4.86 (s, 
4H, 2xOCH2), 5.19 (s, 2H, 5-H and 5’-H), 5.40 (d, 1H, > 1 7 .6  Hz, N tt/H ), 5.48 (d, 
1H, > 1 7 .6  Hz, NCHH), 6.57 (d, 2H, > 7 .9  Hz, 1-H + l ’-H), 6.61-6.64 (m, 2H, 2-H +
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2’-H), 7.23-7.27 (m, 2H), 7.42-7.68 (m, 6 H), 8.06-8.15 (m, 4H); 13C NMR (67.8 
MHz, CDC13): 3.47 (2xNCH2CH(CH2CH2)), 3.93 (2xNCH2CH(CH2CH2)), 9.58 
(2xNCH2CH(CH2CH2)), 22.42 (2xCH3), 23.67 (10-C + lO’-C), 24.77 (8 -C + 8 ’-C),
31.28 (15-C + 15’-C), 43.49 (16-C + 16’-C), 46.80 (NCH2PhN02), 48.18 (13-C + 
13’-C), 55.99 (9- C + 9’-C), 59.56 (18- C + 18’-C), 70.46 (2xOCH2), 83.93 (14-C + 
14’-C), 84.30 (5-C + 5’-C), 116.51 (C), 117.01 (CH), 118.86 (CH), 120.62 (CH), 
121.70 (CH), 122.21 (CH), 122.76 (CH), 125.48 (C), 128.24 (C), 128.81 (CH), 
129.30 (CH), 130.75 (C), 131.57 (CH), 133.15 (CH), 139.41 (C), 141.19 (C), 141.64 




A solution of imidazole (80 mg, 1.16 mmol) and triphenylphosphine (0.30 g, 1.16 
mmol) in DCM (5 mL) was cooled down to 0°C under a nitrogen atmosphere. 
Bromine (60 pL, 1.16 mmol) was added dropwise and the reaction mixture was stirred 
for 10 minutes. A solution of 190 (0.18 g, 0.53 mmol) in DCM (1 mL) was then 
added and the reaction mixture allowed to warm up to room temperature and stirred 
for a further 3 hrs. Water was added and the aqueous phase extracted several times 
with DCM. The organic phase was dried (MgS0 4 ) and the solvent evaporated. 
Purification by flash chromatography, eluting with H-hexanes/ethyl acetate: 4/1, gave 
182 as a white solid (0 . 1 0  g, 60%).
Method B.
Bromine (0.18 mL, 3.51 mmol), triphenylphosphine (0.95 g, 3.62 mmol) and 194 
(1.14 g, 3.10 mmol) were treated as described for the preparation of 184, which 
afforded 182 (0.53 g, 54%) as a white solid.
Method C.
To a solution of N aB r03 (6.75 g, 45 mmol) in water (22.5 mL) was added 244 (3.55 
g, 15 mmol) in ethyl acetate (30 mL). Stirring was continued for 10 minutes after 
which a solution o f N aH S03 (4.65 g, 45 mmol) in water (45 mL) was added dropwise. 
The reaction mixture was stirred for 6  hours at room temperature then poured into 200
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mL of diethyl ether. The organic phase was collected and the aqueous phase further 
extracted with diethyl ether. The combined organic phase was washed with a solution 
of sodium hydrogensulfite, dried (MgS0 4 ) and concentrated under vacuum. 182 was 
isolated as a white solid after recrystallisation in acetone (2.94 g, 62%).
I R  v „ / c m  (KBr): 2920, 2859 (C-H aromatic), 1707 (CO); 'H  NMR (270 MHz, 
CDCb): 4.52 (s, 2H, CH2), 7.43 (d, 2H, .7=8.5 Hz), 7.52 (d, 2H, 7=8.5 Hz), 7.77-7.80 
(m, 2H), 7.93-7.96 (m, 2H); ,3C NMR (100.5 MHz, CDCb): 32.63 (CH2), 123.89 
(CH), 126.73 (CH), 129.88 (CH), 131.68 (C), 134.58 (CH), 137.52 (C), 167.15 (CO); 
MS (FAB): m/z = 315.9960 (M+H, 79Br) and 317.9945 (M+H, 8lBr); C15H1 i79B rN 02 
requires 315.9972; CisHnS1BrN02 requires 317.9952; R f  (n-hexanes/ethyl acetate: 
4/1): 0.17, (n-hexanes/ethyl acetate: 1/1): 0.70; mp : 205°C
3-PhthaIimidobenzyl bromide (183)
Bromine (0.15 mL, 2.81 mmol), triphenylphosphine (0.77 g, 2.93 mmol) and 195 
(0.85 g, 2.45 mmol) were treated as described for the preparation of 182, affording 
183 as a white solid (0.58 g, 75%).
]H NMR (270 MHz, CDC13): 4.52 (s, 2H, CH2), 7.36-7.50 (m, 4H), 7.77-7.80 (m, 
2H), 7.93-7.96 (m, 2H); 13C NMR (67.8 MHz, CDC13): 32.53 (CH2), 123.74 (CH),
126.29 (CH), 126.90 (CH), 128.55 (CH), 129.44 (CH), 131.53 (C), 131.97 (C), 
134.46 (CH), 138.74 (C), 166.98 (CO); MS (FAB): m/z = 315.9971 (M+H, 79Br) and 
317.9954 (M+H, 81Br); Ci5H n 79BrN02 requires 315.9972; Ci5H n 81BrN02 requires 
317.9952; R f  (n-hexanes/ethyl acetate: 4/1): 0.33
2-Phthalimidobenzyl bromide (184)207
A solution o f  triphenylphosphine (0.145 g, 55 pmol) in DCM (1 mL) was cooled to 
0°C under a nitrogen atmosphere. Bromine (30 pL, 55 pmol) was added dropwise and 
the reaction mixture stirred for 10 minutes. A solution of 196 (0.160 g, 46 pmol) in 
DCM (1 mL) was added and the reaction mixture allowed to warm up to room 
temperature and stirred for a further 3 hrs. Water was then added, and the aqueous 
phase extracted several times with DCM. The organic phase was dried (MgS0 4 ) and
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the solvent evaporated. Purification by flash chromatography, eluting with n- 
hexanes/ethyl acetate: 4/1, gave 184 as a white solid (0.10 g, 69 %).
I R  Vn^/cm (KBr): 3049-2995 (C-H aromatic), 1714 (CO); ‘H NMR (270 MHz, 
CDCb): 4.35 (s, 2 H, CH2), 7.17-7.21 (m, 1H), 7.37-7.41 (m, 1H), 7.43-7.50 (m, 1H), 
7.79-7.82 (m, 2H), 7.95-7.98 (m, 2H); 13C NMR (67.8 MHz, CDCb): 29.43 (CH2), 
123.89 (CH), 129.74 (CH), 129.79 (CH), 130.81 (C), 131.07 (CH), 131.82 (C),
134.45 (CH), 135.76 (CN), 167.16 (CO); MS (FAB): m/z = 315.9970 (M+H, 79Br) 
and 317.9959 (M+H, slBr); Ci5Hi079BrNO2 requires 314.9894 and C ,5H i081BrNO2 
requires 316.9874; R f  (n-hexanes/ethyl acetate: 8/1): 0.14; mp : 168°C (lit. 157- 
162°C)207
4-Aminobenzyl alcohol (185)
A solution of 4-nitrobenzyl alcohol (4.54 g, 30 mmol) and palladium (10 wt. % on 
activated carbon) (1.03 g, 10 mmol) in ethanol (50 mL) was stirred overnight at room 
temperature under a hydrogen atmosphere. The reaction mixture was then filtered 
through a short column of celite and the filtrate concentrated under vacuum. 
Purification by column chromatography, eluting first with DCM, then with 
DCM/MeOH/NRtOH: 300/10/1, gave two main fractions, one containing p-toluidine 
(0.54 g, 17 %) and the other containing the desired product 185 as a light-brown solid 
(2.46 g, 67 %).
'H  NMR (270 MHz, CDCb): 1.65 (br, s, 1H, N //H  or OH), 2.15 (br, s, 1H, N/fH or 
OH), 3.66 (br, s, 1H, NH//), 4.50 (s, 2H, CH2), 6.64 (d, 2H, 7=8.4 Hz), 7.12 (d, 2H, 
7=8.4 Hz); 13C NMR (67.8 MHz, CDCb): 65.05 (CH2), 115.09 (CH), 128.67 (CH),
131.04 (C), 145.86 (C); MS (FAB): m/z = 123 (M); C7H9NO requires 123
Side product: p-toluidine
*H NMR (270 MHz, CDC13): 2.30 (s, 3H, CH3), 3.58 (br, s, 2H, NH2), 6.63 (d, 2H, 
7=8.1 Hz), 7.02 (d, 2H, 7=8.1 Hz); 13 C NMR (67.8 MHz, CDC13): 21.12 (CH3), 
115.37 (CH), 128.52 (C), 129.88 (CH), 145.12 (C); MS (El): m/z = 165.0790 (M); 
C7H9N requires 165.0789; Rf (DCM/MeOH/NPLjOH: 100/10/1): 0.65
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2084-Amino-0-(tetrahydropyranyI)benzyl alcohol (189)
A solution of 4-nitrobenzyl alcohol (1.53 g, 10.00 mmol), 3,4-dihydro-2//-pyran (0.84 
g, 0.91 mL, 10.00 mmol) and p-toluenesulfonic acid monohydrate (20 mg, 0.11 
mmol) was stirred overnight at room temperature in CHCI3, then washed several 
times with water and brine, dried (MgSO-i) and finally concentrated under vacuum. 
Purification by column chromatography, eluting with n-hexanes/ethyl acetate: 9/1, 
afforded 188 (2.06 g, 87 %). Palladium (10 wt. % on activated carbon) (0.29 g, 0.27 
mmol) was added to a solution of 188 (2.00 g, 8.43 mmol) in ethanol (20 mL). The 
reaction mixture was stirred overnight at room temperature under a hydrogen 
atmosphere and then filtered through a short column o f celite. The solvent was 
evaporated and the crude product purified by column chromatography, eluting with n- 
hexanes/ethyl acetate: 5/1, which gave 189 as an orange oil (0.80 g, 46 %).
I R  Vm ax/cm  (neat): 3446, 3360 (br, bonded NH), 1625 (N-H); ]H NMR (270 MHz, 
CDCI3): 1.42-1.89 (m, 6 H), 3.47-3.55 (m, 1H), 3.68 (br, s, 2H, NH2), 3.86-3.95 (m, 
1H), 4.36 (d, 1H, 7=1 1.3 Hz, CHRO), 4.64 (d, 1H, 7=1 1.3 Hz, C H //0), 4.64-4.67 (m, 
1H, OCHO), 6.60 (d, 2H, 7=8.4 Hz), 7.12 (d, 2H, 7=8.4 Hz); 13C NMR (67.8 MHz, 
CDCI3): 19.02 (CH2), 25.06 (CH2), 30.18 (CH2), 61.59 (CH2), 68.29 (CH2Ph), 96.78 
(CH), 114.29 (CH), 126.98 (C), 129.10 (CH), 145.97 (C); MS (FAB): m/z = 207.1266 
(M) and 208.1337 (M+H); Ci2HigN02 requires 208.1337; R f  (n-hexanes/ethyl acetate: 
8/ 1): 0.66
4-Phthalimido-0-(tetrahydropyranyl)benzyl alcohol (190)
A solution of 189 (0.40 g, 1.93 mmol) and phthalic anhydride (0.28 g, 1.93 mmol) in 
mixed xylenes ( 6  mL) was reacted according to the general procedure H, giving 190 
(0 .1 0  g, 16 %) as a white solid.
IR vmax/cm (neat): 1707 (CO); ]H NMR (270 MHz, CDCI3): 1.47-1.91 (m, 6 H), 3.50-
3.59 (m, 1H), 3.86-3.95 (m, 1H), 4.54 (d, 1H, 7=12.5 Hz, CifflO), 4.72 (t, 1H, 7=3.2 
Hz, OCHO), 4.81 (d, 1H, 7=12.5 Hz, CH//0), 7.42 (d, 2H, 7=8.6 Hz), 7.48 (d, 2H, 
7=8.6 Hz), 7.73-7.79 (m, 2H), 7.90-7.96 (m, 2H); 13C NM R (67.8 MHz, CDC13): 
19.21 (CH2), 25.38 (CH2), 30.45 (CH2), 62.02 (CH2), 68.04 (CH2Ph), 97.62 (CH), 
123.69 (CH), 126.43 (CH), 128.30 (CH), 130.75 (C), 131.70 (C), 134.34 (CH),
138.36 (C), 167.24 (CO); MS (FAB): m/z = 337.1315 (M) and 338.1396 (M+H);
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C 20H 20N O 4 requires 3 3 8 . 1 3 8 2 ;  R f  (n-hexanes/ethyl acetate: 4 / 1 ) :  0 . 12 ,  R f  ( n -  
hexanes/ethyl acetate: 1 / 1 ) :  0 . 6 4 ;  mp : 1 2 5 ° C
4-Amino-0-(te#*M)utyIdimethylsilyI)benzyl alcohol (191) 209,210
4-Aminobenzyl alcohol (1.17 g, 9.5 mmol), tert-butyldimethylsilyl chloride (2.15 g,
14.2 mmol) and imidazole (1.29 g, 19.0 mmol) were reacted according to the general 
procedure G. After purification by column chromatography, eluting with n- 
hexanes/ethyl acetate: 8/1,191 was isolated as an orange oil (1.82 g, 81 %).
IR Vmax/cm (neat): 3 4 4 5 ,  3 3 6 3  (br, bonded N H ) ,  1 6 2 2  ( N - H ) ;  ] H  N M R  ( 2 7 0  M H z ,  
C D C I 3) :  0 . 1 3  (s, 6 H ,  2 x C H 3 ) ,  0 . 9 7  (s, 9 H ,  C ( C H 3 ) 3 ) ,  3 . 6 2  (s, br, N H 2 ) ,  4 . 6 6  (s, 2 H ,  
C H 2 ) ,  6 .6 6  (d, 2 H ,  . 7 = 8 . 0  H z ) ,  7 . 1 4  (d, 2 H ,  . 7 = 8 . 0  H z ) ;  1 3 C  N M R  ( 6 7 . 8  M H z ,  C D C 1 3 ) :  -
5 . 2 2  ( 2 x C H 3 ) ,  1 8 . 3 4  ( C ( C H 3 ) 3 ) ,  2 5 . 9 1  ( C ( C H 3 ) 3 ) ,  6 4 . 9 1  ( C H 2 ) ,  1 1 4 . 8 3  ( C H ) ,  1 2 7 . 5 7  
( C H ) ,  1 3 1 . 2 8  ( C ) ,  1 4 5 . 3 3  ( C ) ;  M S  ( F A B ) :  m/z = 2 3 7 . 1 5 5 5  ( M ) ,  2 3 8 . 1 6 1 4  ( M + H ) ;  
Ci3H24NOSi requires 2 3 8 . 1 6 2 6 ;  R f  (n-hexanes/ethyl acetate: 8 / 1 ) :  0 . 1 7 ,  R f  (n- 
hexanes/ethyl acetate: 1 / 1 ) :  0 . 7 3
3-Amino-0-(terf-butyldimethyIsilyl)benzyl alcohol (192) 210,211
3-Aminobenzyl alcohol (1.85 g, 15 mmol), tert-butyldimethylsilyl chloride (3.39 g, 
22.5 mmol) and imidazole (2.04 g, 30 mmol) were reacted according to the general 
procedure G. 192 was isolated as a dark oil (2.89 g, 81 %).
I R  Vmax/cm (neat): 3449, 3361 (br, bonded NH), 1620 (N-H); *H NMR (270 MHz, 
CDC13): 0.12 (s, 6 H, 2xCH3), 0.97 (s, 9H, C(CH3)3), 3.65 (br, 2H, NH2), 4.68 (s, 2H, 
CH2), 6.65-6.60 (m, 1H), 6.67-6.75 (m, 2H), 7.12 (t, 1H, .7=7.7 Hz), 7.89-7.95 (m, 
2H); 13C NMR (67.8 MHz, CDC13): -5.31 (2xCH3), 18.37 (C(CH3)3), 25.91 
(C(CH3)3), 64.83 (CH2), 112.67 (CH), 113.61 (CH), 116.17 (CH), 129.01 (CH),
142.61 (C), 146.30 (C); MS (FAB): m/z = 237.1537 (M), 238.1622 (M+H); 
Ci3H24NOSi requires 238.1626; R f  (n-hexanes/ethyl acetate: 4/1): 0.38, R f  (n- 
hexanes/ethyl acetate: 1/1): 0.54
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2-Amino-0-(te/?-butyIdimethyIsilyI)benzyl alcohol (193)212
2-Aminobenzyl alcohol (1.23 g, 10 mmol), tert-butyldimethylsilyl chloride (2.26 g, 
15 mmol) and imidazole (1.36 g, 20 mmol) were reacted according to the general 
procedure G. 193 was isolated as a brown oil (2.32 g, 98 %).
IR vmax/cm (neat): 3461, 3373 (br, bonded NH), 1621 (N-H); *H NMR (270 MHz, 
CDCI3): 0.08 (s, 6 H, 2xCH3), 0.91 (s, 9H, C(CH3)3), 4.69 (s, 2H, CH2), 6.65-6.75 (m, 
2H), 7.02-7.15 (m, 2H); 13C NMR (67.8 MHz, CDC13): -5.29 (2xCH3), 18.17 
(C(CH3)3), 25.84 (C(CH3)3), 64.84 (CH2), 115.64 (CH), 117.80 (CH), 125.13 (C),
128.39 (CH), 128.65 (CH), 146.06 (C); MS (FAB): m/z = 237.1551 (M), 238.1607 
(M+H); Ci3H24NOSi requires 238.1626; Rf (/z-hexanes/ethyl acetate: 4/1): 0.65
4-Phthalimido-0-(te#?-butyldimethylsilyl)benzyl alcohol (194)
A solution o f 191 (3.96 g, 16.7 mmol) and phthalic anhydride (2.42 g, 16.3 mmol) in 
mixed xylenes (40 mL) was reacted according to the general procedure H, which 
afforded 194 as colourless crystals (2.72 g, 45%).
IR Vmax/cm (neat): 2942-2857 (C-H aromatic), 1714 (CO); ]H NMR (270 MHz, 
CDC13): 0.09 (s, 6 H, 2xCH3), 0.94 (s, 9H, C(CH3)3), 4.79 (s, 2H, CH2), 7.39 (d, 2H, 
.7=8.5 Hz), 7.45 (d, 2H, .7=8.5 Hz), 7.72-7.79 (m, 2H), 7.89-7.95 (m, 2H); 13C NMR 
(67.8 MHz, CDC13): -5.37 (2xCH3), 18.27 (C(CH3)3), 25.82 (C(CH3)3), 64.28 (CH2),
123.53 (CH), 126.21 (CH), 126.39 (CH), 130.12 (C), 131.62 (C), 134.20 (CH), 
141.35 (C), 167.16 (CO); MS (FAB): 368.1673; C2 iH26N 0 3Si requires 368.1681; Rf 
(w-hexanes/ethyl acetate: 4/1): 0.41; mp : 114°C
3-Phthalimido-0-(tert-butyIdimethylsilyl)benzyI alcohol (195)
A solution o f 192 (1.29 g, 5.43 mmol) and phthalic anhydride (0.77 g, 5.43 mmol) in 
mixed xylenes (30 mL) was reacted according to the general procedure H. 195 was 
isolated as a white solid (1.33 g, 71 %).
IR Vmax/cm (neat): 1721 (CO); ’H NMR (270 MHz, CDCI3): 0.10 (s, 6 H, 2xCH3), 0.93 
(s, 9H, C(CH3)3), 4.79 (s, 2H, CH2), 7.24-7.52 (m, 4H), 7.76-7.79 (m, 2H), 7.93-7.96 
(m, 2H); l3C NMR (67.8 MHz, CDC13): -5.45 (2xCH3), 18.17 (C(CH3)3), 25.75
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(C(CH3)3), 64.22 (CH2), 123.40 (CH), 123.84 (CH), 124.76 (CH), 125.34 (CH), 
128.67 (CH), 131.42 (C), 131.47 (C), 134.11 (CH), 142.47 (C), 166.93 (CO); MS 
(FAB): m/z = 367.1572 (M) and 368.1672 (M+H); C2iH25N 0 3Si requires 367.1603; 
Rf (w-hexanes/ethyl acetate: 4/1): 0.42; mp : 87°C
2-Phthalimido-0-(ferf-butyldimethylsilyl)benzyl alcohol (196)
A solution of 193 (0.20 g, 0.84 mmol) and phthalic anhydride (0.12 g, 0.84 mmol) in 
mixed xylenes (5 mL) was reacted according to the general procedure H. 196 was 
isolated as a white solid (0.28 g, 96 %).
IR Vmax/cm (neat): 1716 (CO); 'H  NMR (270 MHz, CDC13): -0.06 (s, 6 H, 2xCH3), 
0.79 (s, 9H, C(CH3)3), 4.65 (s, 2H, CH2), 7.22 (dd, 1H, 7=1.3 and 7.5 Hz), 7.39 
(virtual double triplet, 1H, J= \.l and 7.4 Hz), 7.46 (virtual double triplet, 1H, 7=1.5 
and 7.4 Hz), 7.58 (dd, 1H, 7=1.4 and 7.3 Hz), 7.75-7.79 (m, 2H), 7.92-7.96 (m, 2H); 
13C NMR (67.8 MHz, CDC13): -5.60 (2xCH3), 18.17 (C(CH3)j), 25.69 (C(CH3)3), 
62.39 (CH2), 123.66 (CH), 127.91 (CH), 128.12 (CH), 128.89 (CH), 129.07 (C),
129.28 (CH), 132.06 (C), 134.20 (CH), 139.15 (C), 167.18 (CO); MS (FAB): 368 




178 (0.34 g, 0.41 mmol), sodium hydride (60% in oil, 6 6  mg, 1.65 mmol), 18-crown-6 
(23 mg, 0.09 mmol) and 182 (0.38 g, 1.20 mmol) in dry THF (5 mL) were reacted 
according to general procedure I. After purification, 197 was obtained as a brown 
solid (0.23 g, 53%).
]H NMR (270 MHz, CDC13): 0.04 (d, 4H, 7=4.5 Hz, NCH2CH (C//HC/m )), 0.43 (d, 
4H, 7=8.0 Hz, NCH2CH(CH//CH/7)), 0.66-0.78 (m, 2 H, NCH2C7/(CH2CH2)), 1.56 
(d, 2H, 7=10.9 Hz), 1.90 (s, CH3), 2.05 (CH3), 4.44 (d, 2H, 7=5.9 Hz), 5.29 (s, 2H, 5- 
H + 5’-H), 5.32 (d, 1H, 7=16.8 Hz, NCifflPh), 5.44 (d, 1H, 7=16.8 Hz, NCHtfPh),
6.62 (d, 2H, 7=8.2 Hz, 1-H + l ’-H), 6.75 (d, 2H, 7=8.2 Hz, 2-H + 2 ’-H), 6.87 (d, 2H, 
7=8.4 Hz), 7.34 (d, 2H, 7=8.4 Hz), 7.75-7.79 (m, 2H), 7.89-7.92 (m, 2H); 13C NMR
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(100.5 MHz, CDCI3): 4.05 (2 xNCH2CH(CH2CH2)), 4.40 (2xNCH2CH(CH2CH2)), 
10.07 (2xNCH2CH(CH2CH2)), 21.00 (2xCH3), 23.02 (2xCH3), 24.36 (10-C + lO’-C),
25.19 (8 -C + 8 ’-C), 31.55 (15-C + 15’-C), 43.85 (16-C + 16’-C), 47.71 (CH2), 48.59 
(13-C + 13’-C), 56.33 (9-C + 9’-C), 59.94 (18-C + 18’-C), 84.22 (14-C + 14’-C),
85.45 (5-C + 5’-C), 116.21, 118.70 (CH), 122.28 (CH), 123.87 (CH), 125.93 (C), 
126.54 (CH), 126.77 (CH), 130.63 (C), 131.28 (C), 131.88 (C), 132.14 (C), 132.86 
(C), 134.61 (CH), 139.12 (C), 147.15 (C), 167.29 (CO), 168.88 (CO), 170.86 (CO)
17,17,-Bis(cyclopropylmethyl)-6,6’,7,7’-tetradehydro-4,5:4, ,5,-diepoxy-6,6,-(4- 
phthalimidobenzylimino)[7,7’-bimorphinan]-3,3’,14,14,-tetrol (204)
197 (0.20 g, 0.19 mmol) was dissolved in conc. HCl/methanol (3 mL, 1/1) and the 
solution was stirred for 72 hours at 80°C. The solvents were then removed by 
evaporation, water was added and the aqueous phase basified to pH= 8  (NH4OH) and 
extracted with DCM/MeOH: 5/1. The organic phase was dried (MgS0 4 ) and 
concentrated under vacuum. The crude material was purified by column 
chromatography, eluting first with CHCl3/Me0 H/NH4 0 H: 500/10/1 then with 
CHCl3/Me0 H/NH4 0 H: 250/10/1. 204 was isolated as an off-white solid (9 mg, 5%).
]H NMR (270 MHz, CDC13): 0.11 (d, 4H, 7=4.4 Hz, NCH2CH(C//HC//H)), 0.51 (d, 
4H, 7=7.7 Hz, NCH2CH(CH//CH//)), 0.78-0.89 (m, 2H, NCH2C//(CH2CH2)), 1.59 
(d, 2H, 7=9.7 Hz), 3.02 (d, 2H, 7=18.3 Hz), 3.17-3.25 (m, 2H), 5.31 (d, 1H, 7=17.8 
Hz, NC//HPh), 5.36 (s, 2H, 5-H + 5’-H), 5.55 (d, 1H, 7=17.8 Hz, NCHtfPh), 6.47 (d, 
2H, 7=8.3 Hz, 1-H + l ’-H), 6.59 (d, 2H, 7=8.3 Hz, 2-H + 2 ’-H), 6.94 (d, 2H, 7=8.2 
Hz), 7.30 (d, 2H, 7=8.2 Hz), 7.77-7.80 (m, 2H), 7.93-7.96 (m, 2H); MS (FAB): m/z = 
897 (M); C55H52N40 8  requires 897; Rf (DCM/MeOH/NFLOH: 100/10/1): 0.44; mp > 
200°C
4-(PhthalimidomethyI)benzyl bromide (206)
A mixture of dibromo-p-xylene (1.0 g, 3.8 mmol), potassium phthalimide (0.7 g, 3.8 
mmol) and 18-crown-6 (0.1 g, 0.4 mmol) in toluene (10 mL) was reacted according to 
the general procedure J. 206 was isolated as a white solid (0.60 g, 48 %).
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IR Vmax/cm (KBr): 3049-2938 (C-H aromatic), 1720 (CO); ]H NMR (270 MHz, 
CDCI3 : 4.42 (s, 2H, CH2Br), 4.81 (s, 2H, CH2N), 7.31 (d, 2H, 7=8.2 Hz), 7.39 (d, 2H, 
7=8.2 Hz), 7.67-7.70 (m, 2H), 7.81-7.84 (m, 2H); 13C NMR (67.8 MHz, CDCI3):
32.96 (CH2Br), 41.09 (CH2N), 123.28 (CH), 128.99 (CH), 129.28 (CH), 131.94 (C),
133.96 (CH), 136.51 (C), 137.29 (C), 167.83 (CO); MS (FAB): m/z = 330.0125 
(M+H, 79Br) and 332.0125 (M+H, slBr); Ci6H l379BrN 02 requires 330.0129 and 
C i 6 H i 3 8 1 B r N 0 2  requires 332.0108; R f  (n-hexanes/ethyl acetate: 4/1): 0.23; mp : 137°C
3-(Phthalimidomethyl)benzyl bromide (207)
A mixture o f dibromo-w-xylene (2.0 g, 7.6 mmol), potassium phthalimide (1.4 g, 7.6 
mmol) and 18-crown-6 (0.20 g, 0.76 mmol) in toluene (20 mL) was reacted according 
to the general procedure J, affording 207 as colourless crystals (1.35 g, 54%).
IR Vmax/cm (KBr): 3042-2931 (C-H aromatic), 1709 (CO); *H NMR (270 MHz, 
CDC13): 4.44 (s, 2H, CH2Br), 4.82 (s, 2H, CH2N), 7.27-7.38 (m, 3H), 7.44 (s, 1H), 
7.67-7.71 (m, 2H), 7.80-7.85 (m, 2H); 13C NMR (100.5 MHz, CDC13): 33.54 
(CH2Br), 41.71 (CH2N), 123.62 (CH), 128.83 (CH), 128.94 (CH), 129.38 (CH),
129.40 (CH), 132.22 (C), 134.23 (CH), 137.09 (C), 138.42 (C), 168.08 (CO); MS 
(FAB): m/z = 330.0118 (M+H, 79Br ) and 332.0127 (M+H, 81Br); Ci6Hi379BrN 02 
requires 330.0129 and C i 6 H i 3 8 1 B r N 0 2  requires 332.0108; R f  («-hexanes/ethyl acetate: 
4/1): 0.24; mp : 124°C . .
2-(Phthalimidomethyl)benzyl bromide (208) 213
A mixture of dibromo-o-xylene (3.0 g, 11.3 mmol), potassium phthalimide (2.1 g,
11.3 mmol) and 18-crown-6 (0.30 g, 1.13 mmol) in toluene (30 mL) was reacted 
according to the general procedure J. 208 was isolated as a white solid (1.77 g, 47 %).
IR vmax/cm (KBr): 1712 (CO); ]H NMR (400 MHz, CDC13): 4.82 (s, 2H, CH2Br), 4.97 
(s, 2H, CH2N), 7.21-7.27 (m, 2H), 7.31-7.39 (m, 1H), 7.42-7.45 (m, 1H), 7.68-7.70 
(m, 2H), 7.81-7.84 (m, 2H); ,3C NMR (67.8 MHz, CDC13): 31.38 (CH2Br), 38.18 
(CH2N), 123.29 (CH), 128.38 (CH), 129.13 (CH), 130.34 (CH), 130.57 (CH), 131.90 
(C), 134.02 (CH), 134.84 (C), 136.02 (C), 168.03 (CO); MS (FAB): m/z = 330.0110
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(M+H, 79Br) and 332.0120 (M+H, 8lBr); Ci6Hi379BrN02 requires 330.0129 and
Ci6Hi38lBrN02 requires 332.0108; Rf (n-hexanes/ethyl acetate: 4/1): 0.25; mp : 144°C
17,17’-Bis(cyclopr opylmethyl)-3,3 ’-(methoxy methyloxy)-l 4,14 ’-dimethoxy
6,6,,7,7,-tetradehydro-4,5:4\5,-diepoxy-6,6,-(methoxymethylimino)[7,7’- 
bim orphinan] (209)
To a solution of norBNI (13) (0.33 g, 0.50 mmol) and imidazole (0.27 g, 4.0 mmol) in 
dry DMF (5 mL) was added trimethylsilyl chloride (0.38 mL, 3.0 mmol). The reaction 
mixture was stirred for two hours at room temperature, after which water (3 mL) was 
added and the aqueous phase extracted with DCM/MeOH: 5/1. The organic phase was 
washed with brine, dried (MgS0 4 ) and concentrated under vacuum. 209 was isolated 
as a brown solid and used without any further purification (0.45 g, 95%).
IR vmax/cm (neat): no specific peak; *H NMR (270 MHz, CDC13):. -0.23 (s, 18H, 
6 xCH3), 0.08 (s, 18H, 6 xCH3), 0.03-0.18 (m, 4H, 2xNCH2CH(C//HC//H)), 0.44-0.54 
(m, 4H, 2xNCH2CH(CH//CH//)), 0.78-0.94 (m, 2H, 2xNCH2C//(CH2CH2)), 5.24 (s, 




To a solution of norBNI (13) (0.66 g, 1.0 mmol) and imidazole (0.30 g, 4.4 mmol) in 
dry DMF (5 mL) was added terf-butyldimethylsilyl chloride (0.63 g, 4.2 mmol). The 
reaction mixture was stirred for two hours at room temperature, after which water (3 
mL) was added and the aqueous phase extracted with DCM/MeOH: 5/1. The organic 
phase was washed with brine, dried (MgS0 4 ) and concentrated under vacuum. 2 1 0  
was isolated as a brown solid and used without any further purification (1.08 g, 97%).
IR Vmax/cm (neat): no specific peak; ]H NMR (270 MHz, CDC13): 0.01-0.10 (m, 4H, 
2xNCH2CH(C//HC//H)), 0.08 (s, 12H, 3-COSi(CH3) 2 + 3’-COSi(CH3)2), 0.09 (s, 6 H, 
14-COSi(C//3CH3) + 14’-COSi(C//3CH3)), 0.10 (s, 6 H, 14-COSi(CH3C //3) + 14’- 
COSi(CH3C i/3)), 0.49 (d, 4H, 7=8.2 Hz, 2xNCH2CH(CH//CHtf)), 0.90 (s, 18H, 
6 xCH3), 0.94 (s, 18H, 6 xCH3), 5.36 (s, 2H, 5-H + 5’-H), 6.43 (d, 2H, 7=8.1 Hz, 1-H +
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l ’-H), 6.53 (d, 2H, 7=8.1 Hz, 2-H + 2’-H), 7.94 (s, br, 1H, NH); Rf 
(DCM/MeOH/NHUOH: 100/10/1): 0.42
17,17,-Bis(cyclopropylmethyl)-14,14’-dimethoxy-6,6,,7,7,-tetradehydro-4,5:4,,5’- 
diepoxy-6,6,-(imino)[7,7’-bim orphinan]-3,3’-diol (211) 163
A solution of 221 (63 mg, 8 6  pmol) in conc. HCl/MeOH (3 mL, 1/1) was stirred 
overnight at 80°C. Similar workup and purification as employed for the preparation of 
204 afforded 211 (47 mg, 79%) as an off-white solid.
*H NMR (270 MHz, CDC13): 0.12 (d, 4H, 7=4.0 Hz, 2xNCH2CH(C//HCHH)), 0.41- 
0.53 (m, 4H, 2xNCH2CH(CH/7CHtf)), 0.78-0.90 (m, 2H, 2xNCH2C/7(CH2CH2)), 
3.09 (s, 6 H, OCH3), 5.55 (s, 2H, 5-H + 5’-H), 6.46 (d, 2H, 7=8.2 Hz, 1-H + l ’-H),
6.61 (d, 2H, 7=8.2 Hz, 2-H + 2 ’-H); 13C NMR (100.5 MHz, CDC13): 3.08 
(2xNCH2CH(CH2CH2)), 4.30 (2xNCH2CH(CH2CH2)), 8.76 (2xNCH2CH(CH2CH2)),
22.28 (CH2), 23.23 (CH2), 29.82 (15-C + 15’-C), 44.88 (16-C + 16’-C), 48.10 (CH3 or 
13-C + 13’-C), 48.68 (CH3 or 13-C + 13’-C), 55.32 (9-C + 9’-C), 59.24 (18-C + 18’- 
C), 78.79 (14-C + 14’-C), 85.31 (5-C + 5’-C), 114.92 (7-C + 7’-C), 117.15 (CH),
118.53 (CH), 124.81 (C), 124.97 (C), 130.81 (C), 139.19 (C), 142.63 (C); Rf 
(DCM/MeOH/NELOH: 100/10/1): 0.39; mp > 215°C
4,5a-Epoxy-3-benzyloxy-14-methoxy-17-cyclopropylmethyl-morphinan-6-one 
(212) 164
A mixture of 215 (6.97 g, 16.2 mmol) and sodium hydride (1.94 g, 48.5 mmol) in dry 
DMF (20 mL) was stirred for 20 minutes at 0°C. Dimethyl sulfate (4.21 mL, 44.5 
mmol) was then added dropwise. After complete addition, the temperature was 
maintained at 0°C for another 2 hours before quenching the reaction with water (5 
mL). The aqueous phase was extracted with DCM/MeOH: 5/1, the organic phase 
dried (MgS0 4 ) and concentrated. The crude product was purified by column 
chromatography, eluting first with CHCI3: 100%, then with CHCL/MeOH/NILOH: 
400/5/1. The product was immediately dissolved in MeOH/conc. HC1: 3/2, and the 
solution was refluxed overnight. The solvents were then removed under vacuum, and 
recrystallisation in ethanol afforded 212 (HC1 salt) as a white solid (4.15 g, 72%).
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IR Vmax/cm (KBr, HC1 salt): 3391 (br, bonded OH), 1730 (CO); *H NMR (270 MHz, 
CDC13, free base): 0.13 (d, 2H, 7=5.3 Hz, NCH2CH(C//HCtfH)), 0.44-0.57 (m, 2H, 
NCH2CH(CH//CH#)), 0.81-0.95 (m, 1H, NCH2Ctf(CH2CH2)), 3.11 (d, 1H, 7=18.3 
Hz, 10-C//H), 3.37 (s, 3H, OCH3), 3.63 (d, 1H, 7=5.3 Hz, 9-CHH), 4.65 (s, 1H, 5-H), 
6.55 (d, 1H, 7=8.2 Hz, 1-H), 6.69 (d, 1H, 7=8.2 Hz, 2-H); 13C NMR (67.8 MHz, 
CDCI3, free base): 3.16 (NCH2CH(CH2CH2)), 4.29 (NCH2CH(CH2CH2)), 9.12 
(NCH2CH(CH2CH2)), 22.63 (10-C), 25.04 (8 -C), 29.15 (15-C), 35.46 (7-C), 44.88 
(16-C), 47.98 (OCH3), 51.02 (13-C), 54.43 (9-C), 59.24 (18-C), 75.59 (14-C), 90.49 
(5-C), 117.85 (2-C), 119.81 (1-C), 124.94 (11-C), 129.42 (12-C), 138.76 (3-C),
I4 3 .4 5  (4-C), 210.28 (CO); MS (FAB, free base): m/z = 355.1771 (M), 356.1850 
(M+H); C2 iH26N 0 4 requires 356.1861; Rf (DCM/MeOH/NILOH: 100/10/1, free 
base): 0.45; mp (HC1 salt) > 220 °C
4,5a-Epoxy-3-benzyloxy-17-cyclopropylmethyl-morphinan-6-one (215)164
To a solution of naltrexone (5.80 g, 17.01 mmol) and potassium carbonate (3.52 g,
22.47 mmol) in DMF (20 mL) was added benzyl bromide (2.04 mL, 17.1 mmol). The 
reaction mixture was stirred overnight at room temperature. Water (7 mL) was added, 
the aqueous phase extracted with DCM/MeOH: 5/1 and the organic phase was dried 
(MgS04) and concentrated. 215 was isolated as a brown solid (7.26 g, 99%) and used 
with no further purification.
]H NMR (270 MHz, CDC13): 0.10-0.15 (m, 2H, NCH2CH(CffHC//H)), 0.51-0.57 (m, 
2H, NCH2CH(CH/JCHtf)), 0.78-0.91 (m, 1H, NCH2Ctf(CH2CH2)), 5.19 (d, 1H, 
7=12.3 Hz, OC//H), 5.27 (d, 1H, 7=12.3 Hz, OCHH), 5.28 (s, 1H, 5-H), 6.54 (d, 1H, 
7=8.1 Hz, 1-H), 6.70 (d, 1H, 7=8.1 Hz, 2-H), 7.26-7.36 (m, 3H, Ar), 7.41-7.46 (m, 
2H, At); 13C NMR (67.8 MHz, CDC13): 3.77 (NCH2CH(CH2CH2)), 3.96 
(NCH2CH(CH2CH2)), 9.38 (NCH2CH(CH2CH2)), 22.63 (10-C), 30.68 (CH2), 31.45 
(CH2), 36.18 (7-C), 43.53 (16-C), 50.71 (13-C), 59.16 (18-C), 61.96 (9-C), 70.10 (14- 
C), 72.04 (OCH2), 90.38 (5-C), 117.87 (CH), 119.37 (CH), 125.55 (C), 127.72 (CH),
128.34 (CH), 129.76 (C), 137.41 (C), 141.74 (C), 145.46 (C), 162.47 (CH), 208.49 





A solution o f hydrocodone (4.00 g, 13.4 mmol) in DCM (80 mL) was cooled to -78°C 
under a nitrogen atmosphere before adding slowly boron tribromide (1 mol/L in 
DCM, 26.6 mL, 26.6 mmol). The reaction mixture was allowed to warm up to room 
temperature and stirred overnight. The reaction was then quenched by the addition of 
methanol (50 mL) and the solvents were removed under vacuum. Methanol (50 mL) 
was added a second time and removed by evaporation. Water (50 mL) was added and 
the pH adjusted to pH=12 (NH4OH). The aqueous phase was extracted several times 
with DCM/MeOH: 5/1. The organic phase was dried over MgS0 4 , concentrated under 
vacuum and the brown oil was purified by column chromatography, eluting with 
CHCb/MeOH/NfLjOH: 500/10/1. 217 was obtained as a brown solid (1.50 g, 40%).
Method B.
A solution o f hydrocodone (2.10 g, 7.0 mmol) in dichloroethane (10 mL) was added 
slowly to a solution of boron tribromide-methyl sulfide complex (8.74 g, 28.0 mmol) 
in dichloroethane (40 mL). The reaction mixture was stirred overnight at 65°C. 
Similar workup and purification as employed for method A afforded 217 as a brown 
solid (0.66 g, 33%).
IR Vmax/cm (neat): 3380 (br, bonded OH), 1724 (CO); *H NMR (270 MHz, CDC13):
2.44 (NMe), 4.59 (5-H), 6.53 (d, 1H, .7=8.1 Hz, 1-H), 6.64 (d, 1H, .7=8.1 Hz, 2-H); 
13C NMR (67.8 MHz, CDC13): 19.94 (10-C), 25.21 (8 -C), 34.61 (15-C), 40.00 (7-C), 
41.27 (14-C), 42.17 (N-Me), 46.50 (13-C), 46.68 (16-C), 58.74 (9-C), 90.81 (5-C),
118.28 (CH), 119.87 (CH), 123.80 (C), 126.56 (C), 139.95 (C), 144.36 (C), 208.77 
(CO); MS (FAB): m/z = 286.1431 (M+H); C 17H20NO3 requires 286.1442; Rf 
(DCM/MeOH/NILOH: 100/10/1): 0.30; mp > 220°C
4,5a-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one (218) 170,215 
Oxycodone (0.58 g, 1.84 mmol) in dichloroethane (10 mL) was added slowly to a 
solution o f boron tribromide-methyl sulfide complex (2.29 g, 7.33 mmol) in 
dichloroethane (20 mL). The reaction mixture was stirred overnight at 65°C, water 
was then added, before stirring for another 30 minutes. The aqueous phase was
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washed several times with DCM, adjusted to pH=12 with diluted NH4OH and 
extracted several times with DCM/MeOH: 5/1. The organic phase was dried over 
MgS0 4 , concentrated under vacuum and the brown oil was purified by column 
chromatography, eluting with CHCh/MeOH/NILOH: 220/10/1. 218 was obtained as 
a brown solid (0.35 g, 63 %).
NMR (270 MHz, CDCI3): 2.39 (s, 3H, CH3), 2.88 (d, 1H, .7=5.7 Hz), 3.02 (td, 1H, 
.7=14.6 Hz and 5.2 Hz), 3.12 (d, 1H, .7=18.6 Hz), 4.70 (s, 1H, 5-H), 6.58 (d, 1H, .7=8.2 
Hz, 1-H), 6.70 (d, 1H, .7=8.2 Hz, 2-H); 13 C NMR (100.5 MHz, CDC13): 21.99 (10-C),
30.39 (CH2), 31.30 (CH2), 36.15 (7-C), 42.76 (N-Me), 45.28 (16-C), 50.46 (13-C),
64.56 (9-C), 70.60 (14-C), 90.51 (5-C), 118.15 (CH), 120.00 (CH), 124.12 (C),
128.85 (C), 138.97 (C), 143.57 (C), 210.21 (CO); Rf (DCM/MeOH/NILOH: 
100/10/1): 0.47; mp > 220°C
17,17’-Bis(cyclopropylmethyl)-3,3’-(methoxymethyloxy)-6,6’,7,7,-tetradehydro- 
4,5:4’,5,-diepoxy-6,6’-(methoxymethylimino)[7,7,-bimorphinan]-14,14’-diol (219)
A mixture of norBNI (13) (0.80 g, 1.20 mmol) and sodium hydride (192 mg, 4.80 
mmol) in dry DMF (10 mL) was stirred for 20 minutes at room temperature before 
adding chloromethyl methyl ether (0.36 mL, 4.80 mmol) and stirring continued for a 
further 2 hrs at room temperature. Water (4 mL) was added and the aqueous phase 
extracted with DCM/MeOH: 5/1. The organic phase was dried (MgS0 4 ) and 
concentrated under vacuum. The product was purified by column chromatography, 
eluting first with CHC13: 100%, then with CHCb/MeOH/NILOH: 800/5/1, which 
afforded 219 as a brown solid (0.72 g, 76%).
IR Vmax/cm (KBr): 3295 (br, bonded OH); !H NMR (270 MHz, CDC13): 0.10 (d, 4H, 
.7=4.2 Hz, 2xNCH2CH(C//HCT/H)), 0.50 (d, 4H, .7=6.9 Hz, 2xNCH2CH(CH7/CH/7)), 
0.75-0.87 (m, 2H, 2xNCH2C77(CH2CH2)), 3.37 (s, 3H, NCH2OC7 / 3), 3.44 (s, 6 H, 
2xOCH2OC773), 5.06 (d, 2H, .7=6.5 Hz, OC//HOCH3), 5.16 (d, 2 H, .7=6.5 Hz, 
OCH//OCH3), 5.19 (d, 1H, .7=10.3 Hz, NC//HOCH3), 5.62 (s, 2H, 5-H + 5 ’-H), 5.78 
(d, 1H, .7=10.3 Hz, NCH//OCH3), 6.50 (d, 2H, .7=8.2 Hz, 1-H + l ’-H), 6.82 (d, 2H, 
.7=8.2 Hz, 2-H + 2 ’-H); 13C NMR (67.8 MHz, CDC13): 3.67 (2xNCH2CH(CH2CH2)),
3.85 (2xNCH2CH(CH2CH2)), 9.29 (2xNCH2CH(CH2CH2)), 22.93 (2xCH2), 28.76
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( 2 x C H 2 ) ,  31.42 (2xCH2), 43.50 (16-C + 16’-C), 47.61 (13-C + 13’-C), 55.51 
(NCH2OCH3), 56.09 (3-COCH2OCH3 + 3’-COCH2OCH3), 59.21 (18-C + 18’-C), 
62.14 (9-C + 9’-C), 72.35 (14-C + 14’-C), 75.02 (NCH2OCH3), 84.22 (5-C + 5’-C), 
95.66 (3-COCH2OCH3 + 3’-COCH2OCH3), 116.60 (C), 117.67 (CH), 118.19 (CH),
125.89 (C), 126.99 (C), 131.21 (C), 140.35 (C), 145.25 (C); Rf
(DCM/Me0 H/NH4 0 H: 100/10/1): 0.54; mp : 114 °C
17,17 ’-Bis(cyclopr opy!methyl)-3,3 ’-(methoxy methyloxy)-l 4,14 ’-dimethoxy-6,6’, 
7,7,-tetradehydro-4,5:4,,5’-diepoxy-6,6,-(methoxymethylimino)[7,7’- 
bimorphinan] (220)
219 (0.65 g, 0.83 mmol), sodium hydride (0.10 g, 2.50 mmol) and dimethyl sulfate 
(0.2 mL, 2.1 mmol) were reacted according to the same procedure as used for the 
preparation o f 212, but the reaction time was increased to 3hrs. After purification by 
column chromatography, eluting first with CHC13: 100%, then with
CHCl3/Me0 H/NH4 0 H: 400/5/1, 220 was isolated as a brown solid (0.15 g, 22%).
IR Vmax/cm (neat): 2913 (C-H aromatic); *H NMR (270 MHz, CDC13): 0.11 (d, 4H, 
7=4.2 Hz, 2xNCH2CH(C//HC//H)), 0.46-0.51 (m, 4H, 2xNCH2CH(CH//CH//)), 
0.82-0.92 (m, 2H, 2xNCH2C//(CH 2CH2)), 3.13 (s, 6 H, 14-OCH3 + 14’-OCH3), 3.33 
(s, 3H, NCH2OC7/3), 3.43 (s, 6 H, 2xOCH2OCi/3), 5.08 (d, 2H, .7=6.5 Hz, 
OCHHOCHi), 5.16 (d, 1H, 7=10.3 Hz, NC77HOCH3), 5.18 (d, 2H, 7=6.5 Hz, 
0CH770CH3), 5.59 (s, 2H, 5-H +5’-H), 5.72 (d, 1H, 7=10.3 Hz, NCH//OCH3), 6.52 
(d, 2H, 7=8.2 Hz, 1-H + l ’-H), 6.82 (d, 2H, 7=8.2 Hz, 2-H + 2 ’-H); 13C NMR (67.8 
MHz, CDC13): 3.01 (2xNCH2CH(CH2CH2)), 4.20 (2xNCH2CH(CH2CH2)), 9.03 
(2xNCH2CH(CH2CH2)), 22.17 (8 -C + 8 ’-C), 23.09 (10-C + lO’-C), 29.99 (15-C + 
15’-C), 44.77 (16-C + 16’-C), 48.12 (13-C + 13’-C), 48.53 (14-COCH3 + 14’- 
COCH3), 55.13 (9-C + 9 ’-C), 55.30 (NCH2OCH3), 56.18 (3-OCH2OCH3 + 3'- 
OCH2OCH3), 59.32 (18-C + 18’-C), 75.05 (NCH2OCH3), 77.99 (14-C + 14’-C),
84.44 (5-C + 5’-C), 95.68 (3-OCH2OCH3 + 3’-OCH2OCH3), 116.11 (7-C + 7’-C),
117.61 (2-C + 2 ’-C), 117.91 (1-C + l ’-C), 125.88 (6 -C + 6 ’-C), 127.82 (11-C + 11’- 
C), 131.80 (12-C + 12’-C), 140.19 (3-C + 3’-C), 145.17 (4-C + 4 ’-C); MS (FAB): m/z 





A solution of 220 (0.11 g, 0.13 mmol) in conc. HCl/MeOH (3 mL, 1/1) was stirred at 
room temperature overnight. The mixture was evaporated to dryness, water was added 
and the pH adjusted to pH=10 with diluted NH4OH. The aqueous phase was extracted 
with DCM/MeOH: 5/1, the organic phase dried over MgS0 4  and concentrated by 
evaporation. Purification by column chromatography, eluting first with CHCI3: 1 0 0 %, 
then with CHCh/MeOH/NILOH: 500/10/1 and finally with CHCb/MeOH/NfLOH: 
250/10/1, afforded 221 (70 mg, 71%) as an off-white solid.
IR vmax/crn (neat): 3370 (br, bonded OH); ]H NMR (270 MHz, CDC13): 0.02-0.10 (m, 
4H, 2xNCH2CH(C77HC//H)), 0.42-0.52 (m, 4H, 2xNCH2CH(CH77CH7/)), 0.86-0.98 
(m, 2H, 2xNCH2C7/(CH2CH2)), 2.56 (s, 6 H, 14-OCH3 + 14’-OCH3), 3.30 (s, 3H, 
NCH2OCHi), 5.34 (d, 1H, .7=9.7 Hz, NC//HOCH3), 5.58 (s, 2H, 5-H +5’-H), 5.81 (d, 
1H, .7=9.7 Hz, NCH//OCH3), 6.42 (d, 2H, .7=7.8 Hz, 1-H + l ’-H), 6.53 (d, 2H, .7=7.8 
Hz, 2-H + 2 ’-H); 13C NMR (67.8 MHz, CDCI3): 3.71 (2xNCH2CH(CH2CH2)), 4.37 
(2xNCH2CH(CH2CH2)), 8.56 (2xNCH2CH(CH2CH2)), 23.26 (CH2), 24.49 (CH2),
29.47 (15-C + 15’-C), 44.54 (16-C + 16’-C), 47.89 (13-C + 13’-C), 50.21 (14- 
COCH3 + 14’-COCH3), 55.18 (OCH3), 58.69 (9-C + 9’-C), 59.88 (18-C + 18’-C),
70.56 (NCH20), 78.25 (14-C + 14’-C), 84.07 (5-C + 5’-C), 116.20 (7-C + 7’-C), 
116.68 (CH), 117.98 (CH), 124.41 (C), 126.17 (C), 131.04 (C), 140.02 (C), 142.50 
(C); MS (FAB): m/z = 733 (M), C44H51N3O7 requires 733; Rf (DCM/MeOH/NHUOH: 
100/10/1): 0.15; mp > 200°C
17.17,-Bis(cyclopropylmethyl)-3,3’-(4-phthalimidomethyl)benzyloxy-14,14’- 
dimethoxy-6,6,,7,7’-tetradehydro-4,5:4,,5’-diepoxy-6,6’-(4-(phthalimidomethyl) 
benzylimino) [7,7’-bim orphinan] (223)
To a solution of 211 (96 mg, 0.14 mmol) and DMAP (28 mg, 0.23 mmol) in pyridine 
(5 mL) was added 4,4’-dimethoxytrityl chloride (95 mg, 0.28 mmol) and the reaction 
mixture was stirred overnight at room temperature. Water was added and the aqueous 
phase extracted with CHCI3 . The organic phase was dried (MgSCU) and concentrated. 
2 2 2  was isolated as a brown solid and used without any further purification.
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]H NMR (270 MHz, CDC13): 0.05-0.07 (m, 4H, 2xNCH2CH(CtfHC//H)), 0.41-0.45 
(m, 4H, 2xNCH2CH(CHtfCHfl)), 0.74-0.82 (m, 2H, 2xNCH2C//(CH2CH2)), 2.99 (s, 
6 H, 2xOCH3), 3.70 (s, 12H, 4xOCH3), 5.53 (s, 2H, 5-H +5’-H), 6.41 (d, 2H, .7=8.1 
Hz, 1-H + l ’-H), 6.63 (d, 2H, .7=8.1 Hz, 2-H + 2 ’-H), 6.75 (d, 8H ,> 8 .9  Hz), 7.09 (d, 
8 H, > 8 .9  Hz), 7.17-7.22 (m, 10H); Rf (DCM/MeOH/NHjOH: 100/10/1): 0.72
222 (0.14 mmol), sodium hydride (23 mg, 0.57 mmol) and 206 (0.14 g, 0.42 mmol) 
were reacted according to the general procedure I. After purification, 223 was isolated 
as a brown solid (41 mg, 2 0 %).
IR Vmax/cm (neat): 2916 (C-H aromatic), 1715 (CO); *H NMR (270 MHz, CDC13): 
0.10 (d, 4H, > 4 .6  Hz, 2xNCH2CH(C77HCT/H)), 0.41-0.53 (m, 4H,
2xNCH2CH(CH/7CH7/)), 0.77-0.91 (m, 2H, 2xNCH2C/7(CH2CH2)), 3.11 (s, 6 H, 
2xOCH3), 4.76 (d, 2H, > 1 2 .3  Hz, 2xOC//H), 4.81 (s, 6 H, 3xNCH2), 4.86 (d, 2H, 
> 1 2 .3  Hz, 2xOCHH), 5.23 (s, 2H, 5-H + 5’-H), 5.24 (d, 1H, > 1 6 .8  Hz, NC7/H),
5.31 (d, 1H, > 1 6 .8  Hz, NCHH), 6.44 (d, 2H, > 8 .2  Hz, 1-H + l ’-H), 6.58 (d, 2H, 
> 8 .2  Hz, 2-H + 2 ’-H), 6 .8 6  (d, 2H, > 8 .2  Hz), 7.13 (d, 2H, > 8 .2  Hz), 7.23 (d, 2H, 
> 8 .2  Hz), 7.37 (d, 2H, > 8 .2  Hz), 7.61-7.65 (m, 6 H), 7.70-7.74 (m, 2H), 7.77-7. 81 
(m, 4H); 13C NMR (67.8 MHz, CDC13): 3.15 (2xNCH2CH(CH2CH2)), 4.22 
(2xNCH2CH(CH2CH2)), 9.18 (2xNCH2CH(CH2CH2)), 22.43 (CH2), 23.18 (CH2),
30.25 (15-C + 15’-C), 40.86 (PhthaNCH2), 41.32 (2xPhthaNCH2), 44,72 (16-C + 16’- 
C), 47.28 (NCH2Ph), 48.15 (13-C + 13’-C), 48.67 (14-COCH3 + 14’-COCH3), 55.36 
(9-C + 9’-C), 59.44 (18-C + 18’-C), 71.16 (2xOCH2Ph), 78.31 (14-C + 14’-C), 84.53 
(5-C + 5’-C), 115.38 (C), 116.66 (CH), 117.76 (CH), 123.19 (CH), 123.25 (CH), 
125.75 (C), 126.39 (CH), 126.82 (C), 127.75 (CH), 128.53 (CH), 128.69 (CH),
131.97 (C), 132.05 (C), 133.65 (CH), 133.87 (CH), 134.81 (C), 135.56 (C), 137.43 
(C), 138.24 (C), 141.93 (C), 144.62 (C), 167.77 (CO), 167.94 (CO); MS (FAB): m/z = 






178 (0.17 g, 0.20 mmol), sodium hydride (60% in oil, 24 mg, 0.60 mmol), 18-crown-6 
(20 mg, 0.08 mmol) and 206 (0.20 g, 0.60 mmol) were reacted according to the 
general procedure I. 224 was isolated as a brown solid (0.08 g, 37 %).
*H NMR (270 MHz, CDC13): 0.01-0.05 (m, 4H, 2xNCH2CH(CM lC/ffl)), 0.43 (d, 
4H, .7=7.4 Hz, 2xNCH2CH(CH7/CH/7)), 0.66-0.78 (m, 2H, 2xNCH2C77(CH2CH2)),
1.85 (s, 3H, CH3), 1.97 (s, 3H, CH3), 4.42 (d, 2H, 7=5.7 Hz), 4.60-4.98 (m, 2H, 
NCH2Ph), 4.83 (s, 2H, CH2NPhtha), 5.21 (s, 2H, 5-H +5’-H), 6.61 (d, 2H, 7=8.2 Hz, 
1-H + l ’-H), 6.73 (d, 2H, 7=8.2 Hz, 2-H + 2’-H), 7.20-7.38 (m, 4H), 7.64-7.71 (m, 
2H), 7.78-7.86 (m, 2H); MS (FAB): m/z = 1079.4450 (M+H); C64H63N4Oi2 requires 
1079.4442; Rf (DCM/MeOH/NKtOH: 200/12/1): 0.55
17,17’-Bis(cyclopropylmethyl)-6,6’,7,7,-tetradehydro-4,5:4’,5,-diepoxy-6,6’-(4- 
(phthalimidomethyl)benzylimino)[7,7,-bimorphinan]-3,3’,14,14,-tetrol (227)
224 (0.15 g, 0.14 mmol) was dissolved in a mixture o f conc. HCl/MeOH (2 mL, 1/1) 
and the reaction was stirred overnight at 85°C. The mixture was evaporated to dryness 
and water was added. The aqueous phase was basified to pH=8 with diluted NH4OH 
and extracted with DCM/MeOH: 5/1. The organic phase was dried (M gS04) and the 
solvent evaporated. Purification by column chromatography (gradient elution, 
CHCh/MeOH/NILOH: 450/10/1 to CHCb/MeOH/NILOH: 100/10/1) afforded 227 
( 6 6  mg, 52%) and 230 (23 mg, 21%) as brown solids.
Data for 227:
IR Vmax/cm (neat): 3404 (br, bonded OH), 1713 (CO); ]H NMR (270 MHz, CDC13): 
0.09 (d, 4H, 7=4.9 Hz, 2xNCH2CH(C//HC//H)), 0.49 (d, 4H, 7=8.0 Hz, 
2xNCH2CH(CH//CHH)), 0.75-0.85 (m, 2H, 2xNCH2C//(CH2CH2)), 3.00 (d, 2H, 
7=18.4 Hz), 3.14 (d, 2H, 7=6.3 Hz), 3.64-4.20 (br, s, 4H, OH), 4.82 (s, 2H, 
CH2NPhtha), 5.19 (d, 1H, 7=17.2 Hz, NCHR), 5.29 (s, 2H, 5-H +5’-H), 5.44 (d, 1H, 
7=17.2 Hz, NCHtf), 6.41-6.48 (m, 4H, 1-H + l ’-H + 2-H + 2’-H), 6.79 (d, 2H, 7=8.0 
Hz, Ar), 7.32 (d, 2H, 7=8.0 Hz, Ar), 7.66-7.69 (m, 2H, Ar), 7.82-7.85 (m, 2H, Ar);
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13C NMR (67.8 MHz, CDCI3): 3.74 (2xNCH2CH(CH2CH2)), 3.83
(2xNCH2CH(CH2CH2)), 9.34 (2xNCH2CH(CH2CH2)), 22.98 (10-C + lO’-C), 28.91 
(8 -C + 8 ’-C), 31.34 (15-C + 15’-C), 41.15 (CH2NPhtha), 43.50 (16-C + 16’-C), 47.05 
(NCH2), 47.96 (13-C + 13’-C), 59.29 (18-C + 18’-C), 62.34 (9-C + 9’-C), 72.66 (14- 
C + 14’-C), 84.74 (5-C + 5’-C), 116.45 (C), 116.66 (CH), 118.45 (CH), 123.26 (CH), 
124.99 (C), 125.60 (C), 125.75 (CH), 128.61 (CH), 130.66 (C), 132.19 (C), 133.87 
(CH), 134.77 (C), 138.68 (C), 139.61 (C), 142.79 (C), 168.12 (CO); MS (FAB): m/z = 
911.4004 (M+H); C56H55N4O8 requires 911.4019; Rf (DCM/MeOH/NH4OH: 
110/10/1): 0.31; m p>  220 °C
17,17,-Bis(cyclopropylmethyl)-6,6’,7,7’-tetradehydro-4,5:4,,5’-diepoxy-6,6’-(3- 
(phthalimidomethyl)benzylimino)[7,7,-bimorphinan]-3,3%14,14’-tetrol (228)
178 (0.33 g, 0.40 mmol), sodium hydride (60% in oil, 64 mg, 1.60 mmol), 18-crown-6 
(20 mg, 0.08 mmol) and 207 (0.40 g, 1.20 mmol) were reacted according to the 
general procedure I, affording 225 as a brown solid (0.18 g, 42 %).
225 (80 mg, 74 pmol) was immediately dissolved in a mixture o f  conc. HCl/MeOH 
(2mL, 1/1) and the solution was stirred overnight at 8 6 °C. The solvents were then 
removed by evaporation and water was added. The aqueous phase was basified to 
pH=10 with diluted NH4OH and extracted with DCM/MeOH: 5/1. The organic phase 
was dried (M gS04) and concentrated under vacuum. Purification by column 
chromatography, eluting first with CHCh/MeOH/NILtOH: 450/10/1, then with 
CHCl3/Me0 H/NH4 0 H: 300/10/1, afforded 228 as a brown solid (47 mg, 70%).
]H NMR (270 MHz, CDC13): 0.09 (d, 4H, 7=4.9 Hz, 2xNCH2CH(C//HC//H)), 0.49 
(d, 4H, 7=7.9 Hz, 2xNCH2CH(CH//CHtf)), 0.73-0.85 (m, 2H,
2xNCH2Ci/(CH2CH2)), 1.54 (d, 2H, 7=8.5 Hz), 3.02 (d, 2H, 7=18.4 Hz), 3.14 (d, 2H, 
7=6.1 Hz), 4.80 (d, 2H, 7=14.9 Hz, CMINPhtha), 4.87 (d, 2H, 7=14.9 Hz, 
CHHNPhtha), 5.25 (d, 1H, 7=16.5 Hz, NGHH), 5.31 (s, 2H, 5-H +5’-H), 5.37 (d, 1H, 
7=16.5 Hz, NCHtf), 6.45 (d, 2H, 7=8.1 Hz, 1-H + l ’-H), 6.57 (d, 2H, 7=8.1 Hz, 2-H + 
2 ’-H), 6.84-6.86 (m, 1H), 7.17-7.39 (m, 3H), 7.65-7.71 (m, 2H), 7.80-7.85 (m, 2H); 
13C NMR (67.8 MHz, CDC13): 3.71 (2xNCH2CH(CH2CH2)), 3.90
(2xNCH2CH(CH2CH2)), 9.34 (2xNCH2CH(CH2CH2)), 22.98 (10-C + lO’-C), 28.91
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(8 -C + 8 ’-C), 31.42 (15-C + 15’-C), 41.58 (CH2NPhtha), 43.56 (16-C + 16’-C), 47.47 
(NCH2), 47.99 (13-C + 13’-C), 59.27 (18-C + 18’-C), 62.28 (9-C + 9’-C), 72.67 (14- 
C + 14’-C), 84.86 (5-C + 5’-C), 116.34 (C), 116.89 (CH), 118.50 (CH), 123.48 (CH), 
125.07 (C), 125.74 (C), 125.94 (CH), 126.73 (CH), 127.14 (CH), 128.95 (CH),
130.72 (C), 132.00 (C), 134.04 (CH), 136.46 (C), 138.79 (C), 139.51 (C), 143.03 (C),
168.31 (CO); C56H54N4O8 requires 910.3941; Rf (DCM/MeOH/NtLjOH: 100/10/1): 
0.38; mp > 220°C
17,17’-Bis(cyclopropylmethyl)-6,6’,7,7,-tetradehydro-4,5:4’,5,-diepoxy-6,6’-(2- 
(phthalimidomethyl)benzylimino)[7,7’-bim orphinan]-3,3’,14,14’-tetrol (229)
178 (0.33 g, 0.40 mmol), sodium hydride (60% in oil, 64 mg, 1.60 mmol), 18-crown-6 
(20 mg, 0.08 mmol) and 208 (0.40 g, 1.20 mmol) were reacted according to the 
general procedure I, but the reaction mixture was stirred at 90°C for 14 hrs then at 
room temperature for 48 hrs. The desired product 226 was obtained as a brown solid 
(0.18 g, 42% ).
226 (0.13 g, 0.12 mmol) was immediately dissolved in a mixture of conc. HCl/MeOH 
(2 mL, 1/1) and the reaction was stirred overnight at 85°C. The solvents were then 
removed and water was added. The aqueous phase was basified to pH=8 with diluted 
NH4OH and extracted with DCM/MeOH: 5/1. The organic phase was dried (MgS0 4 ) 
and concentrated. Purification by column chromatography, eluting first with 
CHCl3/Me0 H/NH4 0 H: 450/10/1, then with CHCh/M eOH/N^O H: 300/10/1, 
afforded 229 (46 mg, 42%) and 231 (29 mg, 31%) as brown solids.
Data for 229:
*H NMR (270 MHz, CD3OD): 0.03 (d, 4H, .7=4.9 Hz, 2xNCH2CH(C/mCM I)), 0.37-
0.44 (m, 4H, 2xNCH2CH(CH/7CH7/)), 0.70-0.78 (m, 2H, 2xNCH2C/7(CH2CH2)),
2.97 (d, 2H, .7=18.6 Hz), 3.14 (d, 2H, .7=6.2 Hz), 5.05 (d, 1H, .7=15.6 Hz, 
CT/HNPhtha), 5.12 (d, 1H, .7=15.6 Hz, CHflNPhtha), 5.12 (s, 2H, 5-H + 5’-H), 5.45 
(d, 1H, .7=16.6 Hz, NC//H), 5.72 (d, 1H, .7=16.6 Hz, NCH77), 6.39 (d, 2H, .7=8.0 Hz, 
1-H + l ’-H), 6.43 (d, 2H, .7=8.0 Hz, 2-H + 2 ’-H), 6.81-6.84 (m, 1H), 7.03-7.14 (m, 
2H), 7.22-7.26 (m, 1H), 7.65-7.68 (m, 2H, Phtha), 7.75-7.78 (m, 2H, Phtha); 13 C 
NMR (67.8 MHz, CD3OD): 4.09 (2xNCH2CH(CH2CH2)), 4.61
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(2xNCH2CH(CH2CH2)), 10.11 (2xNCH2CH(CH2CH2)), 23.92 (10-C + lO’-C), 30.00 
(8 -C + 8 ’-C), 32.49 (15-C + 15’-C), 39.92 (NCH2Phtha), 44.82 (16-C + 16’-C), 45.65 
(CH2), 49.10 (13-C + 13’-C), 60.33 (18-C + 18’-C), 63.36 (9-C + 9’-C), 74.36 (14-C 
+ 14’-C), 85.41 (5-C + 5’-C), 117.07 (C), 117.95 (CH), 119.70 (CH), 124.40 (CH),
125.90 (C), 127.60 (C), 128.11 (CH), 129.26 (CH), 129.43 (CH), 129.47 (CH),
132.30 (C), 133.36 (C), 134.20 (C), 135.49 (CH), 137.99 (C), 141.15 (C), 144.40 (C),
169.95 (CO); MS (FAB): m/z = 911 (M); C56H54N4O8 requires 911; Rf 
(DCM/MeOH/NILjOH: 110/10/1): 0.40; mp > 220°C
17,17’-Dimethyl-6,6,,7,7’-tetradehydro-4,5:4,,5,-diepoxy-6,6,-(benzylimino)[7,7’- 
bimorphinan]-3,3’,14,14’-tetrol (233)
237 (0.17 g, 0.20 mmol) was dissolved in a mixture o f MeOH/conc. HBr ( 6  mL, 1/1) 
and the solution was stirred overnight at room temperature. The solvents were 
removed by evaporation, water was added and the pH adjusted to pH=12 with diluted 
NH4OH. The aqueous phase was extracted with DCM/MeOH: 5/1 and the organic 
phase was dried (MgS0 4 ) and concentrated. The crude product was purified by 
column chromatography, eluting with CHCL/MeOH/NILOH: 250/10/1, which gave 
233 as an off white solid (0.125 g, 93 %).
IR Vmax/cm (KBr): 3400 (br); ]H NMR (270 MHz, CDCI3): 2.35 (s, 6 H, 2xNMe), 5.25 
(d, 1H, .7=16.9 Hz, C77H), 5.33 (s, 2H, 5-H + 5’-H), 5.50 (d, 1H, .7=16.9 Hz, CH/7), 
6.50 (d, 2H, .7=8.1 Hz, 1-H + l ’-H), 6.58 (d, 2H, .7=8.1 Hz, 2-H + 2’-H), 6 .8 8  (d, 2H, 
.7=6.7 Hz), 7.24-7.37 (m, 3H); 13C NMR (100.5 MHz, CDC13): 22.34 (CH2), 28.97 
(CH2), 31.23 (CH2), 42.94 (NMe), 45.28 (CH2), 47.35 (CH2), 47.43 (13-C + 13’-C), 
64.92 (9-C + 9 ’-C), 73.02 (14-C + 14’-C), 84.89 (5-C + 5’C), 116.32 (C), 116.88 
(CH), 118.71 (CH), 125.23 (C), 125.61 (CH), 125.67 (C), 126.85 (CH), 128.65 (CH),
130.56 (C), 138.75 (C), 140.02 (C), 142.91 (C); MS (FAB): m/z = 672.3063 (M+H); 
C4 iH42N30 6  requires 672.3073; Rf (DCM/MeOH/NFLjOH: 110/10/1): 0.27; Anal. 
(C4iH4iN30 6 :2 HCl:4 H20 ) requires C 60.32 %, H 6.29 %, N 5.14 %, found: C 60.30 
%, H 6.05 %, N 4.81 %; mp > 240°C
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l T j n ’-Dimethyl-fi^’jT J’-te tradehydro -^S ^’jS’-d iep o x y ^ ^ ’-flmino)!?,?’- 
bim orphinan]-3,3\14,14’-tetrol (235)102
218 (0.66 g, 2.21 mmol), hydrazine sulfate (0.15 g, 1.15 mmol) and methanesulfonic 
acid (0.07 mL, 1.08 mmol) were reacted according to the general procedure K, the 
reaction being however stirred in DMF at 105°C overnight. After purification, 235 
was isolated as a brown solid (0.48 g, 75 %).
IR vmax/cm (KBr): 3413 (br, bonded OH); !H NMR (270 MHz, CDC13): 2.36 (s, 3H, 
N-Me), 5.60 (s, 2H, 5-H and 5’-H), 6.52 (d, 2H, .7=8.0 Hz, 1-H and l ’-H), 6.67 (d, 
2H, .7=8.0 Hz, 2-H and 2’-H); 13C NMR (100.5 MHz, CDC13): 22.35 (CH2), 28.78 
(CH2), 31.37 (CH2), 42.96 (2xN-Me), 45.27 (CH2), 47.27 (13-C + 13’-C), 64.88 (9-C 
+ 9’-C), 73.11 (14-C + 14’-C), 85.59 (5-C + 5’-C), 116.46, 117.56, 118.97, 125.03, 
125.15, 130.34, 138.81, 142.83; MS (FAB): m/z = 582.2583 (M+H); C34H36N3O6 
requires 582.2608; Rf (DCM/MeOH/NFLjOH: 100/10/1): 0.19; mp > 220°C
17,17’-Dimethyl-3,3’-dibenzyloxy-6,6,,7,7’-tetradehydro-4,5:4,,5,-diepoxy-6,6’- 
(benzylimino)[7,7’-bimorphinan]-14,14’-diol (237)
235 (0.16 g, 0.31 mmol), sodium hydride (0.12 g, 3.0 mmol), 18-crown-6 (33 mg,
0.12 mmol) and benzyl bromide (0.19 mL, 1.59 mmol) were reacted according to the 
general procedure I, but the reaction was carried out at room temperature. The crude 
oil was purified by column chromatography (gradient elution, with 100% CHCI3 then 
CHCl3/Me0 H/NH4 0 H: 400/10/1 to 400/25/1) to yield 237 as a brown solid (0.23 g, 
87 %).
*H NMR (270 MHz, CDCI3): 2.35 (s, 6 H, 2xNMe), 4.95 (s, 4H, 2xOCH2), 5.29 (s, 
2H, 5H + 5’-H), 5.31-5.42 (m, 2H, NCH2), 6.52 (d, 2H, .7=8.3 Hz, 1-H + l ’-H), 6 .6 6  
(d, 2H, .7=8.3 Hz, 2-H + 2 ’-H), 6.97-7.06 (m, 1H), 7.13 (d, 4H, 7=4.5 Hz), 7.24-7.35 
(m, 10H); 13C NMR (67.8 MHz, CDC13): 22.26 (CH2), 28.94 (CH2), 31.45 (CH2), 
42.88 (NMe), 45.23 (CH2), 47.05 (13-C + 13’-C), 47.61 (CH2), 64.86 (9-C + 9’-C), 
71.42 (OCH2), 72.82 (14-C + 14’-C), 84.41 (5-C + 5’C), 115.79 (C), 116.46 (CH),
118.17 (CH), 125.84 (C), 126.09 (C), 126.72 (CH), 127.56 (CH), 128.26 (CH),
131.22 (C), 137.63 (C), 138.33 (C), 142.19 (C), 144.87 (C); MS (FAB): m/z = 852 




217 (1.45 g, 4.51 mmol), hydrazine sulfate (0.31 g, 2.38 mmol) and methanesulfonic 
acid (0.14 mL, 2.16 mmol) were reacted according to the general procedure K. After 
purification by column chromatography, 239 was isolated as a brown solid (0.43 g, 35 
%).
IR vmax/cm (KBr): 3380 (br, bonded OH); ]H NMR (270 MHz, CDCI3): 1.57-1.79 (m, 
3H), 1.97 (dd, 1H, > 1 4 .7  Hz and 5.6 Hz), 2.10-2.40 (m, 5H), 2.22 (s, 3H, NMe), 2.82 
(d, 1H, > 1 8 .5  Hz), 2.98-3.01 (m, 1H), 5.20 (s, 2H, 5H and 5’-H), 6.33 (d, 2H, > 8 .2  
Hz, 1-H and l ’-H), 6.39 (d, 2H, > 8 .2  Hz, 2-H and 2 ’-H); 13 C NMR (67.8 MHz, 
CDCI3): 20.26 (2xCH2), 20.93 (2xCH2), 34.99 (15-C + 15’-C), 40.58 (14-C + 14’-C), 
42.11 (2xNMe), 42.97 (13-C + 13’-C), 46.40 (16-C + 16’-C), 59.56 (9-C + 9’-C),
85.44 (5-C + 5’-C), 116.29 (CH), 116.86 (C), 118.39 (CH), 124.99 (C), 125.09 (C),
128.44 (C), 139.21 (C), 143.25 (C); MS (FAB): m/z = 550.2702 (M+H); C34H36N3O4 
requires 550.2705; Rf (DCM/MeOH/NILjOH: 100/16/1.6): 0.13; mp > 240°C
17,17’-Dimethyl-3,3,-dibenzyloxy-6,6,,7,7’-tetradehydro-4,5:4’,5,-diepoxy-6,6,- 
(benzylimino)[7,7’-bimorphinan] (240)
239 (0.13 g, 0.24 mmol), sodium hydride (90 mg, 2.25 mmol), 18-crown-6 (30 mg,
0.11 mmol) and benzyl bromide (0.14 mL, 1.18 mmol) were reacted according to the 
general procedure I, but the reaction was carried out at room temperature. The crude 
oil was purified by column chromatography (gradient elution with 100% CHCI3 then 
CHCl3/Me0 H/NH4 0 H: 400/10/1 to 400/25/1) to yield 240 as a brown solid (37 mg, 
19 %).
*H NMR (270 MHz, CDC13): 2.39 (s, 6 H, 2xNMe), 3.00 (d, 2H, > 1 8 .5  Hz), 3.14- 
3.19 (m, 2H), 4.96 (s, 4H, 2xOCH2), 5.26 (s, 2H, 5-H and 5’-H), 5.29 (d, 1H, > 1 6 .3  
Hz, NC//H), 5.37 (d, 1H, > 1 6 .3  Hz, NCHtf), 6.55 (d, 2H, > 8 .2  Hz, 1-H and l ’-H), 
6.69 (d, 2H, > 8 .2  Hz, 2-H and 2 ’-H), 7.04-7.13 (m, 5H), 7.24-7.33 (m, 10H); 13 C 
NMR (67.8 MHz, CDCI3): 20.46 (CH2), 21.45 (CH2), 35.83 (15-C + 15’-C), 41.18 
(C), 42.88 (2xNMe), 43.33 (C), 46.65 (CH2), 47.63 (CH2), 59.77 (9-C + 9 ’-C), 71.65 
(OCH2), 85.08 (5-C + 5’-C), 116.65 (CH), 117.65 (C), 118.51 (CH), 126.69 (CH),
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126.96 (CH), 127.57 (CH), 127.62 (CH), 128.24 (CH), 128.35 (CH), 129.68 (C), 
137.58 (C), 138.27 (C), 141.87 (C), 145.08 (C); MS (FAB): m/z = 820 (M); 
C55H53N3O4 requires 820; Rf (DCM/MeOH/NfLjOH: 100/10/1): 0.43
n j n ’-Dimethyl-SjS’-d im e th o x y ^ ^ V ^ ’-te trad eh y d ro ^ jS ^ ’jS’-d iep o x y ^ ^ ’- 
(imino)[7,7’-bimorphinan] (242)
Hydrocodone hydrochloride (1.81g, 5.39 mmol), hydrazine sulfate (0.31 g, 2.84 
mmol) and methanesulfonic acid (0.34 mL, 5.26 mmol) were reacted according to the 
general procedure K. After purification by column chromatography, 242 was isolated 
as a brown solid (1.10 g, 71 %).
]H NMR (270 MHz, CDC13): 2.39 (s, 6 H, 2xNCH3), 3.79 (s, 6 H, 2xOCH3), 5.39 (s, 
2H, 5-H and 5’-H), 6.59 (d, 2H, .7=8.3 Hz, 1-H and l ’-H), 6 . 6 6  (d, 2H, .7=8.3 Hz, 2-H 
and 2’-H), 8.09 (br, s, 1H, NH); 13 C NMR (100.5 MHz, CDCI3): 19.82 (2xCH2), 
20.73 (2xCH2), 35.37 (15-C + 15’-C), 40.74 (14-C + 14’-C), 42.45 (2xNCH3), 42.86 
(13-C + 13’-C), 46.11 (16-C + 16’-C), 55.48 (2xOCH3), 59.22 (9-C + 9’-C), 85.35 (5- 
C + 5’-C), 112.28 (CH), 117.00 (C), 117.79 (CH), 125.13 (C), 126.72 (C), 128.67 (C),
142.22 (C), 144.10(C)
4-Phthalimidotoluene (244) 216
A solution of toluidine (4.28 g, 40 mmol) and phthalic anhydride (5.91 g, 40 mmol) in 
acetic acid (80 mL) was refluxed for two hours. The reaction mixture was then cooled 
down to room temperature and poured into water. The precipitate was filtered off, 
washed with water, dissolved in DCM and dried over MgSC>4. The solvent was 
removed by evaporation to yield 244 (8.0 g, 84 %) as an off-white solid.
IR  v m a x / c m  ( K B r ) :  1 7 0 9  ( C O ) ;  ' H  N M R  ( 4 0 0  M H z ,  C D C U ) :  2 . 3 9  ( s ,  3 H ,  C H 3) ,  7 . 2 8 -
7 . 3 0  ( m ,  4 H ) ,  7 . 7 3 - 7 . 7 5  ( m ,  2 H ) ,  7 . 9 0 - 7 . 9 2  ( m ,  2 H ) ; 13 C  N M R  ( 1 0 0 . 5  M H z ,  C D C I 3) :  
2 1 . 1 0  ( C H 3 ) ,  1 2 3 . 5 4  ( C H ) ,  1 2 6 . 3 5  ( C H ) ,  1 2 8 . 8 9  ( C ) ,  1 2 9 . 6 6  ( C H ) ,  1 3 1 . 6 9  ( C ) ,  1 3 4 . 2 1  
( C H ) ,  1 3 8 . 0 3  ( C ) ,  1 6 7 . 3 0  ( C O ) ;  M S  (FAB): m/z = 2 3 8 . 0 8 6 0  ( M + H ) ;  C 15H 12N O 2 
requires 2 3 8 . 0 8 6 7 ;  R f  (w-hexanes/ethyl acetate: 4 / 1 ) :  0 . 2 2 ;  m p  : 1 9 3 - 1 9 4 ° C  (lit.: 2 0 1 -  
2 0 3 ° C )  216
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iV-(4-Phthalimidobenzyl)carbazole (247)
Carbazole (167 mg, 1.0 mmol), sodium hydride (80 mg, 2.0 mmol), 15-crown-5 (0.02 
mL, 0.1 mmol) and 182 (0.35 g, 1.1 mmol) in dry DMF (5 mL) were reacted 
according to the general procedure I. After purification by column chromatography, 
247 was isolated as a brown solid (0.15 g, 37%).
*H NMR (270 MHz, CDC13): 5.51 (s, 2H, CH2), 7.17-7.20 (m, 4H), 7.25-7.29 (m, 
2H), 7.31 (d, 2H, .7=7.9 Hz), 7.35-7.41 (m, 2H), 7.69-7.72 (m, 2H, Phtha), 7.84-7.88 
(m, 2H, Phtha), 8.08 (d, 2H, .7=7.9 Hz); 13 C NMR (67.8 MHz, CDC13): 46.19 (CH2),
108.93 (CH), 119.45 (CH), 120.49 (CH), 123.14 (C), 123.85 (CH), 126.03 (CH),
126.93 (CH), 127.12 (CH), 131.72 (C), 134.53 (CH), 140.61 (C), 167.33 (CO); mp : 
187 °C
7V-(4-Aminobenzyl)-carbazole (248)
To a solution o f 247 (49 mg, 0.12 mmol) in ethanol (1 mL) was added DCM until the 
solution became completely clear. Hydrazine hydrate (11.6 pL, 0.37 mmol) was 
added and the reaction mixture stirred for two days. The solvent was then removed 
under vacuum and the crude product purified by column chromatography. 248 was 
isolated as a brown solid (19 mg, 57%).
*H NMR (270 MHz, CDC13): 3.50 (br, s, 2H, NH2), 5.32 (s, 2H, CH2), 6.48 (d, 2H, 
.7=6.5 Hz), 6 . 8 8  (d, 2H, 7=6.5 Hz), 7.12-7.18 (m, 2H), 7.28-7.38 (m, 2H), 8.04 (d, 2H, 
7=7.9 Hz); 13 C NMR (67.8 MHz, CDC13): 46.15 (CH2), 108.96 (CH), 115.24 (CH),
118.95 (CH), 120.27 (CH), 122.89 (C), 125.70 (CH), 127.01 (C), 127.63 (CH),
140.61 (C), 145.63 (C)
17-Methyl-6,7-didehydro-4,5a-epoxy-3-methoxy-14-acetoxy-indolo[2,,3, :6,7]- 
morphinan (249)
A solution o f 17-methyl-6,7-didehydro-4,5a-epoxy-3-methoxy-14-hydroxy- 
indolo[2’,3’:6,7]-moiphinan (0.13 g, 0.33 mmol) in acetic anhydride (10 mL) was 
treated according to the same method as used for the preparation of 178. Purification 
by column chromatography, eluting first with CHCI3 then with 
CHCb/MeOH/NHiOH: 400/5/1, afforded 249 as an off-white solid (0.142 g, 98%).
192
IR Vmax/cm (KBr): 1705 (CO); *H NMR (270 MHz, CDC13): 1.92 (s, 3H, OCOCH3),
2.34 (s, 3H, NCH3), 3.25 (d, 1H, 7=18.6 Hz), 3.74 (s, 3H, 3-COCH3), 3.75 (d, 1H, 
.7=16.8 Hz), 4.40 (d, 1H, 7=6.2 Hz), 5.64 (s, 1H, 5-H), 6.58-6.64 (m, 2H, 1-H and 2- 
H), 6.99-7.05 (m, 1H, 5’-H), 7.12-7.18 (m, 1H, 6 ’-H), 7.30 (d, 1H, 7=8.1 Hz, 7 ’-H),
7.39 (d, 1H, 7=7.4 Hz, 4 ’-H), 8.17 (br, s, 1H, NH); 13 C NMR (67.8 MHz, CDC13): 
22.37 (OCOCH3), 22.69 (CH2), 24.48 (CH2), 30.85 (CH2), 42.83 (NMe), 45.52 (16- 
C), 47.63 (13-C), 55.92 (OMe), 58.02 (9-C), 83.93 (14-C), 84.91 (5-C), 110.58 (C),
111.25 (CH), 113.06 (CH), 118.60 (CH), 118.92 (CH), 119.26 (CH), 122.73 (CH), 
126.52 (C), 126.55 (C), 129.08 (C), 129.76 (C), 136.89 (C), 143.10 (C), 143.95 (C),
170.72 (CO); mp > 210°C
17-Methyl-6,7-didehydro-4,5a-epoxy-3-methoxy-14-acetoxy-(4-(phthalimido 
methyl)benzylindolo)[2’,3’:6,7]-morphinan (251)
249 (72 mg, 0.17 mmol), sodium hydride (60% in oil, 27 mg, 0.67 mmol), 15-crown- 
5 (0.01 mL, 0.05 mmol) and 182 (0.17 g, 0.51 mmol) in dry DMF (5 mL) were 
reacted according to the general procedure I. After purification by column 
chromatography, eluting first with CHCI3 then with C H Ch/M eOH/NEUOH : 400/5/1, 
251 was obtained as a brown solid (34 mg, 31%).
IR Vmax/cm (KBr): 1760, 1715 (CO); *H NMR (270 MHz, CDC13): 1.91 (s, 3H, 
OCOCH3), 2.34 (s, 3H, NCH3), 3.26 (d, 1H, 7=18.3 Hz), 3.72 (s, 3H, 3-COCH3), 3.80 
(d, 1H, 7=16.5 Hz), 4.41 (d, 1H, 7=5.7 Hz), 5.56 (d, 1H, 7=17.3 Hz, NCtfH), 5.63 (d, 
1H, 7=17.3 Hz, NCHfl), 5.64 (s, 1H, 5-H)), 6.60 (d, 1H, 7=8.2 Hz, 1-H), 6.64 (d, 1H, 
7=8.2 Hz, 2-H), 7.00-7.07 (m, 1H, 5’-H), 7.12-7.15 (m, 3H, 6 ’-H + 2Ar), 7.31-7.34 
(m, 3H, 7 ’-H + 2Ar), 7.43 (d, 1H, 7=7.6 Hz, 4 ’-H), 7.74-7.79 (m, 2H), 7.90-7.94 (m, 
2H); 13 C NMR (67.8 MHz, CDC13): 22.42 (OCOCH3), 22.77 (CH2), 24.72 (CH2), 
31.02 (CH2), 42.88 (NMe), 45.56 (16-C), 46.76 (NCH2Ph), 47.87 (13-C), 56.23 
(OMe), 58.08 (9-C), 84.02 (14-C), 84.07 (5-C), 110.03 (CH), 110.35 (C), 113.74 
(CH), 118.68 (CH), 119.17 (CH), 119.40 (CH), 122.83 (CH), 123.75 (CH), 126.49 
(C), 126.56 (C), 126.65 (CH), 126.85 (CH), 130.05 (C), 130.40 (C), 130.66 (C), 
131.71 (C), 134.42 (CH), 137.32 (C), 138.05 (C), 143.26 (C), 144.06 (C), 167.27 
(CO), 170.69 (CO); mp > 215°C
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D erivatives of the  highly selective K-opioid receptor an tagonist GNTI (2a) have been prepared. 
B inding and  functional studies conducted on cloned hum an opioid receptors expressed in  
Chinese ham ster ovarian (CHO) cells suggested th a t  adding a benzyl or a  substitu ted  benzyl 
group to th e  guanidino moiety led, in general, to a  retention  of high K-affinity and an tagon ist 
potency. D isubstitution of the guanidino moiety led to reduced K-selectivity.
In tro d u c tio n
One of the principal goals for medicinal chemists 
w ithin the field of drug abuse, and in particular opioid 
abuse, has been the development of selective antago­
nists for each of the opioid receptors (w, k ,  and <5). The 
availability of such agents greatly facilitates the study 
of the physiological function of these receptors. Though 
the role of opioids in the treatm ent of pain has long been 
recognized, it has become increasingly apparent that 
they have a  significant role to play in a wider range of 
clinical situations and thus there is a continuing need 
for the development of selective ligands, both as tools 
for basic research and as leads for potential pharma­
cotherapies. Of the three opioid receptor types, the 
//-receptor has been the most thoroughly investigated 
due to its involvement in the treatm ent of pain and 
opiate abuse. It is, however, becoming increasingly 
apparent th a t both the k -  and 6-receptors represent 
viable molecular targets for a  number of indications. Of 
particular interest to ourselves are reports on the role 
of K-opioid agonists in cocaine abuse, and in particular, 
the findings that K-agonists can block many of cocaine’s 
behavioral effects.1-6 Thus K-agonists may be of use in 
the development of a treatm ent for cocaine abuse.
K-Antagonists have also been studied in the preclinical 
setting w ith reports of their utility in improving recov­
ery after traumatic brain injury in rats,7 for determining 
the underlying mechanisms tha t cause the motor fluc­
tuations th a t develop during the treatm ent of Parkin­
son’s disease,8 and as antidepressants in the forced 
swim test in rats.9 In  feeding studies, administration 
of the K-antagonist norBNI (1) significantly reduced 
deprivation intake and suppressed other forms of food 
intake in ra ts10 and has also been shown to attenuate 
drinking in genetically polydipsic mice.11
At present, norBNI, discovered by Portoghese and co­
workers, is the K-antagonist of choice.12-14 Extensive 
investigation of the structural requirements for k -  
antagonist selectivity has led to GNTI (2a), a simplified
* Corresponding author. Tel: (1225) 383103. Fax: (1225) 386114. 
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* University of Bath.













structure based on the indolomorphinan naltrindole.1516 
Initial reports suggest that 2a has comparable, or better, 
K-antagonist selectivity than I 1516 and shares w ith 1 an 
extended duration of action.17 We were interested in the 
possibilities th a t the guanidine group provided for 
further structural elaboration. Introduction of a lipo­
philic group into the side chain of p- and 6-opioid 
antagonists can have a profound effect on the selectivity, 
efficacy, and reversibility of the ligands. For example, 
introduction of arylalkyl groups to the 14-position in a 
series of 6-antagonists related to naltrindole resulted 
in a /4-agonist/low-efficacy 6-partial agonist profile.18 In 
addition, the indole Af-benzyl derivative of naltrindole, 
BNTI (3, R = H),19,20 has no means of forming a  covalent 
bond to the receptor and yet is reported to have an in 
vivo profile very similar to th a t of the isothiocyanate- 
containing BNTII (3, R =  p-NCS), with antagonist 
effects lasting up to 5 days. A similar effect has been 
observed with the well-known /4-receptor irreversible 
antagonist C-CAM (4).21-23 The available evidence does 
not suggest th a t 4 forms a  covalent bond w ith the 
receptor, yet it displays a pharmacological profile con­
sistent with nonsurmountable binding to the receptor. 
Presumably, in these cases noncompetitive binding is 
a result of extremely tight binding involving the benzyl 
and cinnamoyl groups. If such an effect were replicated 
in the GNTI (2a) series at the K-receptor, it would result 
in the first nonsurmountable K-antagonist based on a
10.1021/Jm0309203 CCC: $25.00 © 2003 Am erican Chem ical Society
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(v) 1 5 R -H
a: R1 = R2 = nBu, n *= 2 
b: R1 = R2 = nBu, n = 0 
c :R 1= R 2- n P r ,n - 0  
d: R1 -  nPr, R2 -  CPM, n 
e: R '- B n ,R : -C P M ,n -
a: R ■= R2 » nBu, n «  2 
b: R 1 •• R2 «  nBu, n •  0 
c: R ' - R 2 - n P r , n - 0  
d: R 1 = nPr, R2 •  CPM, n = 0 
e: R1 = Bn, R2 = CPM, n = 0
a (i) ClzCS, CaC 03l H 20; (ii) RNHZ, acetone; (iii) NaH, (BOC)zO, THF; (iv) HgCl2, N Et3, DMF; (v) TFA, CH2C12.
x-antagonist, and not x-agonist, structure. For these 
reasons benzyl-substituted analogues of 2 were targeted 
along with a small number of disubstituted aliphatic 
analogues to extend the SAR.
C h em istry
The synthesis of guanidines 2a and 2b has been 
previously reported by Stevens et al.24 They were 
obtained by mercury-assisted condensation of amines 
6a,b with bis(fe/t-butoxycarbonyl)-2-methyl-2-thiopseudo- 
urea. To access the related AAbenzyl guanidines it 
was decided to utilize TV, Af-bis (ferf-butoxycarbonyl)-/V- 
benzyl-2-methylthiopseudourea and substituted benzyl 
analogues (8), in an analogous reaction. The guanidi- 
nylating agents (8) were prepared by reaction of the 
appropriately substituted benzyl bromide with 1,3-bis- 
(ferf-butoxycarbonyl)-2-methyl-2-thiopseudourea (7) in 
the presence of sodium hydride. Coupling with amine 
6b, to give 9 a -c , was carried out a t 50 °C in the 
presence of mercuric chloride, with the less reactive 
aniline 6a requiring extended reaction time at 60 °C to 
yield 9e—g. Removal of the te/T-butoxycarbonyl protect­
ing group was accomplished using standard conditions 
of trifluoroacetic acid to give the products (10a—c,e—g)
as their trifluoroacetic acid salts. The nitro analogues 
9c,g were also converted to their amino counterparts 
9d,h by Raney Ni catalyzed transfer hydrogenation in 
50% MeOH/cyclohexene before removal of the protecting 
groups with trifluoroacetic acid to yield 10d,h.
The p- and m-hydroxy analogues (lOi j) were prepared 
in similar fashion (Scheme 1), the appropriate guanidi- 
nylating agents being synthesized from the m- and 
/>benzyloxybenzyl bromides reported previously.2526 
Simultaneous removal of the ferf-butoxycarbonyl and 
benzyl protecting groups of lOi and lOj was found to 
proceed most efficiently in HCl/MeOH to give lOi and 
lOj as their hydrochloride salts.
Disubstituted thioureas 15 were prepared by coupling 
of 6a and 6b with symmetric and unsymmetric N,N- 
disubstituted thioureas (13), themselves prepared from 
the appropriate amines and thiophosgene (Scheme 2). 
The coupling would not take place directly with thio­
ureas (12), in agreement w ith literature precedent,27 
and required the presence of a  terf-butoxycarbonyl group 
on one of the nitrogens. Interestingly, in the same 
report27 it is suggested th a t the thiourea group should 
have one proton on each of the  nitrogens in order for 
the coupling reaction to be successful. This does not
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T ab le  1. Antagonist Potency in [35S]GTPyS Assays Performed in Cloned Human Opioid Receptors*











2b 2 H H 1.25 ±0 .12 0.88 ± 0 .1 5 0.40 ±  0.06 3 2
10a 2 H benzyl 2.94 ±  0.31 1.36 ± 0 .1 0 0.13 ±0.01 23 10
10b 2 H p-chlorobenzyl 2.61 ±0.41 1.48 ± 0 .1 4 0.23 ±  0.02 11 6
10c 2 H p-nitrobenzyl 2.20 ±  0.60 1.34 ± 0 .2 4 0.17 ±0 .01 13 8
lOd 2 H p-aminobenzyl 1.57 ± 0 .13 0.95 ± 0 .1 4 0.25 ±  0.03 6 4
lOe 0 H benzyl 1.41 ± 0 .17 4.09 ±  0.63 0.06 ±  0.01 24 68
lOf 0 H p-chlorobenzyl 5.24 ±  1.13 7.67 ±  1.36 0.14 ±0.01 37 55
10g 0 H p-nitrobenzyl 3.71 ± 0 .59 16.66 ±  1.30 0.18 ±0 .01 21 93
lOh 0 H p-aminobenzyl 1.22 ± 0 .06 10.80 ±  0.80 0.09 ±  0.01 14 120
101 0 H p-hydroxybenzyl 12.66 ±  0.84 18.31 ±  0.95 0.10 ±0 .01 127 183
IQj 0 H m-hydroxybenzyl 4.28 ±  0.52 4.35 ±  0.22 0.13 ±  0.02 33 33
15a 2 butyl butyl 4.62 ±  0.59 1.05 ±  0.08 0.39 ±  0.03 12 3
15b 0 butyl butyl 5.66 ±  0.39 5.24 ±  0.67 0.44 ±  0.03 13 12
15c 0 propyl propyl 4.59 ±  0.80 2.43 ± 0 .31 0.26 ±  0.05 18 9
15d 0 propyl cyclopropylmethyl 3.26 ±  0.32 6.31 ± 0 .3 4 0.08 ±  0.01 41 79
15e 0 benzyl cyclopropylmethyl 2.75 ±  0.24 3.28 ±  0.37 0.17 ± 0 .05 16 19
1 norBNI 18.9 ±  1.8 4.42 ±  0.38 0.04 ±  0.004 484 113
2 a fc GNTI H H 3.23 15.49 0.04 81 389
a Values are means from five or six experiments. b Converted from pA2 values from ref 16.
T ab le  2. Binding Affinities to Cloned Human Opioid Receptors Transfected into Chinese H am ster Ovary (CHO) Cells*
K\ (nM) ±  SEM
P <3 K
compd n R1 R2 |3H]-DAMGO pH] Cl-DPDPE pH]U69,593 plic 61k
2b 2 H H 5.69 ±  1.28 4.93 ±  1.28 0.49 ±  0.00 12 10
10a 2 H benzyl 3.54 ±  0.25 7.24 ±  0.86 1.42 ± 0 .1 7 2 5
10b 2 H p-chlorobenzyl 7.74 ±  1.98 19.18 ± 0 .1 7 2.41 ± 0 .22 3 8
10c 2 H p-nitrobenzyl 9.21 ±  3.73 11.70 ± 0 .2 8 2.14 ± 0 .34 4 5
lOd 2 H p-aminobenzyl 7.78 ±  2.71 5.05 ±  0.23 0.95 ±  0.04 8 5
lOe 0 H benzyl 10.47 ±  1.87 26.81 ± 6 .47 0.86 ±  0.20 12 31
lOf 0 H p-chlorobenzyl 29.78 ±  0.50 85.05 ±  5.06 0.66 ±  0.05 45 129
lOg 0 H p-nitrobenzyl 26.28 ±  3.82 95.82 ±  3.49 1.61 ± 0 .45 16 60
10b 0 H p-aminobenzyl 7.89 ±  2.45 23.91 ±  5.69 0.63 ±  0.10 13 38
101 0 H p-hydroxybenzyl 14.67 ±  3.65 41.86 ± 0 .93 3.26 ± 0 .12 4.5 13
10J 0 H m-hydroxybenzyl 14.16 ±4.11 17.58 ± 0 .2 9 2.74 ±  0.74 5 6
15a 2 butyl butyl 7.89 ±  0.57 6.73 ±  1.80 4.80 ±  0.02 1.5 1.5
15b 0 butyl butyl 18.27 ± 0 .34 15.04 ±  3.26 6.96 ±  0.85 3 2
15c 0 propyl propyl 9.83 ±  0.09 8.52 ±  1.99 2.72 ±  0.39 4 3
15d 0 propyl cyclopropylmethyl 22.44 ±  7.27 15.48 ± 3 .47 2.38 ±  0.37 9 6.5
15e 0 benzyl cyclopropylmethyl 17.73 ±  0.30 18.06 ±  1.72 3.91 ±  0.60 4.5 5
1 norBNI 21.0 ±  5.0 5.7 ±  0.9 0.20 ±  0.05 105 28
2ab GNTI H H 36.9 ±  2.3 70.0 ±  0.3 0.18 ± 0 .1 0 205 389
a Data are the average from two experiments, each carried out in triplicate. 6 Data from ref 16.
appear to be the case in the current work and may argue 
against formation of the previously proposed carbodi- 
imide intermediate in these instances.27
R esu lts  a n d  D iscussion
Opioid agonist and antagonist activity was deter­
mined using the [35S]GTPyS assay in cloned human 
opioid receptors transfected into Chinese ham ster ovaiy 
(CHO) cells (Table I).2829 None of the compounds 
stimulated [35S]GTPyS binding for any type of opioid 
receptor but were found to be antagonists of the selec­
tive agonists DAMGO ip), Cl-DPDPE (6), and U69.593 
(k ) (Table 1 ) . The ligands were also evaluated in 
competition binding assays in CHO cells transfected 
with cloned human opioid receptors (Table 2).29 The 
displaced radioligands were [3H] DAMGO (a), [3H]Cl- 
DPDPE (d), and [3H]U69,593 (k).
Each of the compounds was found to be a potent 
/c-antagonist with varying selectivity over the p- and 
5-receptors (Table 1). ^-Antagonist potency was consis­
tent throughout the series with little variation between
compounds (Ke = 0.06—0.44 nM). Those ligands lacking 
the ethylene spacer group were consistently more selec­
tive for the /c-receptor than  those with the spacer group 
lOe—h  vs 10a—d and 15a vs 15b. This effect was 
particularly prominent for x/6-selectivity but less so for 
Kip. This appears to confirm earlier reports suggesting 
that in the majority of cases a spacer group was not 
beneficial for ^-selectivity.24 In neither series (n =  0, 2) 
was there any evidence of consistent effects of the 
substituents on the benzyl ring, with the unsubstituted, 
p-amino, p-nitro, p-chloro, and 777-hydroxy all having 
similar /c-antagonist potency and selectivity. The one 
compound that stood out was lOi, having a p-hydroxy 
substituent. While lOi retained antagonist potency at 
x-receptors, it was less potent than the other ligands at 
5- and p-receptors, leading to increased x-selectivity 
(183-fold over d and 127-fold over p). These results are 
intriguing as the p-hydroxy group of lOi can exactly 
overlay the second phenolic group of norBNI (1) and 
thus may be interacting unfavorably with the same site/ 
residues on the p- and 5-receptors. While GNTI (2a) was
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F ig u r e  1. Schild plot of th e  x-an tagonist activity of lOf.
not evaluated in this current study, data from the same 
source and using the same assays as in the present 
study have been reported previously. Thus, some com­
parison can be made between 2 a  and the current series 
of compounds with reasonable confidence. 101 appears 
sim ilar to both 1 and 2a in these assays. Of the three, 
1 is the most selective for Ktfi, but the least selective for 
k / 6 . 2a is the opposite, with the greatest selectivity over 
<5 and the least over/a while lOi displays a balance, with 
good selectivity over both <5 and ft receptors.
The dialkylguanidines (15a—e) were again selective 
antagonists for the x-receptor, bu t in general with 
somewhat reduced selectivity as compared to the benzyl 
guanidines (Table 1). The most direct comparison is 
between lOe, having a benzyl group, and 15e, having 
benzyl and cyclopropylmethyl groups. lOe showed higher 
selectivity, particularly with respect to x/<5. That 15d 
also displayed higher selectivity than  15e suggests that 
the increase in steric bulk on having both cyclopropyl­
methyl and benzyl groups is detrim ental for selectivity. 
This is a result of slightly reduced /e-antagonist potency 
and slightly increased /1- and <5-antagonist potencies for 
15e compared to 15d.
In the binding assays, all of the ligands bound with 
highest affinity a t the x receptor (Table 2) with Hill 
slopes approximating unity, indicating competitive bind­
ing. Selectivity varied considerably, but with the broad 
trends comparable to those noted in the functional 
assay. Thus, benzyl guanidines 10a—d had substan­
tially lower x-selectivity than their analogues lO e-h ; 
this was particularly evident for x/<5 selectivity. There 
again appears to be no consistent SAR relating to the 
ring substituent within this series. Whereas in the 
functional assays lOi was most selective, in the binding 
assays it was the p-chloro analogue lOf. GNTI (2a) and 
its benzyl analogues (n  =  0) each had higher selectivity 
for x/<5 than k I / j l ,  whereas, as found in the functional 
assays, norBNI (1) was more selective for k!/x than x/<5.
The difference between the disubstituted guanidines 
(15a-e) and the monosubstituted benzyl guanidines 
was even more pronounced in the binding assays than 
in the functional assays, with 15a—e displaying little 
or no x-selectivity against the other two opioid receptors.
In the [35S]GTPyS assays, while the ligands caused 
a  shift in the agonist dose-response curves, there was 
no indication of flattening of the dose—response curve 
tha t would be expected if the compounds were acting 
in a nonsurmountable manner. However, in C6(<5) and 
CHO(x), but not C6(u) cells, the compounds tended to 
display wash-resistant binding th a t could be indicative 
of pseudo-irreversibility (data not shown). As norBNI 
(1) also displayed similar binding characteristics in
these cell lines, it was felt th a t further studies in the 
mouse vas deferens (mvd) would provide a more ac­
curate assessm ent of their reversibility. To this end, two 
compounds, 10b and lOf, were evaluated for ^-antago­
nist activity in the mvd. Both compounds produced 
surmountable antagonism and parallel shifts of the 
dose-response curve for the selective x-agonist E2078.30 
For lOf the antagonism was studied in more detail, and 
the effects were found to be dose^dependent. A Schild 
plot of the antagonist activity of lOf indicates a  linear 
relationship w ith a slope approximating unity (0.7), 
again indicating competitive binding characteristics 
(Figure 1). I t  was noted th a t the IQ of 20 nM obtained 
in this mvd assay is considerably higher than the value 
suggested by the binding and GTPyS data.
C onclusions
The addition of benzyl and substituted-benzyl groups 
to the guanidino moiety of GNTI (2a) results in ligands 
tha t retain  high affinity and selectivity for the x-opioid 
receptor. D isubstituted guanidines displayed reduced 
selectivity compared to their monosubstituted counter­
parts, prim arily as a result of lower x-affinity. That the 
benzyl group of these ligands may interact with the 
same site on the receptor as the second phenolic group 
of norBNI (1) seemed to be confirmed by the substantial 
selectivity displayed by the />-hydroxy analogue (101) in 
the functional assays. The discrepancy between wash- 
resistant binding in the C6(<5) and CHO(x) cell lines, yet 
fully reversible binding in the mvd, may suggest th a t 
wash-resistance is not a  suitable definition of irrevers­
ibility.
E x p e rim e n ta l S ection
Column chrom atography was perform ed under gravity, over 
silica gel 60 (35—70 ftm) purchased from Merck. P repara tive  
TLC was perform ed on p lates m ade w ith  Kieselgel 60 P F 254+366 
for p rep ara tiv e  TLC, obtained from Merck. The th ickness of 
th e  silica lay er w as approxim ately 1 mm. Analytical TLC w as 
perform ed usin g  alum inum -backed p lates coated w ith  Kiesel­
gel 60 F 254, from  M erck. The chrom atogram s were visualized  
using eith e r UV ligh t (UVGL-58, short wavelength), n inhydrin  
(acidic), or po tassium  perm anganate  (basic). M elting poin ts 
were carried  o u t using  a  R eichert-Jung Thermo Galen Kopfler 
block or a  G allenkam p MFB-595 m elting point a p p ara tu s and  
are unconnected. High- and  low-resolution fast atom bom bard­
m en t (FAB) m ass spectra  w ere recorded on a  Fisons VG 
AutoSpec Q in stru m en t, w ith  a  m atrix  of m -nitrobenzyl 
alcohol. H igh- an d  low-resolution electron im pact (El) m ass 
spectra w ere  recorded using E l ionization a t 70 eV, on a  VG 
AutoSpec in s tru m e n t, equipped w ith  a  Fisons autosam pler. 
'H  NMR and  13C NM R spectra  were recorded using e ith e r 
JEO L 270 (operating  a t  270 MHz for ‘H  and 67.8 MHz for 
l3C), JE O L  L am bda 300 (operating a t  300 MHz for 'H  an d
75.4 MHz for I3C), o r JE O L  EX 400 (operating a t 400 MHz for 
‘H  and 100.5 M H z for 13C) spectrom eters. Chemical sh ifts (<5) 
are  m easured  in  ppm. Spectra were referenced internally using 
th e  residual so lven t resonance. Coupling constants (J) a re  
expressed in  h e rtz , and  th e  m ultiplicities are abbreviated a s  
follows: s  (singlet), d (doublet), t  (triplet), m (multiplet), an d  
b r (broad). O nly diagnostic peaks have been quoted for proton 
NMR. M icroanalysis w as performed w ith  a  Perkin-Elm er 240C 
analyzer. A nalytical RP-HPLC was performed w ith a B eckm an 
System  Gold 125 solvent m odule, equipped w ith  a B eckm an 
System Gold 166 detector (A =  254 nm). The column sta tionary  
phase was B eckm an u ltrasphere  ODS, 5 ^ m  (15 cm x 4.6 mm). 
A mobile p h ase  of [MeOH/O.3% NH 4CO3 (80:20)] was used  a t  
a  flow ra te  of 1 m L/m in. In frared  spectroscopy w as perform ed
Derivatives o f the k-Opioid Antagonist GNTI
on e ith e r a  Perkin-E lm er 782 In stru m en t or a  Perkin-E lm er 
RX I FT-IR  In strum en t. A nhydrous THF, DMF, DCM, and 
M eOH w ere purchased from Aldrich. HPLC solvent grade 
chloroform  and  MeOH w ere purchased  from Merck. All o ther 
so lvents u sed  were GPR grade, purchased from Merck or 
F ish e r Scientific. Chem icals w ere purchased from Aldrich, 
F luka, L ancaster, and  Acros chem ical companies.
D etails a re  given for rep resen ta tiv e  exam ples lO f and 15d. 
F ull experim ental de ta ils for a ll compounds are  provided as 
S upporting  Inform ation.
l,3-Bis-ferf-butoxycarbonyl-l-(4'-chlorobenzyl)-2-m eth- 
y l-2 -th io p seu d o u rea  (8b). To l,3-bis-rerf-butoxycarbonyl-2- 
m ethyl-2-thiopseudourea (7) (2 g, 6.90 mmol) in dry DMF (20 
mL) in  an  ice-bath w as added N aH  (60% in oil, 0.334 g, 8.36 
mmol), and  th e  m ixture s tirred  for 1 h. 4-Chlorobenzyl bromide 
(1.56 g, 7.60 mmol) w as added, and  the  m ixture stirred  a t room 
tem p e ra tu re  for a  fu rth e r 12 h. W ater (30 mL) w as added and  
th e  m ix tu re  extracted w ith  e thy l acetate (3x). The combined 
organic layers were w ashed  w ith  brine (2 x), dried (NaaSO*), 
an d  concentra ted  to give crude 8b. Column chrom atography 
[hexane/EtOAc (9:2)] provided pure  8b (2.21 g, 5.33 mmol, 
77%): Rf =  0.42 [hexane/EtOAc (9:2)] ;'H  NMR (400 MHz, 
CDC13) <5 1.36 [s, 9H, C(CH3)3], 1.47 [s, 9H, C(CHjA, 2.24 (s, 
3H, SCH3), 4.68 (s, 2H, CHA. an d  7.24 (s, 4H, ArM : 13C NMR 
(100.5 MHz, CDCla) <5 16.0 (SCH3), 28.3 [C(CH3)3], 28.4 
[C(CH3)3], 52.0 (CHz), 82.0 [q C H 3)3], 83.1 [qCHaJa], 128.7 (Ar),
129.4 (Ar), 133.4 (quaternary  A r), 136.0 (quaternary Ar), 151.9 
(0 = 0 ), 157.9 (0 = 0 ), and  162.7 (0=N ); FAB+MS mlz 415 
[(M +  1)+, 30%] and  259 (65); HRMS (FAB) mlz 415.1439 
(M +  1)+, C 19H 28N 2O 4SCI req u ires  415.1458.
17-CyclopropyImethyl-6,7-didehydro-4,5a-epoxy-5'-bis- 
tert-butoxycarbonyl-(AT-4-chlorobenzyl)guanidtnyl-3,14- 
d ihydroxy indo lo [2 ',3 ':6 ,7 ]m orph inan  (9f). 1,3-Bis-ferf- 
bu toxycarbonyl-l-(4 '-ch lo robenzy l-2 -m ethy l-2 -th iopseudo- 
u rea  (8b) (0.243 g, 0.59 mmol), 5'-am ino-17-cyclopropylmethyl- 
6,7-didehydro-4,5a-epoxy-3,14-dihydroxyindolo[2',3':617]mor- 
p h inan  (6a) (0.126 g, 0.29 mmol), H gC h (0.079 g, 0.29 mmol), 
trie thy lam ine  (0.059 g, 0.082 mL, 0.59 mmol), and  DMF (10 
mL) w ere s tirred  a t  50 °C for 24 h. The solution was 
subsequently  filtered and  sodium  bicarbonate (30 mL) added. 
T he solution was ex tracted  w ith  e thyl acetate and th e  organic 
layer w ashed  successively w ith  w a ter and brine, dried (Naz- 
SO4), filtered, and concentrated under reduced pressure to give 
th e  crude product m ix ture , w hich w as purified by column 
ch rom atography-grad ien t elution (C H 2C I2) until unreacted 8b 
had  been removed th e n  [CH30 H/CH 2Cl2/NH 4 0 H (10:89:1)], 
affording 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'- 
bis-fe/t-butoxycarbonyl-(AM -chlorobenzyl)guanidinyl-3,l 4-di- 
hydroxyindolo[2',3 ':6,7]m orphinan (0.103 g, 0.13 mmol, 44%): 
Rf =  0.47 [C H 30 H / C H 2 C l2 /N H 4 0 H  (89:10:1)]; *H NMR (400 
MHz, C D C ls) 6 0 .1 6 -0 .2 7  [m, 2H, N C H ZC H (C M 1 C M 1 )] ,  
0 .56-0 .68  [m, 2H, N C H ZC H (C H H C H M ]. 0 .88-1 .00  [m, 1H, 
N C H 2C M C H 2C H 2)], 1.37 [s, 9H, C (C Hfo], 1.43 [s, 9H, C(CHM. 
5.60 [s, 1H, C(5)M , 6.55 [d, J =  8.2 Hz, 1H, C(1)M . 6.59 [d, J  
=  8.2 Hz. 1H, C(2)M, 6.70 (s, 1 H , C(40M . 6.78 [d, J =  8.6 Hz, 
1H, C(60M . 7.21 [d, J =  8.6 Hz, 1H, C(7OM. and 7 .25 -7 .48  
[m, 4H, ArH[; 13C NMR (100.5 MHz, CDC13) d 3.4 [N C H ZC H -  
(CH2C H 2)], 3.9 INCHZCH(CHZCH2)]. 9.2 [NCHZCH(CHZCH 2)],
22.9 [C(10)], 27.2 [C(CH3)3], 27.6 [qi5)]f 27.7 [C(CH3)3], 28.4 
[0(8)], 43.5 [qi6)], 47.6 (CHzPh), 47.9 [quaternary 0(13)], 59.1 
[0(18)], 61.8 [0(9)], 72.3 [quaternary  0(14)], 79.7 [ q C H 3)3],
82.6 [C(CH3)3], 84.3 [0(5)], 110.2 (Ar), 111.2 (Ar), 112.0 (Ar),
116.6 (Ar), 118.1 (Ar), 118.4 (Ar), 124.2 (Ar), 126.3 (Ar), 127.8 
(Ar), 128.2 (Ar), 129.9 (Ar), 130.1 (Ar), 130.2 (Ar), 130.4 (Ar), 
132.8 (Ar), 135.1 (Ar), 135.3 (Ar), 139.0 (Ar), 142.6 (C =0) and
162.7 (O N ) ;  FAB+MS m/z 796 [(M +  1)+, 100%], 696 (20), 
and 596 (30); HRMS (FAB) m /z796.3463 (M +  1)+, C44H 51N 5O7- 
C1 requires 796.3477.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-(7V- 
4 -c h lo ro b e n z y l)g u a n id in y l-3 ,1 4 -d ih y d ro x y  in d o lo -  
[2 ',3 ':6 ,7]m orphinan (lOf). 17-Cyclopropylmethyl-6,7-dide- 
hydro-4,5a-epoxy-5 '-bis-ferf-butoxycarbonyl-(./V '-4-chloro- 
benzyl) guanidinyl-3,14-dihydroxyindolo [2', 3':6,7] morphinan (9f) 
(0.100 g ,0 .13  mmol) w as dissolved in  dichlorom ethane (4 mL)
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an d  allowed to s tir  for 10 m in a t  0 °C. T rifluoroacetic acid (2 
mL) w as added and  th e  solution allowed to  w a rm  to room 
tem p era tu re . S tirring  was continued for 12 h, a f te r  w hich the 
solu tion  w as concentrated u n d e r reduced p ressu re . W ashing 
th e  re su lta n t oil w ith  diethyl e th e r  afforded a p rec ip ita te  th a t 
could be isolated by vacuum  filtration . F u rth e r  purification 
w as achieved by recrysta lliza tion  (m ethanol/diethyl ether) to 
give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-(Af -4- 
chlorobenzyl)guanidinyl-3,14-dihydroxyindolo[2',3':6,7]morphi- 
nan  (lOf) as the  bistrifluoroacetic acid sa lt (0.077 g, 0.09 mmol, 
74%): mp 186-189 °C; R f =  0.13 [CH30H /C H ZC1Z/N H 40H  (89: 
10:1)]; IR vmax/crn (KBr) 3 630-2475  (br, bonded O H  and  NH) 
and  1678 (br, O N ,  N H  and NH Z); lH  NMR (400 M Hz, CD3OD) 
6 0 .4 8 -0 .5 9  [m, 2H, NCHZCH(CM 1C/^H)]I 0 .7 3 -0 .9 1  [m, 2H, 
NCHzC H (C H M ;H M ]. 1.09- 1.22 [m, 1H. NCH 2C M C H 2CH2)], 
5.71 [s, 1H, C(5)M . 6.64 [d, J =  8.2 Hz, 1H, C(1 )H\, 6.68 [d, J  
=  8.2 Hz, 1H, C(2)M , 6 .9 8 -7 .0 2  (m, 1H, ArH), a n d  7 .2 8 -7 .4 6  
[m, 6H, A rM : ,3C NMR (100.5 MHz, CD3OD) <5 3.5 [NCHZCH- 
(CH2CH 2)], 6.3 [NCHzCH(CHzCH2)], 6.9 [NCHZCH(CHZCHZ)], 
25.1 [C(10)], 29.7 [C(15)], 30.2 [C(8)], 45.3 [C(16)], 47.5 
[quaternary  0(13)], 48.0 (CHzPh), 58.9 [0(18)], 63.6 [0(9)], 73.5 
[quaternary  C(14)], 84.8 [0(5)], 109.9 (Ar), 113.7 (Ar), 118.0 
(Ar), 119.2 (Ar), 120.5 (Ar), 122.2 (Ar), 122.4 (Ar), 126.6 (Ar),
128.3 (Ar), 129.6 (Ar). 129.7 (Ar), 130.1 (Ar). 132.3 (Ar), 134.4 
(Ar), 136.4 (Ar), 138.0 (Ar), 141.8 (Ar), 144.5 (Ar), an d  157.5 
(O N H ); FAB+MS m/z 596 [(M +  1)+, 100%]; H R M S (FAB) 
m/z 596.2416 (M +  1)+, CmHssNsOsCI requires 596.2428. Anal. 
(C34HmN50 3C1-2TFA-3Hz0) C, H, N.
M Propyl-TV -cyclopropylm ethylthiourea (12d). Calcium 
carbonate  (1.97 g, 19.67 mmol) w as dissolved in  H 2O (2 mL) 
an d  added to a  s tirred  solution of propylam ine (1.16 g, 19.67 
mmol) in CHC13 (30 mL). Thiophosgene (4.52 g, 3 m L, 39.34 
mmol) w as added and  th e  solution stirred  a t  room tem p era tu re  
for 24 h. The aqueous layer w as w ashed w ith  H 2O and  
concentrated  to give propylisothiocyanate; R f=  0 .72 [EtOAc/ 
hexane  (1:1)]. Propylisothiocyanate (0.44 g, 4.38 mmol) was 
th en  dissolved in acetone (15 mL) and added dropw ise to 
aminom ethylcyclopropane (0.31 g. 4.38 mmol) in  acetone (15 
mL). T he solution w as refluxed gently  for 3 h, concentra ted , 
and  purified by colum n chrom atography [hexane/EtOAc 
(1:1)], providing th e  desired 7V-propyl-Af-cyclopropylmethyl- 
th io u rea  (0.42 g, 2.44 mmol, 56%): Rr=  0.38 [EtOAc/hexane 
(1:1)]; ‘H  NMR (270 MHz, CDC13) <5 0 .2 1 -0 .3 0  [m, 2H, NCHZ- 
CH(CM1CHH)], 0 .52-0.62 [m, 2H, NCHzC H (C H M :H M ]. 0.97 
(t, J =  7.3 Hz. 3H, CM), 1.02-1.13 [m, 1H, NCH2C M C H 2CH2)],
1.64 [q, J =  7.3 Hz. 2H, CH2CH3), 3 .30-3 .41  [m, 4H, 2 x 
NCMZ], and  6.24 [br s, 2H, 2 x  N M ; l3C NMR (67.8 MHz, 
CDC13) <5 3.5 [NCHZCH(CHZC H 2)] and [NCHZC H (C H ZCHZ)],
10.0 [NCHzCH(CHzCH2)], 11.3 (CH3), 22.1 (CH2C H 3), 45.9 
(NCHZ), 49.4 (NCHzCH), and  181.0 ( O S ) ;  FAB+MS m/z 173 
[(M +  1)+, 100%]; HRMS (FAB) m/z 173.1116 (M +  1)+, 
C8H 17N 2S requires 173.1112.
A^-fert-Butoxycarbonyl-TV-propyl-TV'-cyclopropylmeth- 
y lth io u rea  (13d). MPropyl-A/-cyclopropylmethylthiourea (12d) 
(0.41 g, 2.38 mmol) w as added to  N aH  (0.19 g, 60% in  oil, 4.75 
mmol) in TH F (40 mL) a t 0 °C an d  stirred  for 10 m in. (tert- 
Butoxycarbonyl)2O (0.60 g, 2.73 mmol) w as added  and  the 
m ix tu re  s tirred  a t  room tem p era tu re  for 12 h before addition  
of 10% NaOH and  stirrin g  for 20 m in. The organic lay er w as 
th e n  sep ara ted  and  th e  aqueous layer fu rth er ex trac ted  w ith  
EtOAc. The combined organic layers w ere concentra ted  and 
subsequently  trea ted  w ith  hexane, which caused un reac ted  
s ta r tin g  m ateria l to p recip ita te  out. The solid w a s  removed 
by filtra tion  and  th e  filtra te  subsequen tly  purified by colum n 
chrom otography [EtOAc/hexane (1:3)], y ielding th e  N-tert- 
butoxycarbonyl-A/-propyl,A/-cyclopropylmethylthiourea (0.30 g,
1.09 mmol, 46%): Rr=  0.66 [EtOAc/hexane (1:3)]; 'H  NMR 
(400 MHz, CDC13) 6 0 .2 2 -0 .4 9  [m, 4H, NCHZC H(CM 1CM 4) 
and  N C H 2CH(CHHCHM1. 0 .5 1 -0 .5 7  [m, 1H, N C H ZC //(C H Z- 
CHZ)], 0.88 (t, J =  7.4 Hz, 3H, C M ). 1.51 [s, 9H , C (C M )3],
1.65 [q, J =  7.4 Hz, 2H, CMZCH3], 3 .3 9 -3 .6 0  (m. 2H, NHCMO, 
4 .1 6 -4 .3 0  (m, 2H, CONCM ). an d  10.86 (br s, 1H, N M : 13C 
NMR (100.5 MHz, CDC13) 6 4.0 [NCHZCH(CHZC H 2)], 4.1 
[NCHzCH(CHzCH2)], 11.0 [NCHzCH(CHzCH2)], 11.7 (CH3),
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22.3 CCH2CH3). 28.4 [C(CH3)3], 51.1 (HNCHz). 57.2 (CONCHA
83.3 IC(CH3)3], 151.7 (C = 0). and 183.0 (0=S); FAB+MS m lz  
273 [(M +  1)+, 25%] and  217 (85); HRMS (FAB) m lz  273.1644 
(M +  1)+, Ci3H 25N 20 2S requires 273.1637.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-£erf- 
butoxycarbonyl-(^V-propyl-^V'-cyclopropylmethyl)guanid- 
inyl-3,14-dihydroxyindolo[2',3':6,7]morphinan (14d). Ntert- 
Butoxycarbonyl-A/-propyl-A/-cyclopropylmethylthiourea (13d) 
(0.152 g, 0.56 mmol), 5'-am ino-17-cyclopropylmethy 1-6, 7-dide- 
hydro4,5a-epoxy-3114-dihydroxyindolo[2',3,:6,7]morphinan (6a) 
(0.120 g, 0.28 mmol), HgClz (0.152 g, 0.56 mmol), triethylam ine 
(0.028 g, 0.040 mL, 0.28 mmol), and  DMF (10 mL) were added 
to g e th e r a t  5°C u n d e r N 2 before being s tirred  a t  50 °C for 48 
h. T he  solu tion  w as subsequently  filtered and  sodium  bicar­
b o n a te  (30 mL) added. T he solution w as extracted  w ith  ethyl 
a ce ta te  and  th en  w ashed  successively w ith  w ater and  brine, 
d ried  (NazSC^), filtered, and concentrated  under reduced 
p re ssu re  to give the  crude product m ixture, which was purified 
by colum n ch rom ato g rap h y -g rad ien t elu tion  (CH2C12) u n til 
un reac ted  13d h a d  been removed and th en  [CH3OH/CH 2CI2/ 
N H 4O H  (10:89:1)], affording 17-cyclopropylmethyl-6,7-dide- 
hydro-4,5a-epoxy-5'-te/t-butoxycarbonyl-(A7 -propyl-TV'-cyclo- 
p ro p y lm eth y l)g u an id in y l-3 ,1 4 -d ih y d ro x y in d o lo [2 ',3 ':6 ,7 ]- 
m orphinan  (0.062 g, 0.09 mmol, 33%): Rr=  0.61 [CH3OH/CH 2- 
C1z/NH4OH (89:10:1)]; lH  NMR (270 MHz, CDCls) <5 0 .05 -0 .10  
[m, 2H , N C H 2C H (C //H C //H )], 0 .1 1 -0 .2 0  [m. 2H, NCH 2CH- 
(C //H C //H )], 0 .3 5 -0 .4 4  [m, 2H, N C H zC H (C H M :H //)],0 .46- 
0.58 [m, 2H, N CH 2CH(CH//CH7fl], 0 .7 3 -0 .8 3  [m, 1H. NCHz- 
C M C H 2CH 2)], 0 .8 4 -0 .9 8  [m, 1H, NCH 2C M C H 2CH2)], 1.47 [s, 
9H, C (C //^3], 5.60 [s, 1 H, C(5)//], and  6 .38-7 .10  (m, 5H, ArH); 
13C NM R (67.8 MHz, CDC13) 6 3.3 [NCH2CH(CH2CHz)]. 3.4 
(NCHzCHfCHzCHz)]. 3.8 [NCH2CH(CH 2 CHz)], 3.9 [NCH2CH- 
(CHzCHz)], 9.4 [NCHzCH(CHzCHz)], 10.5 [NCH2 CH(CH2CHz)],
11.4 (CH3), 21.8 (CHz), 23.1 [0(10)], 28.3 [C(CH3)3], 28.8 (CHz).
31.4 (CHz), 43.6 (CHz). 47.9 [quaternary  0(13)], 59.5 [C(18)],
62.4 [0(9)], 72.7 [quaternary  0(14)], 81.0 [quaternary C(CH3)3],
85.0 [0(5)], 110.7 (Ar), 111.7 (Ar), 117.5 (Ar), 117.9 (Ar), 118.5 
(Ar), 124.5 (Ar), 127.3 (Ar), 129.6 (Ar), 130.6 (Ar), 134.2 (Ar),
139.6 (Ar), 143.4 (Ar), 153.9 (Ar), and  154.1 (0=N); FAB+MS 
m lz  6 6 8  [(M +  1)+, 100%] and 568 (30); HRMS (FAB) m /z  
668.3819 (M +  1)+, C39H 50N 5O5 requ ires 668.3812.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-(/V’- 
propyl-7V "-cyclopropylm ethylthiourea)guanidinyl-3,14- 
d ihydroxy indo lo [2 ',3 ':6 ,7 ]m orph inan  (15d). 17-Cyclopro- 
pylm ethyl-6,7-didehydro-4,5a-epoxy-5'-terf-butoxycarbonyl- 
(A /'-p ro p y l-A /"-cy c lo p ro p y lm eth y l)g u an ld in y l-3 ,1 4 -d ih y - 
droxyindolo[2',3':6,7]morphinan (14d) (0.046 g, 0.07 mmol) w as 
tre a te d  a s described for lOf, to give 17-cyclopropylmethy 1-6,7- 
didehydro-4,5a-epoxy-5'-(A/'-propyl-A7/-cyclopropylm ethyl)- 
guanidinyl-3,14-dihydroxyindolo[2\3':6,7]rnorphirian (15d) as 
th e  b istrifluoroacetic acid sa lt (0.039 g, 0.07 mmol, 99%): m p 
17 7 -1 7 8  °C; R r =  0.24 [CHaOH/CHzClz/NFLOH (89:10:1)]; IR 
Vmax/cm (KBr) 3700—2620 (br, bonded OH and  NH) an d  1678 
(br, C -N , N H  an d  NHz); >H NMR (400 MHz, CD3OD) <5 0 .1 2 -  
0.21 [m, 2H, NCHzCH(CM lCHH)], 5.65 [s, 1H, C(5)H\, 6.56 
[d, J =  8.2 Hz, 1H, C (l) //] t 6.59 [d, J =  8.2 Hz, 1H, C(2)H\, 
6.93 [dd, J\ =  8 . 6  Hz, J 2 =  1.9 Hz. 1H, C ( 6 0 ^ ,  7.25 [d, J  =
1.9 Hz, 1H. 0(407/1, and  7.38 [d, J =  8 . 6  Hz, 1H. C(7')H\\ 13C 
NMR (100.5 MHz, CD3OD) d 3.7 [NCH2CH(CH2CH2)], 4.2 
[NCH2CH(CH 2 CHz)], 6.5 [NCH2CH(CH 2CH2)], 7.1 [NCHzCH- 
(CHzCHz)], 11.5 [NCH2 CH(CH2CH2)], 11.7 (CH3), 23.6 [0(10)],
25.3 (CH2), 30.0 (CH2), 30.5 (CHz), 44.6 [0(16)], 47.6 (CH2),
47.9 [quaternary  C(13)], 59.2 [0(18)], 63.9 [0(9)], 73.9 [qua­
te rn a ry  C(14)], 85.2 [C(5)]> 110.3 (Ar), 114.2 (Ar), 118.6 (Ar),
119.7 (Ar), 120.9 (Ar), 122.8 (Ar), 122.9 (Ar), 127.4 (Ar), 129.0 
(Ar), 130.6 (Ar), 132.9 (Ar), 138.5 (Ar), 142.4 (Ar), 145.1 (Ar). 
and  156.6 (C=N); FAB+MS m /z  568 [(M +  1 )+, 100%]; HRM S 
(FAB) m /z  568.3275 (M +  1)+, C34H 4ZN5O3 requires 568.3288. 
Anal. (C34H 4 ,N 50 3 -2 TFA-2 Hz0 ) C, H, N.
B iological M ethods. The m ethods utilized  have been 
reported  previously .29
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Major Effect o f Pyrrolic N-Benzylation in  Norbinaltorphim ine, the Selective  
fc-Opioid Receptor A ntagonist
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Indolic N-benzylation of naltrindole reportedly extends the du ra tion  of <5-opioid receptor (DOR) 
antagonism . S im ilar modification of the x-opioid receptor (KOR) an tagonist norBNI ( la )  and 
its  17,17'-diNMe analogue (Id ), a  low potency ^-opioid receptor (MOR) partia l agonist, was 
found to affect predom inan tly  th e ir MOR activity. W hen adm inistered  systemically in mouse 
antinociceptive assays, iV-benzyl-norBNI (lb ) had only MOR agonist activity of relatively short 
duration  w hereas on cen tra l adm inistration i t  had only a  K O R-antagonist action of extremely 
long duration.
In tro d u c tio n
For the past 30 years there has been considerable 
interest in the development of nonpeptidic ligands for 
k (KOR) and <5 (DOR) opioid receptors. Discovery of 
antagonists with selectivity for KOR1-3 and DOR1,4 has 
enabled the  function of these receptor systems to be 
explored. The prototype KOR antagonist norBNI (la) 
was designed on the message—address principle in 
which the address component which confers KOR 
selectivity is the basic nitrogen of the second N-cyclo- 
propylmethyl (CPM) group.6 The follow-up to norBNI 
was GNTI (2b) in which the guanidino KOR address 
component was introduced into the selective DOR- 
antagonist, naltrindole (NTT, 2a).6 The effect of benzyl 
substitution a t the indole N-atom in NTI to give BNTI 
(2c) was to bring selectivity for the putative DOR2- 
subtype in an antagonist of substantially longer dura­
tion than NTI.7 I t was thus of in terest to investigate 
the effect of equivalent N-benzylation of norBNI (la) 
and its 17,17'-diNMe analogue (Id). Herein we report 
the results of the in vitro (binding and [35S]GTPyS) 
pharmacological evaluation of l b  and analogues, plus 
the further evaluation of l b  in vivo.
C hem istry . Two complimentary methods were uti­
lized for the synthesis of BnorBNI (lb ). In the first, the 
reported method for the synthesis of BNI (lc) from 
naltrexone (4) and iV-methylhydrazine sulfate8 was 
modified by the use of JV-benzylhydrazine sulfate and 
extending the reaction time to one week, then at 
elevated tem perature for 2 days. Unfortunately, under 
these conditions only 1% of l b  could be isolated with 
the major identifiable m aterial appearing to be hydra- 
zone (5) in 20% yield (Scheme 1). The alternative meth­
od, direct benzylation of l a  (prepared from naltrexone 
in 62% yield)9 using excess sodium hydride and benzyl- 
bromide, yielded a mixture of tri- and pentabenzyl- 
substituted norBNI, th a t was hydrolyzed immediately
* Corresponding author. Tel: (1225) 383103. Fax: (1225) 386114. 
E-mail: s.m.husbands@bath.ac.uk.
t University of Bath.
* University of Michigan.
HO
b:R = H, R* =  CHjcCjHj 
b:R •  CH2C6Hj , R '-C H jcCjH, 
c:R »  CHj, R' *■ CHjCCjH, 
d: R = H, R' =  CHj 
e: R “  CH2C6Hj, R' = CH3
CH ,0
a: R = R‘ - H .R J -C H jcC jH , NTI ■ 3
b: R = H, R1 = NHC(=NH)NHj, R2 = CHjcC3H3 GNTI ^
c: R = CHjCjHj, R1 = H, R2 = CH2cC3H3 BNTI b; R "  CH’
d: R = R1 =■ H, R2 *= CHj OMI 
e: R = H, R1 = NHC(=NH)NH2> R2 = CH,
in hydrochloric acid/methanol to yield lb  in 63% yield 
(39% from naltrexone). Similar treatm ent of Id , pre­
pared from oxymorphone (4b), with benzyl bromide 
yielded the tribenzyl-substituted compound th a t was 
hydrolyzed to l e  with HBr/MeOH.
R esu lts  a n d  D iscussion
Affinities of the compounds for opioid receptors were 
measured using radioligand binding assays in  mem­
branes from C6fi, C6<5, and CHO/c cells and competition 
for the nonselective antagonist [3H]diprenorphine as 
previously described.10 BnorBNI (lb) had subnanomolar 
affinity for KOR with modest selectivity over MOR and 
DOR (Table 1). When compared w ith norBNI (la ), the 
prototypic KOR-antagonist lb  was as, or slightly more, 
selective under these conditions. The modest selectivity 
observed for these compounds was not surprising since 
Takemori et al.3 showed th a t binaltorphimine (BNI, lc )  
had very little KOR selectivity in binding assays. The 
17-NMe analogues (Id , le )  had a t least an order of
10.1021/jm 049172n CCC: $30.25 © 2005 A m erican Chem ical Society
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Schem e 1°




O " using 4a 'N -NHO
HO HO OHOH
la : R = CHjCCjHj 




lb : R = CHjCC,Hj 
le : R = CH,
0 R eagents and conditions: (i) B11HNNH2 .H2SO4 , AcOH (ii) H2NNH2 , DMF, 100 °C then MeSOsH, DMSO, 130 °C (iii) N aH , 18-crown- 
6 , BnBr th en  methanol, 12 N  HC1, 90 °C (for l b ) ,  HBr, r.t. (for l e ) .
T ab le  1. Binding Affinities for Ligand Binding to Opioid Receptors0
compound MOR
Ki (nM) ±  SEM6 
DOR KOR MOR/KOR DOR/KOR
l a ,  norBNI 1 . 2 0  ±  0 . 2 5.8 ±  0.645 0.4 ±  0.06 3 15
lb ,  BnorBNI 10.0 ±2.5 8 . 6  ±  0.7 0.7 ± 0 .1 14 1 2
I d 63.6 ±  39.1 98.2 ±  25.3 7.7 ±  1.0 8 13
l e 6.4 ±  1.1 207 ±  96 24.9 ±  5.6 0.3 8
0 R at MOR or DOR receptors in C6  cells and hum an KOR receptors in CHO cells. 6 Values are the mean of three experiments, each 
performed in  duplicate. Experim ents were performed as described in  ref 10 using [3H]diprenorphine.
T ab le  2. Agonist Effects of Ligands a t Opioid Receptors 




l a JB _e JB
l b 187d 38 jb 1906^ 29
I d 1388 ±  370 6 6 j e JB
l e 526 ±  279 54 JB JB
0  Com pared to the full agonist DAMGO. 6 Compared to the full 
agonist SNC80. c Compared to the  full agonist U69593. d 95% Cl 
42-844nM. * No stimulation up to  10 000 nM. f 95% Cl 269-13490 
nM. * Experim ents were performed using membranes from Rat 
MOR or DOR receptors in  C6  cells and human KOR receptors in 
CHO cells a s  described in  re f  11. Values are from three separate 
experiments.
m agnitude lower affinity than l a  and lb  a t each 
receptor. The exception was for l e  a t the MOR where 
affinity was similar to lb ,  resulting in l e  displaying 
modest selectivity for MOR.
In the [35S]GTPyS functional assay10,11 in 06/*, C6<3, 
and CHOk cells Bnor BNI (lb ) showed partial MOR and 
KOR agonism, reaching approximately 40% and 30% 
respectively of maximal effect compared with the ap­
propriate full agonists a t each receptor (Table 2). The 
MOR partial agonist effect of BnorBNI, though of 
modest potency, was ten-times higher than  its potency 
as a KOR-partial agonist. In contrast, there are no 
unequivocal reports in the literature tha t l a  or l c  have 
opioid agonist actions in vitro or in vivo, with evidence 
only of very limited agonism in isolated tissue assays.12 
However, Takemori et al.3 reported th a t 24.5 /*mol/kg 
l a  sc enhanced the potency of the selective peptidic
MOR agonist DAMGO 3-fold in the acetic acid induced 
stretching assay in mice (AS).3 As expected from stand­
ard opioid SAR regarding 17-NMe and 17-NCPM sub­
stituents, I d  and l e  had higher efficacy a t MOR than 
norBNI ( la )  and BnorBNI (lb ) but were substantially 
less potent. However, the additional benzyl group in l e  
increased MOR potency rather than efficacy compared 
to Id , which is in contrast to the la / lb  comparison 
where the additional benzyl group increased MOR 
efficacy. The activity of Id  in the [36S]GTPyS assay, low 
potency MOR partial agonist, is in agreement with that 
of Portoghese’s group who found similar activity in the 
guinea pig ileum assay.9
The antagonist potency of BnorBNI (lb ) determined 
against the selective KOR agonist U69593 (Ke =  0.26 
nM) was 50-fold greater than its potency determined 
against the selective DOR agonist SNC80 and nearly 
100-fold greater than  its potency against the MOR 
agonist DAMGO (Table 3). Once again these data for 
BnorBNI (lb ) compare favorably with those obtained 
for norBNI ( la )  (50- and 22- fold selective for KOR over 
DOR and MOR respectively) under the sam e assay 
conditions. Thus, the selectivity of the KOR antagonist 
action of both norBNI and BnorBNI is substantially 
greater in this functional assay than  th e ir  KOR- 
selectivity in binding assays. The 17-NMe analogues 
(Id , le )  were very much less potent KOR antagonists 
than  norBNI and BnorBNI to the extent of 2—3 orders 
of magnitude (Table 3).
It is of interest to compare the binding and  in vitro 
effects of 17-N-Me versus 17-N-CPM substitution in the
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T a b le  3. Antagonist Effects of Ligands a t Opioid Receptors 
M easured by the  [35S]GTPyS Binding Assay*
compd
Kt (±  SEM)/nM
MOR° DOR° KOR°
l a 2.38 ±  0.58 5.17 ±  0.73 0 . 1 1  ± 0 . 0 1
l b 25.5 ±  2.3 13.3 ±  4.5 0.26 ±  0.085
I d NT NT 27.0 ± 4 .3
l e NT NT 311 ± 3 0
° Ke values were determined from dose-response curves for 
DAMGO (MOR), SNC80 (DOR), and U89593 (KOR) in the pres­
ence o r absence of test ligand according to the formula: K* = 
[antagonist]/(dose-ratio — 1 ). * Experiments were performed using 
m em branes from Rat MOR or DOR receptors in C6  cells and 
hum an KOR receptors in  CHO cells as described in ref 11. Values 
are from 3 separate experiments.
current series with equivalent substitutions in series 
of selective OR ligands having indolomorphinan struc­
tures. The 17-NMe analogue (2e) of GNTI (2b) in 
binding assays had substantially lower KOR affinity 
th an  GNTI but greater KOR selectivity as a result of 
even lower MOR and DOR affinity.13 This was also true 
of OMI (2d) in comparison to NTI.14*16 In the present 
series the loss of affinity in substituting 17-NCPM by 
NMe is sim ilar for KOR and DOR so tha t there is no 
gain of KOR over DOR selectivity. There was a small 
gain of KOR over MOR selectivity from norBNI (la ) to 
Id , bu t the reverse was true when the pyrrolic N-benzyl 
group was introduced ( le  versus lb).
The effects on the in vitro OR functioned profiles of 
GNTI (2b) and NTI (2a) when the 17-NCPM group is 
exchanged for NMe are quite different. The analogue 
(2e) of GNTI rem ains a KOR antagonist but with very 
much lower potency and selectivity than  GNTI; there 
was no evidence of agonist activity in isolated tissue 
preparations.13 By contrast, the selective, potent DOR 
antagonist activity of NTI (2a) was totally lost in OMI 
(2d) bu t the la tter had substantial DOR partial agonist 
activity.15 In  the present series the effects of 17-NMe 
for 17-NCPM substitution in norBNI (Id  cf. la )  was 
reduction of KOR antagonist potency as in NTI but of 
greater significance was the appearance of a  MOR 
partial agonist effect of substantial efficacy though of 
low potency. The la tter was increased by introduction 
of the pyrrolic JV-benzyl group (in le).
The action of BnorBNI (lb ) a t opioid receptors was 
further investigated in vivo in the mouse tail w ith­
drawal assay for antinociception (TW), in which the 
w ater tem perature was 50 °C (Table 4).16 When lb  (10 
mg/kg) was administered subcutaneously (sc) 1 h  or 3 
h  before U69593 (sc), the dose-response curve of the 
agonist was shifted 2.6-fold to lower doses, suggesting 
an  additive antinociceptive effect of lb . By 24 h the 
effect was no longer significant and a t no time point (up 
to 48 h) was an  antagonist effect detected, or a t 24 h 
w ith 32 mg/kg lb . In contrast, norBNI (la : 32 mg/kg 
sc, 24 h  pretreatm ent) gave a 4-fold rightward shift of 
the dose-response curve for U69593.
Administration (sc) of BnorBNI (lb ) alone in TW gave 
a  substantial antinociceptive effect measured 30 min or 
1 h  after adm inistration, but there was no significant 
effect by 3 h. The antinociceptive effect of BnorBNI (lb ) 
was not inhibited by norBNI ( la )  (data not shown) but 
was antagonized by the selective MOR antagonist 
methocinnamox (M-CAM)16 (Figure 1), indicating it was 
mediated by an agonist effect a t MOR. In contrast
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Table 4. Effect of Ligands on the  Dose—Effect Curve for 
U69593 Administered sc in  the W arm W ater Tail W ithdrawal 
Assay (TW) after Systemic (sc) or C entral (icv) Administration0
route of 
admin









+vehicle a t - 1  h* 5.2 — —
sc + 1 0  mg/kg l b  a t - 1  h 2 . 0 -2 .5 6 0 . 0 0 0 2
sc +10 mg/kg l b  a t - 3  h 2 . 1 -2 .5 5 0.0145
sc + 1 0  mg/kg l b  a t -1 8  h 9.0 1.73 n.s.
sc +10 mg/kg l b  a t -2 4  h 4.4 -1 .1 7 n.s.
sc +32 mg/kg l b  a t -2 4  h 5.7 1.09 n.s.
sc +10 mg/kg l b  a t -4 8  h 9.9 1.90 n.s.
sc +32 mg/kg l a  a t -2 4  h 22.7 4.12 0.0003
icv + 1 0  nmol l b  a t - 1  h 49.1 9.41 <0 . 0 0 0 1
icv +10 nmol l b  a t -2 4  h 26.3 5.04 0.0003
icv +10 nmol l b  a t -4 8  h 74.2 14.22 <0 . 0 0 0 1
icv + 1 0  nmol l b  a t -168  h 37.0 7.09 <0 . 0 0 0 1
icv +10 nmol l a  a t -2 4  h 31.8 6 . 1 0 <0 . 0 0 0 1
0 Assays were performed as previously described in re f 12. 
Negative shift values reflect a leftward shift; positive values reflect 
a rightward shift. Significance of the  shifts in  agonist effect was 
determined by 2-way ANOVA. 6 Vehicle is 10% DMSO in normal 
saline. c n.s. =  not significant.






-30 min -1 h -3h -24 h
Treatment Tim*
F ig u re  1. A gonist activity  o f B norB N I ( lb )  in  th e  tail 
w ithdraw al assay.
norBNI ( la )  has no antinociceptive activity in the AS 
antinociceptive assay when adm inistered sc but is an 
effective and selective KOR antagonist.17
When administered icv, BnorBNI (lb ) had no agonist 
effect in the TW test but was an effective and selective 
KOR antagonist lasting a t least 168 h, with the peak 
effect around 48 h  (Table 4). The antagonist selectivity 
of BnorBNI (lb ) (icv) was assessed after 1 h  pretreat­
ment by comparison of its ability to antagonize U69593 
(KOR) compared with its antagonism  of SNC80 (DOR) 
and morphine (MOR). In the case of SNC80 the water 
temperature in TW was set a t 48 °C since DOR agonists 
have very little antinociceptive effect a t higher temper­
atures. Compared with the 9-fold shift in the U69593 
dose—effect curve there was no inhibition of the agonist 
effects of SNC80 and morphine in  the presence of 10 
nmoles BnorBNI (lb ) (data not shown). This confirms 
th a t BnorBNI (lb ) is a substantially  selective KOR 
antagonist under these conditions, in accord with its 
selectivity as a KOR antagonist in the [35S]GTPyS 
assay. At 24 h  pretreatm ent the shift in the U69593 
dose-response curve produced by. 10 nmol of BnorBNI 
(lb ) icv was similar to th a t of 10 nmol of norBNI (la) 
(Table 4). The lack of agonist action on direct central 
administration of BnorBNI (lb ) is surprising, but there
B rief Articles Journal o f Medicinal Chemistry, 2005, Vol. 48, No. 5 1679
are other examples of opioid ligands w ith agonist and 
antagonist effects th a t exhibit agonism only when 
adm inistered systemically. The 14-cinnamoylamino- 
codeinone (3b) when administered sc showed very 
potent and efficacious MOR-mediated antinociceptive 
effects in TW with no evidence of delayed antagonism.18 
In contrast on icv administration this same compound 
was w ithout antinociceptive effects, but was a  potent, 
delayed morphine antagonist.19
In conclusion, the effect of introducing a benzyl 
substituent to the pyrrole-N of norBNI (la )  and its 17- 
NMe analogue (Id) was predominantly on their MOR 
pharmacology. In the former case, the effect was to 
increase MOR efficacy, but not potency, while in the 
latter, MOR potency was increased but w ith no effect 
on efficacy. Unlike norBNI (la), BnorBNI ( lb )  acts as 
a partial MOR agonist in vitro tha t shows an antino­
ciceptive effect of relatively short duration when ad­
ministered systemically. However, when administered 
centrally the compound lacks this effect and instead is 
a selective KOR antagonist of very long duration, 
comparable to norBNI (la).
E x p e rim en ta l Section
C h e m is try . R eagents and solvents were pu rch ased  from 
A ldrich or L ancaster. M elting points w ere recorded on a 
Gallenkam p MFB-595 m elting point appara tus an d  are  uncor­
rected. High and  low resolution fast atom  bom bardm ent (FAB) 
m ass spec tra  w ere recorded on a  Fisons VG AutoSpec Q 
in stru m en t, w ith  a  m atrix  of m -nitrobenzyl alcohol. Micro­
analyses w ere perform ed w ith  a  Perkin-E lm er 240C analyzer.
1 7 ,1 7 '-B is (cy c lo p ro p y lm eth y l)-6 ,6 ',7 ,7 '-te trah y d ro -4 ,5 : 
4 ',5 /- d ie p o x y - 6 ,6 '- ( b e n z y l im in o ) [ 7 ,7 '- b im o r p h in a n ] -  
3 ,3 ',1 4 ,1 4 '-te tro l ( lb ) .  To a  solution of norB N I2 (0.30 g: 0.45 
mmol) in  d ry  T H F u nder a  Na atm osphere w ere added N aH 
(0.18 g: 4.52 mmol) and 18-crown-6 (30 mg: 0.11 mmol). This 
m ixture was stirred  for 20 m in a t r.t. before adding B nB r (0.16 
mL: 1.36 mmol) and stirring  continued for a  fu r th e r  43 h. The 
reaction  w as quenched by th e  addition of H 2O, th e  organic 
layer collected and  dried (M gSOJ, and  solvent rem oved in  
vacuo. The crude oil was purified by column chrom atography 
(CH zC ^M eO H N ILO H  400:10:1 to 290:10:1) to yield a  mixture 
of tri-  and pentabenzyl-substitu ted  norB N I (0.33 g). This 
m ixture was dissolved in  MeOH/cHCl (20 m L, 1:1) an d  heated  
to 90 °C for 40 h. Cooling, basification (aqueous am m onia), 
and  rem oval of th e  precip itate  by filtra tion  w as followed by 
evaporation o f th e  filtrate  to d iyness. Column chrom atography 
(CHaCLiMeOHiNILOH 200:10:1) yielded BnorB N I as an  off- 
w hite  solid (0.21 g: 63%), MS (FAB): m/z =  752 (M +  H)+, 
HRMS (FAB) m/z 752.3715 (M +  H)+, C47H 49N 3O6 requ ires 
751.3620, R/(CHaCla/M eOH/NIhOH: 110/10/1) =  0.76, m p > 
240°C, Anal. (C47H49N306:2HC1:5H20 )  C, H , N.
1 7 ,1 7 '-D im e th y l-6 ,6 ',7 ,7 '- te tra h y d ro -4 ,5 :4 ',5 '-d ie p o x y - 
6 ,6 '-(benzylim ino)[7,7/-b im o rp h in a n ]-3 ^ /,14 ,14 '-te tro l (le ). 
17,17'-Dimethyl-6,6/,7,7/-tetrahydro-4,5:4',5'-diepoxy-6,6'-(imino)- 
[7,7,-bim orphinan]-3,3',14,14'-tetrol (Id )9 w as tre a te d  as for 
l b  above except MeOH/HBr replaces M eOH/HCl for the 
O-debenzylation. Yield 80%, MS (FAB): mlz =  672 (M +  H)+, 
HRMS (FAB) m/z 672.3063 (M +  H)+; C41H 41N 3O6 requ ires 
671.2995, ^(C H zC la /M eO H /N IL O H llO /lO /l) 0.27 m p > 240 
°C, Anal. (C4iH4iN30 6:2HCl:4H20) C, H, N.
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